HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
20230068538 · 2023-03-02
Inventors
- Jun LOU (Wuhan, Hubei, CN)
- Yongkai CHEN (Wuhan, Hubei, CN)
- Junhua LIU (Wuhan, Hubei, CN)
- Yihan ZHANG (Wuhan, Hubei, CN)
- Xiaodan GUO (Wuhan, Hubei, CN)
- Li Liu (Wuhan, Hubei, CN)
- Lina Qian (Wuhan, Hubei, CN)
- Chaodong WANG (Wuhan, Hubei, CN)
Cpc classification
A61P29/00
HUMAN NECESSITIES
C07D209/18
CHEMISTRY; METALLURGY
A61P13/02
HUMAN NECESSITIES
C07D491/048
CHEMISTRY; METALLURGY
C07D317/26
CHEMISTRY; METALLURGY
International classification
C07D413/06
CHEMISTRY; METALLURGY
C07D491/048
CHEMISTRY; METALLURGY
C07D209/18
CHEMISTRY; METALLURGY
Abstract
Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.
##STR00001##
Claims
1. A heterocyclic compound of formula I or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, ##STR00990## wherein, ##STR00991## is a 5 membered heteroaryl or a 5 membered heterocycloalkenyl, wherein the 5 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 5 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S; ##STR00992## is phenyl, a 5-6 membered heterocycloalkyl, a 5-6 membered heterocycloalkenyl, or a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkyl contains 1-3 heteroatoms selected from one or more of N, O and S, the 5-6 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, Z.sup.5, Z.sup.6, Z.sup.7, Z.sup.8 and Z.sup.9 independently represent a ring atom; and when ##STR00993## is a 5 membered heterocycloalkyl, a 5 membered heterocycloalkenyl or a 5 membered heteroaryl, Z.sup.6 or Z.sup.9 represents a single bond; m is 1, 2, 3 or 4; R.sup.3 is H, halogen, —OH, a C.sub.1-C.sub.6 haloalkyl, —CN or a C.sub.1-C.sub.6 alkyl; when m is not 1, R.sup.3 is independently the same or different; or when two adjacent R.sup.3 are present, they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.6 cycloalkyl, a C.sub.3-C.sub.6 cycloalkenyl, a C.sub.3-C.sub.9 heterocycloalkyl, a C.sub.3-C.sub.9 heterocycloalkenyl, phenyl or a 5-6 membered heteroaryl; wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N; and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of O, S and N; W is a single bond or —C(═O)—NH—; ##STR00994## is phenyl, a 5-6 membered heteroaryl, or a C.sub.3-C.sub.9 heterocycloalkyl; wherein the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; n is 1, 2, 3 or 4; R.sup.1 is independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O); when a plurality of substituents are present, they are the same or different; and when n is not 1, R.sup.1 is independently the same or different; Q is H, halogen, —OH, —CF.sub.3, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═O)—N(R.sup.1-5R.sup.1-6), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13, —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, or an unsubstituted or substituted 5-10 membered heteroaryl; wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N; and the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of O, S and N; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.6-C.sub.10 aryl, the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), —N(R.sup.1-21R.sup.1-22), —C(═O)—N(R.sup.1-23R.sup.1-24), —S(═O).sub.2—N(R.sup.1-25R.sup.1-26), —C(═O)—O—R.sup.1-27, and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.a are present, they are the same or different, and each R.sup.a is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1- 21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkynyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted phenyl, or an unsubstituted or substituted 5-10 membered heteroaryl; wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N; and the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.2-C.sub.6 alkynyl, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl, the substituted phenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —COOCH.sub.3, —NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.d, wherein when a plurality of R.sup.d are present, they are the same or different, and each R.sup.d is independently H, halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; or R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, or an unsubstituted or substituted 5-10 membered heteroaryl; wherein the C.sub.3-C.sub.9 heterocycloalkyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom; the C.sub.3-C.sub.9 heterocycloalkenyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom; the 5-10 membered heteroaryl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom; and the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O—, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.b, wherein when a plurality of R.sup.b are present, they are the same or different, and each R.sup.b is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.2 is independently ##STR00995## —C(═O)N(R.sup.2-5R.sup.2-6) or an unsubstituted or substituted 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CN, an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl-O—, —C(═O)R.sup.2-7 or —C(═O)N(R.sup.2-8R.sup.2-9), wherein when a plurality of substituents are present, they are the same or different; R.sup.2-1 and R.sup.2-2 are each independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O); wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and when a plurality of substituents are present, they are the same or different; X and Y are each independently a single bond, methylene, —O—, —N(R.sup.2-3)— or ##STR00996## R.sup.2-3, R.sup.2-4, R.sup.2-5 and R.sup.2-6 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl-O—, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.3-C.sub.8 cycloalkyl, the substituted C.sub.3-C.sub.8 cycloalkyl-O— or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and when a plurality of substituents are present, they are the same or different; R.sup.2-7 is independently H, halogen, —OH, —CN, an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl-O—; and R.sup.2-8 and R.sup.2-9 are each independently H, or an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl.
2. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein when ##STR00997## is a 5 membered heteroaryl, the 5 membered heteroaryl is pyrrolyl, furanyl, thienyl, imidazolyl or pyrazolyl, the pyrrolyl is preferably ##STR00998## the furanyl is preferably ##STR00999## the imidazolyl is preferably ##STR01000## the thienyl is preferably ##STR01001## and the pyrazolyl is preferably ##STR01002## and/or when ##STR01003## is a 5 membered heterocycloalkenyl, the 5 membered heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 5 membered heterocycloalkenyl is preferably 2,3-dihydro-1H-pyrazolyl, and more preferably ##STR01004## and/or when ##STR01005## is a 5-6 membered heterocycloalkyl, the 5-6 membered heterocycloalkyl is a 6 membered heterocycloalkyl, wherein the 6 membered heterocycloalkyl contains 1-3 N heteroatoms; and the 5-6 membered heterocycloalkyl is preferably piperazinyl or piperidinyl, the piperazinyl is preferably ##STR01006## and the piperidinyl is preferably ##STR01007## wherein the right-side carbon-nitrogen bond ##STR01008## represents the position fusing to ##STR01009## and/or when ##STR01010## is a 5-6 membered heterocycloalkenyl, the 5-6 membered heterocycloalkenyl is a 6 membered heterocycloalkenyl, wherein the 6 membered heterocycloalkenyl contains 1-3 N heteroatoms; and the 5-6 membered heterocycloalkenyl is preferably 1,2-dihydropyridinyl or 1,6-dihydropyrimidinyl, the 1,2-dihydropyridinyl is preferably ##STR01011## and the 1,6-dihydropyrimidinyl is preferably ##STR01012## wherein the right-side carbon-nitrogen bond ##STR01013## represents the position fusing to ##STR01014## and/or when ##STR01015## is a 5-6 membered heteroaryl, the 5-6 membered heteroaryl is a 6 membered heteroaryl, wherein the 6 membered heteroaryl contains 1-3 N heteroatoms; and the 5-6 membered heteroaryl is preferably pyridinyl, and the pyridinyl is preferably or ##STR01016## and/or m is 1 or 2; and/or Z.sup.7 is substituted with R.sup.3, Z.sup.8 is unsubstituted or substituted with R.sup.3, Z.sup.6 and Z.sup.9 are unsubstituted; when a plurality of R.sup.3 are present, they are the same or different; and more preferably, Z.sup.7 is substituted with R.sup.3, and Z.sup.6, Z.sup.8 and Z.sup.9 are unsubstituted; and/or when R.sup.3 is halogen, the halogen is fluorine, chlorine, bromine or iodine; and/or when R.sup.3 is a C.sub.1-C.sub.6 alkyl, the C.sub.1-C.sub.6 alkyl is C.sub.1-C.sub.4 alkyl, and preferably methyl; and/or when R.sup.3 is a C.sub.1-C.sub.6 haloalkyl, the halogen is fluorine, chlorine, bromine or iodine; and/or when R.sup.3 is a C.sub.1-C.sub.6 haloalkyl, it contains one or more halogens, and preferably 1, 2 or 3 halogens; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.6 cycloalkyl, the C.sub.3-C.sub.6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.6 cycloalkenyl, the C.sub.3-C.sub.6 cycloalkenyl is cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cyclohexadienyl; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.9 heterocycloalkyl, the C.sub.3-C.sub.9 heterocycloalkyl is a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.9 heterocycloalkenyl, the C.sub.3-C.sub.9 heterocycloalkenyl is a C.sub.4-C.sub.5 heterocycloalkenyl, wherein the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a 5-6 membered heteroaryl, the 5-6 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or n is 1 or 2; and/or each R.sup.1 is independently located at position α or β of the linkage between ##STR01017## and Z.sup.2; and/or when R.sup.1 is halogen, the halogen is fluorine, chlorine, bromine or iodine; and/or when R.sup.1 is an unsubstituted or substituted C.sub.1-C.sub.6 alkyl or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl; and/or when R.sup.1 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituents are each independently halogen, the halogen is fluorine, chlorine, bromine or iodine; and/or when R.sup.1 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituents are each independently a C.sub.1-C.sub.6 alkyl or a C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl in the substituents is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl; and/or when R.sup.1 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, the number of the substituents is independently 1, 2 or 3; and/or Q is located at position β or γ of the linkage between ##STR01018## and W; when ##STR01019## is a 5-6 membered heteroaryl, the 5-6 membered heteroaryl is a 5 membered heteroaryl, wherein the 5 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 5 membered heteroaryl is preferably imidazolyl, thienyl, furanyl or pyrrolyl, the imidazolyl is preferably ##STR01020## and more preferably ##STR01021## the thienyl is preferably ##STR01022## and more preferably ##STR01023## the furanyl is preferably ##STR01024## and more preferably ##STR01025## and the pyrrolyl is preferably ##STR01026## and more preferably ##STR01027## or the 5-6 membered heteroaryl is a 6 membered heteroaryl, wherein the 6 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 6 membered heteroaryl is preferably pyridinyl or pyrazinyl, the pyridinyl is preferably ##STR01028## and more preferably ##STR01029## and the pyrazinyl is preferably ##STR01030## and more preferably ##STR01031## and/or when ##STR01032## is a C.sub.3-C.sub.9 heterocycloalkyl, the C.sub.3-C.sub.9 heterocycloalkyl is a C.sub.3-C.sub.5 heterocycloalkyl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of N, O and S; and the C.sub.3-C.sub.9 heterocycloalkyl is preferably a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S, the C.sub.4-C.sub.5 heterocycloalkyl is preferably piperidinyl, and the piperidinyl is preferably ##STR01033## and more preferably ##STR01034## and/or when Q is halogen, the halogen is fluorine, chlorine, bromine or iodine; and/or when Q is an unsubstituted or substituted C.sub.1-C.sub.6 alkyl or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl; and/or when Q is an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl or an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, the C.sub.2-C.sub.6 alkenyl is a C.sub.2-C.sub.4 alkenyl; and/or when Q is an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, the C.sub.3-C.sub.10 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; and/or when Q is an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, the C.sub.3-C.sub.9 heterocycloalkyl is a C.sub.3-C.sub.5 heterocycloalkyl, wherein the C.sub.3-C.sub.65 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; the C.sub.3-C.sub.9 heterocycloalkyl is preferably a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and the C.sub.3-C.sub.9 heterocycloalkyl is preferably glycidyl, pyrrolidinyl or piperazinyl, the glycidyl is preferably ##STR01035## the pyrrolidinyl is preferably ##STR01036## and the piperazinyl is preferably ##STR01037## and/or when Q is an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, the C.sub.3-C.sub.9 heterocycloalkenyl is a C.sub.3-C.sub.5 heterocycloalkenyl, wherein the C.sub.3-C.sub.5 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N; and the C.sub.3-C.sub.9 heterocycloalkenyl is preferably a C.sub.4-C.sub.5 heterocycloalkenyl, wherein the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S, and the C.sub.4-C.sub.5 heterocycloalkenyl is preferably ##STR01038## the ##STR01039## is preferably ##STR01040## the ##STR01041## is preferably ##STR01042## the ##STR01043## is preferably ##STR01044## and the ##STR01045## is preferably ##STR01046## and/or when Q is an unsubstituted or substituted C.sub.6-C.sub.10 aryl, the C.sub.6-C.sub.10 aryl is phenyl; and/or when Q is an unsubstituted or substituted 5-10 membered heteroaryl, the 5-10 membered heteroaryl is a 5-6 membered heteroaryl, and preferably imidazolyl, oxazolyl, furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, pyridinyl, triazolyl or pyrimidinyl, the imidazolyl is preferably ##STR01047## the oxazolyl is preferably ##STR01048## the furanyl is preferably ##STR01049## the thienyl is preferably ##STR01050## the pyrrolyl is preferably ##STR01051## the pyrazolyl is preferably ##STR01052## the isoxazolyl is preferably ##STR01053## the pyridinyl is preferably ##STR01054## the pyrimidinyl is preferably ##STR01055## and the triazolyl is preferably ##STR01056## and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.3-C.sub.10 cycloalkyl, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, the number of substituents is independently 1, 2, 3 or 4; and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.3-C.sub.10 cycloalkyl, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine, or iodine, and preferably fluorine; and/or the C.sub.1-C.sub.6 alkyl in the C.sub.1-C.sub.6 alkyl or the C.sub.1-C.sub.6 alkyl-O— that is unsubstituted or substituted with one or more R.sup.a is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and/or the C.sub.3-C.sub.6 cycloalkyl in the C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or when R.sup.a is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl, ethyl or tert-pentyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, or an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, the C.sub.2-C.sub.6 alkenyl is independently a C.sub.2-C.sub.4 alkenyl, and preferably ethenyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-18, R.sup.1-19, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.2-C.sub.6 alkynyl, the C.sub.2-C.sub.6 alkynyl is ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 1-butynyl or butadiynyl, and preferably ethynyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, the C.sub.3-C.sub.10 cycloalkyl is a C.sub.3-C.sub.6 cycloalkyl, and preferably cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, the C.sub.3-C.sub.9 heterocycloalkyl is a C.sub.3-C.sub.5 heterocycloalkyl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; the C.sub.3-C.sub.9 heterocycloalkyl is preferably a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and the C.sub.3-C.sub.9 heterocycloalkyl is preferably glycidyl, tetrahydrofuranyl, tetrahydropyranyl or tetrahydrothienyl, the glycidyl is preferably ##STR01057## the tetrahydrofuranyl is preferably ##STR01058## the tetrahydropyranyl is preferably ##STR01059## and the tetrahydrothienyl is preferably ##STR01060## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, the C.sub.3-C.sub.9 heterocycloalkenyl is a C.sub.3-C.sub.5 heterocycloalkenyl, wherein the C.sub.3-C.sub.5 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N; and the C.sub.3-C.sub.9 heterocycloalkenyl is preferably a C.sub.4-C.sub.5 heterocycloalkenyl, wherein the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted 5-10 membered heteroaryl, the 5-10 membered heteroaryl is a 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl contains 1-2 heteroatoms selected from one or two of N, O and S; and the 5-10 membered heteroaryl is preferably furanyl or pyridinyl, the furanyl is preferably ##STR01061## and the pyridinyl is preferably ##STR01062## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.2-C.sub.6 alkynyl, a substituted C.sub.3-C.sub.10 cycloalkyl, a substituted phenyl, a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine, and preferably fluorine; and/or when R.sup.d is independently halogen, the halogen is independently fluorine, chlorine, bromine or iodine, and preferably fluorine; and/or the number of R.sup.d is independently 1, 2, 3, or 4, and preferably 1 or 2; and/or the C.sub.1-C.sub.6 alkyl in the C.sub.1-C.sub.6 alkyl or the C.sub.1-C.sub.6 alkyl-O— that is unsubstituted or substituted with one or more R.sup.d is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and/or the C.sub.3-C.sub.6 cycloalkyl in the C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.d is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.2-C.sub.6 alkynyl, a substituted C.sub.3-C.sub.6 cycloalkyl, a substituted phenyl, a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, the number of the substituents is independently 1, 2, 3 or 4, and preferably 1 or 2; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, the C.sub.3-C.sub.9 heterocycloalkyl contains no heteroatom or one heteroatom selected from one of O, S and N in addition to the existing N atom, and is preferably a C.sub.3-C.sub.5 heterocycloalkyl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, the C.sub.3-C.sub.9 heterocycloalkenyl contains no heteroatom or one heteroatom selected from one of O, S and N in addition to the existing N atom, and is preferably a C.sub.3-C.sub.5 heterocycloalkenyl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form an unsubstituted or substituted 5-10 membered heteroaryl, the 5-10 membered heteroaryl contains no heteroatom or one heteroatom selected from one of O, S and N in addition to the existing N atom, and is preferably a 5-6 membered heteroaryl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or the C.sub.1-C.sub.6 alkyl in the C.sub.1-C.sub.6 alkyl or the C.sub.1-C.sub.6 alkyl-O— that is unsubstituted or substituted with one or more R.sup.b is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and/or the C.sub.3-C.sub.6 cycloalkyl in the C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.b is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or when R.sup.b is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form a substituted C.sub.3-C.sub.9 heterocycloalkyl, a substituted C.sub.3-C.sub.9 heterocycloalkenyl or a substituted 5-10 membered heteroaryl, the number of the substituents is independently 1, 2, 3 or 4, and preferably 1 or 2; and/or when R.sup.2-1 or R.sup.2-2 is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.2-1 or R.sup.2-2 is an unsubstituted or substituted C.sub.1-C.sub.6 alkyl or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl; and/or when R.sup.2-1 or R.sup.2-2 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.2-1 or R.sup.2-2 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituent is a C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl in the substituent is independently a C.sub.1-C.sub.4 alkyl; and/or when R.sup.2-1 or R.sup.2-2 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, the number of the substituents is independently 1, 2, 3 or 4, and preferably 1 or 2; and/or when R.sup.2-3, R.sup.2-4, R.sup.2-5 or R.sup.2-6 is an unsubstituted or substituted C.sub.1-C.sub.6 alkyl or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl; and/or when R.sup.2-3, R.sup.2-4, R.sup.2-5 or R.sup.2-6 is an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl or an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl-O—, the C.sub.3-C.sub.8 cycloalkyl is a C.sub.3-C.sub.6 cycloalkyl; and/or when R.sup.2-3, R.sup.2-4, R.sup.2-5 or R.sup.2-6 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.3-C.sub.8 cycloalkyl, a substituted C.sub.3-C.sub.8 cycloalkyl-O— or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.2-3, R.sup.2-4, R.sup.2-5 or R.sup.2-6 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.3-C.sub.8 cycloalkyl, a substituted C.sub.3-C.sub.8 cycloalkyl-O— or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituent is a C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl in the substituent is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl or ethyl; and/or when R.sup.2-3, R.sup.2-4, R.sup.2-5 or R.sup.2-6 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.3-C.sub.8 cycloalkyl, a substituted C.sub.3-C.sub.8 cycloalkyl-O— or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituent is a C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, the number of the substituents is independently 1, 2, 3 or 4, and preferably 1 or 2; and/or when R.sup.2-7 is independently halogen, R.sup.2-7 is independently a halogen-substituted C.sub.1-C.sub.6 alkyl, or R.sup.2-7 is independently a halogen-substituted C.sub.1-C.sub.6 alkyl-O—, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.2-7 is independently an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or R.sup.2-7 is independently an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and/or when R.sup.2-8 or R.sup.2-9 is independently a halogen-substituted C.sub.1-C.sub.6 alkyl, the halogen is independently fluorine, chlorine, bromine or iodine; when R.sup.2-8 or R.sup.2-9 is independently an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl, the C.sub.1-C.sub.6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and/or when R.sup.2 is independently an unsubstituted or substituted 5-6 membered heteroaryl, the 5-6 membered heteroaryl is independently pyridinyl; and/or when R.sup.2 is independently a substituted 5-6 membered heteroaryl that may be substituted with halogen, a halogen-substituted C.sub.1-C.sub.6 alkyl or a halogen-substituted C.sub.1-C.sub.6 alkyl-O—, the halogen in the substituents is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.2 is independently a substituted 5-6 membered heteroaryl that may be substituted with an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl in the substituents is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
3. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 2, wherein when R.sup.1 is a substituted C.sub.1-C.sub.6 alkyl or a substituted C.sub.1-C.sub.6 alkyl-O—, and the substituents are each independently halogen, the C.sub.1-C.sub.6 alkyl in the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is independently —CF.sub.3; and/or when R.sup.3 is a C.sub.1-C.sub.6 haloalkyl, the C.sub.1-C.sub.6 haloalkyl is —CF.sub.3, —CH.sub.2F or —CHF.sub.2; and/or ##STR01063## and preferably ##STR01064## and/or at least one R.sup.1 is located at position α of the linkage between ##STR01065## and Z.sup.2, and preferably, when n is 2, each R.sup.1 is independently located at position α of the linkage between ##STR01066## and Z.sup.2; or at least one R.sup.1 is located at position β of the linkage between ##STR01067## and Z.sup.2, and preferably, when n is 2, each R.sup.1 is independently located at position β of the linkage between ##STR01068## and Z.sup.2; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl is ##STR01069## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl is ##STR01070## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15R.sup.1-16, R.sup.1- 21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.2-C.sub.6 alkynyl, the substituted C.sub.2-C.sub.6 alkynyl is ##STR01071## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.10 cycloalkyl is ##STR01072## and preferably ##STR01073## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each a substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl is ##STR01074## and preferably ##STR01075## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted phenyl, the substituted phenyl is ##STR01076## and preferably ##STR01077## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each an unsubstituted or substituted 5-10 membered heteroaryl, the substituted 5-10 membered heteroaryl is ##STR01078## and preferably ##STR01079## and/or —C(═O)N(R.sup.2-5R.sup.2-6) is —C(═O)NH.sub.2; and/or ##STR01080## and preferably ##STR01081## and/or —C(═O)N(R.sup.2-8R.sup.2-9) is —C(═O)NHCH.sub.3.
4. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 3, wherein the C.sub.1-C.sub.6 alkyl substituted with one or more R.sup.a is ##STR01082## and/or the C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.a is ##STR01083## and preferably ##STR01084## and/or the C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.d is ##STR01085## and preferably ##STR01086## and/or —N(R.sup.1-21R.sup.1-22) is —NHCH.sub.3 or —NH.sub.2; and/or —C(═O)—N(R.sup.1-23R.sup.1-24) is —C(═O)—NH.sub.2 or —C(═O)—NHCH.sub.3; and/or —S(═O).sub.2—N(R.sup.1-25R.sup.1-26) is —S(═O).sub.2—NH.sub.2; and/or —C(═O)—O—R.sup.1-27 is —COOH, —COOC.sub.2H.sub.5 or —COOCH.sub.3; and/or when R.sup.2 is independently an unsubstituted or substituted 5-6 membered heteroaryl, the substituted 5-6 membered heteroaryl is independently ##STR01087##
5. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 4, wherein when ##STR01088## is phenyl, ##STR01089## wherein R.sup.1′ has the definition as described for R.sup.1, and R.sup.1′ is the same as or different from R.sup.1; preferably ##STR01090## and more preferably ##STR01091## and/or when the ##STR01092## is a 5-6 membered heteroaryl, the ##STR01093## and preferably ##STR01094## and/or —NH—C(═O)—R.sup.1-1 is —NH—C(═O)—CH.sub.3, —NH—C(═O)—O—CH.sub.3, ##STR01095## and/or —C(═O)—R.sup.1-2 is —C(═O)—CH.sub.3 or —C(═O)—O—CH.sub.3; and/or —O—C(═O)—N(R.sup.1-3R.sup.1-4) is —O—C(═O)—NH—CH.sub.3; and/or —C(═O)—N(R.sup.1-5R.sup.1-6) is —C(═O)—NH—CH.sub.3; and/or —C(═NH)—N(R.sup.1-7R.sup.1-8) is —C(═NH)—NH—CH.sub.3; and/or —S(═O).sub.2—N(R.sup.1-9R.sup.1-10) is —S(═O).sub.2—NH—CH.sub.3 or —SO.sub.2NH.sub.2; and/or —O—C(═O)—R.sup.1-13 is —O—C(═O)—NH—CH.sub.3; and/or —N(R.sup.1-14R.sup.1-15) is —NH.sub.2, ##STR01096## and/or —NH—S(═O).sub.2—R.sup.1-16 is —NH—S(═O).sub.2—CH.sub.3; and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl is ##STR01097## and/or when Q is a substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.10 cycloalkyl is ##STR01098## and preferably ##STR01099## and/or when Q is a substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl is ##STR01100## and preferably ##STR01101## and/or when Q is a substituted C.sub.3-C.sub.9 heterocycloalkenyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl is ##STR01102## and preferably ##STR01103## and/or when Q is a substituted 5-6 membered heteroaryl, the substituted 5-10 membered heteroaryl is ##STR01104## ##STR01105## ##STR01106## ##STR01107## ##STR01108## and/or when R.sup.2 is ##STR01109## one of X and Y is ##STR01110## and the other is a single bond, methylene or —O—; preferably X is —O—; and more preferably R.sup.2 is ##STR01111## or when R.sup.2 is ##STR01112## X or Y is —N(R.sup.2-3)—; preferably one of X and Y is —N(R.sup.2-3)—, and the other is —O—, —N(R.sup.2-3)— or ##STR01113## and more preferably R.sup.2 is ##STR01114##
6. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 5, wherein ##STR01115## and preferably ##STR01116## ##STR01117## and/or Q is H, —OH, —CF.sub.3, —CN, —NH.sub.2, —NH—C(═O)—CH.sub.3, —NH—C(═O)—O—CH.sub.3, ##STR01118## —C(═O)—CH.sub.3, —C(═O)—C.sub.2H.sub.5, —C(═O)—O—CH.sub.3, —O—C(═O)—NH—CH.sub.3, —C(═O)—NH—CH.sub.3, —C(═NH)—NH—CH.sub.3, —S(═O).sub.2—NH—CH.sub.3, —S(═O).sub.2—NH.sub.2, ##STR01119## ##STR01120## ##STR01121## ##STR01122## ##STR01123## ##STR01124## and/or R.sup.2 is ##STR01125## and more preferably ##STR01126##
7. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein R.sup.3 is halogen, —CHF.sub.2, —CH.sub.2F or a C.sub.1-C.sub.6 alkyl; Q is —NH—C(═O)—R.sup.1-1, —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16 an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: —N(R.sup.1-21R.sup.1-22), —C(═O)—N(R.sup.1-23R.sup.1-24), —S(═O).sub.2—N(R.sup.1-25R.sup.1-26) or —C(═O)—O—R.sup.1-27, wherein when a plurality of substituents are present, they are the same or different; R.sup.1-1, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1-21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkynyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.2-C.sub.6 alkynyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CN, ═O, —COOH, —C(═O)NH.sub.2, —COOCH.sub.3, —NH.sub.2, and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.d, wherein when a plurality of R.sup.d are present, they are the same or different, and each R.sup.d is independently H, halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; or R.sup.3 is halogen, a C.sub.1-C.sub.6 haloalkyl or a C.sub.1-C.sub.6 alkyl; Q is —NH—C(═O)—R.sup.1-1, —C(═O)—N(R.sup.1-5R.sup.1-6), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: —OH, —CF.sub.3, —CN, —N(R.sup.1-21R.sup.1-22), —C(═O)—N(R.sup.1-23R.sup.1-24), —S(═O).sub.2—N(R.sup.1-25R.sup.1-26), —C(═O)—O—R.sup.1-27, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.a are present, they are the same or different, and each R.sup.a is halogen, —OH or —COOH; and when a plurality of substituents are present, they are the same or different; R.sup.2 is independently ##STR01127## —C(═O)N(R.sup.2-5R.sup.2-6) or an unsubstituted or substituted 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S, and the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CN, an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or halogen-substituted C.sub.1-C.sub.6 alkyl-O—, —C(═O)R.sup.2-7 or —C(═O)N(R.sup.2-8R.sup.2-9), wherein when a plurality of substituents are present, they are the same or different.
8. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I is embodiment I or embodiment II, embodiment I: ##STR01128## is a 5 membered heteroaryl or a 5 membered heterocycloalkenyl, wherein the 5 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 5 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S; ##STR01129## is phenyl, a 5-6 membered heterocycloalkyl, a 5-6 membered heterocycloalkenyl, or a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkyl contains 1-3 heteroatoms selected from one or more of N, O and S, the 5-6 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, Z.sup.5, Z.sup.6, Z.sup.7, Z.sup.8 and Z.sup.9 independently represent a ring atom; and when ##STR01130## is a 5 membered heterocycloalkyl, a 5 membered heterocycloalkenyl or a 5 membered heteroaryl, Z.sup.6 or Z.sup.9 represents a single bond; m is 1, 2, 3 or 4; R.sup.3 is H, halogen, —OH, a C.sub.1-C.sub.6 haloalkyl, —CN or a C.sub.1-C.sub.6 alkyl; when m is not 1, R.sup.3 is independently the same or different; or when two adjacent R.sup.3 are present, they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.6 cycloalkyl, a C.sub.3-C.sub.6 cycloalkenyl, a C.sub.3-C.sub.9 heterocycloalkyl, a C.sub.3-C.sub.9 heterocycloalkenyl, phenyl or a 5-6 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of O, S and N; W is a single bond or —C(═O)—NH—; ##STR01131## is phenyl, a 5-6 membered heteroaryl, or a C.sub.3-C.sub.9 heterocycloalkyl, wherein the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S, and the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; n is 1, 2, 3 or 4; R.sup.1 is independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O); when a plurality of substituents are present, they are the same or different; and when n is not 1, R.sup.1 is independently the same or different; Q is H, halogen, —OH, —CF.sub.3, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═O)—N(R.sup.1-5R.sup.1-6), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13, —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of O, S and N; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.6-C.sub.10 aryl, the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), —N(R.sup.1-21R.sup.1-22), —C(═O)—N(R.sup.1-23R.sup.1-24), —S(═O).sub.2—N(R.sup.1-25R.sup.1-26), —C(═O)—O—R.sup.1-27, and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.a are present, they are the same or different, and each R.sup.a is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12, R.sup.1-13, R.sup.1-14, R.sup.1-15, R.sup.1-16, R.sup.1- 21, R.sup.1-22, R.sup.1-23, R.sup.1-24, R.sup.1-25, R.sup.1-26 and R.sup.1-27 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkynyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted phenyl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.9 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-10 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.2-C.sub.6 alkynyl, the substituted C.sub.3-C.sub.10 cycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl, the substituted phenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —COOCH.sub.3, —NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.d, wherein when a plurality of R.sup.d are present, they are the same or different, and each R.sup.d is independently H, halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; or R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, R.sup.1-11 and R.sup.1-12, R.sup.1-14 and R.sup.1-15, R.sup.1-21 and R.sup.1-22, R.sup.1-23 and R.sup.1-24, or R.sup.1-25 and R.sup.1-26, independently together with the N atom to which they directly link, form an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, or an unsubstituted or substituted 5-10 membered heteroaryl, wherein the C.sub.3-C.sub.9 heterocycloalkyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom, the C.sub.3-C.sub.9 heterocycloalkenyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom, the 5-10 membered heteroaryl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom; and the substituted C.sub.3-C.sub.9 heterocycloalkyl, the substituted C.sub.3-C.sub.9 heterocycloalkenyl or the substituted 5-10 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O—, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.b, wherein when a plurality of R.sup.b are present, they are the same or different, and each R.sup.b is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.2 is ##STR01132## or —C(═O)N(R.sup.2-5R.sup.2-6); R.sup.2-1 and R.sup.2-2 are each independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O); wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and when a plurality of substituents are present, they are the same or different; X and Y are each independently a single bond, methylene, —O—, —N(R.sup.2-3)— or ##STR01133## R.sup.2-3, R.sup.2-4, R.sup.2-5 and R.sup.2-6 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl-O—, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.3-C.sub.8 cycloalkyl, the substituted C.sub.3-C.sub.8 cycloalkyl-O— or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and when a plurality of substituents are present, they are the same or different; embodiment II: ##STR01134## is a 5 membered heteroaryl or a 5 membered heterocycloalkenyl, wherein the 5 membered heteroaryl contains 1-2 heteroatoms selected from one or more of N, O and S, and the 5 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S; ##STR01135## is phenyl, a 5-6 membered heterocycloalkyl, a 5-6 membered heterocycloalkenyl, or a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkyl contains 1-3 heteroatoms selected from one or more of N, O and S, the 5-6 membered heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of N, O and S, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, Z.sup.5, Z.sup.6, Z.sup.7, Z.sup.8 and Z.sup.9 independently represent a ring atom; and when ##STR01136## is a 5 membered heterocycloalkyl, a 5 membered heterocycloalkenyl or a 5 membered heteroaryl, Z.sup.6 or Z.sup.9 represents a single bond; m is 1, 2, 3 or 4; R.sup.3 is H, halogen, —OH, —CF.sub.3, —CN or a C.sub.1-C.sub.6 alkyl; when m is not 1, R.sup.3 is the same or different; or when two adjacent R.sup.3 are present, they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.6 cycloalkyl, a C.sub.3-C.sub.6 cycloalkenyl, a C.sub.3-C.sub.5 heterocycloalkyl, a C.sub.3-C.sub.5 heterocycloalkenyl, phenyl or a 5-6 membered heteroaryl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.5 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of O, S and N; W is a single bond or —C(═O)—NH—; ##STR01137## is phenyl, a 5-6 membered heteroaryl, or a C.sub.3-C.sub.5 heterocycloalkyl, wherein the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S, and the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N; n is 1, 2, 3 or 4; R.sup.1 is independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O; when a plurality of substituents are present, they are the same or different; and when n is not 1, R.sup.1 is the same or different; Q is H, halogen, —OH, —CF.sub.3, —CN, —NH.sub.2, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═O)—N(R.sup.1-5R.sup.1-6), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, or an unsubstituted or substituted 5-6 membered heteroaryl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.5 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.6-C.sub.10 aryl, the substituted C.sub.3-C.sub.8 heterocycloalkyl, the substituted C.sub.3-C.sub.8 heterocycloalkenyl or the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.a are present, they are the same or different, and each R.sup.a is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 and R.sup.1-13 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.3-C.sub.6 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, an unsubstituted or substituted phenyl, or an unsubstituted or substituted 5-6 membered heteroaryl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains 1-3 heteroatoms selected from one or more of O, S and N, the C.sub.3-C.sub.5 heterocycloalkenyl contains 1-3 heteroatoms selected from one or more of O, S and N, and the 5-6 membered heteroaryl contains 1-3 heteroatoms selected from one or more of N, O and S; and the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.3-C.sub.6 cycloalkyl, the substituted C.sub.3-C.sub.5 heterocycloalkyl, the substituted C.sub.3-C.sub.5 heterocycloalkenyl, the substituted phenyl or the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O—, a C.sub.3-C.sub.6 cycloalkyl, —COOH or ═O, wherein when a plurality of substituents are present, they are the same or different; or R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, or R.sup.1-11 and R.sup.1-12, independently together with the N atom to which they directly link, form an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, or an unsubstituted or substituted 5-6 membered heteroaryl, wherein the C.sub.3-C.sub.5 heterocycloalkyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom, the C.sub.3-C.sub.8 heterocycloalkenyl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom, and the 5-6 membered heteroaryl contains no heteroatom or 1-2 heteroatoms selected from one or more of O, S and N in addition to the existing N atom; and the substituted C.sub.3-C.sub.5 heterocycloalkyl, the substituted C.sub.3-C.sub.5 heterocycloalkenyl or the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O—, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.b are present, they are the same or different, and each R.sup.b is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; R.sup.2 is ##STR01138## or —C(═O)N(R.sup.2-5R.sup.2-6); R.sup.2-1 and R.sup.2-2 are each independently H, halogen, —OH, —CN, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, or ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O); wherein the substituted C.sub.1-C.sub.6 alkyl or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O, and when a plurality of substituents are present, they are the same or different; X and Y are each independently a single bond, methylene, —O—, —N(R.sup.2-3)— or ##STR01139## R.sup.2-3, R.sup.2-4, R.sup.2-5 and R.sup.2-6 are each independently H, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.8 cycloalkyl-O—, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—; wherein the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.3-C.sub.8 cycloalkyl, the substituted C.sub.3-C.sub.8 cycloalkyl-O— or the substituted C.sub.1-C.sub.6 alkyl-O— is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or ═O, and when a plurality of substituents are present, they are the same or different.
9. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 8, wherein when ##STR01140## is a 5 membered heteroaryl, the 5 membered heteroaryl is pyrrolyl, furanyl, thienyl or imidazolyl, the pyrrolyl is preferably ##STR01141## the furanyl is preferably ##STR01142## the imidazolyl is preferably ##STR01143## the thienyl is preferably ##STR01144## and the pyrazolyl is preferably ##STR01145## and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.5 heterocycloalkyl, the C.sub.3-C.sub.5 heterocycloalkyl is a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when two adjacent R.sup.3 are present and they, together with the ring atom to which they directly link, form a C.sub.3-C.sub.5 heterocycloalkenyl, the C.sub.3-C.sub.5 heterocycloalkenyl is a C.sub.4-C.sub.5 heterocycloalkenyl, and the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when ##STR01146## is a C.sub.3-C.sub.5 heterocycloalkyl, the C.sub.3-C.sub.5 heterocycloalkyl is a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S, and the C.sub.4-C.sub.5 heterocycloalkyl is preferably piperidinyl, the piperidinyl is preferably ##STR01147## and more preferably ##STR01148## and/or when Q is an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, the C.sub.3-C.sub.5 heterocycloalkyl is a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and the C.sub.3-C.sub.5 heterocycloalkyl is preferably pyrrolidinyl or piperazinyl, the pyrrolidinyl is preferably ##STR01149## and the piperazinyl is preferably ##STR01150## and/or when Q is an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, the C.sub.3-C.sub.5 heterocycloalkenyl is a C.sub.4-C.sub.5 heterocycloalkenyl, wherein the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S, and the C.sub.4-C.sub.5 heterocycloalkenyl is preferably 2,5-dihydro-1H-pyrrolyl, and more preferably ##STR01151## and/or when Q is an unsubstituted or substituted 5-6 membered heteroaryl, the 5-6 membered heteroaryl is imidazolyl, oxazolyl, furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, pyridinyl or pyrimidinyl, the imidazolyl is preferably ##STR01152## the oxazolyl is preferably ##STR01153## the furanyl is preferably ##STR01154## the thienyl is preferably ##STR01155## the pyrrolyl is preferably ##STR01156## the pyrazolyl is preferably ##STR01157## the isoxazolyl is preferably ##STR01158## the pyridinyl is preferably ##STR01159## and the pyrimidinyl is preferably ##STR01160## and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine, and preferably fluorine; and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.1-C.sub.6 alkyl or a C.sub.1-C.sub.6 alkyl-O— substituted with one or more R.sup.a, the C.sub.1-C.sub.6 alkyl in the substituent is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl; and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.a, the C.sub.3-C.sub.6 cycloalkyl in the substituent is cyclopropyl; and/or when Q is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted C.sub.6-C.sub.10 aryl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, the substituent is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.a, and R.sup.a is halogen, the halogen is independently fluorine, chlorine, bromine or iodine; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl is independently a C.sub.1-C.sub.4 alkyl, and preferably methyl or ethyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, the C.sub.3-C.sub.5 heterocycloalkyl is a C.sub.4-C.sub.5 heterocycloalkyl, wherein the C.sub.4-C.sub.5 heterocycloalkyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, the C.sub.3-C.sub.5 heterocycloalkenyl is a C.sub.4-C.sub.5 heterocycloalkenyl, and the C.sub.4-C.sub.5 heterocycloalkenyl contains 1-2 heteroatoms selected from one or more of N, O and S; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is an unsubstituted or substituted 5-6 membered heteroaryl, the 5-6 membered heteroaryl contains 1-2 heteroatoms selected from one or two of N, O and S; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted phenyl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is halogen, the halogen is independently fluorine, chlorine, bromine or iodine, and preferably fluorine; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted phenyl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.1-C.sub.6 alkyl or a C.sub.1-C.sub.6 alkyl-O—, the C.sub.1-C.sub.6 alkyl in the substituent is independently a C.sub.1-C.sub.4 alkyl; and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is a substituted C.sub.1-C.sub.6 alkyl, a substituted C.sub.1-C.sub.6 alkyl-O—, a substituted C.sub.2-C.sub.6 alkenyl, a substituted C.sub.2-C.sub.6 alkenyl-O—, a substituted phenyl, a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.3-C.sub.6 cycloalkyl, the C.sub.3-C.sub.6 cycloalkyl in the substituent is cyclopropyl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, or R.sup.1-11 and R.sup.1-12, independently together with the N atom to which they directly link, form a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.1-C.sub.6 alkyl or a C.sub.1-C.sub.6 alkyl-O— substituted with one or more R.sup.b, the C.sub.1-C.sub.6 alkyl in the substituent is independently a C.sub.1-C.sub.4 alkyl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, or R.sup.1-11 and R.sup.1-12, independently together with the N atom to which they directly link, form a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, and the substituent is a C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.b, the C.sub.3-C.sub.6 cycloalkyl in the substituent is cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; and/or when R.sup.1-3 and R.sup.1-4, R.sup.1-5 and R.sup.1-6, R.sup.1-7 and R.sup.1-8, R.sup.1-9 and R.sup.1-10, or R.sup.1-11 and R.sup.1-12, independently together with the N atom to which they directly link, form a substituted C.sub.3-C.sub.5 heterocycloalkyl, a substituted C.sub.3-C.sub.5 heterocycloalkenyl, or a substituted 5-6 membered heteroaryl, the substituent is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl substituted with one or more R.sup.b, wherein when R.sup.b is halogen, the halogen is independently fluorine, chlorine, bromine or iodine.
10. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 9, wherein ##STR01161## and preferably ##STR01162## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13, is a substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl is ##STR01163## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is a substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl is ##STR01164## and/or when R.sup.1-1, R.sup.1-2, R.sup.1-3, R.sup.1-4, R.sup.1-5, R.sup.1-6, R.sup.1-7, R.sup.1-8, R.sup.1-9, R.sup.1-10, R.sup.1-11, R.sup.1-12 or R.sup.1-13 is a substituted C.sub.3-C.sub.6 cycloalkyl, the substituted C.sub.3-C.sub.6 cycloalkyl is ##STR01165##
11. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 10, wherein when Q is a substituted C.sub.3-C.sub.5 heterocycloalkyl, the substituted C.sub.3-C.sub.5 heterocycloalkyl is ##STR01166## and/or when Q is a substituted C.sub.3-C.sub.5 heterocycloalkenyl, the substituted C.sub.3-C.sub.5 heterocycloalkenyl is ##STR01167## and/or when Q is a substituted 5-6 membered heteroaryl, the substituted 5-6 membered heteroaryl is ##STR01168## and/or when Q is —NH—C(═O)—R.sup.1-1, the —NH—C(═O)—R.sup.1-1 is —NH—C(═O)—CH.sub.3, —NH—C(═O)—O—CH.sub.3, ##STR01169## and/or when Q is —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), the —S(═O).sub.2—N(R.sup.1-9R.sup.1-10) is —S(═O).sub.2—NH—CH.sub.3; and/or when R.sup.2 is ##STR01170## one of X and Y is ##STR01171## and the other is a single bond, methylene or —O—; preferably X is —O—; and more preferably R.sup.2 is ##STR01172## or when R.sup.2 is ##STR01173## X or Y is —N(R.sup.2-3)—; preferably one of X and Y is —N(R.sup.2-3)—, and the other is —O—, —N(R.sup.2-3)— or ##STR01174## and more preferably R.sup.2 is ##STR01175##
12. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 11, wherein ##STR01176## and preferably ##STR01177## and/or ##STR01178## and/or Q is H, —OH, —CF.sub.3, —CN, —NH—C(═O)—CH.sub.3, —NH—C(═O)—O—CH.sub.3, ##STR01179## —C(═O)—CH.sub.3, —C(═O)—C.sub.2H.sub.5, —C(═O)—O—CH.sub.3, —O—C(═O)—NH—CH.sub.3, —C(═O)—NH—CH.sub.3, —C(═NH)—NH—CH.sub.3, —S(═O).sub.2—NH—CH.sub.3, ##STR01180## and/or R.sup.2 is ##STR01181## and preferably ##STR01182##
13. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I is of formula I-A as shown below: ##STR01183## wherein ##STR01184## preferably, the heterocyclic compound of formula I is of formula I-A-1 as shown below ##STR01185## wherein R.sup.1′ has the definition as described for R.sup.1, R.sup.1′ is the same as or different from R.sup.1, and W is a single bond; and more preferably, the heterocyclic compound of formula I is of formula I-A-2 as shown below: ##STR01186## wherein X is a single bond, methylene or —O—; or the heterocyclic compound of formula I is of formula I-B as shown below: ##STR01187## wherein R.sup.2 is ##STR01188## or —C(═O)N(R.sup.2-5R.sup.2-6), and X or Y is —N(R.sup.2-3)—; preferably, the heterocyclic compound of formula I is of formula I-B-1 as shown below: ##STR01189## wherein R.sup.1′ has the definition as described for R.sup.1, R.sup.1′ is the same as or different from R.sup.1, and W is a single bond; and more preferably, the heterocyclic compound of formula I is of formula I-B-2 as shown below: ##STR01190## or the heterocyclic compound of formula I is of formula I-C as shown below: ##STR01191## wherein Q is H, halogen, —OH, —CF.sub.3, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13, —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16 an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, or an unsubstituted or substituted 5-10 membered heteroaryl; preferably, the heterocyclic compound of formula I is of formula I-C-1 as shown below: ##STR01192## and more preferably, the heterocyclic compound of formula I is of formula I-C-2 as shown below: ##STR01193## wherein R.sup.1′ has the definition as described for R.sup.1, R.sup.1′ is the same as or different from R.sup.1, and X is a single bond, methylene or —O—; or the heterocyclic compound of formula I is of formula I-C′ as shown below: ##STR01194## wherein Q is H, halogen, —OH, —CF.sub.3, —CN, —NH.sub.2, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13 an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.5 heterocycloalkenyl, or an unsubstituted or substituted 5-6 membered heteroaryl; preferably, the heterocyclic compound of formula I is of formula I-C′-1 as shown below: ##STR01195## and more preferably, the heterocyclic compound of formula I is of formula I-C′-2 as shown below: ##STR01196## wherein R.sup.1′ has the definition as described for R.sup.1, and R.sup.1′ is the same as or different from R.sup.1; or the heterocyclic compound of formula I is of formula I-D as shown below: ##STR01197## wherein ##STR01198## is a 5-6 membered heteroaryl or a C.sub.3-C.sub.5 heterocycloalkyl; preferably, the heterocyclic compound of formula I is of formula I-D-1 as shown below: ##STR01199## and more preferably, the heterocyclic compound of formula I is of formula I-D-2 as shown below: ##STR01200## wherein X is a single bond, methylene or —O—, and W is a single bond; or the heterocyclic compound of formula I is of formula I-E as shown below: ##STR01201## wherein R.sup.2 is independently ##STR01202## or an unsubstituted or substituted 5-6 membered heteroaryl; for example, W is a single bond; preferably, the heterocyclic compound of formula I is of formula I-E-1 as shown below: ##STR01203## for example, ##STR01204## is phenyl or 6 membered heteroaryl; and more preferably, the heterocyclic compound of formula I is of formula I-E-2 as shown below: ##STR01205## for example, ##STR01206## is phenyl.
14. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein ##STR01207## is a 5 membered heteroaryl; and/or ##STR01208## is phenyl, a 6 membered heterocycloalkyl, a 6 membered heterocycloalkenyl, or a 6 membered heteroaryl; and/or m is 1 or 2; and/or R.sup.3 is H, halogen, —OH, a C.sub.1-C.sub.6 haloalkyl or a C.sub.1-C.sub.6 alkyl; and/or W is a single bond; and/or n is 1 or 2; and/or R.sup.1 is independently H, halogen, —OH, —CN or an unsubstituted or substituted C.sub.1-C.sub.6 alkyl; and/or the substituent in R.sup.1 is independently one or more selected from the following: halogen, —OH, —CN or —C(═O)NH.sub.2; and/or Q is H, halogen, —OH, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═O)—N(R.sup.1-5R.sup.1-6), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, or an unsubstituted or substituted 5-10 membered heteroaryl, and preferably H, halogen, —OH, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═O)—N(R.sup.1-5R.sup.1-6), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, or an unsubstituted or substituted 5-10 membered heteroaryl; and/or the substituted C.sub.1-C.sub.6 alkyl, the substituted C.sub.1-C.sub.6 alkyl-O—, the substituted C.sub.2-C.sub.6 alkenyl, the substituted C.sub.2-C.sub.6 alkenyl-O—, the substituted C.sub.6-C.sub.10 aryl, the substituted C.sub.3-C.sub.5 heterocycloalkyl, the substituted C.sub.3-C.sub.5 heterocycloalkenyl or the substituted 5-6 membered heteroaryl is substituted with one or more substituents independently selected from the following: halogen, —OH, —CF.sub.3, —CN, —COOH, —C(═O)NH.sub.2, ═O (i.e., two geminal hydrogens on a carbon atom are substituted with the group O), and a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkyl-O— or a C.sub.3-C.sub.6 cycloalkyl that is unsubstituted or substituted with one or more R.sup.a, wherein when a plurality of R.sup.a are present, they are the same or different, and each R.sup.a is halogen, —OH, ═O, —CF.sub.3, —CN, —COOH or —C(═O)NH.sub.2; and when a plurality of substituents are present, they are the same or different; and/or R.sup.2 is independently ##STR01209## or —C(═O)N(R.sup.2-5R.sup.2-6).
15. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I is the following embodiments: embodiment I: when Q is H, halogen, —OH, —CF.sub.3, —CN, —NH—C(═O)—R.sup.1-1, —C(═O)—R.sup.1-2, —O—C(═O)—N(R.sup.1-3R.sup.1-4), —C(═NH)—N(R.sup.1-7R.sup.1-8), —S(═O).sub.2—N(R.sup.1-9R.sup.1-10), —S(═O)—N(R.sup.1-11R.sup.1-12), —O—C(═O)—R.sup.1-13, —N(R.sup.1-14R.sup.1-15), —NH—S(═O).sub.2—R.sup.1-16 an unsubstituted or substituted C.sub.1-C.sub.6 alkyl, an unsubstituted or substituted C.sub.1-C.sub.6 alkyl-O—, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl, an unsubstituted or substituted C.sub.2-C.sub.6 alkenyl-O—, an unsubstituted or substituted C.sub.3-C.sub.10 cycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkyl, an unsubstituted or substituted C.sub.3-C.sub.9 heterocycloalkenyl, an unsubstituted or substituted C.sub.6-C.sub.10 aryl, or an unsubstituted or substituted 5-10 membered heteroaryl, ##STR01210## or R.sup.2 is ##STR01211## wherein X and Y are each independently a single bond, methylene, —O— or ##STR01212## or embodiment II: when ##STR01213## or R.sup.2 is independently ##STR01214## —C(═O)N(R.sup.2-5R.sup.2-6) or an unsubstituted or substituted 5-6 membered heteroaryl, wherein X or Y is —N(R.sup.2-3)—.
16. The heterocyclic compound of formula I or the stereoisomer, the geometric isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the ester, the pharmaceutically acceptable salt or the prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I is preferably any one of the following compounds: ##STR01215## ##STR01216## ##STR01217## ##STR01218## ##STR01219## ##STR01220## ##STR01221## ##STR01222## ##STR01223## ##STR01224## ##STR01225## ##STR01226## ##STR01227## ##STR01228## ##STR01229## ##STR01230## ##STR01231## ##STR01232## ##STR01233## ##STR01234## ##STR01235## ##STR01236## ##STR01237## ##STR01238## ##STR01239## ##STR01240## ##STR01241## ##STR01242## ##STR01243## ##STR01244## ##STR01245## ##STR01246## ##STR01247## ##STR01248## ##STR01249## ##STR01250## ##STR01251## ##STR01252## ##STR01253## ##STR01254## ##STR01255## ##STR01256## ##STR01257## ##STR01258## ##STR01259## ##STR01260## ##STR01261## ##STR01262## and the pharmaceutically acceptable salt of the heterocyclic compound of the formula I is the following compound: ##STR01263##
17. A preparation method of the heterocyclic compound of formula I according to claim 1, wherein the preparation method is Scheme I, Scheme II, Scheme III, Scheme IV, Scheme V, Scheme VI, Scheme VII or Scheme VIII, wherein Scheme I comprises the following step: performing Stille coupling reaction as shown below on a compound of formula II-1 and an organic tin reagent of formula III-1 in an organic solvent in the presence of a catalyst to give the heterocyclic compound of formula I: ##STR01264## wherein X.sup.1 is Br or Cl; Scheme II comprises the following step: performing Suzuki coupling reaction as shown below on a compound of formula II-2 and a compound of formula III-2 in a solvent in the presence of a catalyst and a basic reagent to give the heterocyclic compound of formula I: ##STR01265## wherein X.sup.2 is Br or Cl; Scheme III comprises the following step: performing the reaction as shown below on a compound of formula II-3, a compound of formula III-3 and formaldehyde in an organic solvent to give the heterocyclic compound of formula I: ##STR01266## Scheme IV comprises the following step: performing the reaction as shown below on a compound of formula II-3 and a compound of formula III-4 in an organic solvent to give the heterocyclic compound of formula I: ##STR01267## wherein X.sup.3 is a leaving group; Scheme V comprises the following step: performing amidation reaction as shown below on a compound of formula I, wherein R.sup.2 is ##STR01268## and Y is —NH—, and a compound of formula III-5 in an organic solvent in the presence of a basic reagent to give the heterocyclic compound of formula I, wherein Y is ##STR01269## ##STR01270## wherein X.sup.4 is halogen; Scheme VI comprises the following step: performing deprotection reaction as shown below on a compound of formula II-4 and a compound of formula III-5 in an organic solvent in the presence of an acid to give the heterocyclic compound of formula I: ##STR01271## wherein Y is —NH—; Scheme VII comprises the following step: performing substitution reaction as shown below on a compound of formula II-5 and NH(R.sup.1-9R.sup.1-10) in an organic solvent to give the heterocyclic compound of formula I, wherein Q is —S(═O).sub.2—N(R.sup.1-9R.sup.1-10): ##STR01272## wherein X.sup.5 is Br or Cl; Scheme VIII comprises the following step: performing deprotection reaction as shown below on a compound of formula II-6 or formula II-6′ in an organic solvent in the presence of an acid to give the heterocyclic compound of formula I: ##STR01273## wherein X.sup.6, X.sup.6′ and X.sup.6″ are N protecting groups; and the ##STR01274## R.sup.3, R.sup.2, R.sup.1, W, X, Y, R.sup.2-1, R.sup.2-2, n and m have the definitions as defined in claim 1.
18. A compound of formula II-1, II-2, II-3, II-4, II-5, II-6 or II-6′: ##STR01275## ##STR01276## wherein the ##STR01277## R.sup.3, R.sup.2, R.sup.1, W, X, Y, R.sup.2-1, R.sup.2-2, n and m have the definitions as defined in claim 1 and X.sup.1 is Br or Cl, X.sup.5 is Br or Cl, X.sup.6, X.sup.6′ and R.sup.6″ are N protecting groups.
19. Compounds as shown below: ##STR01278## ##STR01279## ##STR01280## ##STR01281## ##STR01282## ##STR01283## ##STR01284## ##STR01285## ##STR01286## ##STR01287## ##STR01288## ##STR01289## ##STR01290## ##STR01291## ##STR01292## ##STR01293## ##STR01294## ##STR01295## ##STR01296## ##STR01297## ##STR01298## ##STR01299## ##STR01300## ##STR01301## ##STR01302## ##STR01303## ##STR01304## ##STR01305## ##STR01306## ##STR01307## ##STR01308## ##STR01309## ##STR01310## ##STR01311## ##STR01312## ##STR01313## ##STR01314## ##STR01315## ##STR01316##
20. A pharmaceutical composition comprising the heterocyclic compound of formula I or the pharmaceutically acceptable salt, the hydrate, the solvate, the metabolite, the stereoisomer, the tautomer or the prodrug thereof according to claim 1.
21. (canceled)
22. A method for preventing, dealing with, treating or ameliorating a disease in a mammal mediated at least in part by P2X3 or associated with P2X3 activity, comprising administering the pharmaceutical composition of claim 20 to a subject in need thereof.
23. The method according to claim 22, wherein the disease is a pain, a urinary tract disease, or a respiratory disease, wherein the pain is inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain resulting from burns, migraine, or cluster headache; the urinary tract disease is urinary incontinence, overactive bladder, dysuria or cystitis; and the respiratory disease is idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, bronchospasm, or chronic cough.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0480]
[0481]
[0482]
[0483]
[0484]
[0485]
[0486]
[0487]
DETAILED DESCRIPTION
[0488] The present invention is further illustrated by the following examples, which are not intended to limit the invention thereto. Experimental procedures without specifying specific conditions in the following examples are conducted in accordance with conventional procedures and conditions, or in accordance with commercial instructions.
[0489] The following abbreviations are used throughout the present invention:
[0490] TEMPO (2,2,6,6-tetramethyl-1-piperidone), LDA (lithium diisopropylamide), DMF (N,N-dimethylformamide), DMA (N,N-dimethylacetamide), DCM (dichloromethane), DME (dimethoxyethane), PE (petroleum ether), EA (ethyl acetate), DIPEA (N,N-diisopropylethylamine), THF (tetrahydrofuran), Ac (acetyl), MeOH (methanol), Boc (tert-butoxycarbonyl), B2Pin2 (bis(pinacolato)diboron), rt (room temperature), HATU (2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), reflux (refluxing conditions), eq (equivalent), Rf (retardation factor), g (gram), mg (milligram), mol (mole), mmol (millimole), h (hour), min (minute), mL (milliliter), μL (microliter).
[0491] Overnight refers to 8-15 h, for example 12 h; the room temperature refers to 10-30° C.; solvent ratio such as PE/EA refers to the volume ratio.
[0492] Unless otherwise indicated, all temperatures in the examples described below are given in Celsius degrees. Unless otherwise indicated, reagents are purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company, and used without further purification. General reagents are purchased from Shantou Xilong Chemical Plant Co. Ltd., Guangdong Guanghua Chemical Reagent Factory, Guangzhou Chemical Reagent Factory, Tianjin Haoyuyu Chemical Co., Ltd., Qingdao Tenglong Chemical Reagent Co., Ltd., and Qingdao Haiyang Chemical Co., Ltd.
[0493] Anhydrous tetrahydrofuran, dioxane, toluene and diethyl ether are obtained by refluxing and drying with metal sodium. Anhydrous dichloromethane and chloroform are obtained by refluxing and drying with calcium hydride. Ethyl acetate, petroleum ether, n-hexane, N,N-dimethylacetamide and N,N-dimethylformamide are pre-dried over anhydrous sodium sulfate.
[0494] The following reactions are generally conducted under a positive pressure of nitrogen or argon or by placing a drying tube over an anhydrous solvent (unless otherwise indicated), the reaction flask is stoppered with a suitable rubber stopper and the substrate is driven in by a syringe. Each piece of glassware is dried.
[0495] Chromatographic column is a silica gel column. Silica gel (300-400 mesh) is purchased from Qingdao Haiyang Chemical Co., Ltd. NMR spectral data are measured on a Bruker Avance 400 NMR spectrometer or a Bruker Avance IIIHD 600 NMR spectrometer using CDCl.sub.3, DMSO-d6, CD.sub.3OD or Acetone-d6 as solvents (reported in ppm) and TMS (0 ppm) or chloroform (7.25 ppm) as reference standards. When multiple peaks are present, the following abbreviations will be used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), ddd (doublet of doublet of doublets), ddt (doublet of doublet of triplets), dddd (doublet of doublet of doublet of doublets). Coupling constants are expressed in hertz (Hz).
[0496] Low-Resolution Mass Spectrometry (MS) data are determined on an Agilent 6320 series LC-MS spectrometer equipped with a G1312A binary pump and an a G1316ATCC (column temperature maintained at 30° C.), with a G1329A autosampler and G1315BDAD detector applied to the analysis and an ESI source applied to the LC-MS spectrometer.
[0497] The above two spectrometers are equipped with an Agilent ZorbaxSB-C18 column (2.1×30 mm, 5 μm). The injection volume is determined by the sample concentration; the flow rate is 0.6 mL/min; peak values of HPLC are recorded at UV-Vis wavelength of 210 nm and 254 nm.
Example 1
[0498] ##STR00410## ##STR00411##
Step (1) Preparation of tert-butyl (R)-2-formyl-morpholine-4-carboxylate
[0499] ##STR00412##
[0500] A mixture of compound 1-1 (10 g, 460 mmol), TEMPO (0.073 g, 0.44 mmol), aqueous sodium bromide solution (0.5 M, 10 mL, 41 mmol) and dichloromethane (100 mL) was cooled to 0-5° C. To a sodium hypochlorite solution (1.5 M, 34 mL, 58 mmol) was added sodium bicarbonate (2.3 g, 23 mmol), and the solution was adjusted to pH 9.3, and added dropwise to the reaction system over 30 min. After the completion of the dropwise addition, the reaction system was stirred for 0.5 h, heated to 20° C., and added with water (50 mL). The aqueous phase was extracted with dichloromethane multiple times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give compound 1-2 (6 g, 60% yield) in the form of an orange-yellow oily liquid. LC-MS: [M+H].sup.+=216.4.
Step (2) Preparation of tert-butyl (S)-2-ethynyl-morpholine-4-carboxylate
[0501] ##STR00413##
[0502] Dimethyl(1-diazo-2-oxopropyl)phosphonate (6 g, 31.3 mmol) was dissolved in a mixture of acetonitrile and methanol (5:1), and K.sub.2CO.sub.3 (59 mmol) was added. The reaction system was stirred at 20° C. for 15 min, and added dropwise with a dissolved solution of compound 1-2 (6 g, 28 mmol) in a mixed solvent (10 mL) of acetonitrile and methanol (5:1) slowly. After the completion of the dropwise addition, the reaction system was incubated at this temperature overnight. The suspension was filtered, and the filtrate was concentrated under reduced pressure to give an oil, which was then added to water (about 100 mL) to precipitate a solid. The mixture was filtered, and the filter cake was washed with water. The residue was purified by silica gel column chromatography to give compound 1-4 (3.4 g, 56.7% yield) in the form of a solid. LC-MS: [M+H].sup.+=212.1.
Step (3)
[0503] ##STR00414##
[0504] To a solution of compound 1-4 (300 mg, 1.4 mmol), compound 1-5 (145 mg, 1.4 mmol) and compound 1-6 (145 mg, 1.4 mmol) in toluene (3 mL) were added CuCl (42 mg, 0.4 mmol) and Cu(CF.sub.3SO.sub.3).sub.2 (154 mg, 0.4 mmol) at room temperature. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with DME (0.1 mL), and reacted at this temperature for 5 h. After the reaction was completed, the reaction system was added with water (15 mL) to quench the reaction, extracted with dichloromethane (10 mL×3), washed with saturated sodium chloride solution (10 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 1/1) to give intermediate 1-7 (500 mg) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=404.2.
Step (4)
[0505] ##STR00415##
[0506] To a solution of intermediate 1-7 (3 g, 7.44 mmol) in THF (20 mL) was added LiOH (936 mg, 22.3 mmol) at 0° C. The reaction system was stirred at room temperature for 2 h. After the reaction was completed, the reaction system was adjusted to pH 6 with HCl (1 M) at 0° C., extracted with DCM (10 mL×3), washed with saturated sodium chloride solution (10 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give intermediate 1-8 (2 g) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=376.1.
Step (5)
[0507] ##STR00416##
[0508] Intermediate 1-8 (375 mg) was dissolved in DCM (10 mL), and HATU (2 mmol) and DIPEA (4 mmol) were added. The reaction system was stirred at room temperature for 15 min, added with N,O-dimethylhydroxylamine hydrochloride (1.2 mmol), and stirred at room temperature for another 6-8 h. After the reaction was completed as monitored by TLC, the residue was purified by column chromatography to give intermediate 1-10 (275 mg, 65.8% yield), LC-MS: [M+H].sup.+=419.3.
Step (6)
[0509] ##STR00417##
[0510] Intermediate 1-10 (418 mg, 1 mmol) was dissolved in anhydrous THF (10 mL), and methyl Grignard reagent was added dropwise at 0° C. After the completion of the dropwise addition, the reaction system was stirred overnight. After the reaction was completed, the reaction was quenched, and the reaction system was extracted with ethyl acetate, washed, dried, and purified by column chromatography to give intermediate 1-11 (236 mg, 63.3% yield). LC-MS: [M+H].sup.+=374.1.
Step (7)
[0511] ##STR00418##
[0512] Intermediate 1-11 (373 mg) was dissolved in DCM (5 mL), and a solution of HCl in EtOH (1 N, 1.5 mL) was added dropwise at 0° C. After the completion of the dropwise addition, the reaction system was stirred for 2 h, and poured into NaHCO.sub.3 solution to adjust the pH to 8. The aqueous phase was extracted with DCM. The organic phase was washed with NaCl solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give intermediate 1-12 (160 mg, 58.6% yield). LC-MS: [M+H].sup.+=274.6.
Step (8)
[0513] ##STR00419##
[0514] Intermediate 1-12 (273 mg, 1 mmol) and DIPEA (258 mg, 2 mmol) were dissolved in DCM (5 mL), and methyl chloroformate (compound 1-13) (282 mg, 3 mmol) was added. The reaction system was stirred at 0° C. for 3 h, poured into H.sub.2O and extracted with DCM. The organic phase was washed with NaCl solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give intermediate 1-14 (300 mg, 91% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=332.2.
Step (9)
[0515] ##STR00420##
[0516] Intermediate 1-14 (331 mg, 1 mmol) was dissolved in tetrahydrofuran (5 mL) and water (2 mL), and N-bromosuccinimide (214 mg, 1.2 mmol) was added. The reaction system was reacted at room temperature for 1 h under nitrogen atmosphere. Then the reaction system was concentrated to half volume, diluted with water (10 mL), and extracted with ethyl acetate (10 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated to give intermediate 1-15 (300 mg, 73.3% yield) in the form of a solid. LC-MS: [M+H].sup.+=410.2.
Step (10)
[0517] ##STR00421##
[0518] Intermediate 1-15 (0.82 g, 2 mmol) was dissolved in absolute ethanol (10 mL), and 1-acetylguanidine (242 mg, 2.4 mmol) and triethylamine (404 mg, 4 mmol) were added. The reaction system was heated to reflux. After the reaction was completed as detected by TLC, the reaction system was concentrated under reduced pressure, extracted with EA, and washed. The residue was purified by column chromatography to give compound 1 (531 mg, 64.4% yield).
[0519] LC-MS: [M+H].sup.+=413.2.
Example 2
[0520] ##STR00422## ##STR00423##
Step (1) Preparation of 2,6-difluoro-4-bromobenzaldehyde
[0521] ##STR00424##
[0522] 3,5-difluorobromobenzene (10 g, 51.8 mmol) was dissolved in anhydrous THF (80 mL), and LDA (31 mL, 62.5 mmol) was added dropwise at −78° C. under N.sub.2 atmosphere. After the completion of the dropwise addition, the reaction system was stirred for 1 h, added with DMF (4 mL, 51.9 mmol), and stirred for another 30 min. The reaction system was poured into NH.sub.4Cl solution and extracted with ethyl acetate. The organic phase was washed with NaCl solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give compound 2-2 (8 g, 70% yield) in the form of a yellow solid.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-bromophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0523] ##STR00425##
[0524] Compound 2-2 (200 mg, 0.9 mmol), 2-amino-4-methylpyridine (100 mg, 0.9 mmol), compound 1-4 (191 mg, 0.9 mmol), CuCl (27 mg, 0.27 mmol), and Cu(CF.sub.3SO.sub.3).sub.2 (100 mg, 0.27 mmol) were dissolved in toluene (3 mL). Under N.sub.2 atmosphere, the reaction system was heated to 85° C., added with DMA (0.05 mL), and stirred for 5 h. Then the reaction system was cooled to room temperature, and incubated overnight. The resulting reaction system was poured into water (5 mL) and extracted with DCM (5 mL×3). The organic phase was washed with saturated NaCl solution, dried over MgSO.sub.4 filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (PE:EA=1:1) to give intermediate 2-4 (100 mg, 21% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=522.3.
Step (3) Preparation of (S)-2-((2-(2,6-difluoro-4-bromophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine
[0525] ##STR00426##
[0526] Intermediate 2-4 (100 mg) was dissolved in DCM (1 mL), and a solution of HCl in EtOH (0.5 mL) was added dropwise at 0° C. After the completion of the dropwise addition, the reaction system was stirred for 2 h, and poured into NaHCO.sub.3 solution to adjust the pH to 8. The aqueous phase was extracted with DCM. The organic phase was washed with NaCl solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give intermediate 2-5 (60 mg, 75% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=422.6.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-bromophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0527] ##STR00427##
[0528] Intermediate 2-5 (320 mg, 0.76 mmol) and DIPEA (86 mg, 0.91 mmol) were dissolved in DCM (5 mL), and methyl chloroformate (compound 2-6) (86 mg, 0.91 mmol) was added. The reaction system was stirred at 0° C. for 3 h, poured into H.sub.2O and extracted with DCM. The organic phase was washed with NaCl solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give intermediate 2-7 (330 mg, 91% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=480.6.
Step (5) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-acetamidophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0529] ##STR00428##
[0530] To a solution of intermediate 2-7 (50 mg, 0.10 mmol), acetamide (compound 2-8) (10 mg, 0.17 mmol) in 1,4-dioxane (2 mL) were added CS.sub.2CO.sub.3 (51 mg, 0.16 mmol), Xantphos (1.2 mg, 0.002 mmol) and Pd.sub.2(dba).sub.3 (2 mg, 0.002 mmol) at room temperature. Under nitrogen atmosphere, the reaction system was heated to 80° C. and reacted overnight. After the reaction was completed, the reaction system was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give compound 2 (18 mg, 38% yield) in the form of a white solid.
[0531] LC-MS: [M+H].sup.+=459.7. .sup.1H NMR (400 MHz, MeOD): δ 8.41 (d, J=7.1 Hz, 1H), 7.43 (d, J=9.7 Hz, 2H), 7.35 (s, 1H), 6.88 (dd, J=7.1, 1.5 Hz, 1H), 3.80 (d, J=12.3 Hz, 3H), 3.67 (s, 3H), 3.59 (m, 1H), 3.43-3.34 (m, 1H), 3.15-3.01 (m, 2H), 2.91 (m, 1H), 2.63 (m, 1H), 2.47 (s, 3H), 2.19 (s, 3H).
Example 3
[0532] ##STR00429##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-aminophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0533] ##STR00430##
[0534] To a solution of compound 2 (145 mg, 0.32 mmol) in ethanol (3 mL) was added hydrochloric acid (1.5 mL) at room temperature. The reaction system was reacted at 100° C. for 1 h. After the reaction was completed, the reaction system was cooled to room temperature, added with NaHCO.sub.3 solution (1 N) to quench the reaction, extracted with DCM (5 mL×3), washed with saturated sodium chloride solution (5 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a yellow oily liquid (90 mg). LC-MS: [M+H].sup.+=417.3.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methoxycarbonylamino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0535] ##STR00431##
[0536] To a solution of intermediate 3-1 (70 mg, 0.17 mmol) and DIPEA (65 mg, 0.5 mmol) in DCM (5 mL) was added methyl chloroformate (20 mg, 0.21 mmol) at 0° C. The reaction system was reacted at this temperature for 3 h. After the reaction was completed, the reaction system was added with water (3 mL), extracted with DCM (3 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH, 40/1) to give compound 3 (20 mg, 25% yield) in the form of a white solid.
[0537] LC-MS: [M+H].sup.+=475.6. .sup.1H NMR (400 MHz, MeOD): δ 8.42 (d, J=7.1 Hz, 1H), 7.35 (s, 1H), 7.30 (d, J=9.9 Hz, 2H), 6.90 (d, J=7.1 Hz, 1H), 3.88-3.81 (m, 2H), 3.80 (s, 3H), 3.79-3.76 (m, 1H), 3.67 (s, 3H), 3.63-3.55 (m, 1H), 3.38 (t, J=10.8 Hz, 1H), 3.15-3.00 (m, 2H), 2.90 (dt, J=20.6, 7.7 Hz, 1H), 2.64 (t, J=11.5 Hz, 1H), 2.47 (s, 3H).
Example 4
[0538] ##STR00432##
Step (1) Preparation of methyl (S)-2-((2-(4-(1-tert-butoxycarbonylpyrrol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0539] ##STR00433##
[0540] To a solution of intermediate 2-7 (50 mg, 0.1 mmol), N-tert-butoxycarbonylpyrrolidine-2-boronic acid (compound 4-1) (26 mg, 0.12 mmol) and K.sub.2CO.sub.3 (36 mg, 0.26 mmol) in H.sub.2O (0.3 mL) and 1,4-dioxane (2 mL) was added Pd(dppf)Cl.sub.2 (2 mg, 0.016 mmol) at room temperature. Under nitrogen atmosphere, the mixture was heated to 80° C. and reacted for 3 h. After the reaction was completed, the reaction mixture was cooled to room temperature, filtered, added with water (3 mL), extracted with ethyl acetate (5 mL×3), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 5/1) to give a yellow oily liquid (50 mg, 93% yield). LC-MS: [M+H].sup.+=567.4.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-pyrrol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0541] ##STR00434##
[0542] To a solution of intermediate 4-2 (20 mg, 0.035 mmol) in methanol (1 mL) was added 1 M NaOH (4 mg, 0.1 mmol). The reaction mixture was reacted at 60° C. for 2 h. After the reaction was completed, the reaction mixture was added with water (1 mL), extracted with DCM (1 mL×3), washed with saturated sodium chloride solution (1 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give compound 4 (17.3 mg, 92.9% yield) in the form of a white solid.
[0543] LC-MS: [M+H].sup.+=467.6. .sup.1H NMR (400 MHz, MeOD): δ 8.41 (d, J=7.1 Hz, 1H), 7.34 (d, J=9.2 Hz, 3H), 6.91 (dd, J=2.6, 1.4 Hz, 1H), 6.88 (dd, J=7.1, 1.5 Hz, 1H), 6.69 (dd, J=3.6, 1.4 Hz, 1H), 6.24 (dd, J=3.5, 2.7 Hz, 1H), 3.81 (d, J=12.4 Hz, 3H), 3.66 (s, 3H), 3.63-3.56 (m, 1H), 3.39 (t, J=10.6 Hz, 1H), 3.17-3.04 (m, 2H), 2.96-2.85 (m, 1H), 2.71-2.59 (m, 1H), 2.47 (s, 3H).
Example 5
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-imidazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0544] ##STR00435##
[0545] Intermediate 2-7 (50 mg, 0.1 mmol) was dissolved in toluene (2 mL), and imidazole (21 mg, 0.31 mmol), (1R,2R)—N1,N2-dimethylcyclohexyl-1,2-diamine (1.5 mg, 0.01 mmol) and K.sub.2CO.sub.3 (15 mg, 0.11 mmol) was added. Under N.sub.2 atmosphere, the reaction system was added with CuI (2 mg, 0.01 mmol), and heated to 110° C. overnight. Then the reaction system was filtered, and the filtrate was purified to give compound 5 (8.4 mg, 17.2% yield) in the form of a yellow solid.
[0546] LC-MS: [M+H].sup.+=468.6. .sup.1HNMR (400 MHz, MeOD): δ 8.44 (d, 1H), 8.42 (s, 1H), 7.78 (s, 1H), 7.56 (d, 2H), 7.36 (s, 1H), 7.22 (s, 1H), 6.91 (dd, 1H), 3.82 (m, 3H), 3.67 (s, 3H), 3.60 (m, 1H), 3.38 (m, 1H), 3.12 (m, 2H), 2.90 (m, 2H), 2.64 (s, 3H).
Example 6
[0547] ##STR00436##
Step (1) Preparation of 2,6-difluoro-4-cyanobenzaldehyde
[0548] ##STR00437##
[0549] To a solution of compound 6-1 (2 g, 14 mmol) in THF (20 mL) was added LDA (8.6 mL, 17.2 mmol) dropwise at −78° C. under nitrogen atmosphere. Then the reaction system was stirred at −78° C. for 1 h under nitrogen atmosphere, and added dropwise with DMF (1.26 g, 17.2 mmol) over 30 min. After the reaction was completed, the reaction system was added with AcOH (10%) to quench the reaction, extracted with ethyl acetate (50 mL×3), washed with saturated sodium chloride solution (50 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 8/1) to give compound 6-2 (1.5 g, 60% yield) in the form of a yellow solid.
Step (2) Preparation of tert-butyl (S)-2-((2-(4-cyano-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0550] ##STR00438##
[0551] To a solution of compound 6-2 (500 mg, 3 mmol), compound 1-5 (330 mg, 3 mmol) and compound 1-4 (630 mg, 3 mmol) in toluene (15 mL) were added CuCl (90 mg, 0.9 mmol) and Cu(CF.sub.3SO.sub.3).sub.2 (330 mg, 0.9 mmol) at room temperature. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with DME (0.1 mL), and reacted at this temperature for 5 h. After the reaction was completed, the reaction system was added with water (15 mL) to quench the reaction, extracted with dichloromethane (10 mL×3), washed with saturated sodium chloride solution (10 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 1/1) to give intermediate 6-3 (450 mg, 32% yield) in the form of a yellow oily liquid.
Step (3) Preparation of (S)-3,5-difluoro-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzonitrile
[0552] ##STR00439##
[0553] To a solution of intermediate 6-3 (400 mg, 1.1 mmol) in DCM (6 mL) was added TFA (2 mL) dropwise at 0° C. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added with saturated NaHCO.sub.3 to quench the reaction at 0° C., extracted with dichloromethane (3 mL×3), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH, 40/1) to give intermediate 6 (280 mg, 79% yield) in the form of a brown solid.
Step (4) Preparation of methyl (S)-2-((2-(4-cyano-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0554] ##STR00440##
[0555] To a solution of intermediate 6-4 (230 mg, 0.6 mmol) and DIPEA (230 mg, 1.8 mmol) in DCM (2 mL) was added methyl chloroformate (66 mg, 0.72 mmol) at 0° C. The reaction system was reacted for 1 h. After the reaction was completed, the reaction system was added with water (3 mL), extracted with dichloromethane (3 mL×3), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 2/1) to give compound 6 (230 mg, 83% yield) in the form of a yellow solid.
[0556] LC-MS: [M+H].sup.+=427.7. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.19 (d, J=7.1 Hz, 1H), 7.41 (s, 1H), 7.37 (d, J=6.2 Hz, 2H), 6.72 (d, J=7.0 Hz, 1H), 4.03-3.74 (m, 3H), 3.71 (s, 3H), 3.61-3.51 (m, 1H), 3.38 (t, J=11.8 Hz, 1H), 3.09-2.82 (m, 3H), 2.68-2.53 (m, 1H), 2.44 (s, 3H).
Example 7
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-imidazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0557] ##STR00441##
[0558] A solution of compound 6 (120 mg, 0.3 mmol) and NaOMe (3 mg, 0.05 mmol) in MeOH (2 mL) was stirred at room temperature for 15 min, and aminoacetaldehyde diethyl acetal (49 mg, 0.4 mmol) and AcOH (34 mg, 0.6 mmol) were added. The reaction system was reacted at 50° C. for 1 h, then cooled to room temperature, added with HCl (0.5 mL) and MeOH (2 mL), and reacted at 65° C. for 18 h. After the reaction was completed, the reaction system was concentrated under reduced pressure. The crude product was purified by preparative HPLC, added with 1 M hydrochloric acid, and lyophilized to give compound 7 (32 mg, 24% yield) in the form of a white solid.
[0559] LC-MS: [M+H].sup.+=468.1. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 16.00 (s, 2H), 15.16 (s, 1H), 8.68 (s, 3H), 8.00 (s, 1H), 7.49 (s, 2H), 7.22 (s, 1H), 3.94 (s, 3H), 3.70 (m, 3H), 3.61 (m, 1H), 3.34 (m, 1H), 2.97 (m, 4H), 2.62 (s, 3H).
Example 8
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(N-methylcarbamimidoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0560] ##STR00442##
[0561] A solution of compound 6 (50 mg, 0.12 mmol) and NaOMe (2 mg, 0.03 mmol) in MeOH (2 mL) was stirred at room temperature for 30 min, then a solution of MeNH.sub.2/THF (2 M, 0.1 mL, 0.15 mmol) and AcOH (14 mg, 0.24 mmol) were added at 50° C. The reaction system was reacted for 1 h. After the reaction was completed, the reaction system was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 8 (17 mg, 31% yield) in the form of a white solid.
[0562] LC-MS: [M+H].sup.+=458.1. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.54 (s, 1H), 8.25 (s, 1H), 7.57 (d, J=6.8 Hz, 2H), 7.39 (s, 1H), 6.74 (d, J=6.8 Hz, 1H), 3.82 (m, 3H), 3.68 (s, 3H), 3.56 (m, 1H), 3.36 (m, 1H), 3.22 (s, 2H), 3.07-2.75 (m, 4H), 2.61 (m, 1H), 2.45 (s, 3H).
Example 9
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0563] ##STR00443##
[0564] Intermediate 2-7 (50 mg, 0.1 mmol) was dissolved in toluene (3 mL), and the reaction system was added with Pd(PPh.sub.3).sub.4 (12 mg, 0.01 mmol) and 1-methyl-2-(tri-n-butylstannyl)imidazole (78 mg, 0.2 mmol). Under N.sub.2 atmosphere, the reaction system was heated to 85° C. and incubated at this temperature for 5 h. Then the reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give compound 9 (24 mg, 49% yield) in the form of a white solid.
[0565] LC-MS: [M+H].sup.+=482.2. .sup.1HNMR (400 MHz, MeOD): δ 8.69 (s, 1H), 8.55 (d, 1H), 7.99 (s, 1H), 7.55 (s, 1H), 7.22 (d, 2H), 7.15 (d, 1H), 4.06 (s, 1H), 3.96 (s, 3H), 3.86 (m, 2H), 3.73 (s, 3H), 3.68 (s, 1H), 3.43 (m, 1H), 3.09 (d, 2H), 2.99 (m, 1H), 2.73 (m, 1H), 2.61 (s, 3H).
Example 10
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(oxazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0566] ##STR00444##
[0567] To a solution of intermediate 2-7 (50 mg, 0.1 mmol) in 1,4-dioxane (2 mL) were added Pd(Ph.sub.3P).sub.4 (12 mg, 0.01 mmol) and 2-(tri-n-butylstannyl)oxazole (119 mg, 0.33 mmol) at room temperature. Under nitrogen atmosphere, the reaction system was heated to 95° C. and reacted for 3 h. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give compound 10 (12 mg, 25% yield) in the form of a white solid.
[0568] LC-MS: [M+H].sup.+=469.7. .sup.1H NMR (400 MHz, MeOD): δ 8.43 (d, J=7.1 Hz, 1H), 8.10 (d, J=0.8 Hz, 1H), 7.80 (d, J=8.0 Hz, 2H), 7.42 (d, J=0.8 Hz, 1H), 7.36 (s, 1H), 6.89 (dd, J=7.2, 1.6 Hz, 1H), 3.93-3.74 (m, 3H), 3.66 (s, 3H), 3.64-3.56 (m, 1H), 3.42-3.34 (m, 1H), 3.13 (d, J=6.3 Hz, 2H), 2.97-2.85 (m, 1H), 2.73-2.60 (m, 1H), 2.48 (s, 3H).
Example 11
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(furan-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0569] ##STR00445##
[0570] Intermediate 2-7 (50 mg, 0.1 mmol) was dissolved in toluene (3 mL), and the reaction system was added with Pd(PPh.sub.3).sub.4 (12 mg, 0.01 mmol) and 2-(tri-n-butylstannyl)furan (37 mg, 0.1 mmol). Under N.sub.2 atmosphere, the reaction system was heated to 110° C. and incubated at this temperature for 18 h. Then the reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give compound 11 (12 mg, 24% yield) in the form of a white solid.
[0571] LC-MS: [M+H].sup.+=468.1. .sup.1HNMR (400 MHz, CDCl.sub.3): δ 8.55 (d, 1H), 8.08 (s, 1H), 7.58 (d, 1H), 7.40 (d, 2H), 7.14 (d, 1H), 6.86 (d, 1H), 6.58 (s, 1H), 3.82 (m, 3H), 3.73 (s, 3H), 3.68 (m, 1H), 3.43 (m, 1H), 3.05 (m, 2H), 2.96 (m, 1H), 2.71 (m, 1H), 2.61 (s, 3H).
Example 12
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(thiophen-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0572] ##STR00446##
[0573] Intermediate 2-7 (50 mg, 0.1 mmol) was dissolved in dioxane (3 mL), and the reaction system was added with Pd(PPh.sub.3).sub.4 (12 mg, 0.01 mmol) and 2-(tri-n-butylstannyl)thiophene (117 mg, 0.31 mmol). Under N.sub.2 atmosphere, the reaction system was heated to 100° C. and incubated at this temperature for 8 h. Then the reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give compound 12 (18 mg, 35% yield) in the form of a white solid. LC-MS: [M+H].sup.+=484.6. .sup.1HNMR (400 MHz, CDCl.sub.3): δ 8.22 (d, 1H), 7.41 (m, 3H), 7.31 (m, 2H), 7.14 (dd, 1H), 6.71 (d, 1H), 3.82 (m, 3H), 3.68 (s, 3H), 3.62 (m, 1H), 3.41 (m, 1H), 3.03 (m, 2H), 2.92 (m, 1H), 2.64 (m, 1H), 2.46 (s, 3H).
Example 13
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1-methyl-1H-pyrrol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0574] ##STR00447##
[0575] Intermediate 2-7 (50 mg, 0.1 mmol) was dissolved in dioxane (3 mL), and the reaction system was added with Pd(PPh.sub.3).sub.4 (12 mg, 0.01 mmol) and 2-(tri-n-butylstannyl)methylpyrrole (115 mg, 0.31 mmol). Under N.sub.2 atmosphere, the reaction system was heated to 100° C. and incubated at this temperature for 8 h. Then the reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give compound 13 (28 mg, 54% yield) in the form of a white solid.
[0576] LC-MS: [M+H].sup.+=481.4. .sup.1HNMR (400 MHz, CD.sub.3OD): δ 8.86 (d, 1H), 7.72 (S, 1H), 7.42 (dd, 1H), 7.39 (d, 2H), 6.91 (t, 1H), 6.49 (dd, 1H), 6.20 (dd, 1H), 4.02 (d, 1H), 3.84 (s, 3H) 3.75 (m, 3H), 3.69 (s, 3H), 3.38 (m, 1H), 3.27 (m, 2H), 2.96 (m, 1H), 2.79 (m, 1H), 2.66 (s, 3H).
Example 14
[0577] ##STR00448##
Step (1) Preparation of methyl (S)-2-((2-(4-(1-ethoxyethenyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0578] ##STR00449##
[0579] Intermediate 2-7 (300 mg, 0.62 mmol) was dissolved in toluene (3 mL), and the reaction system was added with PdCl.sub.2(PPh.sub.3).sub.2 (44 mg, 0.062 mmol), tri-tert-butyl(1-ethoxyethenyl)tin (680 mg, 1.88 mmol). Under N.sub.2 atmosphere, the reaction system was heated to 95° C. and incubated at this temperature for 3 h. Then the reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to give intermediate 14-2 (215 mg, 73% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=472.7.
Step (2) Preparation of methyl (S)-2-((2-(4-acetyl-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0580] ##STR00450##
[0581] Intermediate 14-2 (250 mg, 0.53 mmol) was dissolved in EtOH (3 mL), and HCl (2 N, 1.7 mL) was added. The reaction system was stirred at room temperature for 2 h. After the reaction was completed, the reaction system was poured into NaHCO.sub.3 solution to adjust the pH to 8. The aqueous phase was extracted with DCM. The organic phase was washed with NaCl solution 2-3 times, followed by liquid separation. The organic phase was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified to give compound 14 (25 mg, 38% yield) in the form of a white solid.
[0582] LC-MS: [M+H].sup.+=444.7. .sup.1HNMR (400 MHz, MeOD): δ 8.43 (d, 1H), 7.76 (d, 2H), 7.36 (s, 1H), 6.90 (dd, 1H), 3.79 (m, 3H), 3.67 (s, 3H), 3.59 (m, 1H), 3.36 (m, 1H), 3.11 (m, 2H), 2.86 (m, 1H), 2.68 (s, 3H), 2.63 (m, 1H), 2.47 (s, 3H).
Example 15
[0583] ##STR00451##
Step (1) Preparation of methyl (S,E)-2-((2-(4-(3-(dimethylamino)acryloyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl) morpholine-4-carboxylate
[0584] ##STR00452##
[0585] Compound 14 (180 mg, 0.41 mmol) was dissolved in DMF-DMA (2 mL). Under N.sub.2 atmosphere, the reaction system was heated to 95° C. and reacted overnight. Then the reaction system was cooled to room temperature, and concentrated under reduced pressure. The residue was purified to give intermediate 15-1 (120 mg, 59.4% yield). LC-MS: [M+H].sup.+=499.7.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-pyrazol-3-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0586] ##STR00453##
[0587] Intermediate 15-1 (80 mg, 0.12 mmol) was dissolved in ethanol (2 mL). The reaction system was added with N.sub.2H.sub.4-H.sub.2O (16 mg, 0.32 mg) dropwise, heated to 100° C. and incubated at this temperature for 2 h. Then the reaction system was concentrated under reduced pressure. The residue was purified to give compound 15 (49.8 mg, 66.4% yield) in the form of a white solid.
[0588] LC-MS: [M+H].sup.+=468.6. .sup.1H NMR (400 MHz, MeOD): δ 8.86 (d, 1H), 7.81 (d, 1H), 7.76 (d, 2H), 7.73 (s, 1H), 7.43 (dd, 1H), 6.91 (d, 1H), 4.02 (m, 1H), 3.79 (m, 3H), 3.69 (s, 3H), 3.37 (m, 1H), 3.27 (m, 2H), 2.94 (m, 1H), 2.73 (m, 1H), 2.66 (s, 3H).
Example 16
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(isoxazol-3-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0589] ##STR00454##
[0590] Intermediate 15-1 (80 mg, 0.12 mmol) was dissolved in methanol (2 mL). The reaction system was added with N.sub.2OH—HCl (21 mg, 0.30 mg) dropwise, heated to 100° C. and incubated at this temperature for 2 h. Then the reaction system was concentrated under reduced pressure. The residue was purified to give compound 16 (34.2 mg, 45.4% yield) in the form of a white solid.
[0591] LC-MS: [M+H].sup.+=469.4. .sup.1H NMR (400 MHz, CDCl.sub.3): δ8.27 (d, 1H), 7.66 (m, 2H), 7.35 (s, 1H), 6.82 (dd, 1H), 3.78 (m, 3H), 3.61 (s, 3H), 3.54 (m, 1H), 3.30 (m, 1H), 3.10 (m, 2H), 2.88 (m, 1H), 2.63 (m, 1H), 2.47 (s, 3H).
Example 17
[0592] ##STR00455##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0593] ##STR00456##
[0594] Intermediate 2-7 (100 mg, 0.21 mmol), boronate (64 mg, 0.25 mmol), Pd(dppf)Cl.sub.2 (8 mg, 0.01 mmol) and AcOK (6.2 mg, 0.625 mmol) were dissolved in dioxane (3 mL). Under N.sub.2 atmosphere, the reaction system was heated to 90° C. and reacted overnight. Then the reaction system was cooled to room temperature to give intermediate 17-2. LC-MS: [M+H].sup.+=528.2.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(pyridin-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0595] ##STR00457##
[0596] Intermediate 17-2 (55 mg, 0.1 mmol), 2-bromopyridine (18 mg, 0.11 mmol), Na.sub.2CO.sub.3 (33 mg, 0.31 mmol), Pd(PPh.sub.3).sub.4 (6 mg, 0.005 mmol) were dissolved in dioxane (3 mL) and a small amount of water. Under N.sub.2 atmosphere, the reaction system was heated to 100° C. After the reaction was completed, the reaction system was filtered, and the filtrate was diluted with water and extracted with EA. The organic phase was washed with NaCl, dried, filtered, and concentrated under reduced pressure. The residue was purified to give compound 17 (25 mg, 50% yield) in the form of a white solid.
[0597] LC-MS: [M+H].sup.+=479.7. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.75 (d, 1H), 8.27 (d, 1H), 7.85 (t, 1H), 7.76 (dd, 3H), 7.56 (m, 1H), 7.35 (m, 1H), 6.76 (d, 1H), 3.82 (s, 3H), 3.68 (s, 3H), 3.62 (s, 1H), 3.41 (s, 1H), 3.03 (dd, 2H), 2.92 (s, 1H), 2.64 (dd, 1H), 2.47 (s, 3H).
Example 18
Preparation of methyl (S)-2-((2-(3-fluoro-4-(methylcarbamoyl)-1H-pyrrol-2-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0598] ##STR00458##
[0599] Intermediate 17-2 (55 mg, 0.1 mmol), 2-bromopyrimidine (19 mg, 0.11 mmol), Na.sub.2CO.sub.3 (27 mg, 0.31 mmol), Pd(PPh.sub.3).sub.4 (4 mg, 0.005 mmol) were dissolved in dioxane (3 mL) and a small amount of water. Under N.sub.2 atmosphere, the reaction system was heated to 90° C. After the reaction was completed, the reaction system was filtered, and the filtrate was diluted with water and extracted with EA. The organic phase was washed with NaCl, dried, filtered, and concentrated under reduced pressure. The residue was purified to give compound 18 (25 mg, 50% yield) in the form of a white solid.
[0600] LC-MS: [M+H].sup.+=480.2. .sup.1HNMR (400 MHz, CDCl.sub.3): δ 8.87 (d, 2H), 8.24 (t, 1H), 8.18 (d, 2H), 7.54 (s, 1H), 7.30 (m, 1H), 6.76 (d, 1H), 3.82 (s, 3H), 3.72-3.77 (m, 3H), 3.68 (s, 3H), 3.62 (s, 1H), 3.41 (s, 1H), 3.03 (t, 2H), 2.92 (s, 1H), 2.64 (dd, 1H), 2.46 (s, 3H).
Example 19
[0601] ##STR00459##
Step (1) Preparation of methyl 2-(2-((2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)acetate
[0602] ##STR00460##
[0603] 3,5-difluoro-4-formyl-N-methylbenzamide (200 mg, 1 mmol), 2-amino-4-methylpyridine (108 mg, 1 mmol), methyl propiolate (84 mg, 1 mmol), CuCl (30 mg, 0.3 mmol), and Cu(CF.sub.3SO.sub.3).sub.2 (109 mg, 0.3 mmol) were dissolved in toluene (3 mL). Under N.sub.2 atmosphere, the reaction system was heated to 85° C., added with DMA (0.05 mL), and stirred for 5 h. Then the reaction system was cooled to room temperature, and incubated overnight. The resulting reaction system was poured into H.sub.2O (5 mL) and extracted with DCM (5 mL×3). The organic phase was washed with saturated NaCl, dried over MgSO.sub.4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (PE:EA=1:1) to give intermediate 19-3 (172 mg, 25% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=374.4.
Step (2) Preparation of 4-(3-(2-amino-2-oxoethyl)-7-methylimidazo[1,2-a]pyridine)-3,5-difluorobenzoylmethylamine
[0604] ##STR00461##
[0605] Intermediate 19-3 (82 mg, 0.22 mmol) was dissolved in methanol (2 mL). The reaction system was added with NH.sub.3.H.sub.2O (1 mL) and stirred overnight. Then the reaction system was concentrated under reduced pressure. The crude product was purified to give compound 19 (25 mg, 32% yield) in the form of a white solid.
[0606] LC-MS: [M+H].sup.+=359.8. .sup.1HNMR (400 MHz, CD.sub.3OD): δ 8.36 (d, 1H), 7.63 (d, 2H), 7.46 (s, 1H), 7.02 (d, 1H), 3.93 (s, 2H), 2.97 (s, 3H), 2.52 (s, 3H).
Example 20
[0607] ##STR00462##
Step (1) Preparation of tert-butyl (S)-2-((2-(3,5-difluorophenyl)carbamoyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0608] ##STR00463##
[0609] A solution of intermediate 1-8 (400 mg, 1.07 mmol) and HATU (608 mg, 1.6 mmol) in DMF (5 mL) was stirred at room temperature for 10 min, and DIPEA (418 mg, 3.24 mmol) and compound 20-1 (168 mg, 1.3 mmol) were added at room temperature. The reaction system was reacted for 1 h. After the reaction was completed, the reaction system was added with water (15 mL) to quench the reaction, extracted with dichloromethane (10 mL×3), washed with saturated sodium chloride solution (10 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH, 10/1) to give intermediate 20-2 (450 mg) in the form of a yellow oily liquid.
Step (2) Preparation of (S)—N-(3,5-difluorophenyl)-7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0610] ##STR00464##
[0611] To a solution of intermediate 20-2 (330 mg, 0.7 mmol) in DCM (4 mL) was added a solution of HCl in ethanol (1 mL) dropwise at 0° C. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added with saturated NaHCO.sub.3 to quench the reaction at 0° C., extracted with dichloromethane (3 mL×3), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH, 10/1) to give intermediate 20-3 (80 mg, 31% yield) in the form of a brown solid.
Step (3) Preparation of ethyl (S)-2-((2-(3,5-difluorophenyl)carbamoyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-acetate
[0612] ##STR00465##
[0613] To a solution of intermediate 20-3 (80 mg, 0.2 mmol) and DIPEA (25 mg, 0.6 mmol) in DCM (2 mL) was added methyl chloroformate (1 mL) at 0° C. The reaction system was reacted for 1 h. After the reaction was completed, the reaction system was added with water (3 mL), extracted with dichloromethane (3 mL×3), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give compound 20 (15 mg, 16% yield) in the form of a white solid.
[0614] LC-MS: [M+H].sup.+=459.7. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.30 (s, 1H), 7.52 (s, 3H), 6.90 (s, 1H), 6.59 (t, J=8.7 Hz, 1H), 4.23 (d, J=9.8 Hz, 1H), 4.16 (dd, J=14.1, 7.1 Hz, 2H), 3.96-3.79 (m, 3H), 3.75 (d, J=12.2 Hz, 1H), 3.41 (dd, J=11.9, 9.2 Hz, 1H), 3.35-3.19 (m, 1H), 2.99-2.85 (m, 1H), 2.84-2.73 (m, 1H), 2.50 (s, 3H), 1.35-1.18 (m, 3H).
Example 21
[0615] ##STR00466##
Step (1) Preparation of 5-formyl-N-methylthiophene-2-carboxamide
[0616] ##STR00467##
[0617] To a solution of 5-formylthiophene-2-carboxylic acid (500 mg, 3.2 mmol) and DMF (12 mg) was added oxalyl chloride (447 mg, 1.1 mmol) at 0° C. The reaction system was reacted at this temperature for 2 h, and added with aqueous methylamine solution (40%, 746 mg, 9.6 mmol) over 10 min. After the reaction was completed, the reaction system was added with water (3 mL) to quench the reaction, extracted with dichloromethane (5 mL×3), washed with saturated sodium chloride solution (5 mL×2), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA, 1/1) to give compound 21-2 in the form of a white solid (300 mg, 56% yield), LC-MS: [M+H].sup.+=170.9.
Step (2) Preparation of tert-butyl (S)-2-((7-methyl-2-(5-(methylcarbamoyl)thiophen-2-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0618] ##STR00468##
[0619] To a solution of compound 21-2 (500 mg, 2.96 mmol), 4-methylpyridin-2-amine (320 mg, 2.96 mmol) and compound 1-4 (625 mg, 2.96 mmol) in toluene (5 mL) were added copper(I) chloride (88 mg, 0.89 mmol) and copper(II) trifluoromethanesulfonate (321 mg, 0.89 mmol) at room temperature. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with DMA (0.05 mL), and reacted at this temperature for 5 h. After the reaction was completed, the reaction system was added with water (5 mL) to quench the reaction, extracted with dichloromethane (5 mL×3), washed with saturated sodium chloride solution (5 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH, 40/1) to give intermediate 21-3 (300 mg, 56% yield) in the form of a yellow oily liquid, LC-MS: [M+H].sup.+=471.7.
Step (3) Preparation of (S)-5-(7-methyl-3-(morpholin-2-yl-methyl)imidazo[1,2-a]pyridin-2-yl)thiophene-2-carboxamide
[0620] ##STR00469##
[0621] To a solution of intermediate 21-3 (400 mg, 0.85 mmol) in DCM (4 mL) was added a solution of HCl in ethanol (0.5 mL, 33%) dropwise at 0° C. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added with saturated NaHCO.sub.3 to quench the reaction at 0° C., extracted with dichloromethane (5 mL×3), washed with saturated sodium chloride solution (5 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give intermediate 21-4 (300 mg) in the form of a yellow oily liquid, LC-MS: [M+H].sup.+=371.8.
Step (4) Preparation of methyl (S)-2-((7-methyl-2-(5-(methylcarbamoyl)thiophen-2-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0622] ##STR00470##
[0623] To a solution of intermediate 21-4 (100 mg, 0.27 mmol) and DIPEA (105 mg, 0.81 mmol) in DCM (2 mL) was added methyl chloroformate (31 mg, 0.33 mol) at 0° C. The reaction system was reacted for 3 h. After the reaction was completed, the reaction system was added with water (3 mL), extracted with dichloromethane (3 mL×2), washed with saturated sodium chloride solution (3 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give compound 21 (28.5 mg, 28% yield) in the form of a yellow solid.
[0624] LC-MS: [M+H].sup.+=429.7. .sup.1H NMR (400 MHz, MeOD): δ 8.32 (d, J=7.0 Hz, 1H), 7.67 (d, J=3.9 Hz, 1H), 7.52 (d, J=3.8 Hz, 1H), 7.31 (s, 1H), 6.88-6.80 (m, 1H), 4.13 (d, J=12.8 Hz, 1H), 3.92-3.75 (m, 3H), 3.72 (s, 3H), 3.46-3.28 (m, 3H), 3.01 (m, 1H), 2.94 (s, 3H), 2.91 (m, 1H), 2.44 (s, 3H).
Examples 22-24
[0625] The compounds were prepared using the corresponding starting materials according to the method as described in Example 21.
TABLE-US-00001 LC-MC (RT, Number Compound structure m/z) Example 22
Example 25
[0626] ##STR00474## ##STR00475##
Step (1) Preparation of benzyl (3,5-difluoro-4-formylphenyl)-carbamate
[0627] ##STR00476##
[0628] To a solution of compound 2-2 (1 g, 4.5 mmol) in toluene (20 mL) were added cesium carbonate (2 g, 6.3 mmol), benzyl carbamate (0.8 g, 5.4 mmol), (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (0.28 g, 0.45 mmol) and tris(dibenzylideneacetone)dipalladium (0.2 g, 0.2 mmol) at room temperature. After the addition, the reaction system was purged with nitrogen three times, heated to 100° C. and stirred overnight (16 h) under nitrogen atmosphere. Then the reaction system was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA/PE=1/10) to give intermediate 25-1 (0.72 g, 55.2% yield) in the form of a yellow solid, LC-MS: [M+H].sup.+=292.1.
Step (2) Preparation of tert-butyl (S)-2-((2-(4-(((benzyloxy)-carbonyl)amino)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[0629] ##STR00477##
[0630] To a 20 mL microwave tube (Biotage) were added compound 25-1 (0.2 g, 0.68 mmol), compound 1-4 (0.22 g, 1.03 mmol) and compound 1-5 (74 mg, 0.68 mmol), copper(I) chloride (20 mg, 0.2 mmol), copper(II) trifluoromethanesulfonate (74 mg, 0.2 mmol) and toluene (6 mL). After the addition, the reaction system was purged with nitrogen for 2 min, and reacted at 120° C. overnight (16 h) after the tube was sealed. A new spot was generated by developing the TLC plate (PE/EA=1/1) with Rf value being about 0.3, and was identified as the target product by liquid chromatography. Then the reaction system was cooled to room temperature and concentrated under reduced pressure. The residue was mixed with silica gel and purified by silica gel column chromatography (EA/PE=1/1) to give intermediate 25-2 (184 mg, 45.5% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=593.6.
Step (3) Preparation of methyl (S)-2-((2-(4-(((benzyloxy)-carbonyl)amino)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[0631] ##STR00478##
[0632] To intermediate 25-2 (0.8 g, 1.35 mmol) was added a solution of HCl in ethyl acetate (about 4 M, 5 mL) at room temperature. After the addition, the reaction system was stirred at room temperature for 2 h. After the reaction was completed as monitored by liquid chromatography, the reaction system was concentrated under reduced pressure to give a crude product, to which were added dichloromethane (5 mL), triethylamine (0.4 g, 4 mmol) and methyl chloroformate (0.19 g, 2 mmol). After the addition, the reaction system was stirred at room temperature for 3 h. After the reaction was completed as monitored by liquid chromatography, the reaction system was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA) to give intermediate 25-3 (675 mg, 90.8% yield) in the form of a brown oil. LC-MS: [M+H].sup.+=551.2.
Step (4) Preparation of methyl (S)-2-((2-(4-amino-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0633] ##STR00479##
[0634] To a solution of intermediate 25-3 (200 mg, 0.363 mmol) in methanol (10 mL) was added palladium hydroxide (about 40 mg, 20% w/w) at room temperature. After the addition, the reaction system was purged with hydrogen balloon 3 times, and stirred at room temperature for 4 h under hydrogen atmosphere. After the reaction was completed as monitored by liquid chromatography, the reaction system was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA) to give intermediate 25-4 (111 mg, 74% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=417.2.
Step (5) Preparation of (S)-4-((3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-phenyl)-amino)-4-oxobutanoic acid
[0635] ##STR00480##
[0636] To a solution of intermediate 25-4 (100 mg, 0.24 mmol) in toluene (5 mL) were added triethylamine (24 mg, 0.24 mmol) and succinic anhydride (28.8 mg, 0.288 mmol) at room temperature. After the addition, the reaction system was heated to 80° C. and reacted for 4 h. After the reaction was completed as monitored by liquid chromatography, the reaction system was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (ammonium bicarbonate method), and lyophilized to give compound 25 (90 mg, 72.5% yield) in the form of a white solid.
[0637] LC-MS: [M+H].sup.+=517.1. .sup.1H NMR (400 MHz, CD.sub.3OD): δ 8.39 (d, J=7.2 Hz, 1H), 7.46-7.38 (m, 2H), 7.33 (s, 1H), 6.87-6.85 (m, 1H), 3.85-3.58 (m, 3H), 3.67 (s, 3H), 3.60-3.56 (m, 1H), 3.39-3.33 (m, 1H), 3.13-3.02 (m, 2H), 2.93-2.87 (m, 1H), 2.74-2.65 (m, 4H), 2.64-2.60 (m, 1H), 2.46 (s, 3H).
Example 26
Preparation of methyl (S)-2-((2-(4-(2,5-dioxopyrrolidin-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0638] ##STR00481##
[0639] To a solution of compound 25 (77.6 mg, 0.15 mmol) in acetic anhydride (2 mL) was added sodium acetate (9.2 mg, 0.11 mmol) at room temperature. The reaction system was stirred at room temperature for 4 h. Then the reaction system was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (trifluoroacetic acid method), and lyophilized to give compound 26 (30 mg, 40% yield) in the form of a white solid.
[0640] LC-MS: [M+H].sup.+=499.1. .sup.1H NMR (400 MHz, CD.sub.3OD): δ 8.84 (d, J=6.8 Hz, 1H), 7.72 (s, 1H), 7.44-7.40 (m, 3H), 4.02-3.99 (m, 1H), 3.82-3.69 (m, 2H), 3.67 (s, 3H), 3.35-3.24 (m, 5H), 2.92-2.88 (m, 4H), 2.76-2.71 (m, 1H), 2.64 (s, 3H).
Example 27
(S,E)-4-((3,5-difluoro-4-(3-((4-(methoxycarbonyl)-morpholin-2-yl)-methyl)-7-methylimidazo[1,2-a]pyri din-2-yl)-phenyl)-amino)-4-oxobutyl-2-enoic acid
[0641] ##STR00482##
[0642] To a solution of intermediate 25-4 (20 mg, 0.048 mmol) in tetrahydrofuran (5 mL) was added maleic anhydride (7 mg, 0.071 mmol) at room temperature. After the addition, the reaction system was heated to 60° C. and reacted overnight (16 h). After the reaction was completed as monitored by liquid chromatography, the reaction system was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (trifluoroacetic acid method), and lyophilized to give compound 27 (16 mg, 65% yield) in the form of a white solid.
[0643] LC-MS: [M+H].sup.+=515.9. .sup.1H NMR (400 MHz, DMSO-d6): δ 12.9 (br, 1H), 10.88 (s, 1H), 8.78 (d, J=2.8 Hz, 1H), 7.68 (s, 1H), 7.56 (d, J=10.4 Hz, 2H), 7.31-7.30 (m, 1H), 6.53 (d, J=12 Hz, 1H), 6.37 (d, J=12 Hz, 1H), 3.90-3.87 (m, 1H), 3.76-3.62 (m, 3H), 3.57-3.54 (m, 3H), 3.25-3.07 (m, 4H), 2.85-2.80 (m, 1H), 2.52 (overlap, 3H).
Example 28
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2,5-dioxo-2,5-dihydropyrrol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0644] ##STR00483##
[0645] To a solution of compound 27 (100 mg, 0.25 mmol) in acetic anhydride (3 mL) was added sodium acetate (32.7 mg, 0.4 mmol) at room temperature. The reaction system was stirred at room temperature for 4 h. Then the reaction system was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (trifluoroacetic acid method), and lyophilized to give compound 28 (40 mg, 30% yield) in the form of a white solid.
[0646] LC-MS: [M+H].sup.+=497.1. .sup.1H NMR (400 MHz, CD.sub.3OD): δ 8.83 (d, J=7.2 Hz, 1H), 7.71 (s, 1H), 7.56-7.52 (m, 2H), 7.43-7.39 (m, 1H), 7.68 (s, 2H), 4.02-3.99 (m, 1H), 3.83-3.69 (m, 3H), 3.67 (s, 3H), 3.36-3.33 (m, 1H), 3.30-3.22 (m, 2H), 2.92-2.90 (m, 1H), 2.87-2.73 (m, 1H), 2.64 (s, 3H).
Example 29
Preparation of methyl (S,E)-2-((2-(2,6-difluoro-4-(4-amino-4-oxobutyl-2-enamido)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0647] ##STR00484##
[0648] To a solution of compound 28 (20 mg, 0.04 mmol) in acetonitrile (3 mL) was added aqueous ammonium bicarbonate solution (5%, 2 mL) at room temperature. The reaction system was reacted at room temperature for 2 h. Then the reaction system was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (ammonium bicarbonate method), and lyophilized to give compound 29 (10 mg, 40% yield) in the form of a white solid.
[0649] LC-MS: [M+H].sup.+=514.1. .sup.1H NMR (400 MHz, DMSO-d6): δ 11.36 (s, 1H), 8.38 (d, J=7.2 Hz, 1H), 7.93 (s, 1H), 7.45-7.42 (m, 3H), 7.33 (s, 1H), 6.82-6.80 (m, 1H), 6.35-6.28 (m, 2H), 3.73-3.62 (m, 3H), 3.55 (s, 3H), 3.51-3.46 (m, 1H), 3.25-3.22 (m, 2H), 3.02-3.00 (m, 2H), 2.83-2.79 (m, 1H), 2.37 (s, 3H).
Example 30
[0650] ##STR00485## ##STR00486##
Step (1) Preparation of (1-acetylpiperidin-4-yl)methyl acetate
[0651] ##STR00487##
[0652] 4-hydroxymethylpiperidine (5.2 g, 45.15 mmol) was dissolved in dichloromethane (60 mL), and triethylamine (13.5 g, 133.61 mmol) was added. The reaction system was cooled to 0° C., added with acetic anhydride (13.8 g, 135.4 mmol), and reacted at room temperature for 15 h. Then the reaction system was washed with diluted hydrochloric acid (1 N, 40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 30-3 (6.2 g) in the form of a yellow oily liquid.
Step (2) Preparation of 1-(4-(hydroxymethyl)piperidin-1-yl)ethan-1-one
[0653] ##STR00488##
[0654] Compound 30-3 (6.2 g) was dissolved in methanol (50 mL), and aqueous lithium hydroxide solution (3.75 N, 25 mL) was added. The reaction system was stirred at room temperature for 12 h. Then the reaction system was concentrated. The residue was separated by column chromatography (EA/MeOH=50/1) to give compound 30-4 (7.5 g) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=158.0.
Step (3) Preparation of 1-acetylpiperidine-4-carbaldehyde
[0655] ##STR00489##
[0656] Compound 30-4 (3.2 g, 20.35 mmol) was dissolved in dichloromethane (40 mL), and Dess-Martin periodinane (12.9 g, 30.52 mmol) was added. The reaction system was reacted at room temperature for 1.5 h. Then the reaction system was added with saturated sodium thiosulfate solution (20 mL), diluted with water (40 mL), and extracted with dichloromethane (40 mL×2). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (EA-EA/MeOH=50/1) to give compound 30-5 (1.0 g, 31% yield) in the form of a white solid. LC-MS: [M+H].sup.+=156.1.
Step (4) Preparation of tert-butyl (S)-2-((2-(1-acetylpiperidin-4-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0657] ##STR00490##
[0658] Compound 30-5 (200 mg, 1.29 mmol) was dissolved in anhydrous toluene (40 mL), and 4-methyl-2-aminopyridine (140 mg, 1.29 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (272 mg, 1.29 mmol), copper(I) chloride (40 mg, 0.4 mmol), and copper(II) trifluoromethanesulfonate (140 mg, 0.39 mmol) were added. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with two drops of N,N-dimethylacetamide, heated and stirred for 6 h. Then the reaction system was cooled to room temperature and stirred overnight. The resulting reaction system was filtered, and the filtrate was concentrated. The residue was separated by column chromatography (DCM/MeOH=20/1) to give intermediate 30-6 (227 mg, 38% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=456.8.
Step (5) Preparation of (S)-1-(4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)piperidin-1-yl)acetamide
[0659] ##STR00491##
[0660] Intermediate 30-6 (227 mg, 0.49 mmol) was dissolved in ethanol (2 mL), and a solution of HCl in ethanol (1 mL, 33%) was added. The reaction system was stirred at room temperature for 1.5 h. Then the reaction system was concentrated to give intermediate 30-7 (250 mg, crude product), which was used directly in the next step. LC-MS [M+H].sup.+=357.8.
Step (6) Preparation of methyl (S)-2-((2-(1-acetylpiperidin-4-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0661] ##STR00492##
[0662] Intermediate 30-7 (356 mg) was dissolved in dichloromethane (5 mL), and pyridine (244 mg, 3.09 mmol) was added, followed by the addition of methyl chloroformate (62 mg, 0.65 mmol). The reaction system was stirred at room temperature for 1.5 h. Then the reaction system was concentrated to give compound 30 (360 mg, 87% yield).
[0663] LC-MS: [M+H].sup.+=415.6. .sup.1HNMR (400 MHz, MeOD): δ 8.42 (s, 1H), 7.56 (d, 1H), 6.91 (d, 1H), 3.82 (m, 3H), 3.67 (s, 3H), 3.60 (m, 1H), 3.54 (t, 4H) 3.38 (dd, 1H), 3.12 (m, 2H), 2.90 (m, 2H), 2.83 (m, 2H), 2.64 (m, 2H), 2.10 (s, 3H), 1.69 (m, 4H).
Example 31
[0664] ##STR00493## ##STR00494##
Step (1) Preparation of methyl 4-bromo-3,5-difluorobenzoate
[0665] ##STR00495##
[0666] 4-bromo-3,5-difluorobenzoic acid (11.5 g, 48.5 mmol) was dissolved in methanol (100 mL), and concentrated sulfuric acid (1.0 mL) was added. The reaction system was reacted under reflux for 15 h. Then the reaction system was concentrated, diluted with water (50 mL) and extracted with ethyl acetate (50 mL×2). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE) to give compound 31-2 (10 g, 82% yield) in the form of a colorless oily liquid.
Step (2) Preparation of methyl 4-(1-ethoxyethenyl)-3,5-difluorobenzoate
[0667] ##STR00496##
[0668] Compound 31-2 (10.0 g, 39.83 mmol) was dissolved in anhydrous toluene (90 mL), and palladium acetate (449 mg, 2 mmol), triphenylphosphine (2.0 g, 8.0 mmol) and tributyl(1-ethoxyethenyl)stannane (15.9 g, 44 mmol) were added. The reaction system was refluxed overnight under nitrogen atmosphere. Then the reaction system was concentrated, diluted with water (100 mL) and extracted with ethyl acetate (50 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was separated by column chromatography (PE) to give compound 31-4 (7.4 g, 76% yield) in the form of a colorless liquid. LC-MS: [M+H].sup.+=214.8/242.8.
Step (3) Preparation of methyl 4-(2-bromoacetyl)-3,5-difluorobenzoate
[0669] ##STR00497##
[0670] Compound 31-4 (7.4 g, 30.46 mmol) was dissolved in tetrahydrofuran (60 mL) and water (20 mL), and N-bromosuccinimide (5.4 g, 30.46 mmol) was added. The reaction system was reacted at room temperature for 1 h under nitrogen atmosphere. Then the reaction system was concentrated to half volume, diluted with water (60 mL), and extracted with ethyl acetate (30 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated to give intermediate 31-5 (9.0 g) in the form of a yellow solid. LC-MS: [M+H].sup.+=292.5.
Step (4) Preparation of methyl 3,5-difluoro-4-(7-methylimidazo[1,2-a]pyridin-2-yl)benzoate
[0671] ##STR00498##
[0672] Intermediate 31-5 (9.0 g) was dissolved in ethanol (90 mL), and 4-methyl-2-aminopyridine (3.3 g, 30.47 mmol) was added. The reaction system was reacted under reflux for 12 h under nitrogen atmosphere. Then the reaction system was concentrated, diluted with water (60 mL), adjusted to pH 7-8 with saturated sodium bicarbonate solution, and extracted with ethyl acetate (40 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (PE/EA=1/1) to give intermediate 31-6 (4.2 g, 56% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=303.8.
Step (5) Preparation of 3,5-difluoro-N-methyl-4-(7-methylimidazo[1,2-a]pyridin-2-yl)benzamide
[0673] ##STR00499##
[0674] Intermediate 31-6 (1.5 g, 4.96 mmol) was dissolved in ethanol (15 mL), and aqueous methylamine solution (6 mL, 25-30%) was added. The reaction system was stirred at room temperature for 12 h. Then the reaction system was concentrated. The residue was separated by column chromatography (EA-EA/MeOH=50/1) to give intermediate 31-7 (1.1 g, 73% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=302.8.
Step (6) Preparation of 3,5-difluoro-4-(7-methyl-3-((3-oxopiperazin-1-yl)methyl)imidazo[1,2-a]pyridin-2-yl)benzamide
[0675] ##STR00500##
[0676] Intermediate 31-7 (150 mg, 0.49 mmol) and piperazin-2-one (50 mg, 0.49 mmol) were dissolved in acetic acid (1 mL), and aqueous formaldehyde solution (40 mg, 37%) was added. The reaction system was heated to 50° C. and reacted for 3 h. Then the reaction system was cooled to room temperature and stirred for 12 h. The resulting reaction system was diluted with dichloromethane (10 mL), and adjusted to pH 8 with aqueous sodium hydroxide solution (2 N). The aqueous phase was extracted with dichloromethane (10 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was purified by preparative thin-layer chromatography (DCM/MeOH=20/1) to give compound 31 (39.2 mg, 19% yield) in the form of a white solid.
[0677] LC-MS: [M+H].sup.+=414.8. .sup.1H NMR (400 MHz, MeOD): δ 8.52 (d, J=7.1 Hz, 1H), 7.62 (d, J=8.0 Hz, 2H), 7.40 (s, 1H), 6.94 (dd, J=7.1, 1.5 Hz, 1H), 3.90 (s, 2H), 3.21 (t, J=5.4 Hz, 2H), 3.05 (s, 2H), 2.97 (s, 3H), 2.66-2.54 (m, 2H), 2.48 (s, 3H).
Example 32
[0678] ##STR00501##
Step (1) Preparation of methyl piperazine-1-carboxylate
[0679] ##STR00502##
[0680] Piperazine (3 g, 34.8 mmol) was dissolved in dichloromethane (50 mL), and methyl chloroformate (658 mg, 6.96 mmol) was added in portions. The reaction system was reacted at room temperature for 30 min. Then the reaction system was added with aqueous potassium hydroxide solution (50 mL, 1 N) to quench the reaction, and extracted with dichloromethane (50 mL×3). The organic phases combined, dried over anhydrous sodium sulfate, and concentrated to give a white solid (1.8 g, 36% yield). LC-MS: [M+H].sup.+=145.7.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)piperazine-4-carboxylate
[0681] ##STR00503##
[0682] Intermediate 31-7 (150 mg, 0.49 mmol) and compound 32-2 (180 mg) were dissolved in acetic acid (1 mL), and aqueous formaldehyde solution (40 mg, 37%) was added. The reaction system was heated to 50° C. and reacted for 3 h. Then the reaction system was cooled to room temperature and stirred for 12 h. The resulting reaction system was diluted with dichloromethane (10 mL), and adjusted to pH 8 with aqueous sodium hydroxide solution (2 N). The aqueous phase was extracted with dichloromethane (15 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was separated by HPLC to give compound 32 (98.2 mg, 43% yield) in the form of a white solid.
[0683] LC-MS: [M+H].sup.+=458.7. .sup.1HNMR: .sup.1H NMR (400 MHz, MeOD): δ 8.55 (d, J=7.0 Hz, 1H), 7.60 (d, J=7.9 Hz, 2H), 7.39 (s, 1H), 6.94 (d, J=7.1 Hz, 1H), 3.80 (s, 2H), 3.66 (s, 3H), 3.47-3.36 (m, 4H), 2.97 (s, 3H), 2.49 (s, 3H), 2.37-2.29 (m, 4H).
Example 33
Preparation of 3,5-difluoro-4-(7-methyl-3-morpholinomethylimidazo[1,2-a]pyridin-2-yl)benzamide
[0684] ##STR00504##
[0685] Intermediate 31-7 (100 mg, 0.33 mmol) and morpholine (29 mg, 0.33 mmol) were dissolved in acetic acid (0.5 mL), and aqueous formaldehyde solution (28 mg, 37%) was added. The reaction system was heated to 50° C. and reacted for 3 h. Then the reaction system was cooled to room temperature and stirred for 12 h. The resulting reaction system was diluted with dichloromethane (15 mL), and adjusted to pH 8 with aqueous sodium hydroxide solution (2 N). The aqueous phase was extracted with dichloromethane (10 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was purified by HPLC to give compound 33 (50.2 mg, 38% yield) in the form of a white solid.
[0686] LC-MS: [M+H].sup.+=401.7. .sup.1HNMR (400 MHz, CDCl.sub.3): δ 8.44 (d, J=7.0 Hz, 1H), 7.58-7.37 (m, 4H), 6.80 (d, J=6.9 Hz, 1H), 3.71 (s, 2H), 3.67-3.60 (m, 4H), 3.03 (d, J=4.6 Hz, 3H), 2.48 (s, 3H), 2.39-2.31 (m, 4H).
Example 34
[0687] ##STR00505## ##STR00506##
Step (1) Preparation of tert-butyl 3,5-difluorobenzoate
[0688] ##STR00507##
[0689] 3,5-difluorobenzoic acid (10.0 g, 63.25 mmol) was dissolved in tert-butanol (100 mL), and DMAP (2.3 g, 18.98 mmol) and di-tert-butyl dicarbonate (27.6 g, 126.50 mmol) were added. The reaction system was reacted at room temperature for 15 h. Then the reaction system was concentrated, diluted with water (80 mL) and extracted with ethyl acetate (50 mL×2). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=20/1) to give compound 34-2 (12.0 g, 88% yield) in the form of a colorless oily liquid.
Step (2) Preparation of tert-butyl 3,5-difluoro-4-formylbenzoate
[0690] ##STR00508##
[0691] LDA (2 N, 8.4 mL) was dissolved in tetrahydrofuran (10 mL). The reaction system was cooled to −78° C. under nitrogen atmosphere. Compound 34-2 (3.0 g, 14.0 mmol) was dissolved in tetrahydrofuran (20 mL), and the solution was added to the reaction system. The reaction system was stirred at −78° C. for 1.5 h, added with DMF (1.2 g, 16.8 mmol), and stirred for another 1 h with the temperature maintained not higher than −70° C. Then the reaction system was added with saturated ammonium chloride solution (60 mL) to quench the reaction, and extracted with ethyl acetate (30 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was separated by column chromatography (PE/EA=10/1) to give compound 34-3 (1.5 g, 44% yield) in the form of a yellow solid.
Step (3) Preparation of tert-butyl (S)-2-((2-(4-(tert-butoxycarbonyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-carboxylate
[0692] ##STR00509##
[0693] Compound 34-3 (480 mg, 1.98 mmol) was dissolved in anhydrous toluene (4 mL), and 4-methyl-2-aminopyridine (215 mg, 1.98 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (419 mg, 1.98 mmol), copper(I) chloride (62 mg, 0.63 mmol), and copper(II) trifluoromethanesulfonate (216 mg, 0.60 mmol) were added. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with two drops of N,N-dimethylacetamide, heated and stirred for 6 h. Then the reaction system was cooled to room temperature and stirred overnight. The resulting reaction system was filtered, and the filtrate was concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give intermediate 34-4 (340 mg, 31% yield) in the form of a brown solid. LC-MS: [M+H].sup.+=544.7.
Step (4) Preparation of (S)-3,5-difluoro-4-(7-methyl-3-(morpholinyl-2-methyl)imidazo[1,2-a]pyridin-2-yl)benzoic acid
[0694] ##STR00510##
[0695] Intermediate 34-4 (340 mg, 0.62 mmol) was dissolved in ethanol (3 mL), and a solution of HCl in ethanol (1 mL, 33%) was added. The reaction system was stirred at room temperature for 1.5 h. Then the reaction system was concentrated to give intermediate 34-5 (400 mg) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=388.7.
Step (5) Preparation of (S)-3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)benzoic acid
[0696] ##STR00511##
[0697] Intermediate 34-5 (400 mg) was dissolved in dichloromethane (5 mL), and pyridine (244 mg, 3.09 mmol) was added, followed by the addition of methyl chloroformate (62 mg, 0.65 mmol). The reaction system was stirred at room temperature for 1.5 h, and concentrated to give intermediate 34-6 (190 mg). LC-MS: [M+H].sup.+=446.6.
Step (6) Preparation of methyl (S)-2-((2-(4-((cyanomethyl)carbamoyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0698] ##STR00512##
[0699] Intermediate 34-6 (445 mg, 1 mmol) was dissolved in CH.sub.3CN (10 mL), and triethylamine (1.2 mmol), DMAP (1.2 mmol) and EDCI (1.2 mmol) were added. The reaction system was stirred at room temperature overnight. After the reaction was completed, the reaction system was purified by column chromatography to give intermediate 34-7 (362 mg, 75% yield). LC-MS: [M+H].sup.+=484.6.
Step (7) Preparation of methyl (S)-2-((2-(4-(4-chloro-1H-imidazol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0700] ##STR00513##
[0701] Intermediate 34-7 (483 mg, 1 mmol) was dissolved in THF (10 mL), and a certain amount of CCl.sub.4 and PPh.sub.3 was added. The reaction system was heated to 50° C., and detected by LC-MS for completion. After the reaction was completed, the reaction system was purified by column chromatography to give compound 34 (50 mg, 10% yield). LC-MS: [M+H].sup.+=502.1.
Example 35
[0702] ##STR00514##
Step (1) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-hydroxyphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0703] ##STR00515##
[0704] 2,6-difluoro-4-hydroxybenzaldehyde (2.0 g, 9.05 mmol), 4-methylpyridin-2-amine (0.97 g, 9.05 mmol), compound 1-4 (1.9 g, 9.05 mmol), copper(I) chloride (0.27 g, 2.70 mmol) and copper(II) trifluoromethanesulfonate (0.98 g, 2.70 mmol) were dissolved in toluene solution (20 mL) under nitrogen atmosphere. The reaction system was reacted at 85° C. for 10 min, added with N,N-dimethylacetamide (0.5 mL), and reacted at 85° C. for another 5 h. Then the reaction system was reacted at room temperature overnight. After the reaction was completed, the reaction system was added with water (40 mL), and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography (40 g of silica gel, petroleum ether:ethyl acetate=1:1) to give intermediate 35-2 (1.2 g, 29% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=460.1.
Step (2) Preparation of (S)-3,5-difluoro-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)phenol
[0705] ##STR00516##
[0706] Intermediate 35-2 (1.0 g, 1.91 mmol) was dissolved in dichloromethane (10 mL), and a solution of HCl in ethanol (2 mL, 33%) was added dropwise. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. After the reaction was completed, the reaction system was added dropwise with saturated sodium bicarbonate solution to adjust the pH to 8, added with water (30 mL), and extracted with dichloromethane (40 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give intermediate 35-3 (800 mg) in the form of a yellow oil. LC-MS [M+H].sup.+=360.7.
Step (3) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-hydroxyphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0707] ##STR00517##
[0708] Intermediate 35-3 (350 mg, 0.97 mmol) and N,N-diisopropylethylamine (378 mg, 2.92 mmol) were dissolved in dichloromethane (10 mL), and methyl chloroformate (110 mg, 1.16 mmol) was added dropwise with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 3 h. After the reaction was completed, the reaction system was added with lithium hydroxide (1.0 mL, 3 N) solution, and reacted at room temperature for 2 h. After the reaction was completed, the reaction system was adjusted to pH 5 with diluted hydrochloric acid, diluted with water (10 mL), and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, and dried. The organic phase was filtered and concentrated by rotary evaporation. The residue was separated by HPLC to give compound 35 (150 mg, 37% yield) in the form of a yellow solid.
[0709] LC-MS: [M+H].sup.+=418.7. .sup.1H NMR (400 MHz, MeOD): δ 8.57 (d, J=6.9 Hz, 1H), 7.47 (s, 1H), 7.08 (d, J=6.9 Hz, 1H), 6.60 (d, J=9.6 Hz, 2H), 3.92-3.76 (m, 3H), 3.68 (s, 3H), 3.69-3.57 (m, 1H), 3.39 (dd, J=11.9, 2.7 Hz, 1H). 3.16-3.10 (m, 2H), 2.98-2.86 (m, 1H), 2.74-2.63 (m, 1H), 2.53 (s, 3H).
Example 36
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyloxy)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0710] ##STR00518##
[0711] Compound 35 (359 mg, 1 mmol) was dissolved in CH.sub.2Cl.sub.2 (10 mL), and triethylamine (2 mmol) was added. Methylaminoformyl chloride (186 mg, 2 mmol) was dissolved in anhydrous CH.sub.2Cl.sub.2 (2 mL) and the solution was added dropwise to the reaction system. After the reaction was completed, the reaction system was neutralized and washed, dried, filtered, and purified by column chromatography to give compound 36 (62 mg, 13% yield). LC-MS [M+H].sup.+=475.1.
Example 37
[0712] ##STR00519## ##STR00520##
Step (1) Preparation of 2-(3,5-difluorophenyl)-1,3-dioxolane
[0713] ##STR00521##
[0714] 3,5-difluorobenzaldehyde (5.68 g, 40 mmol), p-toluenesulfonic acid (0.69 g, 4 mmol) and ethylene glycol (7.45 g, 120 mmol) were dissolved in toluene (80 mL). The reaction system was refluxed for separating water overnight. Then the reaction system was cooled to room temperature, diluted with ethyl acetate (40 mL) and washed with NaHCO.sub.3 solution (40 mL×2). The organic phase was dried over Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The residue was purified by silica gel column chromatography (PE:EA=20:1) to give compound 37-3 (7.0 g, 94% yield) in the form of a white solid.
[0715] .sup.1H NMR (400 MHz, CDCl.sub.3): δ 7.03-7.00 (m, 2H), 6.82-6.76 (m, 1H), 5.79 (s, 1H), 4.09-4.05 (m, 2H), 4.07-3.99 (m, 2H).
Step (2) Preparation of 4-(1,3-dioxolan-2-yl)-2,6-difluorobenzaldehyde
[0716] ##STR00522##
[0717] Compound 37-3 (7.0 g, 37.8 mmol) was dissolved in tetrahydrofuran (50 mL). The reaction system was cooled to −78° C. under nitrogen atmosphere, and added dropwise with LDA (22.4 mL, 44.8 mmol). After the completion of the dropwise addition, the reaction system was reacted at this temperature for 30 min, then added with anhydrous DMF (3.3 g, 44.3 mmol). After the completion of the dropwise addition, the reaction system was reacted at this temperature for 2.5 h. Then the reaction system was added with saturated NH.sub.4Cl (20 mL) to quench the reaction, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated by rotary evaporation. The resulting crude product was purified by silica gel column chromatography (PE:EA=10:1) to give intermediate 37-4 (0.90 g, 12% yield) in the form of a white solid.
[0718] .sup.1H NMR (300 MHz, DMSO): δ 10.18 (s, 1H), 7.28 (d, J=9.8 Hz, 2H), 5.82 (s, 1H), 4.06-4.00 (m, 2H), 4.01-3.93 (m, 2H).
Step (3) Preparation of tert-butyl (S)-2-((2-(4-(1,3-dioxolan-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0719] ##STR00523##
[0720] Intermediate 37-4 (100 mg, 0.47 mmol), compound 1-4 (100 mg, 0.47 mmol), 4-methylpyridin-2-amine (51 mg, 0.47 mmol), copper(I) chloride (25 mg, 0.14 mmol), and copper(II) trifluoromethanesulfonate (51 mg, 0.14 mmol) were dissolved in toluene (3 mL) in a single-necked flask. The reaction system was heated to 85° C. under nitrogen atmosphere, added dropwise with two drops of DMA and reacted at this temperature for 5 h. Then the reaction system was cooled to room temperature and stirred overnight. The resulting reaction system was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The resulting crude product was purified by silica gel column chromatography (PE:EA=5:1) to give intermediate 37-5 (150 mg, 62% yield). LC-MS: [M+H].sup.+=516.7.
Step (4) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-formylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0721] ##STR00524##
[0722] Intermediate 37-5 (150 mg, 0.29 mmol) was dissolved in acetone (10 mL) and water (1 mL), and TsOH (90 mg, 0.3 mmol) was added. The reaction system was heated to 50° C. and reacted overnight. Then the reaction system was diluted with water (50 mL), added with Na.sub.2CO.sub.3 (92 mg, 0.87 mmol) and (Boc).sub.2O (75 mg, 0.35 mmol), stirred for 1.5 h and extracted with ethyl acetate (15 mL×2). The organic phases were combined, dried over anhydrous Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The resulting crude product was purified by silica gel column chromatography (PE:EA=5:1) to give intermediate 37-6 (60 mg, 44.8% yield) in the form of a white solid. LC-MS: [M+H].sup.+=472.7.
Step (5) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(4-trifluoromethyl-1H-imidazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0723] ##STR00525##
[0724] 3,3-dibromo-1,1,1-trifluoropropan-2-one (35 mg, 0.13 mmol) was dissolved in sodium acetate (2 mL, 15 weight %) solution. The reaction system was stirred at 90° C. for 30 min and cooled to room temperature. Intermediate 37-6 (50 mg, 0.11 mmol) was dissolved in methanol (3 mL) and strong ammonia (0.6 mL), and the solution was added to the reaction system, and stirred at room temperature overnight. Then the reaction system was concentrated by rotary evaporation. The residual liquid was extracted with ethyl acetate (5 mL×3) and washed with saturated brine (10 mL). The organic phase was dried over Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography (dichloromethane:methanol=50:1) to give intermediate 37-8 (45 mg, 72.2% yield) in the form of a white solid. LC-MS: [M+H].sup.+=578.6.
Step (6) Preparation of (S)-2-((2-(2,6-difluoro-4-(4-trifluoromethyl-1H-imidazole)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)meth yl)morpholine
[0725] ##STR00526##
[0726] Intermediate 37-8 (45 mg, 0.08 mmol) was dissolved in dichloromethane (3 mL), and a solution of HCl in ethanol (0.5 mL) was added. The reaction system was stirred at room temperature for 3 h. Then the reaction system was concentrated by rotary evaporation to give intermediate 37-9 (80 mg, crude product). LC-MS: [M+H].sup.+=478.7.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-trifluoromethyl-1H-imidazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0727] ##STR00527##
[0728] Intermediate 37-9 (80 mg, crude product) and DIPEA (30 mg, 0.23 mmol) were dissolved in dichloromethane (3 mL). The reaction system was cooled to 0° C. and stirred for 10 min. Then the reaction system was added dropwise with a solution of methyl chloroformate in dichloromethane (0.1 N, 0.8 mL), stirred for 3 h, added with water (10 mL) to quench the reaction and extracted with ethyl acetate (10 mL×3). The organic phase was dried over Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography (dichloromethane:methanol=20:1), prepared and lyophilized to give compound 37 (7.0 mg, 16.3% yield) in the form of a white solid product.
[0729] LC-MS: [M+H].sup.+=536.7. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 13.18 (s, 1H), 8.58 (brs, 1H), 7.97-7.93 (m, 3H), 7.53 (s, 1H), 7.16 (d, J=6.0 Hz, 1H), 4.05-3.70 (m, 3H), 3.71 (s, 3H), 3.64-3.56 (m, 1H), 3.45-3.30 (m, 1H), 3.09-2.85 (m, 3H), 2.74-2.64 (m, 1H), 2.60 (s, 3H).
Example 38
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-cyano-1H-imidazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0730] ##STR00528##
[0731] Compound 37 (30 mg, 0.05 mmol) was dissolved in methanol (2 mL), and strong ammonia (0.8 mL) and water (0.8 mL) were added. The reaction system was stirred at room temperature for 36 h. Then the reaction system was diluted with water (10 mL) and extracted with ethyl acetate (10 mL×3). The organic phase was dried over Na.sub.2SO.sub.4 and filtered, and the filtrate was concentrated by rotary evaporation. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol=20:1) and lyophilized to give compound 38 (11 mg, 44.6% yield) in the form of a white solid product.
[0732] LC-MS: [M+H].sup.+=493.6. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 15.61 (brs, 1H), 8.31 (d, J=7.0 Hz, 1H), 7.74 (s, 1H), 7.47 (s, 1H), 7.33 (d, J=7.2 Hz, 2H), 6.85 (d, J=7.0 Hz, 1H), 3.97-3.72 (m, 3H), 3.66 (s, 3H), 3.62-3.52 (m, 1H), 3.42-3.30 (m, 1H), 3.03-2.85 (m, 3H), 2.65-2.55 (m, 1H), 2.54 (s, 3H).
Example 39
[0733] ##STR00529## ##STR00530##
Step (1) Preparation of N-(2-bromo-5-methylphenyl)-2,2,2-trifluoroacetamide
[0734] ##STR00531##
[0735] 2-bromo-5-methylbenzenamine (2.5 g, 13.44 mmol) and pyridine (3.3 mL, 40.32 mmol) were dissolved in dichloromethane (30 mL). The reaction system was added dropwise with trifluoroacetic anhydride (3.4 g, 16.12 mmol) at 0° C. and reacted at room temperature overnight. The reaction mixture was washed with water (10 mL×2) and diluted hydrochloric acid (30 mL, 1 mol/L) sequentially, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to give compound 39-3 (3.4 g, 90% yield) in the form of a gray solid, LC-MS: [M+H].sup.+=281.7.
Step (2) Preparation of R-(morpholin-2-yl) methanol
[0736] ##STR00532##
[0737] (R)—N-Boc-2-hydroxymethylmorpholine (3.5 g, 16.13 mmol) was dissolved in dichloromethane (20 mL), and a solution of HCl in ethanol (3.5 mL, 33%) was added dropwise at 0° C. The reaction system was stirred at room temperature overnight, and concentrated under reduced pressure to give compound 39-5 (1.8 g, 95% yield, crude product) in the form of a yellow oil. LC-MS: [M+H].sup.+=118.1.
Step (3) Preparation of methyl (R)-2-(hydroxymethyl)morpholine-4-carboxylate
[0738] ##STR00533##
[0739] Compound 39-5 (4.0 g, 16.13 mmol) was dissolved in dichloromethane (40 mL), and DIPEA (12.5 g, 96.78 mmol) was added dropwise at 0° C. Then methyl chloroformate (1.97 g, 20.97 mmol) was dissolved in dichloromethane (10 mL) and added dropwise to the reaction system at 0° C. The reaction system was stirred at room temperature overnight, added with dichloromethane (100 mL), washed with brine (35 mL×2), and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20 g of silica gel, ethyl acetate:petroleum ether=1:2) to give intermediate 39-6 (1.0 g, 35% yield) in the form of a colorless oil. LC-MS: [M+H].sup.+=176.9.
Step (4) Preparation of methyl (R)-2-formylmorpholine-4-carboxylate
[0740] ##STR00534##
[0741] Intermediate 39-6 (600 mg, 3.43 mmol) was dissolved in dichloromethane (10 ml), and Dess-Martin periodinane (1.74 g, 4.11 mmol) was added. The reaction system was reacted at room temperature for 2 h, added with saturated sodium thiosulfate (2 mL) and stirred for 30 min. Then the reaction system was extracted with dichloromethane (30 mL×2), washed with brine (15 mL), and purified by silica gel column chromatography (12 g of silica gel, ethyl acetate:petroleum ether=1:1) to give intermediate 39-A (180 mg, 30% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=174.5.
Step (5) Preparation of 4-ethynyl-3,5-difluoro-N-methylbenzamide
[0742] ##STR00535##
[0743] Dimethyl (1-diazo-2-oxopropyl)phosphonate (2.2 g, 11.3 mmol) was dissolved in acetonitrile (15 mL) and methanol (3 mL), then potassium carbonate (2.3 g, 16.56 mmol) was added. The reaction system was stirred at room temperature for 30 min, added with 3,5-difluoro-4-formyl-N-methylbenzamide (1.5 g, 7.53 mmol), and stirred at room temperature overnight. Then the reaction system was filtered and concentrated. The residue was purified by silica gel column chromatography (20 g of silica gel, ethyl acetate:petroleum ether=1:5) to give intermediate 39-8 (1.2 g, 81% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=196.1.
Step (6) Preparation of 3,5-difluoro-4-(6-methyl-1H-indol-2-yl)benzamide
[0744] ##STR00536##
[0745] Intermediate 39-8 (1.4 g, 7.18 mmol), intermediate 39-3 (2.43 g, 8.61 mmol), potassium carbonate (1.97 g, 15.09 mmol), copper(I) iodide (0.14 g, 1.43 mmol) and L-proline (0.25 g, 2.87 mmol) were added to N,N-dimethylformamide (20 mL). The reaction system was reacted at 80° C. overnight under nitrogen atmosphere. Then the reaction system was cooled, poured into water (60 mL), extracted with ethyl acetate (50 mL×2), washed with saturated brine (30 mL×3), and purified by silica gel column chromatography (20 g of silica gel, developing agent: ethyl acetate:petroleum ether=1:2) to give intermediate 39-9 (800 mg, 44% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=301.8.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylindol-3-yl)methyl)morpholine-4-carboxylate
[0746] ##STR00537##
[0747] Trifluoroacetic acid (304 mg, 2.66 mmol) and triethylsilane (617 mg, 5.32 mmol) were dissolved in dichloromethane (3 mL) in a round-bottom flask (25 mL). Intermediate 39-9 (160 mg, 0.53 mmol) and intermediate 39-A (110 mg, 0.64 mmol) were then dissolved in dichloromethane (3 mL), and the solution was added dropwise to the reaction system at 0° C. The reaction system was stirred at room temperature overnight. Then the reaction system was added with water (20 mL), extracted with dichloromethane (20 mL×2), and separated by preparative reverse phase chromatography to give compound 39 (18 mg, 7.4% yield) in the form of a white solid.
[0748] LC-MS: [M+H].sup.+=458.2. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.18 (brs, 1H), 7.62 (d, J=8.2 Hz, 1H), 7.43 (d, J=7.5 Hz, 2H), 7.21 (s, 1H), 7.02 (d, J=8.1 Hz, 1H), 6.29 (brs, 1H), 3.88-3.75 (m, 3H), 3.64 (s, 3H), 3.60-3.55 (m, 1H), 3.45-3.39 (m, 1H), 3.07 (d, J=3.6 Hz, 3H), 3.04-2.98 (m, 1H), 2.90-2.88 (m, 1H), 2.78 (dd, J=14.9, 6.6 Hz, 1H), 2.50 (s, 3H), 2.49-2.41 (m, 1H).
Example 40
[0749] ##STR00538##
Step (1) Preparation of methyl (R)-2-(((methylsulfonyl)oxo)methyl)morpholine-4-carboxylate
[0750] ##STR00539##
[0751] Intermediate 39-6 (400 mg, 2.28 mmol) and N,N-diisopropylethylamine (737 mg, 5.71 mmol) were dissolved in dichloromethane (10 mL), and methylsufonyl chloride (313 mg, 2.74 mmol) was added dropwise at 0° C. After the completion of the dropwise addition, the reaction system was reacted at room temperature overnight. Then the reaction system was added with dichloromethane (20 mL), washed with saturated brine (15 mL×2), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to give intermediate 40-1 (600 mg, crude product) in the form of a brown oil. LC-MS: [M+H].sup.+=254.9.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-indol-1-yl)methyl)morpholine-4-carboxylate
[0752] ##STR00540##
[0753] Intermediate 39-9 (250 mg, 0.83 mmol) was dissolved in N,N-dimethylformamide (5 mL), and intermediate 40-1 (421 mg, 1.67 mmol) and potassium tert-butoxide (205 mg, 1.83 mmol) were added at room temperature. The reaction system was stirred at 120° C. overnight under nitrogen atmosphere. Then the reaction system was cooled to room temperature, added with water (20 mL), and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by preparative reverse phase chromatography to give compound 40 (35 mg, 9.2% yield) in the form of a white solid.
[0754] LC-MS: [M+H].sup.+=458.8. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 7.57 (d, J=8.1 Hz, 1H), 7.43 (d, J=7.7 Hz, 1H), 7.22 (s, 1H), 7.03 (d, J=8.1 Hz, 1H), 6.61 (s, 1H), 6.22 (brs, 1H), 4.15-3.99 (m, 2H), 3.85-3.60 (m, 3H), 3.67 (s, 3H), 3.60-3.50 (m, 1H), 3.32 (t, 1H), 3.08 (d, J=4.7 Hz, 3H), 2.81 (t, J=11.6 Hz, 1H), 2.54 (s, 3H), 2.39 (dd, J=13.0, 10.8 Hz, 1H).
Example 41
[0755] ##STR00541##
[0756] The compound was prepared according to the preparation method as described in Example 40.
[0757] LC-MS: [M+H].sup.+=461.2.
Example 42
[0758] ##STR00542## ##STR00543## ##STR00544##
Step (1) Preparation of ethyl 2-(4-phenylmethylmorpholin-2-yl)acetate
[0759] ##STR00545##
[0760] 2-(phenylmethylamino)ethanol (45.0 g, 298 mmol) and triethylamine (30.0 g, 298 mmol) were dissolved in water (450 mL). The reaction system was heated to 100° C., added with (E)-ethyl-4-bromobut-2-enoate (57.5 g, 298 mmol), reacted overnight, and extracted with ethyl acetate (200 mL×3). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=10/1) to give compound 42-3 (27.0 g, 35% yield) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=264.2.
Step (2) Preparation of 2-(4-phenylmethylmorpholin-2-yl)ethanol
[0761] ##STR00546##
[0762] Compound 42-3 (27.0 g, 103 mmol) was dissolved in tetrahydrofuran (300 mL). The reaction system was cooled to 0° C. under nitrogen atmosphere. added with lithium aluminum hydride (3.9 g, 103 mmol) in portions, and warmed to room temperature and stirred for 3 h. Then the reaction system was added with sodium sulfate decahydrate to quench the reaction, filtered, and washed with ethyl acetate, and the filtrate was concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give compound 42-4 (17.4 g, 76% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=222.1.
Step (3) Preparation of tert-butyl 2-(2-hydroxyethyl)morpholine-4-carboxylate
[0763] ##STR00547##
[0764] Compound 42-4 (17.6 g, 78.4 mmol) and di-tert-butyl dicarbonate (51.3 g, 235 mmol) were dissolved in absolute methanol (180 mL), and palladium on carbon (1.74 g, 10%) was added. The reaction system was purged with hydrogen and stirred at room temperature overnight. Then the reaction system was filtered, and the filtrate was concentrated. The residue was separated by column chromatography (PE/EA=3/1) to give compound 42-5 (12.5 g, 68% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=232.3.
Step (4) Preparation of tert-butyl 2-(2-carbonylethyl)morpholine-4-carboxylate
[0765] ##STR00548##
[0766] Compound 42-5 (2.0 g, 1.44 mmol) was dissolved in dichloromethane (40 mL), and Dess-Martin periodinane (5.5 g, 2.15 mmol) was added. The reaction system was stirred at room temperature for 2 h. Then the reaction system was added with sodium thiosulfate to quench the reaction, and extracted with dichloromethane (40 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give compound 42-6 (1.1 g, 67% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=230.1.
Step (5) Preparation of tert-butyl 2-(prop-2-yn-1-yl)morpholine-4-carboxylate
[0767] ##STR00549##
[0768] Dimethyl (1-diazo-2-oxopropyl)phosphonate (4.0 g, 20.9 mmol) was dissolved in dichloromethane (40 mL) and acetonitrile (8 mL). The reaction system was stirred at room temperature for 15 min, added with compound 42-6 (4.0 g, 17.5 mmol) and potassium carbonate (2.4 g, 17.5 mmol), and stirred at room temperature overnight. Then the reaction system was filtered, and the filtrate was concentrated. The residue was separated by column chromatography (PE/EA=10/1) to give compound 42-7 (2.1 g, 53% yield) in the form of a colorless oily liquid. LC-MS: [M−55].sup.+=226.2.
Step (6) Preparation of tert-butyl 2-(3-bromoprop-2-yn-1-yl)morpholine-4-carboxylate
[0769] ##STR00550##
[0770] Compound 42-7 (2.1 g, 9.3 mmol) and silver nitrate (1.9 g, 11.1 mmol) were dissolved in acetone (20 mL), and N-bromosuccinimide (1.8 g, 10.2 mmol) was added. The reaction system was stirred at room temperature for 4 h, and extracted with ethyl acetate (60 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=20/1) to give intermediate 42-8 (2.0 g, 71% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=304.2.
Step (7) Preparation of tert-butyl 2-((2-bromo-7-methylimidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine-4-carboxylate
[0771] ##STR00551##
[0772] Intermediate 42-8 (2.0 g, 6.5 mmol), 6-methylpyrimidin-4-amine (0.85 g, 7.9 mmol) and copper(II) trifluoromethanesulfonate (0.24 g, 0.65 mmol) were dissolved in acetonitrile (20 mL). The reaction system was stirred at room temperature overnight under oxygen atmosphere, diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give intermediate 42-10 (400 mg, 15% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=411.1.
Step (8) Preparation of tert-butyl 2-((7-methyl-2-(tributylstannyl)imidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine-4-carboxylate
[0773] ##STR00552##
[0774] Intermediate 42-10 (40 mg, 0.1 mmol), 1,1,1,2,2,2-hexabutyldistannane (170 mg, 0.3 mmol) and tetrakis(triphenylphosphine)palladium (11 mg, 0.01 mmol) were dissolved in 1,4-dioxane (2 mL). The reaction system was stirred at 100° C. overnight under nitrogen atmosphere, and detected by LC-MS for completion to give intermediate 42-11 (5% yield). LC-MS: [M+H].sup.+=623.5.
Step (9) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine-4-carboxylate
[0775] ##STR00553##
[0776] The compound was prepared according to the preparation method for compound 37-9.
Step (10) Preparation of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine
[0777] ##STR00554##
[0778] The compound was prepared according to the preparation method as described in step (6) of Example 37.
Step (11) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine-4-carboxylate
[0779] ##STR00555##
[0780] The compound was prepared according to the preparation method as described in step (7) of Example 37.
[0781] LC-MS: [M+H].sup.+=460.2.
Example 43
[0782] ##STR00556## ##STR00557##
Step (1) Preparation of 4-bromo-3,5-difluoro-N-(4-methoxybenzyl)-N-methylbenzenesulfonamide
[0783] ##STR00558##
[0784] 1-(4-methoxyphenyl)-N-methylmethylamine (1.30 g, 8.24 mmol) and triethylamine (2.10 g, 20.61 mmol) were dissolved in dichloromethane (16 mL), and a solution of 4-bromo-3,5-difluorobenzenesulfonyl chloride (2.00 g, 6.87 mmol) in dichloromethane (4 mL) was added dropwise at 0° C. The reaction system was warmed to room temperature and reacted for 4 h. Then the reaction system was added with water (50 mL) to quench the reaction, extracted with dichloromethane (50 mL×2), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 43-3 (2.30 g, 78% yield) in the form of a white solid. MS [M+Na]=427.6, 429.6.
Step (2) Preparation of 3,5-difluoro-4-formyl-N-(4-methoxybenzyl)-N-methylbenzenesulfonamide
[0785] ##STR00559##
[0786] Intermediate 43-3 (1.70 g, 4.19 mmol) was dissolved in anhydrous tetrahydrofuran (17 mL) under nitrogen atmosphere, and n-butyllithium (2.4 mol/L, 1.75 mL) was added dropwise at 78° C. After the completion of the dropwise addition, the reaction system was stirred at this temperature for 0.5 h, added dropwise with N,N-dimethylformamide (367 mg, 5.03 mmol), and reacted for 3 h. Then the reaction system was added with diluted hydrochloric acid (0.5 mol/L, 10 mL) to quench the reaction, diluted with water (50 mL) and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 43-4 (600 mg, 32% yield) in the form of a white solid. MS [M+Na]=377.8.
Step (3) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(N-(4-methoxybenzyl)-N-methylsulfamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0787] ##STR00560##
[0788] Intermediate 43-4 (600 mg, 1.69 mmol), 4-methylpyridin-2-amine (183 mg, 1.69 mmol) and tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (359 mg, 1.69 mmol) were dissolved in toluene (6 mL) under nitrogen atmosphere, and copper(I) chloride (50 mg, 0.51 mmol) and copper(II) trifluoromethanesulfonate (183 mg, 0.51 mmol) were added. The reaction system was reacted at 85° C. for 10 min, added with dimethylacetamide (0.1 mL), and reacted at 85° C. for another 5 h. Then the reaction system was stirred at room temperature overnight. The resulting reaction system was filtered, and the filtrate was added with water (30 mL) and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 43-5 (298 mg, 27% yield) in the form of a light yellow solid. MS [M+H].sup.+=656.7.
Step (4) Preparation of (S)-3,5-difluoro-N-(4-methoxybenzyl)-N-methyl-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzenesulfonamide hydrochloride
[0789] ##STR00561##
[0790] Intermediate 43-5 (298 mg, 0.45 mmol) was dissolved in dichloromethane (5 mL), and a solution of HCl in ethanol (33%, 0.45 mL) was added dropwise. The reaction system was reacted at room temperature for 16 h. Then the reaction system was concentrated under reduced pressure to give intermediate 43-6 (300 mg, crude product as a hydrochloride) in the form of a light yellow solid. MS [M+H].sup.+=556.8.
Step (5) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(N-(4-methoxybenzyl)-N-methylsulfamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0791] ##STR00562##
[0792] Intermediate 43-6 (300 mg, 0.50 mmol) was dissolved in dichloromethane (5 mL) under nitrogen atmosphere, and triethylamine (202 mg, 2.00 mmol) was added at 0° C., followed by the dropwise addition of a solution of methyl chloroformate (57 mg, 0.60 mmol) in dichloromethane (1 mL). The reaction system was reacted at 0° C. for 4 h. Then the reaction system was added with water (20 mL) to quench the reaction, and extracted with dichloromethane (20 mL×2). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 43-7 (200 mg, 88% purity, 64.5% yield) in the form of a brown solid. MS [M+H].sup.+=615.2.
Step (6) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(N-methylsulfamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0793] ##STR00563##
[0794] Intermediate 43-7 (200 mg, 0.32 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added at 0° C. The reaction system was reacted at room temperature for 16 h. Then the reaction system was concentrated under reduced pressure. The residue was dissolved in dichloromethane (40 mL), washed with aqueous sodium bicarbonate solution (10%, 15 mL×2) and saturated brine (15 mL) sequentially, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative chromatography to give compound 43 (80.2 mg, 49.8% yield) in the form of a white solid.
[0795] MS [M+H].sup.+=494.7. 1H NMR (400 MHz, CDCl3) δ 8.58 (d, J=5.2 Hz, 1H), 7.93 (s, 1H), 7.61 (d, J=6.7 Hz, 2H), 7.20 (d, J=7.1 Hz, 1H), 5.11-4.95 (m, 1H), 4.22-4.06 (m, 1H), 3.96-3.90 (m, 1H), 3.86-3.77 (m, 1H), 3.74 (s, 3H), 3.69-3.63 (m, 1H), 3.45-3.39 (m, 1H), 3.13-3.02 (m, 2H), 3.01-2.92 (m, 1H), 2.79 (s, 3H), 2.75-2.70 (m, 1H), 2.63 (s, 3H).
Example 44
[0796] ##STR00564##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0797] ##STR00565##
[0798] The compound was prepared according to patent literature CN105246888A.
Step (2) Preparation of methyl (2S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[0799] ##STR00566##
[0800] Positive compound 1 (120 mg, 0.3 mmol) and concentrated hydrochloric acid (0.1 mL) were dissolved in absolute methanol (3 mL). The reaction system was purged with hydrogen and stirred at room temperature for 6 h. Then the reaction system was filtered and concentrated. The residue was diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate (15 mL) and saturated brine (15 mL) sequentially, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH=40/1) to give compound 44 (61 mg, 50% yield) in the form of a white solid.
[0801] LC-MS: [M+H].sup.+=463.2. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 7.48 (brs, 2H), 4.30-4.23 (m, 1H), 4.12-4.04 (m, 1H), 3.99-3.69 (m, 4H), 3.68 (s, 3H), 3.40-3.30 (s, 2H), 3.20-3.10 (m, 1H), 3.03 (d, J=3.5 Hz, 3H), 2.92-2.80 (m, 1H), 2.74-2.62 (m, 2H), 2.60-2.44 (m, 2H), 2.18-2.06 (m, 2H), 1.80-1.68 (m, 1H), 1.20 (d, J=5.8 Hz, 3H).
Example 45
[0802] ##STR00567##
Step (1) Preparation of methyl (S)-2-((2-(4-(4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0803] ##STR00568##
[0804] Intermediate 2-7 (250 mg, 0.52 mmol) was dissolved in anhydrous toluene (3 mL) and tert-butyl 3-carbonylpiperazine-1-carboxylate (125 mg, 0.62 mmol), potassium carbonate (216 mg, 1.56 mmol), trans-(1R,2R)—N,N′-dimethyl-1,2-cyclohexanediamine (7.4 mg, 0.052 mmol) and copper(I) iodide (10 mg, 0.052 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 110° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature, and filtered, and the filtrate was added with water (10 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×1), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by column chromatography (4 g of silica gel column, petroleum ether:ethyl acetate=1:1) to give intermediate 45-2 in the form of a yellow oil (200 mg, 64% yield), LC-MS: [M+H].sup.+=600.9.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2-oxopiperazin-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0805] ##STR00569##
[0806] Intermediate 45-2 (200 mg, 0.33 mmol) was dissolved in dichloromethane (5 mL), and a solution of HCl in ethanol (33%, 0.5 mL) was added dropwise with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. After the reaction was completed, the reaction system was added dropwise with saturated sodium bicarbonate solution to adjust the pH to 8 with the temperature maintained at 0° C., added with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×1), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give intermediate 45-3 (175 mg) in the form of a yellow oil, LC-MS: [M+H].sup.+=500.9.
Step (3) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-methyl-2-oxopiperazin-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[0807] ##STR00570##
[0808] Intermediate 45-3 (175 mg, 0.35 mmol) and aqueous formaldehyde solution (37%, 30 mg, 0.364 mmol) were dissolved in dichloromethane (3 mL), and sodium triacetoxyborohydride (287 mg, 1.36 mmol) was slowly added. The reaction system was reacted at room temperature for 3 h. After the reaction was completed, the reaction system was added with water (10 mL) and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL×1), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by column chromatography to give compound 45 (74 mg, 41% yield) in the form of a yellow solid.
[0809] LC-MS: [M+H].sup.+=514.7. .sup.1H NMR (400 MHz, MeOD): δ 8.86 (d, J=7.1 Hz, 1H), 7.73 (s, 1H), 7.51 (d, J=9.0 Hz, 2H), 7.43 (dd, J=7.1, 1.4 Hz, 1H), 4.18 (m, 3H), 4.18-4.11 (m, 1H), 4.01 (d, J=13.0 Hz, 1H), 3.88-3.74 (m, 4H), 3.70 (s, 3H), 3.69-3.65 (m, 1H), 3.40-3.32 (m, 1H), 3.26 (d, J=5.7 Hz, 2H), 3.10 (s, 3H), 2.00-2.86 (m, 1H), 2.82-2.70 (m, 1H), 2.65 (s, 3H).
Example 46
[0810] ##STR00571## ##STR00572##
Step (1) Preparation of 1-tert-butyl-4-methyl (R)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate
[0811] ##STR00573##
[0812] Tert-butyl (R)-2-(hydroxymethyl)piperazine-1-carboxylate (2.0 g, 9.0 mmol) and N,N-diisopropylethylamine (3.6 g, 27.0 mmol) were dissolved in dichloromethane (20 mL). Under nitrogen atmosphere, the reaction system was cooled to 0° C., added with methyl chloroformate (1.0 g, 11.0 mmol), and warmed to room temperature and reacted for 1 h. Then the reaction system was extracted with ethyl acetate (25 mL×3). The organic phase was washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give intermediate 46-2 (1.7 g, 68% yield) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=275.2.
Step (2) Preparation of 1-tert-butyl-4-methyl (R)-2-formylpiperazine-1,4-dicarboxylate
[0813] ##STR00574##
[0814] Intermediate 46-2 (1.7 g, 6.0 mmol) was dissolved in dichloromethane (30 mL). Under nitrogen atmosphere, the reaction system was cooled to 0° C., added with Dess-Martin periodinane (3.9 g, 9.0 mmol), and warmed to room temperature and stirred for 2 h. Then the reaction system was extracted with dichloromethane (30 mL×3). The organic phase was washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give intermediate 46-3 (360 mg, 21% yield) in the form of a colorless oily liquid. LC-MS: [M−55].sup.+=217.1.
Step (3) Preparation of 1-tert-butyl-4-methyl (S)-2-ethynylpiperazine-1,4-dicarboxylate
[0815] ##STR00575##
[0816] Compound 1-3 (305 mg, 1.6 mmol) and potassium carbonate (365 mg, 2.6 mmol) were dissolved in acetonitrile (2.5 mL) and absolute methanol (0.5 mL). The reaction system was stirred at room temperature for 15 min, added with a dissolved solution of intermediate 46-3 (360 mg, 1.3 mmol) in acetonitrile (2.5 mL) and absolute methanol (0.5 mL), and stirred at room temperature overnight. Then the reaction system was filtered and concentrated. The residue was separated by column chromatography (PE/EA=10/1) to give intermediate 46-4 (165 mg, 46% yield) in the form of a white oily liquid. LC-MS: [M−55].sup.+=213.7.
Step (4) Preparation of methyl (S)-2-((2-(2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-1-tert-butyl carboxylate-piperazine-4-carboxylate
[0817] ##STR00576##
[0818] Intermediate 46-4 (165 mg, 0.6 mmol), 4-methylpyridin-2-amine (66 mg, 0.6 mmol), 3,5-difluoro-4-formyl-N-methylbenzamide (123 mg, 0.6 mmol), copper(I) chloride (18 mg, 0.2 mmol) and copper(II) trifluoromethanesulfonate (67 g, 0.2 mmol) were dissolved in anhydrous toluene (3 mL). The reaction system was heated to 85° C., added with N,N-dimethylacetamide (0.2 mL), and reacted at 85° C. for 5 h. Then the reaction system was cooled to room temperature and reacted overnight, and extracted with dichloromethane (15 mL×3). The organic phase was washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (DCM/MeOH=40/1) to give intermediate 46-6 (105 mg) in the form of a brown solid. LC-MS: [M+H].sup.+=558.2.
Step (5) Preparation of methyl (S)-2-((2-(2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)piperazine-4-carboxylate
[0819] ##STR00577##
[0820] Intermediate 46-6 (105 mg, 0.2 mmol) was dissolved in anhydrous dichloromethane (2 mL). The reaction system was cooled to 0° C., added dropwise with a solution of HCl in ethanol (0.5 mL), and warmed to room temperature and stirred for 1 h. Then the reaction system was concentrated. The residue was separated by preparative reverse phase chromatography to give compound 46 (3.5 mg) in the form of a white solid.
[0821] LC-MS: [M+H].sup.+=458.5. .sup.1H NMR (400 MHz, MeOD): δ 8.75 (brs, 1H), 7.84 (m, 3H), 7.42 (brs, 1H), 4.10-4.02 (m, 2H), 3.70-3.66 (m, 1H), 3.66 (s, 3H), 3.57-3.37 (m, 3H), 3.20-3.10 (m, 2H), 2.98 (s, 3H), 2.95-2.85 (m, 1H), 2.64 (s, 3H).
Example 47
[0822] ##STR00578##
Step (1) Preparation of methyl 3,5-difluoro-4-(3-(hydroxymethyl)-7-methylimidazo[1,2-a]pyridin-2-yl)benzoate
[0823] ##STR00579##
[0824] Intermediate 47-1 (synthesized according to the preparation method for intermediate 31-7, LC-MS [M+H].sup.+: 303.18) (1.2 g, 4.0 mmol) was dissolved in acetonitrile (8 mL), and acetic acid (8 mL), aqueous formaldehyde solution (0.25 mL, 24 mmol) and sodium acetate (1.31 g, 16 mmol) were added. The reaction system was heated to 50° C. and reacted for 16 h. Then the reaction system was concentrated by rotary evaporation to remove the solvent. The residue was diluted with dichloromethane (50 mL), and washed with saturated aqueous sodium bicarbonate solution (20 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (DCM/MeOH=50/1) to give intermediate 47-2 (945 mg, 71% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=333.2.
Step (2) Preparation of methyl 4-(3-(chloromethyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzoate
[0825] ##STR00580##
[0826] Intermediate 47-2 (1.2 g, 4.0 mmol) was dissolved in dichloromethane (15 mL), and thionyl chloride (4 mL) was added at 0° C. The reaction system was reacted at 0° C. for 3 h. Then the reaction system was concentrated by rotary evaporation to remove the solvent to give intermediate 47-2 (900 mg) in the form of a yellow solid. LC-MS: [M+H].sup.+=336.1.
Step (3) Preparation of methyl 3,5-difluoro-4-(7-methyl-3-((3-oxo-4-morpholinyl)methyl)imidazo[1,2-a]pyridin-2-yl)benzoate
[0827] ##STR00581##
[0828] Morpholin-3-one (101 mg, 1.0 mmol) was dissolved in DMF (5 mL), and sodium hydride (80 mg, 2 mol) was added in an ice bath. The reaction system was reacted for 0.5 h, added with methyl intermediate 47-4 (351 mg, 1 mmol), and reacted at room temperature for 16 h. Then the reaction system was poured into ice water (10 mL), extracted with dichloromethane (10 mL×2), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated by rotary evaporation to give intermediate 47-5 (120 mg) in the form of a yellow solid. LC-MS: [M+H].sup.+=416.4.
Step (4) Preparation of 3,5-difluoro-4-(7-methyl-3-((3-oxo-4-morpholinyl)methyl)imidazo[1,2-a]pyridin-2-yl)benzoic acid
[0829] ##STR00582##
[0830] Intermediate 47-5 (120 mg, 0.29 mmol) was dissolved in THF (9 mL), and MeOH (3 mL), H.sub.2O (3 mL), and lithium hydroxide (61 mg, 1.45 mmol) were added sequentially. The reaction system was stirred at room temperature overnight, then diluted with water (10 mL), and concentrated by rotary evaporation under reduced pressure to remove the organic solvent. The aqueous phase was adjusted to pH 5-6 with hydrochloric acid (1 N), and extracted with dichloromethane (10 mL×2). The organic phase was dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated by rotary evaporation. The residue was purified by silica gel column chromatography (DCM/MeOH=15:1) to give intermediate 47-6 (85 mg, 72.4% yield) in the form of a white solid. LC-MS: [M+H].sup.+=402.3.
Step (5) Preparation of 3,5-difluoro-N-methyl-4-(7-methyl-3-((3-oxo-4-morpholinyl)methyl)imidazo[1,2-a]pyridin-2-yl)benzamide
[0831] ##STR00583##
[0832] Intermediate 47-6 (80 mg, 0.2 mmol) was dissolved in DMF (5 mL), and methylamine hydrochloride (20 mg, 0.3 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and triethylamine (44 mg, 0.4 mmol) were added sequentially. The reaction system was stirred at room temperature overnight. Then the reaction system was diluted with water (15 mL), extracted with ethyl acetate (10 mL×2), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated by rotary evaporation. The residue was purified by silica gel column chromatography (DCM/MeOH=30:1) to give compound 47 (21 mg, 20% yield) in the form of a white solid.
[0833] LC-MS: [M+H].sup.+=415.1. .sup.1H NMR (400 MHz, MeOD): δ 8.44 (d, J=6.9 Hz, 1H), 7.64 (d, J=7.8 Hz, 2H), 7.43 (s, 1H), 6.96 (d, J=6.9 Hz, 1H), 5.00 (s, 2H), 4.14-4.12 (m, 2H), 3.75-3.71 (m, 2H), 3.04-3.01 (m, 2H), 2.98 (s, 3H), 2.47 (s, 3H).
Example 48
[0834] ##STR00584##
Step (1) Preparation of 4-(3-((4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro benzoic acid
[0835] ##STR00585##
[0836] Tert-butyl 3-carbonylpiperazine-carboxylate (400 mg, 2.0 mmol) was dissolved in N,N-dimethylformamide (10 mL). The reaction system was cooled in an ice water bath for 5 min, added with sodium hydride (120 mg, 3.0 mmol) slowly, and reacted for 30 min. Then the reaction system was added with intermediate 47-3 (350 mg, 1.0 mmol) (60% purity shown on LC-MS) and stirred overnight. After the reaction was quenched with saturated ammonium chloride solution (5 mL), the reaction system was added dropwise with hydrochloric acid (1 N) to adjust the pH to 3-4, diluted with water (20 mL), and extracted with dichloromethane extraction (45 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by column chromatography (DCM/CH.sub.3OH=10/1) to give intermediate 48-1 (300 mg, 50% purity shown on LC-MS) in the form of a light yellow solid. LC-MS: [M+H].sup.+=501.2.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-carbomethoxyphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-carbonylpiperazine-carboxylate
[0837] ##STR00586##
[0838] Intermediate 48-1 (300 mg, 0.69 mmol) was dissolved in methanol (5 mL). The reaction system was added dropwise with acetyl chloride (0.5 mL), and stirred overnight. Then the reaction system was concentrated, diluted with dichloromethane (25 mL), and washed with saturated sodium bicarbonate solution (15 mL). The aqueous phase was extracted with dichloromethane (20 mL×2). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by column chromatography (PE/EA=1/1) to give intermediate 48-2 (70 mg, 60% purity shown on LC-MS) in the form of a colorless oily liquid, LC-MS: [M+H].sup.+=515.1.
Step (3) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-carbonyl piperazine-carboxylate
[0839] ##STR00587##
[0840] Intermediate 48-2 (70 mg, 0.13 mmol) was dissolved in ethanol (5 mL), and aqueous methylamine solution (2 mL, 25-30% w/w) was added. The reaction system was stirred at room temperature overnight. Then the reaction system was added with H.sub.2O (15 mL) to quench the reaction, and extracted with ethyl acetate (15 mL×2). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give intermediate 48-3 (60 mg, 60% purity shown on LC-MS) in the form of a colorless oily liquid. LC-MS: [M+H].sup.+=514.1.
Step (4) Preparation of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-2-carbonyl-piperazine
[0841] ##STR00588##
[0842] Intermediate 48-3 (60 mg, 0.12 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (3 mL) was added. The reaction system was stirred overnight at room temperature, concentrated by rotary evaporation, diluted with dichloromethane (40 mL), washed with saturated sodium bicarbonate solution (10 mL), washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The residue was purified by preparative chromatography, and lyophilized to give compound 48 (3 mg) in the form of a white solid.
[0843] LC-MS: [M+H].sup.+=414.1. .sup.1H NMR (400 MHz, MeOD): δ 8.47 (d, J=7.2 Hz, 1H), 7.64 (d, J=7.8 Hz, 2H), 7.42 (s, 1H), 6.95 (d, J=7.2 Hz, 2H), 4.99 (s, 2H), 3.42 (s, 2H), 3.00-2.95 (m, 5H), 2.87 (t, J=5.2 Hz, 2H), 2.49 (s, 3H).
Example 49
[0844] ##STR00589## ##STR00590##
Step (1) Preparation of tert-butyl 3,5-difluorobenzoate
[0845] ##STR00591##
[0846] 3,5-difluorobenzoic acid (10 g, 63.25 mmol) was dissolved in tert-butanol (100 mL), and DMAP (12.3 g, 18.975 mmol) and Boc-anhydride (27.6 g, 126.5 mmol) were added. The reaction system was reacted at room temperature for 15 h. Then the reaction system was concentrated, diluted with water (150 mL) and extracted with ethyl acetate (50 mL×3). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography (PE/EA=20/1) to give compound 49-2 (12 g, 88% yield) in the form of a colorless oily liquid.
Step (2) Preparation of tert-butyl 3,5-difluoro-4-formylbenzoate
[0847] ##STR00592##
[0848] LDA (2 M, 8.4 mL) was dissolved in tetrahydrofuran (10 mL). The reaction system was cooled to −78° C. under nitrogen atmosphere. Compound 49-2 (3 g, 14 mmol) was dissolved in tetrahydrofuran (20 mL), and the solution was added to the reaction system. The reaction system was stirred at −78° C. for 1.5 h, added with DMF (1.228 g, 16.8 mmol), and stirred for another 1 h with the temperature maintained not higher than −70° C. Then the reaction system was added with saturated aqueous ammonium chloride solution (60 mL) to quench the reaction, and extracted with ethyl acetate (30 mL×3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was separated by column chromatography (PE/EA=10/1) to give compound 49-3 (1.5 g, 44% yield) in the form of a yellow solid.
Step (3) Preparation of tert-butyl (S)-2-((2-(4-(tert-butoxycarbonyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0849] ##STR00593##
[0850] Compound 49-3 (480 mg, 1.98 mmol) was dissolved in anhydrous toluene (4 mL), and compound 1-4 (419 mg, 1.98 mmol), compound 1-5 (215 mg, 1.98 mmol), copper(I) chloride (62 mg, 0.63 mmol), and copper(II) trifluoromethanesulfonate (216 mg, 0.60 mmol) were added. Under nitrogen atmosphere, the reaction system was heated to 85° C., added with two drops of N,N-dimethylacetamide, heated and stirred for 6 h. Then the reaction system was cooled to room temperature and stirred overnight. Then the reaction system was filtered, and the filtrate was concentrated. The residue was separated by column chromatography (PE/EA=2/1) to give intermediate 49-4 (340 mg, 31% yield) in the form of a brown solid. LC-MS: [M+H].sup.+=544.7.
Step (4) Preparation of (S)-3,5-difluoro-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzoic acid
[0851] ##STR00594##
[0852] Intermediate 49-4 (340 mg, 0.62 mmol) was dissolved in ethanol (3 mL), and a solution of HCl in ethanol (1 mL, 33%) was added. The reaction system was stirred at room temperature for 1.5 h. Then the reaction system was concentrated to give intermediate 49-5 (400 mg) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=388.7.
Step (5) Preparation of (S)-3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)benzoic acid
[0853] ##STR00595##
[0854] Intermediate 49-5 (400 mg) was dissolved in dichloromethane (5 mL), and pyridine (244 mg, 3.09 mmol) was added, followed by the addition of methyl chloroformate (62 mg, 0.65 mmol). The reaction system was stirred at room temperature for 1.5 h, and concentrated to give intermediate 49-6 (190 mg). LC-MS: [M+H].sup.+=446.6.
Step (6) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-carbomethoxyphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[0855] ##STR00596##
[0856] Intermediate 49-6 (50 mg, 0.1124 mmol) was dissolved in absolute methanol (5 mL), and concentrated sulfuric acid (0.1 mL) was added. The reaction system was stirred under reflux overnight. Then the reaction system was concentrated, diluted with water (10 mL), and extracted with ethyl acetate (10 mL×2). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was separated by thin-layer chromatography (PE/EA=3/1) to give compound 49 (20.8 mg, 40% yield) in the form of a white solid.
[0857] LC-MS: [M+H].sup.+=460.7. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.27 (brs, 1H), 7.73 (d, J=7.1 Hz, 2H), 7.54 (brs, 1H), 6.80 (brs, 1H), 4.00 (s, 3H), 3.99-3.75 (m, 3H), 3.70 (s, 3H), 3.65-3.56 (m, 1H), 3.45-3.35 (m, 1H), 3.10-3.85 (m, 3H), 2.67-2.57 (m, 1H), 2.48 (s, 3H).
Example 50
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-parazole)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0858] ##STR00597##
[0859] Intermediate 2-7 (120 mg, 0.25 mmol) was dissolved in anhydrous toluene (3 mL), and potassium carbonate (104 mg, 0.75 mmol), copper(I) iodide (4.8 mg, 0.025 mmol), 1H-pyrazole (34 mg, 0.50 mmol) and trans-(1R,2R)—N,N′-dimethyl-1,2-cyclohexanediamine (3.6 mg, 0.025 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 110° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (10 mL) and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×1), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 50 (18.7 mg, 16% yield) in the form of a yellow solid.
[0860] LC-MS: [M+H].sup.+=468.7. .sup.1H NMR (400 MHz, MeOD): δ 8.44-8.40 (m, 2H), 7.80 (s, 1H), 7.67 (d, J=8.1 Hz, 2H), 7.35 (s, 1H), 6.88 (d, J=7.0 Hz, 1H), 6.61 (s, 1H), 3.89-3.76 (m, 3H), 3.66 (s, 3H), 3.65-3.56 (m, 1H), 3.42-3.36 (m, 1H), 3.15-3.06 (m, 2H), 2.96-2.80 (m, 1H), 2.72-2.60 (m, 1H), 2.47 (s, 3H).
Example 51
[0861] ##STR00598##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-formylaminophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0862] ##STR00599##
[0863] Intermediate 3-1 (360 mg, 0.86 mmol) was dissolved in formic acid (5 mL). The reaction system was reacted at 90° C. for 2 h. After the reaction was completed as monitored by TLC, the reaction system was concentrated under reduced pressure, added with saturated brine (10 mL), adjusted to pH 7-8 with saturated sodium bicarbonate solution, and extracted with DCM (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 51-1 (220 mg, 52% yield) in the form of a yellow solid. MS [M+H].sup.+=445.1.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-isocyanophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0864] ##STR00600##
[0865] Intermediate 51-1 (220 mg, 0.49 mmol) and triethylamine (149 mg, 1.5 mmol) were dissolved in dichloromethane (25 mL) and phosphorus oxychloride (115 mg, 0.75 mmol) was added dropwise slowly at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 2 h. After the reaction was completed as monitored by LCMS, the reaction system was added with water at 0° C. to quench the reaction, with the temperature maintained at 25° C. below. Then the reaction system was adjusted to pH 7-8 with saturated sodium bicarbonate solution, and washed with saturated saline (10 mL). The organic phase was dried, and concentrated to give intermediate 51-2 (210 mg, 84% yield, crude product) in the form of a yellow oily liquid, which was used directly in the next step without purification. MS [M+H].sup.+=427.0.
Step (3) Preparation of methyl (S)-2-((2-(4-(4-(carbethoxy<ethoxycarbonyl>)-1H-imidazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0866] ##STR00601##
[0867] Intermediate 51-2 (170 mg, 0.4 mmol), ethyl isocyanoacetate (45 mg, 0.4 mmol), copper(I) chloride (8.6 mg, 0.06 mmol) and 1,10-phenanthroline (22 mg, 0.12 mmol) were dissolved in tetrahydrofuran (15 mL). The reaction system was reacted at 60° C. for 3 h under nitrogen atmosphere, and reacted at room temperature overnight. Then the reaction system was added with saturated brine (20 mL), and extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by FCC to give compound 51 (160 mg, 70% yield) in the form of a white solid. MS [M+H].sup.+=540.1.
[0868] 1H NMR (400 MHz, d6-DMSO) δ 8.70 (d, J=1.3 Hz, 1H), 8.60 (d, J=1.3 Hz, 1H), 8.44 (d, J=7.1 Hz, 1H), 7.89 (d, J=8.6 Hz, 2H), 7.37 (s, 1H), 6.85 (dd, J=7.1, 1.5 Hz, 1H), 4.30 (q, J=7.1 Hz, 2H), 3.77 (d, J=12.2 Hz, 1H), 3.66 (t, J=12.1 Hz, 2H), 3.56 (s, 3H), 3.53-3.47 (m, 1H), 3.29-3.21 (m, 1H), 3.10-3.00 (m, 2H), 2.90-2.74 (m, 1H), 2.60-2.45 (m, 1H), 2.40 (s, 3H), 1.32 (t, J=7.1 Hz, 3H).
Example 52
Step (1)
[0869] Compound 52-1 was prepared by replacing methyl chloroformate with acetyl chloride, according to the preparation method for compound 6 in Example 6.
##STR00602##
Step (2)
[0870] Compound 52 was prepared by using compound 52-1 as the starting material, according to the preparation method as described in Example 7.
##STR00603##
[0871] LC-MS: [M+H].sup.+=466.1.
Example 53
[0872] ##STR00604## ##STR00605##
Step (1) Preparation of 1-bromo-2-(methoxymethoxy)-4-methylbenzene
[0873] ##STR00606##
[0874] 2-bromo-5-methylphenol (1.6 g, 8.55 mmol) was dissolved in tetrahydrofuran (20 mL), and sodium hydride (855 mg, 21.37 mmol) was added in portions under nitrogen atmosphere in an ice water bath. The reaction system was reacted at 0° C. for 30 min, added dropwise with bromomethyl methyl ether (1.4 g, 11.12 mmol), and stirred at room temperature overnight. Then the reaction system was poured into ice water (20 mL), and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 53-2 (1.7 g, 68% yield) in the form of a colorless oil.
Step (2) Preparation of 1-iodo-2-(methoxymethoxy)-4-methylbenzene
[0875] ##STR00607##
[0876] Intermediate 53-2 (528 mg, 2.29 mmol) was dissolved in tetrahydrofuran (10 mL) under nitrogen atmosphere, and n-butyllithium (1.2 mL, 2.75 mmol) was added dropwise at −78° C. The reaction system was reacted at this temperature for 20 min, added dropwise with a solution of iodine (874 mg, 3.44 mmol) in tetrahydrofuran (5 mL), and reacted for 2 h. Then the reaction system added with ice water (20 mL) to quench the reaction, added with saturated sodium thiosulfate solution (2 mL), stirred at room temperature for 5 min, and extracted with ethyl acetate (25 mL×2). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give intermediate 53-3 (570 mg, 80% purity, 72% yield, crude product) in the form of a brown oil.
Step (3) Preparation of 2-iodo-5-methylphenol
[0877] ##STR00608##
[0878] Intermediate 53-3 (570 mg, 2.05 mmol) was dissolved in tetrahydrofuran (8 mL), and a solution of HCl in ethanol (1.03 mL, 4.1 mmol) was added dropwise at 0° C. The reaction system was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give intermediate 53-4 (400 mg, 70% purity, 58% yield) in the form of a colorless oil.
Step (4) Preparation of tert-butyl 3,5-difluoro-4-((2-iodo-5-methylphenoxy)methyl)benzoate
[0879] ##STR00609##
[0880] Intermediate 53-4 (400 mg, 1.71 mmol), triphenylphosphine (673 mg, 2.57 mmol) and tert-butyl 3,5-difluoro-4-(hydroxymethyl)benzoate (418 mg, 1.71 mmol) were dissolved in tetrahydrofuran (6 mL) under nitrogen atmosphere, and di-tert-butyl azodicarboxylate (591 mg, 2.57 mmol) was added. The reaction system was reacted at room temperature overnight. Then the reaction system was concentrated under reduced pressure, added with ethyl acetate (30 mL), washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 53-6 (375 mg, 75% purity, 37% yield) in the form of a yellow oil. ESI-MS [M+Na].sup.+: 462.5.
Step (5) Preparation of tert-butyl (S)-2-((2-((4-(tert-butoxycarbonyl)-2,6-difluorobenzyl)oxo)-4-methylphenyl)ethynyl)morpholine-4-carboxylate
[0881] ##STR00610##
[0882] Intermediate 53-6 (290 mg, 0.63 mmol) and tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (146 mg, 0.69 mmol) were dissolved in N,N-dimethylformamide (1.5 mL) under nitrogen atmosphere, and copper(I) iodide (12 mg, 0.063 mmol), bis(triphenylphosphine)palladium(II) chloride (91 mg, 0.13 mmol) and triethylamine (4 mL) were added. The reaction system was reacted at 80° C. for 8 h, cooled to room temperature, added with water (40 mL), and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 53-7 (132 mg, 75% purity, 29% yield) in the form of a brown solid. ESI-MS [M+Na].sup.+: 565.6.
Step (6) Preparation of (S)-4-(3-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-6-methylbenzofuran-2-yl)-3,5-difluorobenzoic acid
[0883] ##STR00611##
[0884] Intermediate 53-7 (132 mg, 0.24 mmol) was dissolved in N,N-dimethylformamide (3 mL) under nitrogen atmosphere, and potassium tert-butoxide (96 mg, 0.72 mmol) was added. The reaction system was reacted at 80° C. for 3 h. Then the reaction system was cooled to room temperature, poured into water (10 mL), adjusted to pH 4 with diluted hydrochloric acid (1 N), and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (15 mL×2), dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 53-8 (100 mg, 70% purity, 55% yield) in the form of a brown solid. ESI-MS [M+Na].sup.+: 510.1.
Step (7) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylbenzofuran-3-yl)methyl)morpholine-4-carboxylate
[0885] ##STR00612##
[0886] Intermediate 53-8 (100 mg, 0.20 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (114 mg, 0.30 mmol) were dissolved in N,N-dimethylformamide (3 mL) under nitrogen atmosphere. The reaction system was stirred at room temperature for 10 min, added with N,N′-diisopropylethylamine (1.79 mL, 1.40 mmol) and methylamine hydrochloride (68 mg, 1.00 mmol), and stirred at room temperature for another 4 h. Then the reaction system was added with water (20 mL) and extracted with ethyl acetate (20 mL×2). The organic phases were combined and washed with saturated brine (15 mL×2). The crude product was purified by silica gel column chromatography to give intermediate 53-9 (65 mg, 63% yield) in the form of a light yellow solid. ESI-MS [M+Na].sup.+: 522.7.
Step (8) Preparation of (S)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-ylmethyl)benzofuran-2-yl)benzamide hydrochloride
[0887] ##STR00613##
[0888] Intermediate 53-9 (65 mg, 0.13 mmol) was dissolved in dichloromethane (2 mL) and a solution of HCl in ethanol (0.5 mL, 0.52 mmol) was added dropwise. The reaction system was stirred at room temperature for 4 h and concentrated under reduced pressure to give intermediate 53-10 in the form of a light yellow solid (70 mg, crude product), ESI-MS [M+H].sup.+: 400.7.
Step (9) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylbenzofuran-3-yl)methyl)morpholine-4-carboxylate
[0889] ##STR00614##
[0890] Intermediate 53-10 (70 mg, 0.18 mmol) and triethylamine (0.99 mL, 0.72 mmol) were dissolved in dichloromethane (2 mL), and methyl chloroformate (21 mg, 0.22 mmol) was added dropwise at 0° C. The reaction system was reacted at this temperature for 4 h. Then the reaction system was poured into ice water (10 mL), and extracted with dichloromethane (15 mL×2). The organic phases were combined, washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 53 (22 mg, 22% yield) in the form of a white solid.
[0891] ESI-MS [M+H].sup.+: 458.8. 1H NMR (400 MHz, MeOD) δ 7.63 (d, J=8.0 Hz, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.35 (s, 1H), 7.17 (d, J=8.0 Hz, 1H), 3.81-3.78 (m, 3H), 3.65 (s, 3H), 3.63-3.58 (m, 1H), 3.39-3.38 (m, 1H), 2.97 (s, 3H), 2.95-2.86 (m, 2H), 2.83-2.76 (m, 1H), 2.62-2.58 (m, 1H), 2.51 (s, 3H).
Example 54
[0892] ##STR00615## ##STR00616##
Step (1) Preparation of 2-iodo-5-methylpyridin-3-ol
[0893] ##STR00617##
[0894] Iodine (2.56 g, 10.08 mmol) was added to a solution of 5-methylpyridin-3-ol (1.10 g, 10.08 mmol) and potassium carbonate (4.18 g, 30.24 mmol) in water (100 mL) while stirring at room temperature. The reaction mixture was stirred at room temperature for 3 h. Then the reaction system was adjusted to pH 6 with diluted hydrochloric acid and extracted with DCM (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and evaporated to dryness. The crude product was purified by silica gel column chromatography to give intermediate 54-2 (1.9 g, 79.4% yield) in the form of a white solid. LC-MS: [M+H].sup.+=235.9.
Step (2) Preparation of tert-butyl 3,5-difluoro-4-(((2-iodo-5-methylpyridin-3-yl)oxy)methyl)benzoate
[0895] ##STR00618##
[0896] Intermediate 54-2 (773 mg, 3.29 mmol), tert-butyl 3,5-difluoro-4-(hydroxymethyl)benzoate (884 mg, 3.62 mmol) and triphenylphosphine (949 mg, 3.62 mmol) were dissolved in THF (15 mL) at 0° C. under nitrogen atmosphere, and a solution of DTAD (833 mg, 3.619 mmol) in THF (5 mL) was added dropwise. After the completion of the dropwise addition, the reaction system was slowly warmed to room temperature and stirred for 4 h. Then the reaction system was added with water (50 mL) to quench the reaction, and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by column chromatography to give intermediate 54-4 (1.5 g, 97.9% yield) in the form of a white solid. LC-MS: [M+H].sup.+=462.0.
Step (3) Preparation of tert-butyl (S)-2-((3-((4-(tert-butoxycarbonyl)-2,6-difluorobenzyl)oxy)-5-methylpyridin-2-yl)ethynyl)morpholine-4-carboxylate
[0897] ##STR00619##
[0898] To a solution of intermediate 54-4 (500 mg, 1.08 mmol) and tert-butyl (2S)-2-ethynylmorpholin-4-yl formate (344 mg, 1.62 mmol) in TEA (30 mL) were added copper(I) iodide (21 mg, 0.11 mmol) and bis(triphenylphosphine)palladium(II) chloride (38 mg, 0.054 mmol) under nitrogen atmosphere. The reaction system was stirred at 90° C. overnight. Then the reaction system was evaporated to dryness to remove the solvent. The crude product was purified by silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to give intermediate 54-6 (452 mg, 73.2% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=545.2.
Step (4) Preparation of (S)-4-(3-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-6-methylfurano[3,2-b]pyridin-2-yl)-3,5-difluorobenzoic acid
[0899] ##STR00620##
[0900] To a solution of intermediate 54-6 (453 mg, 0.83 mmol) in THF (20 mL) was added t-BuOK (232 mg, 2.08 mmol) at room temperature. The reaction system was reacted at 60° C. for 2 h. Then the reaction system was cooled to room temperature, added with water (50 mL), adjusted to pH 6 with formic acid, and extracted with EA (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 54-7 (230 mg, 56.7% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=489.2.
Step (5) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[3,2-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0901] ##STR00621##
[0902] To a solution of intermediate 54-7 (230 mg, 0.47 mmol) and HATU (268 mg, 0.71 mmol) in DMF (10 mL) was added DIEA (243 mg, 1.88 mmol) at room temperature under nitrogen atmosphere. The reaction system was stirred for 10 min, added with methylamine hydrochloride (63 mg, 0.94 mmol), and stirred at room temperature overnight. Then the reaction system was added with water (50 mL) to quench the reaction and extracted with EA (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 54-8 (162 mg, 68.1% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=502.2.
Step (6) Preparation of (S)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-ylmethyl)furano[3,2-b]pyridin-2-yl)benzamide
[0903] ##STR00622##
[0904] A solution of HCl in EA (3 M, 2 mL) was added dropwise to a solution of intermediate 54-8 (162 mg, 0.32 mmol) in EA (1 mL). The reaction system was stirred at room temperature for 2 h, and concentrated by rotary evaporation to give (S)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-ylmethyl)furano[3,2-b]pyridin-2-yl)benzamide hydrochloride in the form of a yellow solid (130 mg, crude product), LC-MS: [M+H].sup.+=402.1.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[3,2-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0905] ##STR00623##
[0906] To a solution of intermediate 54-8 (130 mg, 0.32 mmol) and TEA (100 mg, 0.96 mmol) in DCM (10 mL) was added methyl chloroformate (61 mg, 0.64 mmol) dropwise while stirring at room temperature. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h, and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography, and lyophilized to give compound 54 (110 mg, 74.3% yield over two steps) in the form of a white solid.
[0907] LC-MS: [M+H].sup.+=460.1. .sup.1H NMR (400 MHz, MeOD): δ8.45 (s, 1H), 7.84 (s, 1H), 7.64 (d, J=8.3 Hz, 2H), 3.93 (d, J=13.6 Hz, 1H), 3.77 (d, J=13.2 Hz, 2H), 3.71-3.63 (m, 4H), 3.38-3.29 (m, 1H), 3.03-2.92 (m, 5H), 2.90-2.80 (m, 1H), 2.67-2.56 (m, 1H), 2.55 (s, 3H).
Example 55
[0908] ##STR00624## ##STR00625##
Step (1) Preparation of 5-iodo-2-methylpyridin-4-ol
[0909] ##STR00626##
[0910] Iodine (7.8 g, 31 mmol) was added to a solution of 6-methylpyridin-2-ol (3.0 g, 28 mmol) and potassium hydroxide (6.3 g, 112 mmol) in methanol (200 mL) in portions while stirring at room temperature. The reaction system was stirred at room temperature overnight. Then the reaction system was adjusted to pH 6 with concentrated hydrochloric acid, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give intermediate 55-2 (1.2 g, 18.6% yield) in the form of an off-white solid. LC-MS: [M+H].sup.+=235.8.
Step (2) Preparation of tert-butyl 3,5-difluoro-4-(((5-iodo-2-methylpyridin-4-yl)oxy)methyl)benzoate
[0911] ##STR00627##
[0912] Intermediate 55-2 (470 mg, 2.0 mmol), tert-butyl 3,5-difluoro-4-(hydroxymethyl)benzoate (733 mg, 3.0 mmol) and triphenylphosphine (1049 mg, 4.0 mmol) were added to THF (25 mL) at 0° C. under nitrogen atmosphere, and a solution of DTAD (1382 mg, 6.0 mmol) in THF (5 mL) was added dropwise. After the completion of the dropwise addition, the reaction system was slowly warmed to room temperature and stirred for 2 h. Then the reaction system was added with water (50 mL) to quench the reaction, and extracted with dichloromethane (30 mL×3). The organic phases were combined, and dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 55-4 (620 mg, 66.5% yield) in the form of a white solid. LC-MS [M+H].sup.+=461.6.
Step (3) Preparation of tert-butyl (S)-2-((4-((4-(tert-butoxycarbonyl)-2,6-difluorobenzyl)oxy)-6-methylpyridin-3-yl)ethynyl)morpholine-4-carboxylate
[0913] ##STR00628##
[0914] To a solution of intermediate 55-4 (620 mg, 1.35 mmol) and tert-butyl (2S)-2-ethynylmorpholin-4-yl formate (436 mg, 2.06 mmol) in TEA (20 mL) were added copper(I) iodide (26 mg, 0.14 mmol) and bis(triphenylphosphine)palladium(II) chloride (48 mg, 0.07 mmol) under nitrogen atmosphere. The reaction system was heated to 90° C. and reacted overnight. Then the reaction system was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give intermediate 55-5 (520 mg, 68.6% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=544.8.
Step (4) Preparation of (S)-4-(3-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-6-methylfurano[3,2-c]pyridin-2-yl)-3,5-difluorobenzoic acid
[0915] ##STR00629##
[0916] To a solution of intermediate 55-5 (500 mg, 0.92 mmol) in THF (15 mL) was added t-BuOK (258 mg, 2.30 mmol) under nitrogen atmosphere. The reaction system was stirred at 70° C. for 2 h. Then the reaction system was cooled to room temperature, adjusted to pH 6 with formic acid, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give intermediate 55-6 (250 mg, 53.3% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=488.7.
Step (5) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[3,2-c]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0917] ##STR00630##
[0918] To a solution of intermediate 55-6 (250 mg, 0.51 mmol) and HATU (233 mg, 0.61 mmol) in DMF (4 mL) was added DIEA (264 mg, 2.04 mmol) under nitrogen atmosphere. The reaction system was stirred at room temperature for 10 min, added with methylamine hydrochloride (52 mg, 0.77 mmol), and stirred at room temperature overnight. Then the reaction system was added with water (30 mL), and extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 55-7 (250 mg, 94.12% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=502.2.
Step (6) Preparation of (S)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-ylmethyl)furano[3,2-c]pyridin-2-yl)benzamide
[0919] ##STR00631##
[0920] To a solution of intermediate 55-7 (250 mg, 0.50 mmol) in EA (5 mL) was added a solution of HCl (g) in EA (3 M, 10 mL) at room temperature. The reaction system was stirred at room temperature for 2 h, and concentrated under reduced pressure to give intermediate 55-8 (250 mg, crude product). LC-MS: [M+H].sup.+=402.1.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[3,2-c]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0921] ##STR00632##
[0922] To a solution of intermediate 55-8 (300 mg, 0.75 mmol) and TEA (228 mg, 2.25 mmol) in DCM (10 mL) was added methyl chloroformate (142 mg, 1.50 mmol) dropwise under nitrogen atmosphere in an ice water bath. After the completion of the dropwise addition, the reaction system was warmed to room temperature and stirred for 2 h. Then the reaction system was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 55 (70 mg, 20.0% yield) in the form of a white solid. LC-MS: [M+H].sup.+=460.2.
[0923] .sup.1H NMR (400 MHz, MeOD) δ 8.93 (s, 1H), 7.63 (d, J=8.4 Hz, 2H), 7.48 (s, 1H), 3.90 (d, J=13.0 Hz, 1H), 3.83-3.77 (m, 2H), 3.65 (s, 3H), 3.64-3.58 (m, 1H), 3.39 (dt, J=11.8, 2.8 Hz, 1H), 2.95 (s, 3H), 2.94-2.81 (m, 3H), 2.70-2.63 (m, 1H), 2.69 (s, 3H).
Example 56
[0924] ##STR00633## ##STR00634##
Step (1) Preparation of 3-iodo-6-methylpyridin-2-ol
[0925] ##STR00635##
[0926] 6-methylpyridin-2-ol (5 g, 46 mmol) and sodium hydrogen carbonate (7.73 g, 92 mmol) were added to a mixture of water and dichloromethane (500 mL, 3/2) while stirring at room temperature, and iodine (11.68 g, 46 mmol) was added. The reaction mixture was stirred at room temperature overnight. Then the reaction system was extracted with dichloromethane (200 mL×2). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 56-2 (2.5 g, 21.74% yield) in the form of an off-white solid. LC-MS: [M+H].sup.+=235.0.
Step (2) Preparation of tert-butyl 3,5-difluoro-4-(((3-iodo-6-methylpyridin-2-yl)oxy)methyl)benzoate
[0927] ##STR00636##
[0928] Intermediate 56-2 (510 mg, 2.17 mmol), tert-butyl 3,5-difluoro-4-(hydroxymethyl)benzoate (583 mg, 2.39 mmol) and triphenylphosphine (626 mg, 2.39 mmol) were dissolved in THF (15 mL) at 0° C. under nitrogen atmosphere, and a solution of DTAD (550 mg, 2.39 mmol) in THF (5 mL) was added dropwise. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. Then the reaction system was added with water (50 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 56-3 (860 mg, 94.84% yield) in the form of a white solid. LC-MS: [M+H].sup.+=462.1.
Step (3) Preparation of tert-butyl (S)-2-((2-((4-(tert-butoxycarbonyl)-2,6-difluorobenzyl)oxy)-6-methylpyridin-3-yl)ethynyl)morpholine-4-carboxylate
[0929] ##STR00637##
[0930] To a solution of intermediate 56-3 (500 mg, 1.08 mmol) and tert-butyl (2S)-2-ethynylmorpholin-4-yl formate (344 mg, 1.62 mmol) in triethylamine (20 mL) were added copper(I) iodide (21 mg, 0.11 mmol) and bis(triphenylphosphine)palladium(II) chloride (38 mg, 0.05 mmol) under nitrogen atmosphere. The reaction mixture was stirred at 90° C. for 12 h. Then the reaction system was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give intermediate 56-4 (570 mg, 91.67% yield) in the form of a brownish-yellow solid. LC-MS: [M+H].sup.+=567.1.
Step (4) Preparation of (S)-4-(3-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-6-methylfurano[2,3-b]pyridin-2-yl)-3,5-difluorobenzoic acid
[0931] ##STR00638##
[0932] To a solution of intermediate 56-4 (502 mg, 0.92 mmol) in DMF (20 mL) was added potassium tert-butoxide (310 mg, 2.76 mmol) under nitrogen atmosphere. The reaction system was stirred at 90° C. for 2 h. After the reaction was completed, the reaction system was cooled to room temperature, adjusted to pH 6 with formic acid, and concentrated by rotary evaporation (oil pump) to remove the solvent. The crude product was purified by silica gel column chromatography to give intermediate 56-5 (108 mg, 39.13% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=489.8.
Step (5) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[2,3-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0933] ##STR00639##
[0934] To a solution of intermediate 56-5 (180 mg, 0.37 mmol) in DMF (5 mL) were added HATU (211.06 mg, 0.56 mmol) and DIEA (143 mg, 1.11 mmol) under nitrogen atmosphere. The reaction system was stirred at room temperature for 10 min, added with methylamine hydrochloride (50 mg, 0.74 mmol), and stirred at room temperature overnight. Then the reaction system was added with water (20 mL), and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 56-6 (90 mg, 48.65% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=502.8.
Step (6) Preparation of (S)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-ylmethyl)furano[2,3-b]pyridin-2-yl)benzamide
[0935] ##STR00640##
[0936] To a solution of intermediate 56-6 (100 mg, 0.20 mmol) in EA (1 mL) was added a solution of HCl (g) in EA (3 M, 2 mL) at room temperature. The reaction system was stirred at room temperature for 2 h. Then the reaction system was concentrated to give intermediate 56-7 hydrochloride (100 mg, crude product), LC-MS: [M+H].sup.+=401.9.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methylfurano[2,3-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0937] ##STR00641##
[0938] To a solution of intermediate 56-7 hydrochloride (100 mg, 0.20 mmol) and TEA (101 mg, 1.0 mmol) in DCM (10 mL) was added a solution of methyl chloroformate (47.25 mg, 0.50 mmol) in dichloromethane (1 mL) dropwise in an ice water bath. The reaction system was stirred at room temperature for 2 h. Then the reaction system was added with water (10 mL) to quench the reaction, and extracted with dichloromethane (10 mL×2). The organic phases were combined, washed with saturated brine (10 mL), filtered and concentrated. The crude product was purified by silica gel column chromatography, and lyophilized to give compound 56 (45 mg, 49.01% yield) in the form of an off-white solid.
[0939] LC-MS: [M+H].sup.+=460.8. .sup.1H NMR (400 MHz, MeOD): δ 8.19 (d, J=7.9 Hz, 1H), 7.65 (d, J=8.4 Hz, 2H), 7.31 (d, J=7.9 Hz, 1H), 3.89 (d, J=12.9 Hz, 1H), 3.85-3.75 (m, 2H), 3.67 (s, 3H), 3.66-3.58 (m, 1H), 3.44-3.35 (m, 1H), 2.97 (s, 3H), 2.92-2.82 (m, 3H), 2.73-2.58 (m, 1H), 2.65 (s, 3H).
Example 57
[0940] ##STR00642##
[0941] The compound was prepared according to the preparation method as described in Example 39. LC-MS: [M+H].sup.+=459.4.
Example 58
[0942] ##STR00643##
[0943] Intermediate 3-1 (400 mg, 0.96 mmol), triethyl orthoformate (456 mg, 3.07 mmol), sodium azide (78 mg, 1.20 mmol) and acetic acid (923 mg, 15.37 mmol) were sequentially added. The reaction system was stirred at room temperature for 10 min, and then stirred at 70° C. for 3 days. Then the reaction system was adjusted to pH 9, and extracted with ethyl acetate three times. The organic phases were combined, dried and concentrated by rotary evaporation. The crude product was purified by column chromatography to give a product (270 mg) in the form of a white solid, which was then purified by preparative HPLC to give compound 58 (109 mg, 99% purity, 24% yield) in the form of a white solid.
[0944] LCMS [M+H]+=470. 1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 8.39 (dd, J=24.5, 7.3 Hz, 1H), 8.01-7.83 (m, 2H), 7.41-7.28 (m, 1H), 6.82 (dd, J=7.1, 1.6 Hz, 1H), 3.79-3.71 (m, 1H), 3.61 (t, J=9.8 Hz, 2H), 3.52 (s, 3H), 3.46 (dd, J=7.5, 2.8 Hz, 1H), 3.20 (m, 2.8 Hz, 1H), 3.10-2.93 (m, 2H), 2.77 (s, 1H), 2.51 (s, 1H), 2.35 (s, 3H).
Example 59
[0945] ##STR00644##
Step (1) Preparation of methyl (S)-2-((2-(4-carbamimidoyl-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0946] ##STR00645##
[0947] Compound 6 (800 mg, 1.88 mmol) and sodium methoxide (51 mg, 0.94 mmol) were dissolved in methanol (8 mL) under nitrogen atmosphere. The reaction system was stirred at room temperature overnight, added with NH.sub.4Cl solid (152 mg, 2.80 mmol), and stirred at room temperature overnight. Then the reaction system was adjusted to pH 8 with saturated sodium bicarbonate solution (10 mL), concentrated under reduced pressure to 1/2 volume, and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated to give intermediate 59-1 (760 mg, crude product) in the form of a brown solid. LC-MS [M+H].sup.+: 444.
Step (2) Preparation of methyl (S)-2-((2-(4-(4-(1-(ethoxycarbonyl)cyclopropyl)-1H-imidazol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0948] ##STR00646##
[0949] Intermediate 59-1 (800 mg, 1.80 mmol) and ethyl 1-(2-bromoacetyl)cyclopropane-1-carboxylate (329 mg, 1.4 mmol) were dissolved in N,N-dimethylformamide (8 mL) under nitrogen atmosphere, and potassium bicarbonate (360 mg, 3.6 mmol) was added. The reaction system was stirred at 70° C. overnight. Then the reaction system was added with water (30 mL) to quench the reaction, and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by silica gel column chromatography to give intermediate 59-3 (600 mg, 57% yield) in the form of a brown solid. LC-MS [M+H].sup.+: 580.
Step (3) Preparation of (S)-1-(2-(3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-imidazol-4-yl)cyclopropane-1-carboxylic acid
[0950] ##STR00647##
[0951] Intermediate 59-3 (600 mg, 1.1 mmol) was dissolved in tetrahydrofuran (4 mL) and absolute methanol (2 mL), and lithium hydroxide solution (1.5 mL, 3 M) was added dropwise at 0° C. The reaction system was warmed to room temperature and stirred for 3 h. Then the reaction system was adjusted to pH 4 with diluted hydrochloric acid (1 N), and concentrated to give a crude product (450 mg) in the from of a yellow solid. The crude product (50 mg) was purified by preparative chromatography to give compound 59 (4.6 mg) in the form of a white solid.
[0952] LC-MS [M+H].sup.+: 552. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J=8.0 Hz, 1H), 7.47 (s, 1H), 7.30 (d, J=8.3 Hz, 2H), 6.81 (d, J=7.7 Hz, 1H), 6.75 (s, 1H)., 4.00-3.81 (m, 3H), 3.67 (s, 3H), 3.63-3.57 (m, 1H), 3.45-3.35 (m, 1H), 3.05-2.85 (m, 3H), 2.66-2.57 (m, 1H), 2.52 (s, 3H), 1.92-1.86 (m, 2H), 1.25-1.19 (m, 2H).
Example 60
[0953] ##STR00648##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1-(methoxycarbonyl)cyclopropane-1-carboxamido)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0954] ##STR00649##
[0955] 1-(methoxycarbonyl)cyclopropane-1-carboxylic acid (104 mg, 0.72 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (275 mg, 0.72 mmol) were dissolved in anhydrous N,N-dimethylformamide (2 mL) under nitrogen atmosphere. The reaction system was reacted at room temperature for 10 min, added with N,N-diisopropylethylamine (252 mg, 1.95 mmol) and intermediate 3-1 (200 mg, 0.48 mmol), and reacted at room temperature overnight. Then the reaction system was added with water (20 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give intermediate 60-2 (100 mg, 51.3% yield) in the form of a white solid. LC-MS: [M+H].sup.+=543.7.
Step (2) Preparation of (S)-2-((2-(2,6-difluoro-4-(1-(methoxycarbonyl)cyclopropane-1-carboxamido)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid
[0956] ##STR00650##
[0957] Intermediate 60-2 (100 mg, 0.18 mmol) was dissolved in tetrahydrofuran (1.5 mL), and lithium hydroxide solution (0.18 mL, 3 M) was added dropwise. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added dropwise with diluted hydrochloric acid (1 M) to adjust the pH to 6, added with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 60 (65.9 mg, 67.6% yield) in the form of a white solid.
[0958] LC-MS: [M+H].sup.+=529.6. .sup.1H NMR (400 MHz, MeOD): δ 8.84 (d, J=7.1 Hz, 1H), 7.70 (s, 1H), 7.64 (d, J=7.4 Hz, 2H), 7.41 (dd, J=7.1, 1.5 Hz, 1H), 4.01-3.97 (m, 1H), 3.86-3.74 (m, 2H), 3.70 (s, 3H), 3.69-3.65 (m, 1H), 3.39-3.36 (m, 1H), 3.25-3.24 (m, J=5.2 Hz, 2H), 2.99-2.85 (m, 1H), 2.81-2.67 (m, 1H), 2.65 (s, 3H), 1.75-1.72 (m, 2H), 1.71-1.68 (m, 2H).
Example 61
[0959] ##STR00651##
Step (1) Preparation of 1-(2,4-dimethoxybenzyl)-4-methyl 2-methylenesuccinate
[0960] ##STR00652##
[0961] Monomethyl itaconate (3.00 g, 21.10 mmol), (2,4-dimethoxy)benzyl alcohol (3.90 g, 23.21 mmol) and triphenylphosphine (6.65 g, 25.33 mmol) were dissolved in THF (50 mL) at 0° C. under nitrogen atmosphere, and a solution of DIAD (5.12 g, 25.33 mmol) in THF (10 mL) was added dropwise. After the completion of the dropwise addition, the reaction system was warmed to room temperature and stirred overnight. Then the reaction system was added with water (60 mL) to quench the reaction, and extracted with ethyl acetate (40 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 61-3 (4.5 g, 72.2% yield) in the form of a white solid. MS [M+Na].sup.+=316.8.
Step (2) Preparation of 2,4-dimethoxybenzyl 1-(2-methoxy-2-carbonylethyl)cyclopropanecarboxylate
[0962] ##STR00653##
[0963] To a mixture of potassium hydroxide (30 mL, 40% aq) and diethyl ether (20 mL) was added 1-methyl-3-nitro-1-nitrosoguanidine (4.0 g, 13.6 mmol, 50% water content) at 0° C. under nitrogen atmosphere. The reaction system was stirred at 0° C. for 15 min and left to stand for liquid separation. The upper organic phase was collected, and dried over anhydrous sodium sulfate. Intermediate 61-3 (600 mg, 2.04 mmol) and palladium acetate (92 mg, 0.41 mmol) were dissolved in diethyl ether (15 mL) at 0° C. under nitrogen atmosphere, and a fresh solution of diazomethane in diethyl ether was added dropwise. After the completion of the dropwise addition, the reaction system was slowly warmed to room temperature and stirred for 16 h. The reaction system was added with absolute methanol (10 mL) to quench the reaction and filtered, and the filtrate was concentrated by rotary evaporation to give a crude product. The crude product was purified by column chromatography to give intermediate 61-4 (520 mg, 82.7% yield) in the form of a colorless oil. MS [M+Na]+=330.8.
Step (3) Preparation of 2-(1-(((2,4-dimethoxybenzyl)oxo)carbonyl)cyclopropyl)acetic acid
[0964] ##STR00654##
[0965] To a mixture of intermediate 61-4 (500 mg, 1.62 mmol) in tetrahydrofuran (40 mL) and water (10 mL) was added lithium hydroxide monohydrate (11.9 mL, 11.9 mmol) at 0° C. The reaction was stirred at 0° C. for 8 h. Then the reaction system was warmed to room temperature, adjusted to pH 4 with diluted hydrochloric acid, and extracted with DCM (20 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give intermediate 61-5 (320 mg, 73.2% yield, crude product) in the form of a yellow oil. MS [M−H].sup.−=292.4.
Step (4) Preparation of methyl (S)-2-((2-(4-(2-(1-(((2,4-dimethoxybenzyl)oxo)carbonyl)cyclopropyl)acetamido)-2,6-difluorophenyl)-7-meth ylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0966] ##STR00655##
[0967] To a solution of intermediate 61-5 (300 mg, 1.02 mmol) in DMF (5 mL) were added DIEA (527 mg, 4.08 mmol) and HATU (466 mg, 1.22 mmol) at room temperature under nitrogen atmosphere. The reaction system was stirred at 45° C. for 0.5 h, added with intermediate 3-1 (213 mg, 0.51 mmol), and stirred at 45° C. for another 18 h. Then the reaction system was cooled to room temperature, added with water (10 mL), and extracted with EA (10 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 61-6 (160 mg, 22.6% yield) in the form of a yellow solid. MS [M+H].sup.+=692.7.
Step (5) Preparation of (S)-1-(2-((3,5-difluoro-4-(3-((4-(carbomethoxy<methoxycarbonyl>)morpholin-2-yl)methyl)-7-methylimidazo [1,2-a]pyridin-2-yl)phenyl)amino)-2-carbonylethyl)cyclopropanecarboxylic acid
[0968] ##STR00656##
[0969] To a solution of intermediate 61-6 (100 mg, 0.14 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at room temperature. The reaction system was stirred at room temperature for 3 h and concentrated. The residue was separated by preparative high performance liquid chromatography, and lyophilized to give compound 61 (29 mg, 36.9% yield) in the form of a white solid. MS [M+H].sup.+=542.7.
[0970] 1H NMR (400 MHz, CDCl3) δ 10.44 (brs, 1H), 8.51 (d, J=7.0 Hz, 1H), 7.96 (s, 1H), 7.43 (d, J=11.1 Hz, 2H), 7.09 (d, J=6.7 Hz, 1H). 4.10-3.75 (m, 3H), 3.69 (s, 3H), 3.65-3.61 (m, 1H), 3.45-3.35 (m, 1H), 3.05-2.85 (m, 3H), 2.76-2.68 (m, 1H), 2.58 (s, 3H), 1.39 (s, 2H), 0.94 (s, 2H).
Example 62
[0971] ##STR00657##
[0972] The compound was prepared according to the preparation method as described in Example 44. LC-MS: [M+H].sup.+=464.2.
Example 63
[0973] ##STR00658##
Step (1) Preparation of methyl (S)-2-((2-(4-(diethylmalonate)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0974] ##STR00659##
[0975] Intermediate 2-7 (300 mg, 0.62 mmol), 1,3-diethyl malonate (200 mg, 1.24 mmol) and bromoidenone (180 mg, 1.24 mmol) were dissolved in 1,4-dioxane (3 mL), and sodium hydride (60%, 55 mg, 1.36 mmol) was added in portions under nitrogen atmosphere. The reaction system was reacted at 100° C. for 10 h. After the reaction was completed, the reaction system was cooled to room temperature, added with water (20 mL) to quench the reaction, and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography to give intermediate 63-2 (230 mg, 66% yield) in the form of a yellow oil. LC-MS: [M+H]+=560.2.
Step (2) (S)-2-(3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)acetic acid
[0976] ##STR00660##
[0977] Intermediate 63-2 (210 mg, 0.38 mmol) was dissolved in absolute ethanol (1.5 mL), and sodium hydroxide solution (3 M, 45 mg, 1.14 mmol) was added. The reaction system was reacted at room temperature for 1 h. After the reaction was competed, the reaction system was adjusted to pH 6 with hydrochloric acid solution (1 M), added with water (5 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 63-3 (140 mg, 77% yield) in the form of a yellow oil. LC-MS: [M+H]+=460.2.
Step (3) Preparation of methyl (S)-2-((2-(4-(2-amino-2-carbonylethyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0978] ##STR00661##
[0979] Intermediate 63-3 (70 mg, 0.15 mmol) and 2-(7-azobenzotriazol)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (87 mg, 0.23 mmol) were dissolved in N,N-dimethylformamide (2 mL) under nitrogen atmosphere. The reaction system was reacted at room temperature for 10 min, added with N,N-diisopropylethylamine (60 mg, 0.46 mmol) and ammonium chloride (10 mg, 0.19 mmol), and reacted at room temperature for another 2 h. After the reaction was completed, the reaction system was added with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by preparative chromatography to give compound 63 (10.5 mg, 15% yield) in the form of a white solid.
[0980] LC-MS: [M+H]+=459.2. .sup.1H NMR (400 MHz, CDCl3): δ8.60 (brs, 1H), 7.97 (brs, 1H), 7.67-7.62 (brs, 1H), 7.27-7.08 (m, 3H), 6.50 (brs, 1H), 4.08-3.78 (m, 4H), 3.73 (s, 3H), 3.71-3.58 (m, 2H), 3.45-3.37 (m, 1H), 3.07-3.03 (m, 2H), 3.00-2.92 (m, 1H), 2.77-2.69 (m, 1H), 2.62 (s, 3H).
Example 64
[0981] ##STR00662##
Step (1) Preparation of methyl (S)-2-((2-(4-(2-ethoxy-2-oxoethyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[0982] ##STR00663##
[0983] Compound 63-3 (459 mg, 1 mmol) was dissolved in absolute ethanol (10 mL), and H.sub.2SO.sub.4 (0.1 mmol) was added. The reaction system was heated to reflux. After the reaction was completed as monitored by TLC, the reaction system was diluted with water with the pH adjusted to be neutral, and concentrated under reduced pressure. The aqueous phase was extracted with EA. The organic phase was dried over anhydrous MgSO.sub.4, filtered, and concentrated under reduced pressure to give intermediate 64-1 (0.36 g, 74% yield), LC-MS: [M+H].sup.+=488.2.
Step (2) Preparation of methyl (S)-2-((2-(4-(2-(methylamino)-2-oxoethyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[0984] ##STR00664##
[0985] Intermediate 64-1 (70 mg, 0.15 mmol) and 2-(7-azobenzotriazol)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (87 mg, 0.23 mmol) were dissolved in N,N-dimethylformamide (2 mL) under nitrogen atmosphere. The reaction system was reacted at room temperature for 10 min, added with N,N-diisopropylethylamine (60 mg, 0.46 mmol) and a solution of methylamine in tetrahydrofuran (1 M, 0.1 mL, 0.15 mmol), and reacted at room temperature for another 2 h. After the reaction was completed, the reaction system was added with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 64 (17.2 mg, 24% yield) in the form of a white solid.
[0986] LC-MS: [M+H].sup.+=473.2. 1H NMR (400 MHz, CDCl3): δ8.59 (brs, 1H), 7.92 (s, 1H), 7.55 (brs, 1H), 7.19 (d, J=7.4 Hz 1H), 7.08 (d, J=8.1 Hz, 2H), 4.10-3.90 (m, 3H), 3.86-3.78 (m, 1H), 3.73 (s, 3H), 3.73-3.65 (m, 2H), 3.46-3.35 (m, 1H), 3.08-3.02 (m, 2H), 3.00-2.90 (m, 1H), 2.85 (s, 3H), 2.76-2.70 (m, 1H), 2.62 (s, 3H).
Example 65
[0987] ##STR00665##
[0988] The compound was prepared according to the preparation method as described in Example 63. LC-MS: [M+H].sup.+=485.2.
Example 66
[0989] ##STR00666##
[0990] The compound was prepared according to the preparation method as described in Example 63. LC-MS: [M+H].sup.+=499.3.
Example 67
[0991] ##STR00667## ##STR00668##
Step (1) Preparation of 1-(3,5-difluorophenyl)cyclopropane-1-amine
[0992] ##STR00669##
[0993] 3,5-difluorobenzonitrile (10.0 g, 71.89 mmol) and tetraisopropyl titanate (27.0 g, 95.00 mmol) were dissolved in methyl tert-butyl ether (120 mL), and ethyl magnesium bromide (3 M in diethyl ether, 55 mL, 165.35 mmol) was added at −20° C. under nitrogen atmosphere. The reaction system was reacted at this temperature for 30 min, added with boron trifluoride diethyl ether (46.5%, 44 g, 143.78 mmol), and stirred at room temperature for another 3 h. Then the reaction system was added with sodium hydroxide solution (3 M, 72 mL, 215.67 mmol) and filtered, and the filtrate was added with water (100 mL) and extracted with dichloromethane (150 mL×3). The organic phases were combined, washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 67-2 (2 g, 16.6% yield) in the form of a yellow oil, MS [M+H].sup.+=170.0.
Step (2) Preparation of tert-butyl (1-(3,5-difluorophenyl)cyclopropyl)carbamate
[0994] ##STR00670##
[0995] Intermediate 67-2 (2.0 g, 11.83 mmol) was dissolved in anhydrous dichloromethane (20 mL), and di-tert-butyl dicarbonate (3.9 g, 17.75 mmol) and triethylamine (2.4 g, 23.67 mmol) were added under nitrogen atmosphere. The reaction system was reacted at room temperature overnight. Then the reaction system was added with water (50 mL), and extracted with dichloromethane (50 mL). The organic phase was washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 67-3 (640 mg, 18.08% yield) in the form of a white solid. MS [M+H].sup.+=269.9.
Step (3) Preparation of tert-butyl (1-(3,5-difluorophenyl)cyclopropyl)(methyl)carbamate
[0996] ##STR00671##
[0997] Intermediate 67-3 (620 mg, 2.30 mmol) was dissolved in anhydrous N,N-dimethylformamide (5 mL) under nitrogen atmosphere, and sodium hydride (60%, 138 mg, 3.45 mmol) was added. The reaction system was reacted at room temperature for 30 min, added with methyl iodide (720 mg, 5.07 mmol) and reacted at 40° C. for 1 h. Then the reaction system was added with ice water (20 mL) to quench the reaction, and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 67-4 (260 mg, 40% yield) in the form of a white solid. MS [M+H].sup.+=283.9.
Step (4) Preparation of tert-butyl (1-(3,5-difluoro-4-formylphenyl)cyclopropyl)(methyl)carbamate
[0998] ##STR00672##
[0999] Intermediate 67-4 (260 mg, 0.92 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) under nitrogen atmosphere, and lithium diisopropylamide (2 M in tetrahydrofuran, 0.6 mL, 1.10 mmol) was added dropwise at −78° C. After the completion of the dropwise addition, the reaction system was reacted at −78° C. for 1 h, added with anhydrous N,N-dimethylformamide (67 mg, 0.92 mmol), and reacted for another 30 min. After the reaction was completed, the reaction system was added with saturated ammonium chloride solution to quench the reaction, diluted with water (20 mL), and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 67-5 (250 mg, 85% yield) in the form of a white solid. MS [M+H].sup.+=311.9.
Step (5) Preparation of (S)-2-ethynylmorpholine
[1000] ##STR00673##
[1001] Intermediate 1-4 (200 mg, 0.95 mmol) was dissolved in anhydrous dichloromethane (3 mL), and a solution of HCl in ethanol (33%, 0.5 mL) was added at 0° C. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 67-6 (230 mg, crude product) in the form of a yellow oil, MS [M+H].sup.+=120.0.
Step (6) Preparation of methyl (S)-2-ethynylmorpholine-4-carboxylate
[1002] ##STR00674##
[1003] Intermediate 67-6 (230 mg, crude product, 0.95 mmol) and N,N-diisopropylethylamine (1.1 g, 8.51 mmol) were dissolved in anhydrous dichloromethane (3 mL), and methyl chloroformate (180 mg, 1.90 mmol) was added dropwise slowly in an ice water bath. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 1 h. After the reaction was completed, the reaction system was added with water (15 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give intermediate 67-7 (160 mg, crude product) in the form of a yellow oil. MS [M+H].sup.+=169.7.
Step (7) Preparation of methyl (S)-2-((2-(4-(1-((tert-butoxycarbonyl)(methyl)amino)cyclopropyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1004] ##STR00675##
[1005] Intermediate 67-5 (250 mg, 0.80 mmol), 4-methylpyridin-2-amine (87 mg, 0.80 mmol), methyl (S)-2-ethynylmorpholine-4-carboxylate (136 mg, 0.80 mmol), copper(I) chloride (24 mg, 0.24 mmol) and copper(II) trifluoromethanesulfonate (87 mg, 0.24 mmol) were dissolved in toluene solution (3 mL) under nitrogen atmosphere. The reaction system was reacted at 85° C. for 10 min, added with N,N-dimethylacetamide (0.1 mL), and stirred at 85° C. for another 5 h. Then the reaction system was reacted at room temperature overnight. The resulting reaction system was filtered, and the filtrate was added with water (20 mL) and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 67-8 (150 mg, 32.6% yield) in the form of a yellow oil. MS [M+H].sup.+=570.8.
Step (8) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1-(methylamino)cyclopropyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[1006] ##STR00676##
[1007] Intermediate 67-8 (150 mg, 0.26 mmol) was dissolved in anhydrous dichloromethane (3 mL), and a solution of HCl in ethanol (33%, 0.5 mL) was added at 0° C. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation, diluted with dichloromethane (30 mL), dissolved with saturated sodium bicarbonate solution (10 mL), and stirred for 5 min. Then the reaction system was extracted. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 67 (55.4 mg, 43.5% yield) in the form of a white solid. MS [M+H].sup.+=470.8.
[1008] 1H NMR (400 MHz, MeOD) δ 8.85 (d, J=7.1 Hz, 1H), 7.73 (s, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.41 (d, J=7.0 Hz, 1H), 4.02-3.93 (m, 1H), 3.87-3.73 (m, 2H), 3.70 (s, 3H), 3.69-3.62 (m, 1H), 3.39-3.35 (m, 1H), 3.28-3.23 (m, 2H), 2.99-2.85 (m, 1H), 2.75 (s, 3H), 2.74-2.66 (m, 1H), 2.65 (s, 3H), 1.61-1.54 (m, 2H), 1.52-1.46 (m, 2H).
Example 68
[1009] ##STR00677## ##STR00678##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-formylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1010] ##STR00679##
[1011] Tert-butyl (R)-2-((2-(4-(1,3-dioxan-2-yl)-2-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (2.0 g, 4.0 mmol) was dissolved in acetone (15 mL). The reaction system was cooled to 0° C., added dropwise with diluted hydrochloric acid (1 N, 5 mL), and warmed to room temperature and stirred for 4 h. Then the reaction system was adjusted to pH 8 with saturated sodium carbonate solution (8 mL), added dropwise with methyl chloroformate (0.45 g, 4.8 mmol) at 0° C., and stirred at 0° C. for 1 h. The resulting reaction system was added with water (50 mL), and extracted with dichloromethane (60 mL×3). The organic phases were combined, washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by silica gel column chromatography to give intermediate 68-1 (770 mg, 46% yield) in the form of a yellow solid. LC-MS [M+H].sup.+=430.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1012] ##STR00680##
[1013] Intermediate 68-1 (100 mg, 0.23 mmol) was dissolved in N,N-dimethylformamide (2 mL) under nitrogen atmosphere, and potassium carbonate (16 mg, 0.11 mmol) was added, followed by the dropwise addition of trifluoromethyl trimethylsilane (50 mg, 0.30 mmol). The reaction system was stirred at room temperature for 4 h, added with HCl (2 mL, 2 N), and stirred at room temperature overnight. Then the reaction system was added with water (20 mL), and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by silica gel column chromatography to give intermediate 68-2 (80 mg, 69% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=500.
Step (3) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2,2,2-trifluoro-1-((trifluoromethyl)sulfonyl)oxy)ethyl))-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1014] ##STR00681##
[1015] Intermediate 68-2 (80 mg, 0.16 mmol) and 2,6-dimethylpyridine (34 mg, 0.32 mmol) were dissolved in dichloromethane (3 mL) under nitrogen atmosphere. The reaction system was cooled to 0° C., added dropwise with trifluoromethanesulfonic anhydride (81 mg, 0.29 mmol), and stirred for 1 h. Then the reaction system was concentrated to give intermediate 68-3 (100 mg) in the form of a brown solid, which was used directly in the next step. LC-MS: [M+H].sup.+=632.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2,2,2-trifluoro-1-(methylamino)ethyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1016] ##STR00682##
[1017] Intermediate 68-3 (100 mg, 0.16 mmol) and N,N-diisopropylethylamine (62 mg, 0.48 mmol) were dissolved in tetrahydrofuran (2 mL), and methylamine in tetrahydrofuran (1 mL, 2 N) was added. The reaction system was stirred at room temperature for 2 h under nitrogen atmosphere. Then the reaction system was added with water (20 mL) to quench the reaction, and extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative chromatography to give compound 68 (trifluoroacetate salt, 18.3 mg, 22% yield) in the form of a white solid. LC-MS: [M+H].sup.+=513.
[1018] .sup.1H NMR (400 MHz, CDCl3) δ 8.58 (d, J=6.9 Hz, 1H), 7.95 (s, 1H), 7.37 (d, J=8.1 Hz, 2H), 7.16 (d, J=7.0 Hz, 1H), 6.56 (brs, 2H), 4.62-4.52 (m, 1H), 4.14-3.77 (m, 3H), 3.72 (s, 3H), 3.71-3.65 (m, 1H), 3.46-3.36 (m, 1H), 3.12-3.11 (m, 2H), 2.01-2.88 (m, 1H), 2.78-2.68 (m, 1H), 2.61 (s, 6H).
Example 69
[1019] ##STR00683##
Step (1) Preparation of methyl (2S)-2-((2-(4-(3-((tert-butylsulfinyl)amino)oxetan-3-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1020] ##STR00684##
[1021] Intermediate 2-7 (300 mg, 0.63 mmol) was dissolved in tetrahydrofuran (5 mL) under nitrogen atmosphere, and n-butyllithium (0.32 mL, 0.76 mmol) was added dropwise at −78° C. in a dry ice-acetone bath. After the completion of the dropwise addition, the reaction system was reacted for 15 min, added dropwise with a solution of 2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (121 mg, 0.69 mmol) in tetrahydrofuran (1 mL), and reacted at −78° C. for 3 h. Then the reaction system was added with saturated aqueous ammonium chloride solution (2 mL) to quench the reaction, diluted with water (20 mL), and extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (15 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 69-2 (60 mg, 70% purity, 12% yield) in the form of a brown solid. ESI-MS [M+H].sup.+: 576.7.
Step (2) Preparation of methyl (2S)-2-((2-(4-(3-((tert-butylsulfinyl)(methyl)amino)oxetan-3-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1022] ##STR00685##
[1023] Intermediate 69-2 (60 mg, 0.10 mmol) was dissolved in anhydrous N,N-dimethylformamide (1 mL) under nitrogen atmosphere, and sodium hydride (10 mg, 0.25 mmol) was added in an ice water bath. The reaction system was stirred for 0.5 h, added dropwise with a solution of iodomethane (21 mg, 0.15 mmol) in N,N-dimethylformamide (0.5 mL), and stirred at 0° C. for 3 h. Then the reaction system was poured into ice water (15 mL), and extracted with ethyl acetate (15 mL×2). The organic phases were combined, washed with saturated brine (10 mL×3), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 69-3 (50 mg, 70% purity, 57% yield) in the form of a brown solid. ESI-MS [M+H].sup.+: 590.8.
Step (3) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(3-(methylamino)oxetan-3-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[1024] ##STR00686##
[1025] Intermediate 69-3 (50 mg, 0.085 mmol) was dissolved in dichloromethane (1.5 mL), and a solution of HCl in ethanol (0.1 mL, 0.40 mmol) was added dropwise at 0° C. The reaction system was stirred for 15 min, poured into ice water (10 mL), adjusted to pH 8 with saturated sodium bicarbonate solution, and extracted with dichloromethane (10 mL×2). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 69 (6.4 mg, 15.6% yield) in the form of a white solid. ESI-MS [M+H].sup.+: 486.8.
[1026] .sup.1H NMR (400 MHz, CDCl3) δ 8.26 (d, J=7.0 Hz, 1H), 7.50 (s, 1H), δ 7.20 (d, J=8.5 Hz, 2H), 6.74 (d, J=6.2 Hz, 1H), 4.93 (d, J=6.7 Hz, 2H), 4.82 (d, J=6.7 Hz, 2H), 3.98-3.80 (m, 3H), 3.70 (s, 3H), 3.64-3.60 (m, 1H), 3.47-3.36 (m, 1H), 3.10-2.97 (m, 2H), 2.97-2.86 (m, 1H), 2.65 (dd, J=13.1, 10.7 Hz, 1H), 2.47 (s, 3H), 2.35 (s, 3H).
Example 70
[1027] ##STR00687##
[1028] The compound was prepared according to the preparation method as described in Example 63. LC-MS: [M+H].sup.+=473.3.
Example 71
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(oxetan-3-ylamino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1029] ##STR00688##
[1030] Intermediate 2-7 (40 mg, 0.08 mmol), 3-oxetane (7 mg, 0.096 mmol), cesium carbonate (78 mg, 0.24 mmol), tris(dibenzylideneacetone)dipalladium (7 mg, 0.008 mmol) and (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (10 mg, 0.016 mmol) were dissolved in anhydrous toluene (5 mL). The reaction system was reacted at 80° C. for 16 h under nitrogen atmosphere, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative high performance liquid chromatography to give compound 71 (25 mg, 62.5% yield) in the form of a white solid. MS [M+H].sup.+=473.1.
[1031] 1H NMR (400 MHz, d6-DMSO) δ 8.35 (d, J=7.0 Hz, 1H), 7.30 (s, 1H), 7.15 (d, J=6.5 Hz, 1H), 6.78 (dd, J=7.1, 1.6 Hz, 1H), 6.27 (d, J=10.6 Hz, 2H), 4.88 (t, J=6.5 Hz, 2H), 4.61 (dt, J=13.1, 6.7 Hz, 1H), 4.44 (td, J=6.1, 2.1 Hz, 2H), 373-3.64 (m, 3H), 3.56 (s, 3H), 3.51-3.45 (m, 1H), 3.25 (dt, J=11.7, 2.6 Hz, 1H), 3.04-2.92 (m, 2H), 2.90-2.77 (m, 1H), 2.60-2.46 (m, 1H), 2.36 (s, 3H).
Example 72
[1032] ##STR00689##
[1033] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=517.1.
Example 73
[1034] ##STR00690##
[1035] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=501.2.
Example 74
[1036] ##STR00691##
[1037] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=483.3.
Example 75
Preparation of methyl 2-((2-(2,6-difluoro-4-((tetrahydrofuran-3-yl)amino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1038] ##STR00692##
[1039] Intermediate 2-7 (50 mg, 0.10 mmol) was dissolved in toluene (5 mL) under nitrogen atmosphere, and oxolane-3-amine (11 mg, 0.12 mmol), cesium carbonate (98 mg, 0.30 mmol), tris(dibenzylideneacetone)dipalladium (9 mg, 0.01 mmol), and (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (13 mg, 0.02 mmol) were added. The reaction system was stirred at 80° C. overnight. Then the reaction system was filtered and concentrated. The residue was separated by preparative high performance liquid chromatography to give compound 75 (14.7 mg, 30.0% yield) in the form of a white solid. LC-MS: [M+H].sup.+=487.1.
[1040] 1H NMR (400 MHz, MeOD) δ 8.47 (d, J=6.8 Hz, 1H), 7.38 (s, 1H), 6.95 (d, J=6.5 Hz, 1H), 6.37 (d, J=10.9 Hz, 2H). 4.19-4.08 (m, 1H), 4.99-3.95 (m, 2H), 3.90-3.78 (m, 4H), 3.77-3.73 (m, 1H), 3.68 (s, 3H), 3.62-3.57 (m, 1H), 3.43-3.36 (m, 1H), 3.14-3.03 (m, 2H), 2.97-2.85 (m, 1H), 2.72-2.62 (m, 1H), 2.49 (s, 3H), 2.38-2.28 (m, 1H), 1.98-1.88 (m, 1H).
Example 76
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-((tetrahydro-2H-pyran-4-yl)amino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1041] ##STR00693##
[1042] Intermediate 2-7 (80 mg, 0.17 mmol) was dissolved in toluene (5 mL) under nitrogen atmosphere, and tetrahydro-2H-pyran-4-amine (21 mg, 0.20 mmol), cesium carbonate (166 mg, 0.51 mmol), tris(dibenzylideneacetone)dipalladium (16 mg, 0.017 mmol), and (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (21 mg, 0.034 mmol) were added sequentially. The reaction system was stirred at 80° C. overnight. Then the reaction system was filtered and concentrated. The residue was separated by preparative high performance liquid chromatography to give compound 76 (51.9 mg, 58.8% yield) in the form of a white solid. LC-MS: [M+H].sup.+=501.2.
[1043] 1H NMR (400 MHz, DMSO) δ 8.36 (d, J=7.0 Hz, 1H), 7.31 (s, 1H), 6.80 (d, J=6.6 Hz, 1H), 6.41-6.34 (m, 1H), 6.38 (d, J=11.0 Hz, 2H), 3.91-3.85 (m, 2H), 3.75-3.63 (m, 3H), 3.56 (s, 3H), 3.55-3.41 (m, 4H), 3.32-3.22 (m, 1H), 3.05-2.92 (m, 2H), 2.90-2.76 (m, 1H), 2.62-2.50 m, 1H), 2.38 (s, 3H), 1.94-1.86 (m, 2H), 1.45-1.34 (m, 2H).
Example 77
[1044] ##STR00694##
[1045] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=502.2.
Example 78
[1046] ##STR00695##
[1047] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=485.2.
Example 79
Preparation of methyl (2S)-2-((2-(2,6-difluoro-4-((3-carbonylcyclopentyl)amino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1048] ##STR00696##
[1049] Intermediate 3-1 (60.0 mg, 0.14 mmol) was dissolved in cyclopent-2-enone (3 mL) under nitrogen atmosphere, and anhydrous aluminium trichloride (117.5 mg, 1.15 mmol) was added. The reaction system was reacted at room temperature for 18 h. Then the reaction system was filtered and concentrated. The crude product was separated by preparative high performance liquid chromatography, and lyophilized to give compound 79 (29.7 mg, 42% yield) in the form of a white solid. LC-MS: [M+H].sup.+=499.3.
[1050] 1H NMR (400 MHz, CDCl3) δ 8.21 (brs, 1H), 7.46 (brs, 1H), 6.70 (brs, 1H), 6.27 (d, J=9.9 Hz, 2H), 4.17-4.08 (m, 1H), 4.00-3.76 (m, 3H), 3.70 (s, 3H), 3.64-3.56 (m, 1H), 3.47-3.36 (m, 1H), 3.02-2.97 (m, 2H), 2.94-2.85 (m, 1H), 2.75 (dd, J=18.2, 6.5 Hz, 1H), 2.64 (dd, J=13.1, 10.7 Hz, 1H), 2.56-2.48 (m, 1H), 2.44 (s, 3H), 2.39-2.32 (m, 1H), 2.30-2.22 (m, 1H), 2.12-2.00 (m, 2H).
Example 80
[1051] ##STR00697##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-((4-hydroxycyclohexyl)amino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[1052] ##STR00698##
[1053] Intermediate 2-7 (200 mg, 0.42 mmol) was dissolved in anhydrous toluene (3 mL) under nitrogen atmosphere, and 4-aminocyclohexanol (58 mg, 0.50 mmol), cesium carbonate (407 mg, 1.25 mmol), (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (52 mg, 0.084 mmol) and tris(dibenzylideneacetone)dipalladium (40 mg, 0.043 mmol) were added. The reaction system was reacted at 80° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (20 mL) and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 80-2 (150 mg, 70% yield) in the form of a yellow oil. LC-MS: [M+H].sup.+=514.8.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-((4-carbonylcyclohexyl)amino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[1054] ##STR00699##
[1055] Intermediate 80-2 (150 mg, 0.29 mmol) was dissolved in anhydrous dichloromethane (2 mL) under nitrogen atmosphere, and Dess-Martin periodinane (185 mg, 0.44 mmol) was added. The reaction system was reacted at room temperature for 1 h. Then the reaction system was added with water (20 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative high performance liquid chromatography to give compound 80 (20.2 mg, 20.3% yield) in the form of a white solid. LC-MS: [M+H].sup.+=512.8.
[1056] .sup.1H NMR (400 MHz, MeOD) δ 8.82-8.78 (m, 1H), 7.65-7.64 (m, 1H), 7.38-7.36 (m, 1H), 6.53 (d, J=11.7 Hz, 1H), 6.46-6.41 (m, 1H), 3.98-3.95 (m, 1H), 3.92-3.75 (m, 3H), 3.70 (s, 3H), 3.39-3.35 (m, 1H), 3.25-3.18 (m, 2H), 2.99-2.90 (m, 1H), 2.80-2.72 (m, 1H), 2.63 (s, 3H), 2.59-2.55 (m, 1H), 2.48-2.44 (m, 1H), 2.34-2.29 (m, 1H), 1.97-1.95 (m, 2H), 1.86-1.49 (m, 4H).
Example 81
Preparation of methyl (2S)-2-((2-(4-((1,1-dihydroxytetrahydrothiophen-3-yl)amino)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1057] ##STR00700##
[1058] Intermediate 2-7 (80 mg, 0.16 mmol), 3-aminotetrahydrothiophene 1,1-disulfone hydrochloride (43 mg, 0.24 mmol), cesium carbonate (217 mg, 0.64 mmol), (±)-2,2′-bis-(diphenylphosphino)-1,1′-binaphthalene (21 mg, 0.03 mmol), and tris(dibenzylideneacetone)dipalladium (15 mg, 0.02 mmol) were dissolved in toluene (3 mL) under nitrogen atmosphere. The reaction system was heated to 80° C., and reacted overnight. Then the reaction system was cooled to room temperature, added with water (20 mL) to quench the reaction, and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by preparative high performance liquid chromatography to give compound 81 (32.4 mg, 36% yield) in the form of a yellow solid, LC-MS: [M+H].sup.+=535.1.
[1059] .sup.1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 7.55 (d, J=7.4 Hz, 1H), 6.77 (d, J=6.9 Hz, 1H), 6.27 (d, J=9.8 Hz, 2H), 4.37-4.30 (m, 1H), 4.01-3.79 (m, 3H), 3.70 (s, 3H), 3.63-3.56 (m, 1H), 3.55-3.48 (m, 1H), 3.45-3.32 (m, 2H), 3.25-3.16 (m, 1H), 3.13-3.05 (m, 1H), 3.03-2.86 (m, 3H), 2.67-2.62 (m, 2H), 2.46 (s, 3H), 2.45-2.36 (m, 1H).
Example 82
[1060] ##STR00701##
[1061] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=571.2.
Example 83
[1062] ##STR00702##
[1063] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=541.3.
Example 84
[1064] ##STR00703##
[1065] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=521.2.
Example 85
[1066] ##STR00704##
Step (1) Preparation of methyl (S)-2-((2-(4-amino-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1067] ##STR00705##
[1068] Intermediate 3-1 (80 mg, 0.19 mmol) and diisopropylethylamine (74 mg, 0.57 mmol) were dissolved in dichloromethane (10 mL). The reaction system was cooled to 0° C., added dropwise with a solution of methyl 4-(chloroformyl)benzoate (75 mg, 0.38 mmol) in dichloromethane (0.2 mL), and stirred at room temperature for 12 h. Then the reaction system was diluted with dichloromethane (10 mL) and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 85-2 (100 mg, 49% yield) in the form of a white solid. MS [M+H].sup.+=579.2.
Step (2) Preparation of (S)-4-((3,5-difluoro-4-(3-((4-(carbomethoxy<methoxycarbonyl>)morpholin-2-yl)methyl)-7-methylimidazo[1, 2-a]pyridin-2-yl)phenyl)carbamoyl)benzoic acid
[1069] ##STR00706##
[1070] Intermediate 85-2 (50 mg, 0.09 mmol) was dissolved in tetrahydrofuran (5 mL) and water (1 mL), and lithium hydroxide monohydrate (22 mg, 0.55 mmol) was added. The reaction system was stirred at room temperature for 1 h. After the reaction was completed, the reaction system was adjusted to pH 4-5 with diluted hydrochloric acid (1 N), and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative high performance liquid chromatography to give compound 85 (35 mg, 59% yield) in the form of a white solid. MS [M+H].sup.+=565.2.
[1071] 1H NMR (400 MHz, d6-DMSO) δ 13.24 (s, 1H), 10.84 (s, 1H), 8.42 (d, J=6.9 Hz, 1H), 8.10 (q, J=7.0 Hz, 4H), 7.69 (d, J=9.9 Hz, 2H), 7.35 (s, 1H), 6.83 (d, J=7.1 Hz, 1H), 3.77-3.59 (m, 3H), 3.56 (s, 3H), 3.52-3.46 (m, 1H), 3.30-3.22 (m, 1H), 3.08-3.00 (m, 2H), 2.90-7.74 (m, 1H), 2.60-2.48 (m, 1H), 2.39 (s, 3H).
Example 86
[1072] ##STR00707##
[1073] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=522.2.
Example 87
[1074] ##STR00708##
[1075] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=471.2.
Example 88
[1076] ##STR00709##
[1077] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=513.3.
Example 89
Preparation of methyl (S)-2-((2-(4-(1-cyanocyclopropane-1-carboxamido<oxalylamino>)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1078] ##STR00710##
[1079] 1-cyanocyclopropane-1-carboxylic acid (52 mg, 0.47 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (180 mg, 0.47 mmol) were dissolved in anhydrous N,N-dimethylformamide (2 mL) under nitrogen atmosphere. The reaction system was reacted at room temperature for 10 min, added with N,N-diisopropylethylamine (162 mg, 1.25 mmol) and intermediate 3-1 (130 mg, 0.31 mmol), and reacted at room temperature overnight. Then the reaction system was added with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 89 (35.8 mg, 23% yield) in the form of a white solid.
[1080] LC-MS: [M+H].sup.+=510.6. 1H NMR (400 MHz, MeOD): δ 8.83 (d, J=7.1 Hz, 1H), 7.69 (s, 1H), 7.67 (d, J=10.1 Hz, 2H), 7.40 (dd, J=7.1, 1.5 Hz, 1H), 3.98 (d, J=12.8 Hz, 1H), 3.83 (d, J=13.6 Hz, 1H), 3.76 (d, J=9.2 Hz, 1H), 3.70 (s, 3H), 3.70-3.65 (m, 1H), 3.37-3.34 (m, 1H), 3.24 (d, J=5.3 Hz, 2H), 3.00-2.85 (m, 1H), 280-2.67 (m, 1H), 2.64 (s, 3H), 1.81-1.76 (m, 2H), 1.75-1.70 (m, 2H).
Example 90
[1081] ##STR00711##
[1082] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=517.2.
Example 91
[1083] ##STR00712##
[1084] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=545.4.
Example 92
[1085] ##STR00713##
[1086] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=531.2.
Example 93
[1087] ##STR00714##
[1088] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=531.4.
Example 94
[1089] ##STR00715## ##STR00716##
Step (1) Preparation of tert-butyl (R)-2-(azidomethyl)morpholine-4-carboxylate
[1090] ##STR00717##
[1091] Tert-butyl (R)-2-(bromomethyl)morpholine-4-carboxylate (1.0 g, 3.58 mmol) was dissolved in N,N-dimethylformamide (8 mL), and sodium azide (700 mg, 10.75 mmol) was added. The reaction system was heated to 90° C. for 8 h. Then the reaction system was cooled to room temperature, added with water (40 mL) to quench the reaction, and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (15 mL×2), dried over anhydrous sodium sulfate, and concentrated. The residue was separated by column chromatography to give intermediate 94-2 (738 mg, 92% yield) in the form of a white solid. LC-MS: [M+H].sup.+=243.2.
Step (2) Preparation of tert-butyl (S)-2-(aminomethyl)morpholine-4-carboxylate
[1092] ##STR00718##
[1093] Intermediate 94-2 (738 mg, 3.05 mmol) was dissolved in methanol (10 mL), and wet palladium on carbon catalyst (200 mg, 10% w/w) was added. The reaction system was purged with hydrogen and reacted at room temperature for 2.5 h. Then the reaction system was filtered and concentrated to give intermediate 94-3 (580 mg, 82% yield) in the form of a light yellow oil. LC-MS: [M+H].sup.+=217.2.
Step (3) Preparation of tert-butyl (S)-2-(((5-methyl-3-nitropyridin-2-yl)amino)methyl)morpholine-4-carboxylate
[1094] ##STR00719##
[1095] Intermediate 94-3 (580 mg, 2.68 mmol) was dissolved in ethanol (10 mL), and 2-chloro-5-methyl-3-nitropyridine (509 mg, 2.95 mmol) and triethylamine (895 mg, 8.84 mmol) were added. The reaction system was heated to reflux for 24 h. Then the reaction system was concentrated by rotary evaporation. The residue was separated by column chromatography (PE/EA=4/1) to give intermediate 94-5 (710 mg, 75% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=353.1.
Step (4) Preparation of tert-butyl (S)-2-(((3-amino-5-methylpyridin-2-yl)amino)methyl)morpholine-4-carboxylate
[1096] ##STR00720##
[1097] Intermediate 94-5 (326 mg, 0.96 mmol) was dissolved in ethyl acetate (20 mL), and wet palladium on carbon catalyst (50 mg, 10% w/w) was added. The reaction system was purged with hydrogen and stirred at room temperature for 2.5 h. Then the reaction system was filtered and concentrated to give intermediate 94-6 (266 mg, 81% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=323.2.
Step (5) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1098] ##STR00721##
[1099] Intermediate 94-6 (266 mg, 0.82 mmol), sodium bisulfite (512 mg, 4.92 mmol), and 3,5-difluoro-4-formyl-N-methylbenzamide (213 mg, 1.07 mmol) were dissolved in N,N-dimethylformamide (8 mL). The reaction system was heated to 100° C. and reacted for 15 h. After the reaction was completed, the reaction system was added with water (30 mL) to quench the reaction, and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The reaction system was separated by column chromatography (EA) to give intermediate 94-8 (210 mg, 46% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=502.1.
Step (6) Preparation of (R)-3,5-difluoro-N-methyl-4-(6-methyl-3-(morpholin-2-yl-methyl)-3H-imidazo[4,5-b]pyridin-2-yl)benzamide
[1100] ##STR00722##
[1101] Intermediate 94-8 (210 mg, 0.52 mmol) was dissolved in ethyl acetate (4 mL), and a solution of HCl in ethyl acetate (1 mL, 4 N) was added dropwise. The reaction system was stirred at room temperature for 2.5 h. Then the reaction system was concentrated to give intermediate 94-9 (hydrochloride, 222 mg, crude product) in the form of a yellow solid, which was used directly in the next step. LC-MS: [M+H].sup.+=402.1.
Step (7) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1102] ##STR00723##
[1103] Intermediate 94-9 (222 mg, 0.52 mmol) was dissolved in anhydrous dichloromethane (10 mL), and triethylamine (157 mg, 1.56 mmol) was added. Under nitrogen atmosphere, the reaction system was cooled to 0° C., added dropwise with methyl chloroformate (59 mg, 0.62 mmol), and reacted for 3 h. Then the reaction system was diluted with dichloromethane (20 mL) and washed with water (20 mL). The aqueous phase was extracted with dichloromethane (15 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative high performance liquid chromatography to give compound 94 (64 mg, 27% yield) in the form of a white solid. LC-MS: [M+H].sup.+=460.8.
[1104] .sup.1H NMR (400 MHz, CDCl.sub.3): δ 8.39 (s, 1H), 8.03 (s, 1H), 7.56 (brs, 2H), 7.02 (brs, 1H), 4.50-4.41 (m, 1H), 4.25-4.15 (m, 1H), 4.12-3.96 (m, 1H), 3.85-3.65 (m, 5H), 3.65-3.55 (m, 1H), 3.30-3.20 (m, 1H), 3.07 (s, 3H), 2.85-2.70 (m, 1H), 2.57 (s, 3H), 2.56-2.46 (m, 1H).
Example 95
[1105] ##STR00724##
[1106] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=543.3.
Example 96
[1107] ##STR00725##
[1108] The compound was prepared according to the preparation method as described in Example 25. LC-MS: [M+H].sup.+=524.3.
Example 97
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methoxycarbonyl)cyclopropane-1-carboxamido)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1109] ##STR00726##
[1110] Intermediate 97-1 (31 mg, 0.22 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (82 mg, 0.22 mmol) were dissolved in anhydrous N,N-dimethylformamide (1.0 mL) under nitrogen atmosphere. The reaction system was reacted at room temperature for 10 min, added with N,N-diisopropylethylamine (75 mg, 0.58 mmol) and intermediate 3-1 (60 mg, 0.14 mmol), and reacted at room temperature overnight. Then the reaction system was added with water (20 mL) to quench the reaction, and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 97 (11.7 mg, 15% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=543.7.
[1111] .sup.1H NMR (400 MHz, MeOD) δ 8.84 (d, J=7.1 Hz, 1H), 7.70 (s, 1H), 7.64 (d, J=10.1 Hz, 2H), 7.41 (dd, J=7.1, 1.4 Hz, 1H), 4.01-3.97 (m, 1H), 3.85-3.82 (m, 1H), 3.80 (s, 3H), 3.78-3.71 (m, 2H), 3.70 (s, 3H), 3.39-3.35 (m, 1H), 3.28-3.21 (m, 2H), 2.98-2.90 (m, 1H), 2.80-2.70 (m, 1H), 2.65 (s, 3H), 1.71-1.64 (m, 4H).
Example 98
[1112] ##STR00727##
[1113] The compound was prepared according to the preparation method as described in Example 5. LC-MS: [M+H].sup.+=484.2.
Example 99
[1114] ##STR00728##
[1115] The compound was prepared according to the preparation method as described in Example 5. LC-MS: [M+H].sup.+=485.3.
Example 100
[1116] ##STR00729##
[1117] The compound was prepared according to the preparation method as described in Example 5. LC-MS: [M+H].sup.+=483.4.
Example 101
[1118] ##STR00730##
[1119] The compound was prepared according to the preparation method as described in Example 5. LC-MS: [M+H].sup.+=485.2.
Example 102
[1120] ##STR00731##
[1121] The compound was prepared according to the preparation method as described in Example 4. LC-MS: [M+H].sup.+=518.2.
Example 103
[1122] ##STR00732##
[1123] The compound was prepared according to the preparation method as described in Example 15. LC-MS: [M+H].sup.+=472.5.
Example 104
[1124] ##STR00733##
[1125] Compound 6 (540 mg, 1.27 mmol) was dissolved in DMF (15 mL), and a magnetic stirrer was added, followed by the addition of NaN.sub.3 (247.7 mg, 3.81 mmol) and NH.sub.4Cl (271 mg, 5.08 mmol). The reaction system was slowly heated to 100° C. and reacted overnight. After the reaction was completed as detected by LCMS, the reaction system was dissolved with water, and extracted with EA, followed by liquid separation. The organic phase was dried over anhydrous sodium sulfate, and concentrated by rotary evaporation to give a crude product (200 mg). The crude product was separated by prep-HPLC, and lyophilized to give compound 104 (54.1 mg, 95.03% purity) in the form of an off-white solid.
[1126] LCMS [M+H]+=470.10. 1H NMR (400 MHz, CD3OD) δ 8.81 (d, J=7.2 Hz, 1H), 7.96 (m, 2H), 7.69 (s, 1H), 7.36 (dd, J=1.2 Hz, 7.2 Hz, 1H), 4.01 (m, 1H), 3.85 (m, 1H), 3.73 (m, 2H), 3.68 (s, 3H), 3.37 (m, 1H), 3.26 (m, 2H), 2.92 (br, 1H), 2.75 (m, 1H), 2.64 (s, 3H).
Example 105
[1127] ##STR00734##
[1128] The compound was prepared according to the preparation method as described in Example 7. LC-MS: [M+H].sup.+=547.2.
Example 106
[1129] ##STR00735##
[1130] The compound was prepared according to the preparation method as described in Example 38. LC-MS: [M+H].sup.+=497.4.
Example 107
Preparation of (S)-1-(3,5-difluoro-4-(3-((4-(carbomethoxy<methoxycarbonyl>)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-imidazole-4-carboxylic acid
[1131] ##STR00736##
[1132] Compound 51 (30 mg, 0.06 mmol) and sodium hydroxide (7 mg, 0.30 mmol) were dissolved in methanol (2 mL) and water (1 mL). The reaction system was stirred at room temperature for 1 h. Then the reaction system was adjusted to pH 4-5 with diluted hydrochloric acid (1 N), and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative high performance liquid chromatography to give compound 107 (10 mg, 33% yield) in the form of a white solid. MS [M+H].sup.+=512.1.
[1133] 1H NMR (400 MHz, d6-DMSO) δ 8.56 (brs, 1H), 8.44 (d, J=5.0 Hz, 1H), 7.89 (brs, 1H), 7.37 (brs, 1H), 6.84 (d, J=6.3 Hz, 1H), 3.74-3.60 (m, 3H), 3.56 (s, 3H), 3.51-3.45 (m, 1H), 3.26-3.21 (m, 1H), 3.10-2.98 (m, 2H), 2.88-2.75 (m, 1H), 2.60-2.48 (m, 1H), 2.38 (s, 3H).
Example 108
[1134] ##STR00737##
[1135] The compound was prepared according to the preparation method as described in Example 50. LC-MS: [M+H].sup.+=526.2.
Example 109
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-trifluoromethyl-1H-imidazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1136] ##STR00738##
[1137] Intermediate 17-2 (130 mg, 0.25 mmol), 4-(trifluoromethyl)-1H-imidazole (40 mg, 0.3 mmol), copper(II) acetate (67 mg, 0.37 mmol), and pyridine (39 mg, 0.5 mmol) were dissolved in acetonitrile (2 mL). The reaction system was heated to 60° C. and reacted overnight. Then the reaction system was cooled to room temperature, diluted with water (10 mL), and extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 109 (13 mg, 9% yield) in the form of a white solid.
[1138] LC-MS: [M+H].sup.+=536.4. .sup.1H NMR (400 MHz, CDCl3): δ 8.29 (d, J=7.3 Hz, 1H), 7.99 (s, 1H), 7.70 (s, 1H), 7.61 (s, 1H), 7.19 (d, J=7.2 Hz, 1H), 6.83 (d, J=7.0 Hz, 1H), 4.10-3.80 (m, 3H), 3.71 (s, 3H), 3.65-3.57 (m, 1H), 3.46-3.35 (m, 1H), 3.09-2.95 (m, 3H), 2.70-2.62 (m, 1H), 2.49 (s, 3H).
Example 110
Preparation of methyl (S)-2-((2-(4-(4-carbamoyl-1H-imidazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1139] ##STR00739##
[1140] Compound 107 (30 mg, 0.06 mmol), HATU (34 mg, 0.09 mmol) and N,N-diisopropylethylamine (23 mg, 0.18 mmol) were dissolved in N,N-dimethylformamide (2 mL). The reaction system was stirred at room temperature for 5 min, added with anhydrous ammonium chloride (10 mg, 0.18 mmol), and stirred at room temperature for another 1 h. Then the reaction system was added with saturated brine (15 mL) to quench the reaction, and extracted with ethyl acetate (10 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give compound 110 (28 mg, 83% yield) in the form of a white solid. LC-MS: [M+H].sup.+=511.1.
[1141] 1H NMR (400 MHz, MEOD) δ 8.43 (d, J=7.2 Hz, 1H), 8.36 (d, J=1.3 Hz, 1H), 8.27 (d, J=1.3 Hz, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.37 (s, 1H), 6.90 (dd, J=7.1, 1.6 Hz, 1H), 3.89-3.76 (m, 3H), 3.67 (s, 3H), 3.63-3.58 (m, 1H), 3.41-3.35 (m, 1H), 3.16-3.10 (m, 2H), 2.98-2.82 (m, 1H), 2.72-2.58 (m, 1H), 2.48 (s, 3H).
Example 111
[1142] ##STR00740##
[1143] The compound was prepared according to the preparation method for compound 5. MS [M+H].sup.+=483.3.
Example 112
[1144] ##STR00741##
[1145] The compound was prepared according to the preparation method for compound 5. MS [M+H].sup.+=498.2.
Example 113
[1146] ##STR00742##
[1147] The compound was prepared according to the preparation method for compound 5. MS [M+H].sup.+=552.2.
Example 114
Preparation of (S)-2-(3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)oxazole-4-carboxylic acid
[1148] ##STR00743## ##STR00744##
Step (1) Preparation of methyl (R)-2-((2-(4-(1,3-dioxolan-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1149] ##STR00745##
[1150] 4-(1,3-dioxolan-2-yl)-2,6-difluorobenzaldehyde (600 mg, 2.8 mmol), 4-methylpyridin-2-amine (302.8 mg, 2.8 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (595 mg, 2.8 mmol), copper(I) chloride (84 mg, 0.84 mmol), and copper(II) trifluoromethanesulfonate (304 mg, 0.84 mmol) were dissolved in toluene (10 mL). The reaction system was stirred at 85° C. for 30 min, added dropwise with N,N-dimethylacetamide (0.1 mL), and stirred at 85° C. overnight. Then the reaction system was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give intermediate 114-2 (1.2 g, 55.36% yield) in the form of a yellow solid. MS [M+H].sup.+=516.2.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-formylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1151] ##STR00746##
[1152] Intermediate 114-2 (1.2 g, 2.33 mmol) was dissolved in acetone (10 mL) at room temperature, and diluted hydrochloric acid (10 mL, 1 N) was added. The reaction system was stirred overnight. After the reaction was completed, the reaction system was adjusted to pH 8-9 with saturated sodium carbonate solution, added with BOC-anhydride (766 mg, 3.5 mmol), and stirred at room temperature for 5 h. Then the reaction system was extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 114-3 (563 mg, 51.3% yield) in the form of a yellow solid. MS [M+H].sup.+=471.2.
Step (3) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(4-(carbomethoxy<methoxycarbonyl>)oxazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1153] ##STR00747##
[1154] Intermediate 114-3 (495 mg, 1.05 mmol) was dissolved in N,N-dimethylacetamide (4 mL) under nitrogen atmosphere, and methyl (2S)-2-amino-3-hydroxypropionate acid (163 mg, 1.05 mmol) and potassium carbonate (290 mg, 2.10 mmol) were added. The reaction system was stirred at room temperature for 18 h. Then the reaction system was cooled to 0° C., added with bromotrichloromethane (625 mg, 3.15 mmol) and 1,8-diaza-cyclo[5.4.0]undec-7-ene (480 mg, 3.15 mmol), stirred at 0° C. for 2 h, and stirred at room temperature for 24 h. The resulting reaction system was added with water (20 mL) to quench the reaction and extracted with diethyl ether (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 114-4 (231 mg, 37.2% yield) in the form of a yellow solid. MS [M+H].sup.+=569.2.
Step (4) Preparation of methyl (S)-2-(3,5-difluoro-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)oxazole-4-carboxylate
[1155] ##STR00748##
[1156] Intermediate 114-4 (231, 0.41 mmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The reaction system was stirred at room temperature for 2 h. Then the reaction system was concentrated by rotary evaporation under reduced pressure, diluted with dichloromethane (30 mL), and slowly added with saturated sodium bicarbonate solution (20 mL) while stirring, followed by liquid separation. The aqueous phase was extracted with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give intermediate 114-5 (195 mg, 97.6% yield) in the form of a brown solid. MS [M+H]+=469.1.
Step (5) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-(carbomethoxy<methoxycarbonyl>)oxazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1157] ##STR00749##
[1158] Intermediate 114-5 (150 mg, 0.30 mmol) and diisopropylethylamine (160 mg, 1.20 mmol) were dissolved in DCM (10 mL) at 0° C. under nitrogen atmosphere. The reaction system was stirred for 10 min, and added dropwise with methyl chloroformate (34 mg, 0.36 mmol). After the completion of the dropwise addition, the reaction was reacted for 2 h. Then the reaction system was concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 114-6 (110 mg, 66.7% yield) in the form of a white solid. MS [M+H].sup.+=527.1.
Step (6) Preparation of 2-[3,5-difluoro-4-(3-{[(2S)-4-(carbomethoxy<methoxycarbonyl>)morpholin-2-yl]methyl}-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-oxazole-4-carboxylic acid
[1159] ##STR00750##
[1160] Intermediate 114-6 (80 mg, 0.15 mmol) was dissolved in methanol (2 mL), and sodium hydroxide solution (1.5 mL, 1 N) was added. The reaction system was reacted at room temperature for 2 h. Then the reaction system was adjusted to pH 5 with diluted hydrochloric acid and concentrated. The residue was separated by preparative high performance liquid chromatography to give compound 114 (33 mg, 40% yield) in the form of a white solid. LC-MS [M+H].sup.+=513.1.
[1161] 1H NMR (400 MHz, DMSO) δ13.24 (brs, 1H), 8.99 (s, 1H), 8.47 (d, J=7.1 Hz, 1H), 7.81 (d, J=7.5 Hz, 2H), 7.39 (s, 1H), 6.88 (d, J=7.0 Hz, 1H), 3.82-3.73 (m, 1H), 3.69-3.60 (m, 2H), 3.56 (s, 3H), 3.49 (s, 1H), 3.27-3.18 (m, 1H), 3.14-3.00 (m, 2H), 2.87-2.75 (m, 1H), 2.55-2.45 (m, 1H), 2.40 (s, 3H).
Example 115
[1162] ##STR00751##
[1163] The compound was prepared according to the preparation method as described in Example 114. LC-MS: [M+H].sup.+=493.2.
Example 116
[1164] ##STR00752##
[1165] The compound was prepared according to the preparation method as described in Example 114. LC-MS: [M+H].sup.+=493.2.
Example 117
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1166] ##STR00753##
[1167] Compound 51 (30 mg, 0.06 mmol) was dissolved in tetrahydrofuran (2 mL), and a solution of methyl magnesium bromide in n-hexane (3 M, 0.06 mL, 0.18 mmol) was added dropwise under nitrogen atmosphere in an ice water bath. After the completion of the dropwise addition, the reaction system was stirred at room temperature for 1 h. Then the reaction system was added with saturated ammonium chloride solution to quench the reaction, and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative high performance liquid chromatography to give compound 117 (5 mg, 17% yield) in the form of a white solid. MS [M+H].sup.+=526.1.
[1168] 1H NMR (400 MHz, d6-DMSO) δ 8.43 (d, J=7.0 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H), 7.73 (d, J=8.8 Hz, 2H), 7.71 (d, J=1.4 Hz, 1H), 7.36 (s, 1H), 6.85 (dd, J=7.1, 1.5 Hz, 1H), 4.84 (s, 1H), 3.78-3.60 (m, 3H), 3.56 (s, 3H), 3.52-3.46 (m, 1H), 3.29-3.21 (m, 1H), 3.08-3.02 (m, 2H), 2.90-2.75 (m, 1H), 2.60-2.46 (m, 1H), 2.39 (s, 3H), 1.45 (s, 6H).
Example 118
[1169] ##STR00754##
[1170] The compound was prepared according to the preparation method as described in Example 114. MS [M+H].sup.+=525.2.
Example 119
[1171] ##STR00755##
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-(2-hydroxypropyl-2-yl)oxazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1172] Intermediate 114-6 (150 mg, 0.29 mmol) was dissolved in tetrahydrofuran (8 mL), and methylmagnesium chloride (0.3 mL, 3.0 M) was added dropwise with the temperature maintained at −20° C. The reaction system was stirred at this temperature for 4 h. Then the reaction system was added with a small amount of water to quench the reaction, and concentrated. The residue was separated by preparative chromatography to give compound 119 (10.8 mg, 7.1% yield) in the form of a white solid. LC-MS [M+H].sup.+: 527.0.
[1173] 1H NMR (400 MHz, CDCl3) δ 8.43 (d, J=7.2 Hz, 1H), 7.89 (s, 1H), 7.80 (d, J=7.9 Hz, 1H), 7.36 (s, 1H), 6.89 (dd, J=7.1, 1.5 Hz, 1H), 3.89-3.74 (m, 3H), 3.70 (s, 3H), 3.64-3.57 (m, 1H), 3.41-3.33 (m, 1H), 3.16-3.09 (m, 2H), 2.96-2.80 (m, 1H), 2.70-2.55 (m, 1H), 2.49 (s, 3H), 1.61 (s, 6H).
Example 120
[1174] ##STR00756##
[1175] The compound was prepared according to the preparation method as described in Example 10. LC-MS: [M+H].sup.+=494.3.
Example 121
[1176] ##STR00757##
[1177] The compound was prepared according to the preparation method as described in Example 10. LC-MS: [M+H].sup.+=492.4.
Example 122
[1178] ##STR00758##
[1179] The compound was prepared according to the preparation method as described in Example 10. LC-MS: [M+H].sup.+=473.5.
Example 123
[1180] ##STR00759##
[1181] The compound was prepared according to the preparation method as described in Example 10. LC-MS: [M+H].sup.+=487.1.
Example 124
[1182] ##STR00760##
[1183] Intermediate 17-2 (190 mg, 0.36 mmol), 1H-pyrazole-3-carbonitrile (40 mg, 0.43 mmol), anhydrous copper(II) acetate (98 mg, 0.54 mmol) and pyridine (57 mg, 0.72 mmol) were dissolved in acetonitrile (3 mL). The reaction system was heated to 60° C. and reacted overnight. Then the reaction system was cooled to room temperature, diluted with water (20 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 124 (70 mg, white solid) and compound 124-2 (5 mg, 42% yield) in the form of a white solid. LC-MS: [M+H].sup.+=493.3.
[1184] Compound 124: .sup.1H NMR (400 MHz, CDCl.sub.3) δ8.33 (d, J=6.0 Hz, 1H), 8.08 (d, J=2.4 Hz, 1H), 7.70 (brs, 1H), 7.52 (d, J=8.0 Hz, 2H), 6.95 (d, J=2.5 Hz, 1H), 6.88 (d, J=6.0 Hz, 1H), 4.05-3.76 (m, 3H), 3.71 (s, 3H), 3.66-3.58 (m, 1H), 3.46-3.36 (m, 1H), 3.10-2.83 (m, 3H), 2.70-2.62 (m, 1H), 2.51 (s, 3H).
[1185] Compound 124-2: .sup.1H NMR (400 MHz, CDCl.sub.3) δ 8.29 (brs, 1H), 7.88 (s, 1H), 7.70-7.50 (m, 3H), 7.14 (s, 1H), 6.83 (brs, 1H), 4.08-3.75 (m, 3H), 3.70 (s, 3H), 3.66-3.58 (m, 1H), 3.46-3.36 (m, 1H), 3.10-2.85 (m, 3H), 2.72-2.62 (m, 1H), 2.49 (s, 3H).
Example 125
[1186] ##STR00761##
Step (1) Preparation of (S)-3,5-difluoro-4-(7-methyl-3-(morpholinyl-2-methyl)imidazo[1,2-a]pyridin-2-yl)-1H-pyrazole-3-carboxylic acid
[1187] ##STR00762##
[1188] Compound 124 (40 mg, 0.08 mmol) was dissolved in ethanol (2 mL) and water (1 mL), and potassium hydroxide (13 mg, 0.24 mmol) was added. The reaction system was reacted at 100° C. for 12 h under nitrogen atmosphere. The reaction system was cooled to room temperature, and concentrated to give intermediate 125-1 (40 mg, crude product), which was used directly in the next step. LC-MS: [M+H].sup.+=454.2.
Step (2) Preparation of (S)-1-(3,5-difluoro-4-(3-((4-(methoxycarbonyl)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-pyrazole-3-carboxylic acid
[1189] ##STR00763##
[1190] The intermediate 125-1 (40 mg, 0.08 mmol, crude product) was dissolved in tetrahydrofuran/water (2 mL, 1/1), and methyl chloroformate (10 mg, 0.108 mmol) was added dropwise in an ice water bath. The reaction system was reacted at this temperature for 1 h. Then the reaction system was adjusted to pH 4 with diluted hydrochloric acid, and concentrated. The residual aqueous phase was lyophilized. The crude product was purified by preparative high performance liquid chromatography to give compound 125 (7.6 mg, 18% yield), LC-MS: [M+H].sup.+=512.3.
[1191] .sup.1H NMR (400 MHz, CDCl3) δ 8.28 (d, J=7.0 Hz, 1H), 7.98 (d, J=2.1 Hz, 1H), 7.70 (s, 1H), 7.49 (d, J=8.2 Hz, 2H), 7.07 (d, J=2.4 Hz, 1H), 6.81 (d, J=7.0 Hz, 1H), 4.06-3.78 (m, 3H), 3.70 (s, 3H), 3.66-3.58 (m, 1H), 3.46-3.35 (m, 1H), 3.05-2.85 (m, 3H), 2.70-2.62 (m, 1H), 2.49 (s, 3H).
Example 126
[1192] ##STR00764##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(3-(carbomethoxy<methoxycarbonyl>)1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1, 2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1193] ##STR00765##
[1194] Methyl (S)-2-((7-methyl-2-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (700 mg, 1.67 mmol), methyl 3-pyrazolecarboxylate (210 mg, 1.67 mmol) and anhydrous potassium carbonate (692 mg, 5.00 mmol) were dissolved in N,N-dimethylformamide (15 mL) under nitrogen atmosphere. The reaction system was stirred at 130° C. for 4 h. Then the reaction system was cooled, added with ice water (15 mL) to quench the reaction, and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 126-2 (300 mg, 80% purity, 27% yield) in the form of a yellow solid. MS [M+H].sup.+=526.2.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(3-(2-hydroxypropan-2-yl)-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1195] ##STR00766##
[1196] Intermediate 126-2 (150 mg, 0.28 mmol) was dissolved in tetrahydrofuran (5 mL) under nitrogen atmosphere. The reaction system was cooled to 0° C. in an ice water bath, added dropwise with methyl magnesium bromide solution (3 M, 0.3 mL, 0.9 mmol) with the temperature maintained at 0° C., and stirred for 1 h. Then the reaction system was added with saturated ammonium chloride solution (10 mL) at 0° C. to quench the reaction, and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 126 (30 mg, 17% yield) in the form of a white solid. MS [M+H].sup.+=525.8.
[1197] .sup.1H NMR (400 MHz, MEOD): δ 8.45 (d, J=7.0 Hz, 1H), 8.31 (d, J=2.6 Hz, 1H), 7.67 (d, J=8.9 Hz, 2H), 7.39 (s, 1H), 6.93 (d, J=7.1 Hz, 1H), 6.60 (d, J=2.6 Hz, 1H), 3.89-3.76 (m, 3H), 3.66 (s, 3H), 3.64-3.60 (m, 1H), 3.42-3.35 (m, 1H), 3.16-3.11 (m, 2H), 3.00-2.85 (m, 1H), 2.71-2.60 (m, 1H), 2.49 (s, 3H), 1.64 (s, 6H).
Example 127
[1198] ##STR00767## ##STR00768##
Step (1) Preparation of 2,6-difluoro-4-(4-nitro-1H-pyrazol-1-yl)benzaldehyde
[1199] ##STR00769##
[1200] 2,4,6-trifluorobenzaldehyde (2.0 g, 12.5 mmol), 4-nitro-1H-pyrazole (1.4 g, 12.5 mmol) and triethylamine (3.8 g, 37.5 mmol) were dissolved in acetonitrile (20 mL) under nitrogen atmosphere. The reaction system was heated to reflux for 3 h. Then the reaction system was cooled to room temperature, added with water (50 mL) to quench the reaction, and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 127-3 (450 mg, 14% yield) in the form of a yellow solid. LC-MS [M+H].sup.+=254.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1201] ##STR00770##
[1202] Intermediate 127-3 (450 mg, 1.78 mmol), 4-methylpyridin-2-amine (192 mg, 1.78 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (375 mg, 1.78 mmol), copper(I) chloride (53 mg, 0.53 mmol) and copper (II) trifluoromethanesulfonate (193 mg, 0.53 mmol) were dissolved in toluene (5 mL) under nitrogen atmosphere The reaction system was heated to 85° C. and stirred for 20 min, added with N,N-dimethylacetamide (0.15 mL), and reacted at 85° C. for 5 h. Then the reaction system was cooled to room temperature and reacted overnight. Then the reaction system was added with water (30 mL) to quench the reaction, and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 127-4 (260 mg, 26% yield) in the form of a brown oily liquid. LC-MS [M+H].sup.+=555.2.
Step (3) Preparation of (S)-2-((2-(2,6-difluoro-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1203] ##STR00771##
[1204] Intermediate 127-4 (260 mg, 0.5 mmol) was dissolved in dichloromethane (3 mL). The reaction system was cooled to 0° C. in an ice water bath, added dropwise with a solution of HCl in ethanol (33%, 1 mL), and stirred at room temperature for 1 h. Then the reaction system was concentrated by rotary evaporation to give intermediate 127-5 (280 mg, crude product), which was used directly in the next step. LC-MS [M+H].sup.+=455.2.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1205] ##STR00772##
[1206] Intermediate 127-5 (200 mg, 0.44 mmol) and N,N-diisopropylethylamine (284 mg, 2.20 mmol) were dissolved in dichloromethane (3 mL) under nitrogen atmosphere. The reaction system was added dropwise with methyl chloroformate (50 mg, 0.52 mmol) at 0° C. in an ice water bath. After the completion of the dropwise addition, the reaction system was reacted for 1 h. Then the reaction system was added with water (20 mL) to quench the reaction, and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by silica gel column chromatography to give intermediate 127-6 (110 mg, 48% yield) in the form of a brown solid. LC-MS [M+H].sup.+=513.3.
[1207] .sup.1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.34 (s, 1H), 8.25 (d, J=7.1 Hz, 1H), 7.52-7.48 (m, 3H), 6.78 (s, 1H), 4.00-3.75 (m, 3H), 3.70 (s, 3H), 3.67-3.56 (m, 1H), 3.45-3.35 (m, 1H), 3.10-2.85 (m, 3H), 2.68-2.60 (m, 1H), 2.47 (s, 3H).
Step (5) Preparation of methyl (S)-2-((2-(4-(4-amino-1H-pyrazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1208] ##STR00773##
[1209] Intermediate 127-6 (80 mg, 0.15 mmol) and saturated ammonium chloride (0.5 mL) were dissolved in ethanol (2 mL) under nitrogen atmosphere. The reaction system was heated to 80° C., added with iron powder (44 mg, 0.75 mmol), and stirred for 15 min. Then the reaction system was cooled to room temperature, filtered and concentrated. The crude product was purified by preparative high performance liquid chromatography to give compound 127 (9 mg, 12% yield) in the form of a white solid. LC-MS [M+H].sup.+=483.2.
[1210] 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J=7.1 Hz, 1H), 7.53 (s, 1H), 7.52 (s, 1H), 7.46 (s, 1H), 7.34 (d, J=8.7 Hz, 2H), 6.76 (d, J=7.0 Hz, 1H), 4.00-3.75 (m, 3H), 3.69 (s, 3H), 3.66-3.56 (m, 1H), 3.45-3.35 (m, 1H), 3.08-2.85 (m, 3H), 2.67-2.61 (m, 1H), 2.46 (s, 3H).
Example 128
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-hydroxy-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1211] ##STR00774## ##STR00775##
Step (1) Preparation of 4-(4-bromo-1H-pyrazol-1-yl)-2,6-difluorobenzaldehyde
[1212] ##STR00776##
[1213] 2,4,6-trifluorobenzaldehyde (2.0 g, 12.49 mmol) was dissolved in anhydrous acetonitrile (20 mL), and 4-bromopyrazole (1.8 g, 12.49 mmol) and triethylamine (3.8 g, 37.47 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 80° C. for 1 h. Then the reaction system was cooled to room temperature, added with water (60 mL), and extracted with ethyl acetate (80 mL×3). The organic phases were combined, washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 128-3 (800 mg, 22.2% yield) in the form of a white solid. MS [M+H].sup.+=287.7.
Step (2) Preparation of tert-butyl (S)-2-((2-(4-(4-bromo-1H-pyrazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1214] ##STR00777##
[1215] Intermediate 128-3 (600 mg, 2.09 mmol), 4-methylpyridin-2-amine (226 mg, 2.09 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (442 mg, 2.09 mmol), copper(I) chloride (62 mg, 0.63 mmol) and copper(II) trifluoromethanesulfonate (227 mg, 0.63 mmol) were dissolved in toluene solution (6 mL) under nitrogen atmosphere. The reaction system was reacted at 85° C. for 10 min, added with N,N-dimethylacetamide (0.2 mL), and reacted at 85° C. for another 5 h. Then the reaction system was reacted at room temperature overnight. After the reaction was completed, the reaction system was filtered, and the filtrate was added with water (30 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 128-4 (200 mg, 17% yield) in the form of a yellow oil. MS [M+H].sup.+=588.8.
Step (3) Preparation of (S)-2-((2-(4-(4-bromo-1H-pyrazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1216] ##STR00778##
[1217] Intermediate 128-4 (200 mg, 0.34 mmol) was dissolved in dichloromethane (2 mL), and a solution of HCl in ethanol (33%, 0.5 mL) was added dropwise with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. Then the reaction system was added dropwise with saturated sodium bicarbonate solution to adjust the pH to 8 with the temperature maintained at 0° C., added with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give intermediate 128-5 (180 mg, crude product) in the form of a yellow oil. MS [M+H].sup.+=488.7.
Step (4) Preparation of methyl (S)-2-((2-(4-(4-bromo-1H-pyrazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1218] ##STR00779##
[1219] Intermediate 128-5 (180 mg, 0.34 mmol) and N,N-diisopropylethylamine (143 mg, 1.11 mmol) were dissolved in dichloromethane (2 mL), and methyl chloroformate (42 mg, 0.44 mmol) was added dropwise under nitrogen atmosphere with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 1 h. Then the reaction system was added with water (10 mL), and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 128-6 (150 mg, 81% yield) in the form of a yellow solid. MS [M+H].sup.+=546.7.
Step (5) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1220] ##STR00780##
[1221] Intermediate 128-6 (150 mg, 0.27 mmol) was dissolved in anhydrous 1,4-dioxane (2 mL) under nitrogen atmosphere, and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bis(1,3,2-dioxaborolan) (87 mg, 0.34 mmol), potassium acetate (54 mg, 0.55 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (10 mg, 0.014 mmol) were added. The reaction system was reacted at 90° C. for 2 h. After the reaction was completed, the reaction system was cooled to room temperature, filtered and concentrated by rotary evaporation to give intermediate 128-7 (180 mg, crude product) in a yellow oil, MS [M+H].sup.+=593.7.
Step (6) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-hydroxy-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1222] ##STR00781##
[1223] Intermediate 128-7 (180 mg, 0.27 mmol) was dissolved in tetrahydrofuran (2 mL), and hydrogen peroxide (0.5 mL) was added dropwise. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added dropwise with saturated sodium thiosulfate solution (2 mL) to quench the reaction, added with water (10 mL), and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by high performance liquid chromatography to give compound 128 (22.9 mg, 17.3% yield) in the form of a white solid. MS [M+H].sup.+=483.8.
[1224] .sup.1H NMR (400 MHz, MeOD) δ 8.86 (d, J=7.1 Hz, 1H), 7.93 (s, 1H), 7.72 (s, 1H), 7.70 (d, J=9.6 Hz, 2H), 7.50 (s, 1H), 7.42 (dd, J=7.1, 1.5 Hz, 1H), 4.03-4.00 (m, 1H), 3.85-3.76 (m, 3H), 3.69 (s, 3H), 3.40-3.36 (m, 1H), 3.28-3.26 (m, 2H), 2.99-2.90 (m, 1H), 2.80-2.72 (m, 1H), 2.66 (s, 3H).
Example 129
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4-methoxy-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1225] ##STR00782##
[1226] Compound 128 (45 mg, 0.09 mmol) was dissolved in N,N-dimethylformamide (1 mL) under nitrogen atmosphere, and cesium carbonate (36 mg, 0.11 mmol) and iodomethane (20 mg, 0.14 mmol) were added sequentially. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added with water (10 mL) to quench the reaction, and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by high performance liquid chromatography to give compound 129 (5.3 mg, 11.4% yield) in the form of a white solid. MS [M+H].sup.+=497.8.
[1227] .sup.1H NMR (400 MHz, MeOD) δ 8.42 (d, J=7.0 Hz, 1H), 8.15 (s, 1H), 7.59 (d, J=9.0 Hz, 2H), 7.56 (s, 1H), 7.35 (s, 1H), 6.88 (dd, J=7.2 Hz, 1.2 Hz, 1H), 3.86 (s, 3H), 3.86-3.76 (m, 3H), 3.66 (s, 3H), 3.63-3.58 (m, 1H), 3.42-3.36 (m, 1H), 3.12-3.11 (m, 2H), 2.93-2.88 (m, 1H), 2.68-2.61 (m, 1H), 2.47 (s, 3H).
Example 130
[1228] ##STR00783## ##STR00784##
Step (1) Preparation of 2-(1H-pyrazol-3-yl)acethydrazide
[1229] ##STR00785##
[1230] 5-nitropyridin-2-ol (10.0 g, 71.38 mmol) was dissolved in hydrazine hydrate (50 mL). The reaction system was stirred at 100° C. for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 130-2 (10.0 g, crude product) in the form of a red oil. LC-MS [M+H]=140.7.
Step (2 Preparation of 2-(1H-pyrazol-3-yl)acetic acid
[1231] ##STR00786##
[1232] Intermediate 130-2 (10 g) was added to concentrated hydrochloric acid (100 mL) under nitrogen atmosphere. The reaction system was heated to 100° C. and stirred for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 130-3 (10 g, crude product) in the form of a colorless transparent oil, MS [M+H].sup.+=127.0.
Step (3) Preparation of ethyl 2-(1H-pyrazol-3-yl)acetate
[1233] ##STR00787##
[1234] Intermediate 130-3 (10.0 g, crude product) was dissolved in ethanol (15 mL), and a solution of HCl in ethanol (33%, 12.5 mL) was added. The reaction system was stirred at room temperature for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 130-4 (12 g, crude product) in the form of a brown oil, MS [M+H].sup.+=155.0.
Step (4) Preparation of ethyl 2-(1-trityl-1H-pyrazol-3-yl)acetate
[1235] ##STR00788##
[1236] Intermediate 130-4 (12.0 g, crude product) was dissolved in anhydrous DMF (100 mL), and triphenylmethyl chloride (20.0 g, 77.42 mmol) and triethylamine (28.8 g, 285.5 mmol) were added. The reaction system was stirred at room temperature overnight. After the reaction was completed, the reaction system was added with water (300 mL), and extracted with ethyl acetate (100 mL×3). The organic phases were combined, washed with saturated brine (150 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 130-5 (2.3 g, 7.5% yield) in the form of a white solid. MS [M+H].sup.+=418.8.
Step (5) Preparation of ethyl 1-(1-trityl-1H-pyrazol-3-yl)cyclopropane-1-carboxylate
[1237] ##STR00789##
[1238] Intermediate 130-5 (1.0 g, 2.52 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). The reaction system was cooled to −78° C., added dropwise with lithium diisopropylamide (2.4 mL, 2 N, 4.80 mmol), and stirred at −78° C. for 20 min. Then the reaction system was added with dibromoethane (2.8 g, 15.13 mmol), slowly warmed to room temperature, and stirred overnight. After the reaction was completed, the reaction system was added with saturated ammonium chloride (10 mL), diluted with water (20 mL), and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 130-6 (550 mg, 51.6% yield) in the form of a yellow oil. MS [M+H].sup.+=444.8.
Step (6) Preparation of ethyl 1-(1H-pyrazol-3-yl)cyclopropane-1-carboxylate
[1239] ##STR00790##
[1240] Intermediate 130-6 (400 mg, 1.01 mmol) was dissolved in dichloromethane (2 mL) and methanol (2 mL), and trifluoroacetic acid (1.2 mL) was added. The reaction system was stirred at room temperature overnight. After the reaction was completed, the reaction system was adjusted to pH 10 with saturated sodium carbonate solution, and extracted with dichloromethane (15 mL×3). The organic phases were combined, dried over sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 130-7 (65 mg, 35.6% yield) in the form of a white solid, MS [M+H]+=181.0.
Step (7) Preparation of methyl (S)-2-((2-(4-(3-(1-(carbethoxy<ethoxycarbonyl>)cyclopropyl)-1H-pyrazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1241] ##STR00791##
[1242] Intermediate 130-7 (35 mg, 0.19 mmol) was dissolved in anhydrous DMSO (1.5 mL), and intermediate 126-1 (87 mg, 0.21 mmol) and potassium carbonate (66 mg, 0.48 mmol) were added. The reaction system was stirred at 130° C. overnight. After the reaction was completed, the reaction system was added with water (15 mL), and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 130-8 (25 mg, 22.7% yield) in the form of a white solid. MS [M+H].sup.+=579.8.
Step (8) Preparation of (S)-1-(1-(3,5-difluoro-4-(3-((4-(carbomethoxy<methoxycarbonyl>)morpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-pyrazol-3-yl)cyclopropane-1-carboxylic acid
[1243] ##STR00792##
[1244] Intermediate 130-8 (25 mg, 0.044 mmol) was dissolved in tetrahydrofuran (1 mL)/methanol (1 mL), and lithium hydroxide solution (0.5 mL, 1 N) was added. The reaction system was stirred at room temperature overnight. After the reaction was completed, the reaction system was adjusted to pH 4 with diluted hydrochloric acid, and extracted with ethyl acetate (5 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was separated by high performance liquid chromatography, and lyophilized to give compound 130 (5.0 mg, 20.6% yield) in the form of a white solid. MS [M+H].sup.+=551.7.
[1245] .sup.1H NMR (400 MHz, CDCl3) δ 8.31 (d, J=6.6 Hz, 1H), 7.93 (d, J=2.6 Hz, 1H), 7.63 (s, 1H), 7.38 (d, J=8.2 Hz, 2H), 6.84 ((d, J=6.8 Hz, 1H), 6.33 (s, 1H), 3.05-3.77 (m, 3H), 3.70 (s, 3H), 3.66-2.59 (m, 1H), 3.46-3.37 (m, 1H), 3.10-2.99 (m, 2H), 2.99-2.87 (m, 1H), 2.70-2.63 (m, 1H), 2.50 (s, 3H), 1.94 (dd, J=7.6, 4.0 Hz, 2H), 1.47 (dd, J=7.6, 4.1 Hz, 2H)
Example 131
[1246] ##STR00793##
[1247] The compound was prepared according to the preparation method as described in Example 126. LC-MS: [M+H].sup.+=524.2.
Example 132
[1248] ##STR00794##
[1249] The compound was prepared according to the preparation method as described in Example 5. LC-MS: [M+H].sup.+=472.2.
Example 133
Preparation of methyl (S)-2-((2-(4-(4-(1-carbamylcyclopropyl)-1H-imidazol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1250] ##STR00795##
[1251] Compound 59 (400 mg, 0.72 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (410 mg, 1.08 mmol) were dissolved in N,N-dimethylformamide (5 mL). The reaction system was stirred at room temperature for 10 min under nitrogen atmosphere, added with N,N-diisopropylethylamine (279 mL, 2.16 mmol) and ammonium chloride (58 mg, 1.1 mmol), and stirred at room temperature for another 2 h. Then the reaction system was added with water (30 mL) to quench the reaction, and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (10 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by silica gel column chromatography to give a crude product (200 mg) in the form of a brown solid. The crude product (50 mg) was purified by preparative chromatography to give compound 133 (11.1 mg) in the form of a white solid. LC-MS [M+H].sup.+: 551.
[1252] 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J=6.9 Hz, 1H), 7.47 (s, 1H), 7.39 (d, J=8.3 Hz, 2H), 6.96 (s, 1H), 6.80 (d, J=6.9 Hz, 1H), 5.56 (brs, 1H), 3.90-3.80 (m, 3H), 3.66 (s, 3H), 3.62-3.54 (m, 1H), 3.43-3.34 (m, 1H), 3.04-2.82 (m, 3H), 2.67-2.56 (m, 1H), 2.51 (s, 3H), 1.65-1.59 (m, 2H), 1.15-1.09 (m, 2H).
Example 134
[1253] ##STR00796## ##STR00797##
Step (1) Preparation of 1-tosyl-1H-pyrrol-3-sulfonyl chloride
[1254] ##STR00798##
[1255] N-p-toluenesulfonylpyrrole (2.00 g, 9.01 mmol) was dissolved in acetonitrile (20 mL), and chlorosulfonic acid (5 mL) was added dropwise slowly at 0° C. in an ice water bath. The reaction system was reacted at room temperature overnight. Then the reaction system was added dropwise slowly to an ice (100 g), and extracted with dichloromethane (80 mL×2). The organic phases were combined, washed with saturated sodium bicarbonate (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 134-3 (600 mg, 21% yield) in the form of a white solid.
Step (2) Preparation of N,N-bis(4-methoxybenzyl)-1-tosyl-1H-pyrrol-3-sulfonamide
[1256] ##STR00799##
[1257] Bis-(4-methoxybenzyl)-amine (195 mg, 0.76 mmol) and triethylamine (191 mg, 1.89 mmol) were dissolved in dichloromethane (5 mL) under nitrogen atmosphere, and a solution of intermediate 134-3 (200 mg, 0.63 mmol) in dichloromethane (1 mL) was added dropwise at 0° C. in an ice water bath. The reaction system was stirred at room temperature overnight. Then the reaction system was poured into water (20 mL), and extracted with dichloromethane (30 mL×2). The organic phases were combined, washed with saturated brine (30 mL), filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 134-5 (300 mg, 88% yield) in the form of a white solid. MS [M+Na].sup.+=562.
Step (3) Preparation of N,N-bis(4-methoxybenzyl)-1H-pyrrol-3-sulfonamide
[1258] ##STR00800##
[1259] Intermediate 134-5 (800 mg, 1.48 mmol) was dissolved in methanol (10 mL) and tetrahydrofuran (10 mL), and aqueous potassium carbonate solution (3 mL, 7.40 mmol) was added. The reaction system was stirred at 60° C. overnight. Then the reaction system was concentrated under reduced pressure. The residue was adjusted to pH 4 with acetic acid, diluted with ethyl acetate (50 mL), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 134-6 (500 mg, 88% yield) in the form of a white solid. MS [M+Na].sup.+=408.8.
Step (4) Preparation of methyl (S)-2-((2-(4-(3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-1H-pyrrol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1260] ##STR00801##
[1261] Methyl (S)-2-((7-methyl-2-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (271 mg, 0.65 mmol, intermediate 134-7, prepared according to the preparation method for intermediate 2-7, LC-MS: [M+H].sup.+=420.2) was dissolved in dimethyl sulfoxide (5 mL), and potassium carbonate (269 mg, 1.95 mmol) and N,N-bis(4-methoxybenzyl)-1H-pyrrol-3-sulfonamide (251 mg, 0.65 mmol) were added. The reaction system was reacted at 130° C. for 6 h under nitrogen atmosphere. Then the reaction system was added with water (30 mL), and extracted with ethyl acetate (30 mL×2). The organic phases were combined, washed with saturated brine (20 mL×2), filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 134-8 (320 mg, 44% yield) in the form of a brown solid. MS [M+H].sup.+=786.2.
Step (5) Preparation of methyl (S) 2-((2-(2,6-difluoro-4-(3-sulfamoyl-1H-pyrrol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1262] ##STR00802##
[1263] Intermediate 134-8 (280 mg, 0.36 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (3 mL) was added. The reaction system was reacted at room temperature for 16 h. Then the reaction system was concentrated under reduced pressure. The crude product was dissolved in dichloromethane (40 mL), washed with aqueous sodium bicarbonate solution (10%, 10 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative chromatography to give compound 134 (22.6 mg, 12% yield) in the form of a white solid. MS [M+H].sup.+=545.7.
[1264] 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J=7.0 Hz, 1H), 7.73-7.63 (m, 1H), 7.45 (s, 1H), 7.16-7.13 (m, 1H), 7.11 (d, J=7.7 Hz, 2H), 6.80-6.69 (m, 2H), 4.96 (s, 2H), 4.00-3.82 (m, 3H), 3.70 (s, 3H), 3.64-3.58 (m, 1H), 3.45-3.38 (m, 1H), 3.12-2.99 (m, 2H), 2.98-2.88 (m, 1H), 2.69-2.59 (m, 1H), 2.46 (s, 3H).
Example 135
[1265] ##STR00803##
[1266] The compound was prepared according to the preparation method as described in Example 126. LC-MS: [M+H].sup.+=525.2.
Example 136
[1267] ##STR00804##
[1268] The compound was prepared according to the preparation method for compound 5. LC-MS: [M+H].sup.+=551.2.
Example 137
[1269] ##STR00805##
[1270] The compound was prepared according to the preparation method for compound 5. LC-MS: [M+H].sup.+=492.7.
Example 138
[1271] ##STR00806##
Step (1) Preparation of methyl (S)-2-((2-(4-(1-(tert-butoxycarbonyl)-5-cyano-pyrrol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[1272] ##STR00807##
[1273] Intermediate 4-2 (290 mg, 0.51 mmol) was dissolved in anhydrous dichloromethane (5 mL) under nitrogen atmosphere, and chlorosulfonyl isocyanate (58 mg, 0.41 mmol) was added dropwise slowly at −78° C. After the completion of the dropwise addition over 2 min, the reaction system was reacted at −78° C. for 1 h, added dropwise with N,N-dimethylformamide (0.44 mL) over 1 min, and reacted at room temperature for 1 h. Then the reaction system was added with water (20 mL), and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 138-2 (200 mg, 66% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=592.8.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(5-cyano-1H-pyrrol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morph oline-4-carboxylate
[1274] ##STR00808##
[1275] Intermediate 138-2 (200 mg, 0.41 mmol) was dissolved in absolute methanol (3 mL), and sodium hydroxide solution (3 M, 0.4 mL) was added. The reaction system was reacted at 60° C. for 1 h. After the reaction was completed, the reaction system was added dropwise with diluted hydrochloric acid (1 M) to adjust the pH to 6, added with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 138 (41.2 mg, 25% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=492.7.
[1276] .sup.1H NMR (400 MHz, MeOD) δ 8.85 (d, J=7.3 Hz, 1H), 7.72 (s, 1H), 7.64 (d, J=9.3 Hz, 2H), 7.42-7.41 (m, 1H), 6.99 (d, J=4.0 Hz, 1H), 6.91 (d, J=4.0 Hz, 1H), 4.02-3.99 (m, 1H), 3.85-3.75 (m, 3H), 3.69 (s, 3H), 3.39-3.34 (m, 1H), 3.28-3.26 (m, 2H), 3.00-2.88 (m, 1H), 2.81-2.71 (m, 1H), 2.65 (s, 3H).
Example 139
Preparation of methyl (S)-2-((2-(4-(5-cyanothiophen-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1277] ##STR00809##
[1278] Intermediate 2-7 (100 mg, 0.21 mmol) was dissolved in anhydrous N,N-dimethylformamide (2 mL), and (5-cyanothiophen-2-yl)boronic acid (32 mg, 0.21 mmol), potassium phosphate (132 mg, 0.62 mmol), palladium acetate (9.4 mg, 0.042 mmol) and tetrabutylammonium bromide (20 mg, 0.062 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 90° C. for 12 h. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (20 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 139 (3.8% yield) in the form of a yellow solid.
[1279] LC-MS: [M+H].sup.+=509.7. .sup.1H NMR (400 MHz, MeOD): δ 8.47 (d, J=6.8 Hz, 1H), 7.83 (d, J=4.0 Hz, 1H), 7.71 (d, J=4.0 Hz, 1H), 7.59 (d, J=8.3 Hz, 2H), 7.40 (s, 1H), 6.95 (d, J=7.0 Hz, 1H), 3.79-3.89 (m, 3H), 3.67 (s, 3H), 3.63-3.59 (m, 1H), 3.40-3.37 (m, 1H), 3.14-3.13 (m, 2H), 2.93-2.88 (m, 1H), 2.70-2.61 (m, 1H), 2.49 (s, 3H).
Example 140
[1280] ##STR00810##
Step (1) Preparation of (S)-1-(2-((2-(4-bromo-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholino)propan-1-one
[1281] ##STR00811##
[1282] Intermediate 2-5 (500 mg, 1.18 mmol) was dissolved in anhydrous dichloromethane (5 mL), and under nitrogen atmosphere, N,N′-diisopropylethylamine (304 mg, 2.36 mmol) was added, followed by the dropwise addition of propionyl chloride (131 mg, 1.42 mmol) with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 2 h. After the reaction was completed, the reaction system was added with water (40 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 140-2 (450 mg, 79% yield) in the form of a brown solid, LC-MS: [M+H]+=478.7.
Step (2) Preparation of (S)-5-(3,5-difluoro-4-(7-methyl-3-((4-propionylmorpholin-2-yl)methyl)imidazo[1,2-a]pyridin-2-yl)phenyl)thiophene-2-carbonitrile
[1283] ##STR00812##
[1284] Intermediate 140-2 (100 mg, 0.21 mmol) was dissolved in anhydrous N,N-dimethylformamide (2 mL), and (5-cyanothiophen-2-yl)boronic acid (32 mg, 0.21 mmol), potassium phosphate (134 mg, 0.63 mmol), palladium acetate (9.6 mg, 0.043 mmol) and tetrabutylammonium bromide (22 mg, 0.068 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 90° C. for 12 h. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (20 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 140 (14.7 mg, 13.9% yield) in the form of a yellow solid.
[1285] LC-MS: [M+H].sup.+=507.6. .sup.1H NMR (400 MHz, MeOD): δ8.45 (brs, 1H), 7.83 (d, J=4.0 Hz, 1H), 7.70 (d, J=3.8 Hz, 1H), 7.58 (t, 2H), 7.37 (brs, 1H), 6.95-6.87 (m, 1H), 4.32-4.23 (m, 1H), 3.84-3.81 (m, 1H), 3.77-3.68 (m, 1H), 3.65-3.56 (m, 1H), 3.44-3.36 (m, 1H), 3.16-3.15 (m, 2H), 2.96-2.85 (m, 1H), 2.76-2.63 (m, 1H), 2.48 (s, 3H), 2.40-2.27 (m, 2H), 1.09-1.03 (m, 3H).
Example 141
[1286] ##STR00813##
Step (1) Preparation of 2,6-difluoro-4-(1H-1,2,3-triazol-1-yl)benzaldehyde
[1287] ##STR00814##
[1288] 2,4,6-trifluorobenzaldehyde (4.0 g, 24.98 mmol) was dissolved in acetonitrile (40 mL), and 1H-1,2,3-triazole (1.7 g, 24.98 mmol) and triethylamine (7.6 g, 74.95 mmol) were added. The reaction system was stirred at 80° C. overnight. After the reaction was completed, the reaction system was concentrated by rotary evaporation. The residue was purified by silica gel column chromatography to give intermediate 141-3 in the form of a light yellow oil (530 mg, 10.2% yield). LC-MS: [M+H].sup.+=209.9.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(1H-1,2,3-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1289] ##STR00815##
[1290] Intermediate 141-3 (520 mg, 2.49 mmol), intermediate 1-5 (268 mg, 2.49 mmol), intermediate 1-4 (525 mg, 2.49 mmol), copper(I) chloride (74 mg, 0.75 mmol) and copper(II) trifluoromethanesulfonate (271 mg, 0.75 mmol) were dissolved in anhydrous toluene (5 mL) under nitrogen atmosphere. The reaction system was heated to 85° C., added with N,N′-dimethylacetamide (0.2 mL), and stirred at 85° C. overnight. After the reaction was completed, the reaction system was filtered, and the filtrate was added with water (20 mL), and extracted with dichloromethane (15 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 141-4 (80 mg, 6.7% yield) in the form of a colorless oil, LC-MS: [M+H].sup.+=510.8.
Step (3) Preparation of (S)-2-((2-(2,6-difluoro-4-(1H-1,2,3-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1291] ##STR00816##
[1292] Intermediate 141-4 (80 g, 0.16 mmol) was dissolved in anhydrous dichloromethane (1 mL), and a solution of HCl in ethanol (0.3 mL) was added. The reaction system was stirred at room temperature for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 141-5 (128 mg, crude product) in the form of a white solid, LC-MS [M+H].sup.+=410.8.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-1,2,3-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1293] ##STR00817##
[1294] Intermediate 141-5 (128 mg, 0.16 mmol, crude product) was dissolved in anhydrous dichloromethane (5 mL), and under nitrogen atmosphere, N,N′-diisopropylethylamine (200 mg, 1.56 mmol) was added, followed by the dropwise addition of a solution of methyl chloroformate in dichloromethane (10 mg/mL, 1.8 mL, 0.19 mmol) with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 2 h. After the reaction was completed, the reaction system was added with water (20 mL), and extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give a product. The product was separated by preparative by high performance liquid chromatography to give compound 141 (14 mg, 19.35% yield) in the form of a white solid, LC-MS: [M+H]+=468.8.
[1295] 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J=7.1 Hz, 1H), 8.08 (d, J=1.0 Hz, 1H), 7.93 (d, J=1.0 Hz, 1H), 7.55 (d, J=7.6 Hz, 2H), 7.47 (s, 1H), 6.75 (d, J=6.7 Hz, 1H), 4.05-3.80 (m, 3H), 3.70 (s, 3H), 3.65-3.57 (m, 1H), 3.46-3.36 (m, 1H), 3.10-2.85 (m, 3H), 2.70-2.60 (m, 1H), 2.46 (s, 3H).
Example 142
[1296] ##STR00818##
Step (1) Preparation of tert-butyl (S)-2-((7-methyl-2-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1297] ##STR00819##
[1298] 2,4,6-trifluorobenzaldehyde (3.0 g, 18.74 mmol), 4-methylpyridin-2-amine (2.0 g, 18.74 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (4 g, 18.74 mmol), copper(I) chloride (562 mg, 5.68 mmol) and copper(II) trifluoromethanesulfonate (2.1 g, 5.68 mmol) were dissolved in toluene solution (30 mL) under nitrogen atmosphere. The reaction system was reacted at 85° C. for 10 min, added with N,N-dimethylacetamide (0.5 mL), and reacted at 85° C. for another 5 h. Then the reaction system was reacted at room temperature overnight. After the reaction was completed, the reaction system was filtered, and the filtrate was added with water (50 mL), and extracted with dichloromethane (100 mL×3). The organic phases were combined, washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 142-2 (3.0 g, 34.8% yield) in the form of a yellow oil, MS [M+H].sup.+=461.8.
Step (2) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(1H-1,2,4-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1299] ##STR00820##
[1300] Intermediate 142-2 (300 mg, 0.65 mmol) was dissolved in anhydrous dimethyl sulfoxide (3 mL), and 1,2,4-triazole (40 mg, 0.58 mmol) and potassium carbonate (180 mg, 1.30 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 85° C. for 1 h. Then the reaction system was cooled to room temperature, added with water (20 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 142-3 (150 mg, 45.2% yield) in the form of a yellow oil. MS [M+H].sup.+=510.8.
Step (3) Preparation of (S)-2-((2-(2,6-difluoro-4-(1H-1,2,4-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1301] ##STR00821##
[1302] Intermediate 142-3 (150 mg, 0.29 mmol) was dissolved in dichloromethane (2 mL), and a solution of HCl in ethanol (33%, 0.5 mL) was added dropwise with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. Then the reaction system was adjusted to pH 8 with saturated sodium bicarbonate solution, diluted with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give intermediate 142-4 (130 mg, crude product) in the form of a yellow solid, MS [M+H].sup.+=410.8.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(1H-1,2,4-triazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1303] ##STR00822##
[1304] Intermediate 142-4 (130 mg, 0.29 mmol) and N,N-diisopropylethylamine (123 mg, 0.95 mmol) were dissolved in dichloromethane (2 mL), and methyl chloroformate (36 mg, 0.38 mmol) was added dropwise under nitrogen atmosphere with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 1 h. Then the reaction system was added with water (20 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 142 (30.4 mg, 20.5% yield) in the form of a yellow solid. MS [M+H].sup.+=468.7.
[1305] 1H NMR (400 MHz, MeOD) δ 9.35 (s, 1H), 8.88 (d, J=7.1 Hz, 1H), 8.29 (s, 1H), 7.97 (d, J=8.7 Hz, 2H), 7.75 (s, 1H), 7.44 (dd, J=7.1, 1.4 Hz, 1H), 4.05-4.02 (m, 1H), 3.85-3.74 (m, 3H), 3.69 (s, 3H), 3.39-3.35 (m, 1H), 3.31-3.22 (m, 2H), 2.98-2.88 (m, 1H), 2.81-2.71 (m, 1H), 2.67 (s, 3H).
Example 143
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(4H-1,2,4-triazol-4-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1306] ##STR00823##
[1307] Intermediate 3-1 (75 mg, 0.18 mmol) and diformylhydrazide (486 mg, 0.54 mmol) were dissolved in anhydrous pyridine (10 mL). The reaction system was cooled to 0° C., added dropwise with triethylamine (128 mg, 1.26 mmol) and trimethylchlorosilane (294 mg, 2.7 mmol) sequentially under nitrogen atmosphere, an stirred under reflux for 24 h. Then the reaction system was concentrated under reduced pressure, added with saturated brine (10 mL), adjusted to pH 7-8 with saturated sodium bicarbonate solution, and extracted with DCM (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative thin-layer chromatography to give compound 143 (30 mg, 36% yield) in the form of a white solid. MS [M+H].sup.+=469.2.
[1308] 1H NMR (400 MHz, d6-DMSO) δ 9.31 (s, 2H), 8.44 (d, J=7.1 Hz, 1H), 7.85 (d, J=8.2 Hz, 2H), 7.37 (s, 1H), 6.85 (d, J=7.1 Hz, 1H), 3.82-3.84 (m, 1H), 3.70-3.61 (m, 2H), 3.56 (s, 3H), 3.52-3.45 (m, 1H), 3.29-3.21 (m, 1H), 3.12-3.00 (m, 2H), 2.90-2.71 (m, 1H), 2.59-2.45 (m, 1H), 2.39 (s, 3H).
Example 144
Preparation of methyl (S)-2-((2-(4-(4-(1-cyanochloropropyl)-1H-imidazol-2-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1309] ##STR00824##
[1310] Compound 133 (150 mg, 0.27 mmol) and triethylamine (121 mg, 1.20 mmol) were dissolved in dichloromethane (3 mL). Under nitrogen atmosphere, the reaction system was cooled to 0° C., added dropwise with trifluoroacetic anhydride (125 mg, 0.60 mmol), and stirred at room temperature overnight. Then the reaction system was added with water (10 mL) to quench the reaction, and extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative chromatography to give compound 144 (23.7 mg, 16% yield) in the form of a white solid. LC-MS [M+H].sup.+: 533.
[1311] 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.62 (s, 1H), 7.44 (d, J=8.2 Hz, 2H), 7.23 (s, 1H), 6.91 (d, J=7.1 Hz, 1H), 4.00-3.75 (m, 3H), 3.68 (s, 3H), 3.62-3.53 (m, 1H), 3.44-3.33 (m, 1H), 3.03-2.82 (m, 3H), 2.66-2.56 (m, 1H), 2.55 (s, 3H), 1.68-1.58 (m, 4H).
Example 145
[1312] ##STR00825##
Step (1) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methoxycarbonyl)pyridin-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1313] ##STR00826##
[1314] Intermediate 17-2 (130 mg, 0.25 mmol) was dissolved in anhydrous 1,4-dioxane (5 mL) under nitrogen atmosphere, and methyl 6-bromonicotinate (64 mg, 0.30 mmol), potassium carbonate (103 mg, 0.74 mmol), and tetrakis(triphenylphosphine)palladium (30 mg, 0.025 mmol) were added, followed by the addition of water (0.5 mL). The reaction system was reacted at 90° C. for 2 h. Then the reaction system was cooled to room temperature, added with water (20 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous magnesium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 145-2 (70 mg, 53% yield) in the form of a yellow solid. LC-MS [M+H].sup.+=553.2.
Step (2) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-nicotinic acid)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)-methyl)morpholine-4-carboxylate
[1315] ##STR00827##
[1316] Intermediate 145-2 (70 mg, 0.13 mmol) was dissolved in tetrahydrofuran (1.5 mL), and lithium hydroxide solution (3 M, 0.13 mL) was added dropwise. The reaction system was reacted at room temperature for 1 h. After the reaction was completed, the reaction system was added dropwise with diluted hydrochloric acid (1 M) to adjust the pH to 6, added with water (10 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 145 (30.1 mg, 44% yield) in the form of a white solid. LC-MS: [M+H].sup.+=523.6.
[1317] .sup.1H NMR (400 MHz, MeOD) δ 9.30 (d, J=2.1 Hz, 1H), 8.88 (d, J=7.1 Hz, 1H), 8.53 (dd, J=8.3, 2.1 Hz, 1H), 8.21 (d, J=8.3 Hz, 1H), 8.13 (d, J=9.3 Hz, 2H), 7.75 (s, 1H), 7.44 (dd, J=7.1, 1.5 Hz, 1H), 4.03-4.01 (m, 1H), 3.87-3.70 (m, 3H), 3.69 (s, 3H), 3.40-3.36 (m, 1H), 3.31-3.23 (m, 2H), 2.98-2.89 (m, 1H), 2.82-2.71 (m, 1H), 2.67 (s, 3H).
Example 146
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(formamido)pyridinyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1318] ##STR00828##
[1319] Intermediate 17-2 (120 mg, 0.23 mmol) was dissolved in 1,4-dioxane (3 mL) under nitrogen atmosphere, and 6-bromonicotinamide (55 mg, 0.27 mmol), potassium carbonate (95 mg, 0.69 mmol) and tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol) were added, followed by the addition of water (0.5 mL). The reaction system was reacted at 90° C. for 2 h. Then the reaction system was cooled to room temperature, added with water (20 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous magnesium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 146 (16.9 mg, 14% yield) in the form of a yellow solid.
[1320] LC-MS: [M+H].sup.+=522.6. .sup.1H NMR (400 MHz, MeOD): δ 9.21 (d, J=2.1 Hz, 1H), 8.88 (d, J=7.2 Hz, 1H), 8.42 (dd, J=8.3, 2.3 Hz, 1H), 8.20 (d, J=8.3 Hz, 1H), 8.12 (d, J=9.4 Hz, 2H), 7.75 (s, 1H), 7.44 (dd, J=7.1, 1.4 Hz, 1H), 4.04-4.01 (m, 1H), 3.86-3.71 (m, 3H), 3.70 (s, 3H), 3.40-3.36 (m, 1H), 3.31-3.25 (m, 2H), 2.99-2.90 (m, 1H), 2.83-2.73 (m, 1H), 2.67 (s, 3H).
Example 147
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-hydroxypyridinyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1321] ##STR00829##
[1322] Intermediate 17-2 (130 mg, 0.25 mmol) was dissolved in 1,4-dioxane (5 mL) under nitrogen atmosphere, and 2-bromo-5-hydroxypyridine (51 mg, 0.30 mmol), potassium carbonate (102 mg, 0.74 mmol) and tetrakis(triphenylphosphine)palladium (28 mg, 0.025 mmol) were added, followed by the addition of water (0.5 mL). The reaction system was reacted at 90° C. for 2 h. After the reaction was completed, the reaction system was cooled to room temperature, added with water (20 mL), and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by high performance liquid chromatography to give compound 147 (62.7 mg, 51.4% yield) in the form of a yellow solid.
[1323] LC-MS: [M+H].sup.+=495.2. .sup.1H NMR (400 MHz, DMSO): δ 10.49 (s, 1H), 8.91 (d, J=7.1 Hz, 1H), 8.30 (d, J=2.8 Hz, 1H), 8.08 (d, J=8.7 Hz, 1H), 8.01 (d, J=9.7 Hz, 2H), 7.80 (s, 1H), 7.44 (dd, J=7.1, 1.2 Hz, 1H), 7.34 (dd, J=8.7, 2.9 Hz, 1H), 3.94 (d, J=12.8 Hz, 1H), 3.64-3.62 (m, 3H), 3.58 (s, 3H), 3.34-3.12 (m, 3H), 2.88-2.76 (m, 1H), 2.68-2.62 (m, 1H), 2.58 (s, 3H).
Examples 148-170
[1324] Examples 148, 151, 152, 154, 155, 156 and 157 were prepared using the corresponding starting materials according to the method as described in Example 2. Examples 165-166 were prepared according to the synthesis method as described in Example 10; and Example 170 was prepared according to the synthesis method as described in Example 25.
TABLE-US-00002 ESI-MS Number Compound structure [M + H].sup.+ Example 148
Example 150
[1325] ##STR00840## ##STR00841##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-(hydroxymethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1326] ##STR00842##
[1327] Intermediate 150-1 (2 g, 16 mmol), intermediate 1-4 (3.4 g, 16 mmol), intermediate 2-2 (3.6 g, 16 mmol), CuCl (0.5 g, 6 mmol) and Cu(CF.sub.3SO.sub.3).sub.2 (1.75 g, 6 mmol) were added to toluene (60 mL) sequentially. The reaction system was purged with N.sub.2 four times, and stirred at room temperature for 15 min. Then the reaction system was heated to 85° C., added with DMA (1 mL), heated and reacted for 5 h, and cooled and stirred overnight (16.5 h) after the heating was stopped. After the reaction was completed as detected by LCMS, the reaction system was diluted with DCM (100 mL), added with water (80 mL) and 25% aqueous ammonia (15 mL), stirred for 30 min, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (100 mL×2). The DCM phases were combined, washed with saturated aqueous ammonium chloride solution and saturated brine sequentially, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography to give intermediate 150-2 (3.4 g) in the form of a light yellow oil.
Step (2)
[1328] ##STR00843##
[1329] Intermediate 150-2 (1.3 g, 2.42 mmol) was dissolved in DCM (30 mL). The reaction system was purged with N.sub.2 three times, and cooled to −5° C. below. Then DAST (0.40 mL, 3.03 mmol) was diluted with DCM (5 mL), and added dropwise to the reaction system. The resulting reaction system was warmed to room temperature and reacted for 16 h. After the reaction was completed as detected by TLC, the reaction system was cooled to 5° C. below, diluted with DCM, slowly poured into saturated NaHCO.sub.3 solution at 5° C. below, stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (30 mL×2). The DCM phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 150-3 (0.32 g) in the form of a yellow oil.
Step (3) Preparation of tert-butyl (S)-2-((2-(4-acetamido-2,6-difluorophenyl)-7-(fluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1330] ##STR00844##
[1331] Intermediate 150-3 (0.32 g, 0.59 mmol), acetamide (0.05 g, 0.71 mmol), Cs.sub.2CO.sub.3 (0.29 g, 0.71 mmol), and Xantphos (0.07 g, 0.12 mmol) were added to dioxane (8 mL) sequentially. The reaction system was purged with N.sub.2 three times, added with Pd.sub.2(dba).sub.3 (0.05 g, 0.06 mmol), purged with N.sub.2 three times, and reacted at 80° C. for 19 h. After the reaction was completed as detected by TLC, the reaction system was diluted with DCM (15 mL) and water (30 mL), stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (15 mL×2). The DCM phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give intermediate 150-4 (0.47 g, crude product) in the form of a red oil, which was used directly in the next step.
Step (4) Preparation of (S)—N-(3,5-difluoro-4-(7-(fluoromethyl)-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)acetamide
[1332] ##STR00845##
[1333] Intermediate 150-4 (0.47 g, crude product) was dissolved in EA (5 mL), and a solution of HCl in EA (15 mL) was added. The reaction system was reacted at room temperature for 5.5 h. After the reaction was completed as detected by TLC, the reaction system was diluted with EA (10 mL) and water (10 mL), back-extracted with stirring to give an aqueous phase, and the EA phase was back-extracted with water (10 mL×1). The aqueous phases were combined, added with DCM (15 mL), adjusted to pH 9-10 with Na.sub.2CO.sub.3 solid, stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (15 mL×2). The DCM phases were combined, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give intermediate 150-5 (0.2 g) in the form of a red oil.
Step (5) Preparation of methyl (S)-2-((2-(4-acetamido-2,6-difluorophenyl)-7-(fluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1334] ##STR00846##
[1335] Intermediate 150-5 (100 mg, 0.227 mmol) was dissolved in DCM (4 mL), and DIPEA (0.4 mL) was added. The reaction system was purged with N.sub.2 once, and cooled to 5° C. below. Then the reaction system was added dropwise with methyl chloroformate (43 mg, 0.504 mmol), warmed to room temperature and reacted for 1 h. After the reaction was completed as detected by TLC, the reaction system was diluted with DCM (15 mL) and water (20 mL), stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (15 mL×2). The DCM phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give a crude product. The crude product was separated by prep-HPLC, and lyophilized to give compound 150 (20.2 mg, 98.34% purity) in the form of a white solid.
[1336] LC-MS: [M+H].sup.+=477.25. 1H NMR (400 MHz, CD3OD) δ 8.52 (d, J=7.1 Hz, 1H), 8.52 (d, J=7.1 Hz, 8H), 8.52 (d, J=7.1 Hz, 1H), 7.54 (s, 7H), 7.46-7.37 (m, 13H), 6.99 (d, J=7.1 Hz, 8H), 5.54 (s, 7H), 5.42 (s, 7H), 4.98-4.83 (m, 169H), 4.79 (d, J=15.2 Hz, 2H), 4.58 (s, 9H), 3.80 (t, J=13.0 Hz, 25H), 3.66 (d, J=11.2 Hz, 19H), 3.58 (s, 8H), 3.33 (tt, J=6.6, 3.2 Hz, 27H), 3.21-3.04 (m, 15H), 2.89 (s, 10H), 2.63 (s, 15H), 2.17 (s, 18H).
Example 153
[1337] ##STR00847##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1338] ##STR00848##
[1339] Compound 153-1 (0.77 g, 4.74 mmol), intermediate 1-4 (1.0 g, 4.74 mmol), intermediate 2-2 (1.04 g, 4.74 mmol), CuCl (0.14 g, 1.42 mmol) and Cu(CF.sub.3SO.sub.3).sub.2 (0.51 g, 1.42 mmol) were dissolved in toluene (10 mL) sequentially. The reaction system was purged with N.sub.2 four times, and stirred at room temperature for 15 min. Then the reaction system was heated to 85° C., added with DMA (0.3 mL), heated and reacted for 6 h, and cooled and stirred overnight (16 h) after the heating was stopped. After the reaction was completed as detected by LCMS, the reaction system was diluted with DCM (100 mL), added with water (100 mL) and 25% aqueous ammonia (10 mL), stirred for 10 min, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (50 mL×3). The DCM phases were combined, washed with saturated aqueous ammonium chloride solution and saturated brine sequentially, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography (a small amount of methanol) to give intermediate 153-2 (0.8 g, 86.37% purity) in the form of a yellow foamy solid. LC-MS: [M+H].sup.+=578.03.
Step (2) Preparation of (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1340] ##STR00849##
[1341] Intermediate 153-2 (0.8 mg, 1.4 mmol) was dissolved in EA (10 mL). The reaction system was cooled to ° C. below. Then the reaction system was added with a solution of HCl in EA (3 M, 15 mL), and reacted at room temperature for 1 h and 50 min. After the reaction was completed as detected by LCMS, the reaction system was diluted with EA (10 mL) and back-extracted with water (20 mL×2). The aqueous phases were combined, added with DCM (20 mL), adjusted to pH 8-9 with Na.sub.2CO.sub.3 solid, stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (20 mL×2). The DCM phases were combined, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give intermediate 153-3 (0.65 g, 94.48% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=476.0.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1342] ##STR00850##
[1343] Intermediate 153-3 (650 mg, 1.4 mmol) was dissolved in DCM (10 mL), and DIPEA (0.21 mL) was added. The reaction system was purged with N.sub.2 once, and cooled to 5° C. below. Then the reaction system was added dropwise with methyl chloroformate (150 mg, 1.6 mmol), and reacted at room temperature for 2 h. After the reaction was completed as detected by LCMS, the reaction system was diluted with DCM (10 mL) and water (30 mL), stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (15 mL×2). The DCM phases were combined, dried over anhydrous sodium sulfate, and concentrated at 40° C. to give intermediate 153-4 (650 mg, 93.67% purity, crude product) in the form of a yellow foamy solid. LC-MS: [M+H].sup.+=534.05.
Step (4) Preparation of methyl (S)-2-((2-(4-acetamido-2,6-difluorophenyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1344] ##STR00851##
[1345] Intermediate 153-4 (300 mg, 0.56 mmol), acetamide (70 mg, 0.84 mmol), Cs.sub.2CO.sub.3 (350 mg, 0.84 mmol), Xantphos (40 mg, 0.056 mmol), and Pd.sub.2(dba).sub.3 (60 mg, 0.056 mmol) were dissolved in dioxane (10 mL) sequentially. The reaction system was purged with N.sub.2 four times and reacted at 80° C. for 20 h. After the reaction was completed as detected by LCMS, the reaction system was diluted with DCM (15 mL) and water (30 mL), stirred, and left to stand to separate the DCM phase. The aqueous phase was extracted with DCM (15 mL×2). The DCM phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give a crude product. The crude product was separated by prep-HPLC (H.sub.2O/CH.sub.3CN), and lyophilized to give compound 153 (60 mg, 99.01% purity) in the form of a white solid. LC-MS: [M+H].sup.+=513.15.
[1346] .sup.1H NMR (400 MHz, d-DMSO) δ 10.45 (s, 1H), 8.74 (d, J=7.3 Hz, 1H), 8.08 (s, 1H), 7.45 (d, J=9.9 Hz, 2H), 7.24 (dd, J=7.3, 1.8 Hz, 1H), 3.78 (d, J=12.9 Hz, 1H), 3.65 (t, J=10.7 Hz, 2H), 3.56 (s, 3H), 3.51 (s, 1H), 3.23 (td, J=11.8, 2.8 Hz, 1H), 3.10 (dd, J=15.4, 7.2 Hz, 2H), 2.81 (s, 1H), 2.54 (s, 1H), 2.11 (s, 3H).
Example 158
[1347] ##STR00852##
Step (1) Preparation of (S)-1-(2-((2-(4-bromo-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1348] ##STR00853##
[1349] The compound was prepared according to the preparation method for intermediate 2-7. LC-MS: [M+H].sup.+=484.0.
Step (2) Preparation of (S)-1-(2-((7-chloro-2-(2,6-difluoro-4-(1H-imidazol-1-yl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1350] ##STR00854##
[1351] Intermediate 158-1 (120 mg, 0.25 mmol) was dissolved in toluene (2 mL), and imidazole (25 mg, 0.37 mmol), potassium carbonate (103 mg, 0.75 mmol), copper(I) iodide (4.7 mg, 0.025 mmol) and trans-(1R,2R)—N,N′-dimethyl-1,2-cyclohexanediamine (3.5 mg, 0.025 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 110° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (20 mL) and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative chromatography to give compound 158 (13.6 mg, 12% yield) in the form of a white solid. MS [M+H].sup.+=471.7.
[1352] .sup.1H NMR (400 MHz, MeOD) δ 8.59 (t, 1H), 8.39 (s, 1H), 7.79 (s, 1H), 7.65-7.63 (m, 1H), 7.61-7.57 (m, 2H), 7.23 (s, 1H), 7.09-7.00 (m, 1H), 4.33-4.24 (m, 1H), 3.92-3.54 (m, 3H), 3.47-3.36 (m, 1H), 3.23-3.12 (m, 2H), 3.01-2.63 (m, 1H), 2.53-2.45 (m, 1H), 2.06 (d, 3H).
Example 159
Preparation of (S)-1-(2-((7-chloro-2-(2,6-difluoro-4-(oxazol-2-yl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1353] ##STR00855##
[1354] Intermediate 158-1 (4.2 g, 8.66 mmol) and tetrakis(triphenylphosphine)palladium (2.0 g, 1.73 mmol) were added to toluene (125 mL) sequentially. The reaction system was stirred under nitrogen atmosphere. Then the reaction system was injected with 2-(tributylstannyl)oxazole (4.9 g, 13.00 mmol) via a syringe, and heated to 80° C. and reacted overnight. Little intermediate 158-1 was remained as detected by TLC, and the work-up was directly performed. The reaction system was cooled, added with saturated aqueous potassium fluoride solution (100 mL), and stirred for 30 min. Then the reaction was extracted with DCM (100 mL), followed by liquid separation. The aqueous phase was back-extracted with DCM (50 mL×2). The organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The crude product was purified by preparative chromatography to give compound 159 (0.49 g, 99% purity) in the form of a white solid. LC-MS: [M+H].sup.+=473.05.
[1355] .sup.1H NMR (400 MHz, dmso) δ 8.66-8.55 (m, 18H), 8.64-8.56 (m, 17H), 8.34 (s, 16H), 8.34 (s, 14H), 7.77 (dd, J=7.6, 2.5 Hz, 45H), 7.77 (dd, J=7.6, 2.5 Hz, 47H), 7.50 (s, 15H), 7.50 (s, 14H), 7.08 (td, J=7.1, 1.9 Hz, 17H), 7.08 (td, J=7.1, 1.9 Hz, 17H), 4.20 (d, J=12.8 Hz, 13H), 4.20 (d, J=12.8 Hz, 11H), 4.05 (d, J=12.0 Hz, 9H), 4.05 (d, J=12.0 Hz, 13H), 3.74 (d, J=12.8 Hz, 9H), 3.70 (dd, J=30.3, 12.1 Hz, 29H), 3.67 (d, J=11.5 Hz, 17H), 3.55 (d, J=13.5 Hz, 19H), 3.45 (dd, J=7.2, 3.2 Hz, 11H), 3.58-3.20 (m, 61H), 3.26 (dd, J=11.6, 9.5 Hz, 11H), 3.26 (dd, J=11.6, 9.5 Hz, 31H), 3.26 (dd, J=11.6, 9.5 Hz, 29H), 3.20-2.94 (m, 51H), 3.23-3.09 (m, 38H), 2.80 (dd, J=12.7, 10.7 Hz, 9H), 2.80 (dd, J=12.7, 10.7 Hz, 10H), 2.55 (d, J=3.1 Hz, 6H), 2.64-2.45 (m, 22H), 2.39-2.22 (m, 12H), 2.36-2.24 (m, 11H), 1.92 (s, 47H), 1.92 (s, 48H).
Example 160
Preparation of (S)-1-(2-((7-chloro-2-(2,6-difluoro-4-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1356] ##STR00856##
[1357] Intermediate 158-1 (170 mg, 0.35 mmol) was dissolved in toluene (2 mL), and parazole (36 mg, 0.53 mmol), potassium carbonate (145 mg, 1.05 mmol), copper(I) iodide (7 mg, 0.037 mmol) and trans-(1R,2R)—N,N′-dimethyl-1,2-cyclohexanediamine (5 mg, 0.035 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 110° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filter cake was washed with dichloromethane. The filtrate was added with water (30 mL) and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative chromatography to give compound 160 (5.8 mg, 3.5% yield) in the form of a white solid. MS [M+H].sup.+=471.7.
[1358] 1H NMR (400 MHz, MeOD) δ 8.93 (dd, J=7.4, 3.2 Hz, 1H), 8.47 (d, J=2.6 Hz, 1H), 8.02-7.98 (m, 1H), 7.85-7.82 (m, 3H), 7.51 (dd, J=7.4, 2.0 Hz, 1H), 6.65-6.64 (m, 1H), 4.43-4.40 (m, 0.5H), 4.29-4.26 (m, 0.5H), 3.92-3.89 (m, 1H), 3.86-3.80 (m, 1H), 3.72-3.69 (m, 1H), 3.46-3.36 (m, 1H), 3.31-3.21 (m, 2H), 3.08-3.02 (m, 1H), 2.75-2.70 (m, 0.5H), 2.58-2.52 (m, 0.5H), 2.08 (s, 3H).
Example 161
Preparation of methyl (S)-2-((2-(4-amino-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1359] ##STR00857##
[1360] Compound 149 (0.3 g) was dissolved in EtOH (4 mL), and concentrated HCl (6 mL) was added. The reaction system was stirred at 100° C. for 2 h. The starting material was consumed, and a new spot was generated as detected by TLC. Then the reaction system was concentrated. The crude product was separated by preparative reverse phase chromatography to give compound 161 (0.14 g) in the form of a white solid, MS [M+H].sup.+=437.2.
[1361] .sup.1H-NMR (1H NMR (400 MHz, DMSO) δ 8.44, 7.56, 6.88, 6.68, 6.68, 4.07, 4.05, 3.96, 3.93, 3.82, 3.78, 3.69, 3.51, 3.46, 2.73, 2.48.) (NB190027-03-02).
Example 162
[1362] ##STR00858##
Step (1) Preparation of (S)-1-(2-((2-(4-bromo-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1363] ##STR00859##
[1364] Intermediate 2-5 (1.20 g, 2.84 mmol) and N,N-diisopropylethylamine (1.10 g, 8.51 mmol) were dissolved in dichloromethane (6 mL), and acetyl chloride (268 mg, 3.41 mmol) was added dropwise in an ice water bath with the temperature maintained at 0° C. After the completion of the dropwise addition was completed, the reaction system was reacted at 0° C. for 2 h. After the reaction was completed, the reaction system was added with water (30 mL) and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate=5:1) to give intermediate 162-1 (700 mg, 53.8% yield) in the form of a yellow oil. MS [M+H].sup.+=464.9.
Step (2) Preparation of (S)-1-(2-((2-(2,6-difluoro-4-(1H-imidazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1365] ##STR00860##
[1366] Intermediate 162-1 (150 mg, 0.32 mmol) was dissolved in toluene (2 mL), and imidazole (33 mg, 0.48 mmol), potassium carbonate (135 mg, 0.98 mmol), copper(I) iodide (6 mg, 0.032 mmol) and trans-(1R,2R)—N,N′-dimethyl-1,2-cyclohexanediamine (4.6 mg, 0.032 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 110° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (20 mL) and extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative chromatography to give compound 162 (21.3 mg, 14.6% yield) in the form of a white solid. MS [M+H].sup.+=451.8.
[1367] 1H NMR (400 MHz, MeOD) δ 8.48 (t, 1H), 8.42 (s, 1H), 7.80 (s, 1H), 7.59 (t, 2H), 7.39 (s, 1H), 7.24 (s, 1H), 6.97-6.91 (m, 1H), 4.33-4.23 (m, 1H), 3.84-3.81 (m, 1H), 3.79-3.68 (m, 1H), 3.67-3.56 (m, 1H), 3.45-3.34 (m, 1H), 3.22-3.21 (m, 0.5H), 3.17-3.15 (m, 2H), 2.98-2.92 (m, 0.5H), 2.73-2.67 (m, 0.5H), 2.49 (s, 3H), 2.47-2.44 (m, 0.5H), 2.05 (d, 3H).
Example 163
Preparation of (S)-1-(2-((2-(2,6-difluoro-4-(oxazol-2-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholino)ethan-1-one
[1368] ##STR00861##
[1369] Intermediate 162-1 (150 mg, 0.32 mmol) was dissolved in 1,4-dioxane (2 mL), and 2-(tributylstannyl)oxazole (174 mg, 0.48 mmol) and tetrakis(triphenylphosphine)palladium (37 mg, 0.032 mmol) were added under nitrogen atmosphere. The reaction system was reacted at 85° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered, and the filtrate was added with water (30 mL) and extracted with dichloromethane (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by preparative chromatography to give compound 163 (78.8 mg, 54% yield) in the form of a white solid. MS [M+H].sup.+=452.8.
[1370] .sup.1H NMR (400 MHz, MeOD) δ 8.47 (t, 1H), 8.11 (s, 1H), 7.85-7.75 (m, 2H), 7.42 (s, 1H), 7.39 (s, 1H), 6.93 (d, J=6.1 Hz, 1H), 4.32-4.22 (m, 1H), 3.84-3.76 (m, 1H), 3.69-3.65 (m, 1H), 3.61-3.54 (m, 1H), 3.45-3.35 (m, 1H), 3.17-3.16 (m, 2H), 2.99-2.88 (m, 1H), 2.74-2.63 (m, 1H), 2.49 (s, 3H), 2.04 (d, 3H).
Example 164
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(3-propionyl-1H-pyrazol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl) morpholine-4-carboxylate
[1371] ##STR00862##
[1372] Intermediate 134-7 (50 mg, 0.12 mmol), 1-(1H-pyrazol-3-yl)propan-1-one (30 mg, 0.12 mmol) and potassium carbonate (30 mg, 0.36 mmol) were added to dimethyl sulfoxide (5 mL). The reaction system was stirred at 130° C. for 4 h under nitrogen atmosphere. The reaction system was cooled to room temperature and filtered, and the filtrate was dispersed in ethyl acetate (15 mL), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative chromatography to give compound 164 (5 mg, 7.5% yield) in the form of a yellow solid.
[1373] MS [M+H].sup.+=523.8. 1H NMR (400 MHz, d4-MeOD) δ 8.51 (d, J=2.7 Hz, 1H), 8.43 (d, J=6.9 Hz, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.37 (s, 1H), 7.03 (d, J=2.6 Hz, 1H), 6.89 (dd, J=7.0, 1.5 Hz, 1H), 3.89-3.78 (m, 3H), 3.66 (s, 3H), 3.68-3.58 (m, 1H), 3.42-3.37 (m, 1H), 3.21-3.12 (m, 4H), 2.94-2.85 (m, 1H), 2.66-2.62 (m, 1H), 2.48 (s, 3H), 1.25 (t, J=7.3 Hz, 3H).
Example 167
Preparation of (S)—N-(4-(3-((4-acetylmorpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorophenyl)acetamide
[1374] ##STR00863##
[1375] Intermediate 162-1 (240 mg, 0.518 mmol) and acetamide (45.9 mg, 0.778 mmol), cesium carbonate (150 mg, 0.778 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (6.00 mg, 0.010 mmol) were added to a reaction flask, and 1,4-dioxane was added. The reaction system was purged with N.sub.2, added with tris(dibenzylideneacetone)dipalladium (9.50 mg, 0.010 mmol), purged with N.sub.2 again, and heated to 80° C. and reacted for 4 h. After the reaction was completed as monitored by LCMS, the reaction system was added with water, and extracted with dichloromethane (30 mL×2). The ester phase was dried over anhydrous sodium sulfate, and concentrated to remove dichloromethane. The residue was purified by preparative high performance liquid chromatography to give compound 167 (102 mg, 52.4% yield) in the form of a white solid. LC-MS [M+H].sup.+=443.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 10.40 (s, 1H), 8.42-8.35 (m, 1H), 7.41 (dd, J=9.8, 1.7 Hz, 2H), 7.32 (s, 1H), 6.80 (dd, J=9.6, 4.1 Hz, 1H), 4.07 (dd, J=23.0, 13.0 Hz, 1H), 3.73-3.56 (m, 2H), 3.51-3.36 (m, 1H), 3.32-3.22 (m, 1H), 3.15 (td, J=11.7, 2.6 Hz, 1H), 3.01 (dd, J=5.8, 2.7 Hz, 2H), 2.77 (dd, J=12.9, 10.5 Hz, 1H), 2.59-2.52 (m, 1H), 2.37 (s, 3H), 2.26 (dd, J=12.6, 11.1 Hz, 1H), 2.10 (s, 3H), 1.91 (d, J=12.7 Hz, 3H).
Example 168
[1376] ##STR00864##
Step (1) Preparation of 6-bromo-4-methyl nicotinaldehyde
[1377] ##STR00865##
[1378] 2,5-dibromo-4-methylpyridine (5.0 g, 17.19 mmol) was dissolved in tetrahydrofuran (60 mL) under nitrogen atmosphere. The reaction system was cooled to −78° C., added with n-butyllithium (7.5 mL, 2.4 N), and stirred at this temperature for 30 min. Then the reaction system was added with N,N-dimethylformamide (2.5 g, 34.38 mmol), and reacted at −78° C. for 3 h. The resulting reaction system was added with diluted hydrochloric acid (1 N, 20 mL) to quench the reaction, diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate solution (80 mL) and saturated brine (80 mL) sequentially, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 168-2 (2.3 g, 54% yield) in the form of a white solid. LC-MS [M+H].sup.+: 199.8.
Step (2) Preparation of tert-butyl (S)-2-((2-(6-bromo-4-methylpyridin-3-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1379] ##STR00866##
[1380] Intermediate 168-2 (320 mg, 1.50 mmol), tert-butyl (2S)-2-ethynylmorpholin-4-ylcarboxylate (317 mg, 1.50 mmol), 4-methylpyridin-2-amine (162 mg, 1.50 mmol), copper(I) chloride (45 mg, 0.45 mmol) and copper(II) trifluoromethanesulfonate (163 mg, 0.45 mmol) were added to anhydrous toluene (6 mL) under nitrogen atmosphere. The reaction system was heated to 85° C., added dropwise with N,N-dimethylacetamide (0.1 mL), and stirred at 85° C. overnight. After the reaction was completed, the reaction system was cooled to room temperature, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 168-3 (324 mg, 41% yield) in the form of a brown powdery solid. MS [M+H].sup.+=500.7.
Step (3) Preparation of tert-butyl (S)-2-((7-methyl-2-(4-methyl-6-(1H-pyrazol-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1381] ##STR00867##
[1382] Intermediate 168-3 (320 mg, 0.64 mmol), 1H-pyrazole (130 mg, 1.92 mmol), copper(I) iodide (12 mg, 0.06 mmol), (1R,2R)—N.sub.1N2-dimethylcyclohexane-1,2-diamine (18 mg, 0.13 mmol) and potassium phosphate (408 mg, 1.92 mmol) were added to dioxane (5 mL) under nitrogen atmosphere. The reaction system was reacted at 100° C. for 6 h. Then the reaction system was cooled to room temperature, added with water (15 mL) to quench the reaction, filtered, and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 168-4 (170 mg, 55% yield) in the form of a brownish-yellow oil. MS [M+H].sup.+=488.9.
Step (4) Preparation of (S)-2-((7-methyl-2-(4-methyl-6-(1H-pyrazol-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1383] ##STR00868##
[1384] Intermediate 168-4 (170 g, 0.35 mmol) was dissolved in dichloromethane (5 mL), and a solution of HCl in ethanol (33%, 1.0 mL) was added. The reaction system was stirred at room temperature for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 168-5 (145 mg) in the form of a brown solid, MS [M+H].sup.+=388.9.
Step (5) Preparation of methyl (S)-2-((7-methyl-2-(4-methyl-6-(1H-pyrazol-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1385] ##STR00869##
[1386] Intermediate 168-5 (135 mg, 0.35 mmol) was dissolved in anhydrous dichloromethane (5 mL) under nitrogen atmosphere, and diisopropylethylamine (225 mg, 1.75 mmol) was added at 0° C., followed by the dropwise addition of a solution of methyl chloroformate in dichloromethane (10 mg/mL, 3.5 mL). The reaction system was stirred at 0° C. for 2 h. After the reaction was completed, the reaction system was added with water (20 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography (dichloromethane:ethyl acetate=2:1) to give a product. The product was purified by preparative by high performance liquid chromatography to give compound 168 (45 mg, 21% yield) in the form of a white solid.
[1387] MS [M+H].sup.+=446.8. .sup.1H NMR (400 MHz, CDCl.sub.3) δ 8.60 (d, J=2.2 Hz, 1H), 8.33 (s, 1H), 8.09 (d, J=7.1 Hz, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.39 (s, 1H), 6.71 (d, J=7.1 Hz, 1H), 6.51-6.47 (m, 1H), 4.00-3.75 (m, 3H), 3.67 (s, 3H), 3.62-3.52 (m, 1H), 3.45-3.34 (m, 1H), 3.08-2.98 (m, 2H), 2.96-2.86 (m, 1H), 2.63-2.52 (m, 1H), 2.44 (s, 3H), 2.41 (s, 3H).
Example 169
Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(2-carbonyl-2,5-dihydro-1H-pyrrol-1-yl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1388] ##STR00870##
[1389] Intermediate 3-1 (100 mg, 0.24 mmol) was dissolved in acetic acid (1 mL) under nitrogen atmosphere, and 2,5-dimethoxy-2,5-dihydrofuran (35 mg, 0.26 mmol) and sodium acetate (50 mg, 0.48 mmol) were added. The reaction system was reacted at 90° C. for 2 h. After the reaction was completed, the reaction system was cooled to room temperature, filtered and concentrated by rotary evaporation. The crude product was separated by preparative by high performance liquid chromatography to give compound 169 (20.2 mg, 17.4% yield) in the form of a white solid. MS [M+H].sup.+=482.8.
[1390] .sup.1H NMR (400 MHz, MeOD) δ 8.42 (d, J=7.0 Hz, 1H), 7.70 (d, J=10.1 Hz, 2H), 7.50 (dt, J=6.1, 1.9 Hz, 1H), 7.35 (s, 1H), 6.89 (dd, J=7.1, 1.4 Hz, 1H), 6.29 (dt, J=4.3, 1.9 Hz, 1H), 4.66 (t, J=1.8 Hz, 2H), 3.82-3.79 (m, 3H), 3.67 (s, 3H), 3.63-3.57 (m, 1H), 3.41-3.38 (m, 1H), 3.15-3.08 (m, 2H), 2.95-2.86 (m, 1H), 2.70-2.59 (m, 1H), 2.47 (s, 3H).
Example 171
[1391] ##STR00871## ##STR00872##
Step (1) Preparation of 4-bromo-3,5-difluoro-N,N-bis(4-methoxybenzyl)benzenesulfonamide
[1392] ##STR00873##
[1393] Bis(4-methoxybenzyl)amine (36.0 g, 140 mmol, compound 171-2) and Et.sub.3N (21.2 g, 210 mmol) were dissolved in dichloromethane (1000 mL) sequentially. The reaction system was stirred in an ice bath, and added with 4-bromo-3,5-difluorobenzenesulfonyl chloride (40.5 g, 139 mmol, compound 171-1) in portions (an exothermic reaction) with the internal temperature maintained at less than 10° C. After the addition of compound 171-1, the ice bath was removed and the reaction system was reacted at room temperature for 1.0 h. After compound 171-1 was consumed as detected by TLC (PE/EA=10/1), the DCM phase was washed with aqueous citric acid solution (400 mL×2, 10% in wt.) and saturated brine (400 mL) sequentially, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation to give intermediate 171-3 (68.3 g, 96% yield) in the form of a white solid. LC-MS: [M+H].sup.+=511.1.
Step (2) Preparation of 3,5-difluoro-4-formyl-N,N-bis(4-methoxybenzyl)benzenesulfonamide
[1394] ##STR00874##
[1395] Intermediate 171-3 (68.3 g, 133.3 mmol) was dissolved in THF (800 mL). The reaction system was heated to 40° C. to dissolve the undissolved solid, purged with N.sub.2 three times, and cooled to −70° C. below. Then the reaction system was added dropwise with n-butyllithium (2.5 M, 64 mL, 1.2 eq) slowly with the internal temperature maintained at less than −70° C. After the completion of the dropwise addition of n-butyllithium, the reaction was reacted for 45 min, added with DMF (12.7 g, 1.3 eq), and reacted for another 2.0 h. The reaction system was added with hydrochloric acid (0.5 M) to quench the reaction and adjust the pH to 4, followed by liquid separation. The organic phase was concentrated by rotary evaporation. The aqueous phase was extracted with DCM (300 mL×2). The residue after the rotary evaporation of THF was dissolved in the combined DCM phases, which was then washed with saturated brine, dried and concentrated by rotary evaporation to give a crude product (74 mg). The crude product was purified by column chromatography to give intermediate 171-4 (55 g, 90% yield, pure product) in the form of a white solid. LC-MS: [M+H].sup.+=461.2.
Step (3) Preparation of tert-butyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1396] ##STR00875##
[1397] To a 100 mL round-bottom flask were added intermediate 171-4 (18.2 g, 39.4 mmol, 1.0 eq), 4-methylpyridin-2-amine (4.26 g, 39.4 mmol, 1.0 eq, compound 1-5), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (8.33 g, 39.4 mmol, 1.0 eq, compound 1-4), CuCl (1.17 g, 11.8 mmol, 0.3 eq), Cu(OTf).sub.2 (4.34 g, 11.8 mmol, 0.3 eq), toluene (200 mL) and DMA (12 mL) sequentially. The reaction system was purged with nitrogen 3 times, and heated in an oil bath at 85° C. overnight (12 h). The starting material (compound 1-5) was consumed, and intermediate 171-4 was remained as detected by TLC. Then the reaction system was cooled to room temperature, added with aqueous ammonia (100 mL) and water (150 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with DCM (150 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 171-5 (11.2 g, 96% purity, 37% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=761.9.
Step (4) Preparation of (S)-3,5-difluoro-N,N-bis(4-methoxybenzyl)-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzenesulfonamide
[1398] ##STR00876##
[1399] Intermediate 171-5 (11.2 g, 14.7 mol) was dissolved in DCM (33 mL), and a solution of HCl in dioxane (4 M, 33 mL) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (100 mL) and dichloromethane (200 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (100 mL×2). The DCM phases were combined, washed with saturated brine, dried and concentrated by rotary evaporation to give intermediate 171-6 (9.7 g) in the form of a white solid, which was used directly in the next step. LC-MS: [M+H].sup.+=622.2.
Step (5) Preparation of methyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1400] ##STR00877##
[1401] Intermediate 171-6 (9.7 g, 14.7 mmol, 1.0 eq) was dissolved in DCM (40 mL), and Et.sub.3N (2.96 g, 29.3 mmol, 2.0 eq) was added, followed by the dropwise addition of methyl chloroformate (2.08 g, 22 mmol, 1.5 eq). The reaction system was reacted for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (150 mL) and DCM (200 mL), and stirred for 10 min, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (50 mL×2). The DCM phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 171-7 (9.4 g, 89% yield) in the form of a white solid. LC-MS: [M+H].sup.+=720.9.
Step (6) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-sulfamoylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1402] ##STR00878##
[1403] Intermediate 171-7 (9.4 g) was dissolved in DCM (30 mL), and TFA (30 mL) was added. The reaction system was stirred at 35° C. overnight. A product (80% yield) was generated as detected by LCMS. Then the reaction system was supplemented with TFA (10 mL), and reacted at 40° C. for 4.0 h. The resulting reaction system was concentrated by rotary evaporation. The crude product was dissolved with acetonitrile and separated by preparative chromatography to give compound 171 (3.165 g, 50.6% yield) in the form of a white solid. LC-MS: [M+H].sup.+=481.1.
[1404] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.41 (d, J=7.11 Hz, 1H), 7.69 (s, 2H), 7.59 (d, J=6.6, 2H), 7.33 (s, 1H), 6.84-6.78 (m, 1H), 3.76 (d, J=12.5 Hz, 1H), 3.60 (d, J=11.6 Hz, 2H), 3.53 (s, 3H), 3.44 (d, J=3.6 Hz, 1H), 3.31 (s, 1H), 3.24-3.14 (m, 1H), 3.02 (qd, J=15.7, 6.1 Hz, 2H), 2.77 (s, 1H), 2.34 (s, 3H).
Example 172
[1405] ##STR00879## ##STR00880##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1406] ##STR00881##
[1407] To a 100 mL round-bottom flask were added tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (3.1 g, 1.0 eq, intermediate 1-4), 4-bromo-2,6-difluorobenzaldehyde (2.76 g, 1.0 eq, compound 172-1), 4-chloropyridin-2-amine (1.61 g, 1.0 eq, compound 172-2), CuCl (0.37 g, 0.3 eq), Cu(OTf).sub.2 (1.36 g, 0.3 eq) and isopropanol (50 mL) sequentially. The reaction system was purged with nitrogen 3 times, and reacted in an oil bath at 80° C. overnight. The starting material (compound 172-2) was consumed as detected by TLC. The reaction system was concentrated by rotary evaporation to remove isopropanol, and extracted with EA and aqueous ammonia sequentially. The EA phase was washed with saturated brine and citric acid sequentially, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 172-3 (3.0 g, 78% purity) in the form of a white solid. LC-MS: [M+H].sup.+=542.2.
Step (4) Preparation of (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1408] ##STR00882##
[1409] Intermediate 172-3 (2.67 g) was dissolved in dichloromethane (24 mL), and a solution of HCl in dioxane (24 mL) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was concentrated by rotary evaporation, added with water (15 mL) and dichloromethane (15 mL), and extracted to give an aqueous phase. The aqueous phase was adjusted to pH 8-9 (weak alkalinity) with aqueous sodium carbonate solution, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 ml×2). The dichloromethane phases were combined, washed with saturated brine, and concentrated by rotary evaporation to give intermediate 172-4 (1.70 g, 88.6% purity) in the form of a white solid. LC-MS: [M+H].sup.+=442.1.
Step (5) Preparation of methyl (S)-2-((2-(4-bromo-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1410] ##STR00883##
[1411] Intermediate 172-4 (1.4 g, 1.0 eq) was dissolved in dichloromethane (10 mL), and triethylamine (480 mg, 1.5 eq) was added, followed by the dropwise addition of methyl chloroformate (388 mg, 1.3 eq). The reaction system was reacted for 1.0 h, and a product was generated as detected by LC-MS. After the reaction was completed, the reaction system was added with water (10 mL), and stirred for 30 min, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 172-5 (1.01 g, 93.02% purity) in the form of a white solid. LC-MS: [M+H].sup.+=499.8.
Step (6) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1412] ##STR00884##
[1413] Intermediate 172-5 (0.73 g, 1.0 eq) was dissolved in dioxane (4 mL), and BnSH (0.24 g, 1.3 eq), Pd.sub.2(dba).sub.3 (0.04 g, 0.03 eq), Xantphos (0.04 g, 0.05 eq) and DIEA (0.60 g, 3.0 eq) were added. The reaction system was purged with N.sub.2 three times and reacted at 80° C. overnight. The starting material was consumed completely as monitored by LCMS. The reaction system was added with dichloromethane (10 mL) and water (10 mL), followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 ml×2). The dichloromethane phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 172-6 (0.82 g, 91.53% purity) in the form of a white solid. LC-MS: [M+H].sup.+=544.2.
Step (7) Preparation of methyl (S)-2-((7-chloro-2-(4-(chlorosulfonyl)-2,6-difluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1414] ##STR00885##
[1415] Intermediate 172-6 (510 mg) was added to a reaction flask, and dissolved with acetonitrile (3 mL), followed by the addition of glacial acetic acid (281 mg, 5.0 eq). The reaction system was added dropwise with SO.sub.2Cl.sub.2 (506 mg, 4.0 eq) in an ice bath, and reacted at 0° C. for 1 h. The starting material was consumed, and intermediate 172-7 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (8) Preparation of methyl (S)-2-((7-chloro-2-(2,6-difluoro-4-sulfamoylphenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1416] ##STR00886##
[1417] Aqueous ammonia (2 mL) was diluted with acetonitrile (1 mL) and added dropwise to the above reaction system at 0° C. The reaction system was reacted at room temperature for 0.5 h. The starting material was consumed completely, and a target product was generated as detected by LCMS. The reaction system was extracted with water and ethyl acetate twice, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative chromatography to give compound 172 (185 mg, 99.74% purity) in the form of a white solid. LC-MS: [M+H].sup.+=501.1.
[1418] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ=8.11 (d, J=7.4, 1H), 7.29 (d, J=1.6, 1H), 7.22 (s, 2H), 7.14 (d, J=6.6, 2H), 6.60 (dd, J=7.4, 2.1, 1H), 3.33 (d, J=12.8, 1H), 3.13 (d, J=11.3, 2H), 3.07 (s, 3H), 2.97 (d, J=7.8, 1H), 2.77-2.69 (m, 1H), 2.69-2.61 (m, 1H), 2.53 (dd, J=15.5, 8.3, 1H).
Example 173
[1419] ##STR00887##
Step (1) Preparation of (S)-3,5-difluoro-N,N-bis(4-methoxybenzyl)-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzenesulfonamide
[1420] ##STR00888##
[1421] Intermediate 171-6 was prepared according to the steps in Example 1. Intermediate 171-6 (620 mg, 0.94 mmol, 1.0 eq) was dissolved in DCM (5 mL), and Et.sub.3N (236 mg, 2.34 mmol, 2.5 eq) was added, followed by the dropwise addition of acetic anhydride (191 mg, 1.88 mmol, 2 eq). The reaction system was reacted for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (30 mL) and DCM (50 mL), and stirred for 10 min, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (20 mL×2). The DCM phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 173-1 (450 mg, 68.3% yield) in the form of a white solid. LC-MS: [M+H].sup.+=705.2.
Step (2) Preparation of (S)-4-(3-((4-acetylmorpholin-2-yl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzenesulfonamide
[1422] ##STR00889##
[1423] Intermediate 173-1 (420 mg) was dissolved in DCM (2 mL), and TFA (2 mL) was added. The reaction system was stirred at room temperature overnight. Then the reaction system was heated to 35° C. and reacted for 4.0 h, and the work-up was performed. The reaction system was added with water (20 mL) and DCM (20 mL). The aqueous phase was adjusted to pH 9 with sodium carbonate solution, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (20 mL×2). The DCM phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give a product, which was then slurried with DCM/PE (1:10) to give compound 173 (104 mg, 37.5% yield) in the form of a white solid.
[1424] .sup.1H NMR (400 MHz, CDCl.sub.3) δ 8.23 (1H, dd, J=36.9, 6.8), 7.60 (1H, s), 7.53 (2H, t, J=6.0), 6.80 (2H, t, J 12.6), 6.57 (1H, s), 4.37 (1H, t, J=11.4), 3.91-3.72 (1H, m), 3.51 (2H, d, J=12.1), 3.35 (1H, dd, J=21.8, 11.9), 3.16 (0.5H, t, J=11.6), 3.09-2.78 (2H, m), 2.66 (0.5H, t, J=11.1), 2.47 (3H, d, J=3.8), 2.44-2.32 (0.5H, m), 2.04 (2H, s), 1.98 (1H, s), 1.82 (2H, s).
Example 174
[1425] ##STR00890##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,6-difluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1426] ##STR00891##
[1427] 3,5-difluoro-4-formyl-N,N-bis(4-methoxybenzyl)benzenesulfonamide (29 g, 62.84 mmol), 4-chloropyridin-2-amine (8.08 g, 62.84 mmol) and tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (13.28 g, 62.84 mmol) were dissolved in toluene (150 mL) and dimethylacetamide (150 mL). The reaction system was stirred well, and into which copper(I) chloride (1.87 g, 18.85 mmol) and copper (II) trifluoromethanesulfonate (6.82 g, 18.85 mmol) were added, and reacted at 85° C. for 16 h under nitrogen atmosphere. Then the reaction system was added with water (750 mL), and extracted with ethyl acetate (150 mL×2). The organic phase was washed with aqueous ammonia (100 mL×1) and saturated brine (100 mL×2) sequentially, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate=10:1-3:1) to give intermediate 174-1 (18 g, 85% purity, 39% yield) in the form of a brownish-yellow foamy solid. LC-MS: [M+H].sup.+=783.0.
Step (2) Preparation of (S)-4-(7-chloro-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N,N-bis(4-methoxybenzyl) benzenesulfonamide
[1428] ##STR00892##
[1429] Intermediate 174-1 (17 g, 21.7 mmol) was dissolved in dichloromethane (60 mL), and a solution of HCl in ethyl acetate (60 mL, 3 M) was added dropwise with the temperature maintained at 0° C. After the completion of the dropwise addition, the reaction system was reacted at room temperature for 2 h. The starting material was consumed completely as detected by TLC (PE/EA=3/1, Rf=0.1). The reaction system was concentrated under reduced pressure. The crude product was adjusted to pH 8 with aqueous sodium bicarbonate solution, extracted with ethyl acetate (150 mL×2), dried over anhydrous sodium sulfate with stirring for 20 min, filtered and concentrated to give intermediate 174-2 (13 g, 90% purity, 87% yield) in the form of a brown foamy solid, LC-MS (M+H).sup.+=683.0.
Step (3) Preparation of (S)-4-(3-((4-acetylmorpholin-2-yl)methyl)-7-chloroimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N,N-bis(4-methoxybenzyl)benzenesulfonamide
[1430] ##STR00893##
[1431] Intermediate 174-2 (1.5 g, 2.2 mmol) was dissolved in dichloromethane (15 mL), and triethylamine (444 mg, 4.39 mmol) was added at 0° C., followed by the dropwise addition of acetic anhydride (336 g, 3.29 mmol). The reaction system was reacted at 0° C. for 1 h. Then the reaction system was added with saturated aqueous sodium chloride solution (40 mL), extracted with dichloromethane (50 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (PE/EA=1/4-1/2) to give intermediate 174-3 (1.1 g, 69% yield) in the form of a yellowish-white solid, LC-MS: [M+H].sup.+=725.1.
Step (4) Preparation of (S)-4-(3-((4-acetylmorpholin-2-yl)methyl)-7-chloroimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzenesulfonamide
[1432] ##STR00894##
[1433] Intermediate 174-3 (1.1 g, 1.52 mmol) was dissolved in dichloromethane (15 mL), and trifluoroacetic acid (3 mL) was added at 0° C. The reaction system was reacted at room temperature for 16 h. The reaction system was added dropwise to an aqueous sodium bicarbonate solution to adjust the pH to 8, and extracted with dichloromethane (50 mL×3). The organic phase was washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative chromatography. The resulting acetonitrile, water, and trifluoroacetic acid phases were concentrated, adjusted to pH 8 with sodium bicarbonate solution, extracted with ethyl acetate (300 mL×3), washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate with stirring for 20 min, filtered and concentrated. The solid after concentration was washed three times with acetonitrile, added with acetonitrile (10 mL) and pure water (30 mL), and lyophilized to give compound 174 (358 mg, 97% purity) in the form of a white solid. LC-MS: [M+H].sup.+=484.2.
[1434] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.62 (t, J=7.3 Hz, 1H), 7.82-7.77 (m, 1H), 7.73 (d, J=2.3 Hz, 2H), 7.64 (d, J=6.6 Hz, 2H), 7.10 (td, J=7.3, 2.3 Hz, 1H), 4.26-4.19 (m, 1H), 4.05 (d, J=13.3 Hz, 1H), 3.78 (d, J=12.7 Hz, 1H), 3.69-3.60 (m, 1H), 3.56 (d, J=13.3 Hz, 1H), 3.52-3.37 (m, 1H), 3.25 (td, J=11.5, 2.3 Hz, 1H), 3.20-2.97 (m, 3H), 2.80 (dd, J=12.9, 10.5 Hz, 1H), 2.54 (dd, J=12.7, 2.9 Hz, 1H), 2.29 (dd, J=12.8, 10.9 Hz, 1H), 1.94 (d, J=4.2 Hz, 3H).
Example 175
[1435] ##STR00895##
Step (1) Preparation of tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylsulfonyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1436] ##STR00896##
[1437] Intermediate 2-4 was prepared according to the steps in Example 2. Intermediate 2-4 (90 mg), NaSO.sub.2Me (22 mg), Cu(OAc).sub.2 (32 mg) and KOAc (34 mg) were added to a reaction flask containing DMSO (5 mL) sequentially. The reaction system was reacted at 100° C. overnight. The starting material was consumed, and a new spot was generated as detected by TLC (PE/EtOAc=1/1). The reaction system was added with EtOAc (10 mL), washed with NH.sub.4Cl (10 mL×3) and saturated brine (10 mL×3) sequentially, dried over Na.sub.2SO.sub.4, and concentrated to give crude product. The crude product was purified by prep-TLC to give intermediate 175-1 (28 mg) in the form of a white solid. LC-MS: [M+H].sup.+=522.1.
Step (2) Preparation of (S)-2-((2-(2,6-difluoro-4-(methylsulfonyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1438] ##STR00897##
[1439] To intermediate 175-1 (0.1 g) was added a solution of HCl in methanol (3 mL, 4 M) at room temperature. The reaction system was reacted at room temperature for 1 h. Then the reaction mixture was concentrated by rotary evaporation to give intermediate 175-2 (80 mg) in the form of a yellow solid, which was used directly in the next step without purification.
Step (3) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylsulfonyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1440] ##STR00898##
[1441] Intermediate 175-2 (80 mg) was added into a reaction flask containing DCM (5 mL), and triethylamine (30 mg) was added. The reaction system was added with methyl chloroformate (27 mg) at 0° C. and reacted at this temperature for 1 h. The starting material was consumed, and a target product was generated as detected by TLC. The product was purified by preparative chromatography to give compound 175 (20 mg, 99.1% purity) in the form of a white solid. LC-MS: [M+H].sup.+=480.1.
[1442] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.44 (d, J=7.2 Hz, 1H), 7.81 (d, J=6.1 Hz, 1H), 7.37 (s, 1H), 6.85 (d, J=6.9 Hz, 1H), 3.77 (d, J=11.6 Hz, 1H), 3.63 (d, J=11.9 Hz, 2H), 3.55 (s, 2H), 3.46 (s, 1H), 3.39 (s, 2H), 3.28-3.16 (m, 1H), 3.13-2.97 (m, 1H), 2.38 (s, 2H).
Example 176
[1443] ##STR00899## ##STR00900##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chlorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1444] ##STR00901##
[1445] To a 100 mL round-bottom flask were added 4-bromo-2-chlorobenzaldehyde (2.0 g, 1 eq, compound 176-1), compound 1-4 (1.9 g, 1 eq), compound 1-5 (1.0 g, 1 eq), CuCl (0.27 g, 0.3 eq), Cu(OTf).sub.2 (0.99 g, 0.3 eq), toluene (20 mL) and DMA (2 mL) sequentially. The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material (compound 176-1) was consumed as detected by TLC. Then the reaction system was cooled to room temperature, added with aqueous ammonia (10 mL) and water (15 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with DCM (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation to give intermediate 176-2 (1.46 g, 95% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=520.2.
Step (2) Preparation of (S)-2-((2-(4-bromo-2-chlorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1446] ##STR00902##
[1447] Intermediate 176-2 (1.46 g) was dissolved in methanol (5 mL), and a solution of HCl in EtOAc (4 M, 10 mL) was added. The reaction system was stirred at room temperature for 1 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (10 mL×2). The DCM phases were combined, washed with saturated brine, dried and concentrated by rotary evaporation to give intermediate 176-3 (1.05 g, 90% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=420.1.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2-chlorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1448] ##STR00903##
[1449] Intermediate 176-3 (1.05 g, 1.0 eq) was dissolved in DCM (10 mL), and DIPEA (0.65 g, 2.0 eq) was added, followed by the dropwise addition of methyl chloroacetate (0.27 g, 1.5 eq). The reaction system was reacted for 1 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and DCM (20 mL), and stirred for 10 min, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (10 mL×2). The DCM phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 176-4 (0.88 g, 96% purity). LC-MS: [M+H].sup.+=478.2.
Step (4) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2-chlorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1450] ##STR00904##
[1451] Intermediate 176-4 (0.78 g, 1.0 eq) was dissolved in dioxane (10 mL), and BnSH (0.23 g, 1.1 eq), Pd.sub.2(dba).sub.3 (0.15 g, 0.1 eq), Xantphos (0.1 g, 0.1 eq) and DIPEA (0.42 g, 2.0 eq) were added. The reaction system was purged with N.sub.2 three times, and reacted at 85° C. overnight. The starting material was consumed completely as monitored by TLC. After the reaction was completed, the reaction system was added with water (10 mL) and EA (20 mL), and stirred for 10 min, followed by liquid separation to give an EtOAc phase. The aqueous phase was extracted with EtOAc (10 mL×2). The EtOAc phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 176-5 (0.85 g, 92% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=522.0.
Step (5) Preparation of methyl (S)-2-((2-(2-chloro-4-(chlorosulfonyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1452] ##STR00905##
[1453] Intermediate 176-5 (150 mg) was added to a reaction flask containing DCM (1 mL), glacial acetic acid (86.3 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (154.9 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at room temperature for 2 h. The starting material was consumed, and intermediate 176-6 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (6) Preparation of methyl (S)-2-((2-(2-chloro-4-sulfamoylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1454] ##STR00906##
[1455] A solution of NH.sub.3 in THF (0.4 M, 5 mL) was added dropwise slowly to the above reaction system at 0° C. The reaction system was reacted at room temperature for 2 h. The starting material was consumed completely, and a target product was generated as detected by LCMS. The reaction system was concentrated to dryness, and purified by preparative chromatography to give compound 176 (18 mg) in the form of a white solid. LC-MS: [M+H].sup.+=479.0.
[1456] 1H NMR (400 MHz, DMSO-d6) δ 8.43 (d, J=7.1 Hz, 1H), 7.96 (d, J=1.7 Hz, 1H), 7.83 (dd, J=8.0, 1.8 Hz, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.59 (s, 2H), 7.36 (s, 1H), 6.83 (dd, J=7.1, 1.6 Hz, 1H), 3.79-3.59 (m, 3H), 3.56 (s, 3H), 3.51 (s, 1H), 3.23 (dd, J=11.8, 9.1 Hz, 1H), 3.05 (qd, J=15.6, 6.3 Hz, 2H), 2.82 (s, 1H), 2.51 (s, 1H), 2.38 (s, 3H).
Example 177
[1457] ##STR00907## ##STR00908##
Step (1) Preparation of 4-bromo-2-chloro-6-fluorobenzaldehyde
[1458] ##STR00909##
[1459] To a 100 mL round-bottom flask were added methyl 4-bromo-2-chloro-6-fluorobenzoate (1.0 g, 1.0 eq, compound 177-1) and anhydrous tetrahydrofuran sequentially. The reaction system was cooled to −70° C., then slowly added with DIBAL-H (3.8 mL, 1.2 eq) and reacted at this temperature for 2 h. The starting material was consumed completely and a new spot was generated as detected by TLC. The reaction system was added with aqueous HCl solution (1 M) to quench the reaction, then stirred at room temperature for 20 min, and extracted with dichloromethane (30 mL×3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 177-2 (0.9 g, 80% purity) in the form of a colorless oil. LC-MS: [M+H].sup.+=237.1.
Step (2) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1460] ##STR00910##
[1461] Intermediate 177-2 (0.75 g, 1.0 eq), compound 1-5 (0.67 g, 1.0 eq), compound 1-4 (0.34 g, 1.0 eq), CuCl (0.19 g, 0.3 eq) and Cu(OTf).sub.2 (0.69 g, 0.3 eq) were added to toluene (20 mL) and DMA (2 mL). The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material compound 1-4 was consumed as detected by TLC. Then the reaction system was cooled to room temperature, added with aqueous ammonia (10 mL) and water (15 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with dichloromethane (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 177-3 (0.2 g, 99% purity) in the form of a brown foamy solid. LC-MS: [M+H].sup.+=538.1.
Step (3) Preparation of (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1462] ##STR00911##
[1463] Intermediate 177-3 (0.2 g) was dissolved in methanol (5 mL), and a solution of HCl in EA (10 mL) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated brine, dried, filtered and concentrated by rotary evaporation to give intermediate 177-4 (170 mg) in the form of a yellow solid. The crude product was used directly in the next step. LC-MS: [M+H].sup.+=438.1.
Step (4) Preparation of methyl (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1464] ##STR00912##
[1465] Intermediate 177-4 (170 mg, 1.0 eq) was dissolved in dichloromethane (2 mL), and triethylamine (120 mg, 2.0 eq) was added, followed by the dropwise addition of methyl chloroacetate (55 mg, 1.5 eq). The reaction system was reacted for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL), and stirred for 10 min, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 177-5 (175 mg, 96% purity) in the form of a white solid. LC-MS: [M+H].sup.+=496.1.
Step (5) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2-chloro-6-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1466] ##STR00913##
[1467] Intermediate 177-5 (175 mg, 1.0 eq) was dissolved in dioxane (10 mL), and BnSH (53 mg, 1.1 eq), Pd.sub.2(dba).sub.3 (36 mg, 0.1 eq), Xantphos (25 mg, 0.1 eq) and DIPEA (95 mg, 2.0 eq) were added. The reaction system was purged with N.sub.2 three times and reacted at 85° C. overnight. The starting material was consumed completely as monitored by TLC. After the reaction was completed, the reaction system was added with water (10 mL) and ethyl acetate (20 mL), and stirred for 10 min, followed by liquid separation to give an ethyl acetate phase. The aqueous phase was extracted with ethyl acetate (10 mL×2). The ethyl acetate phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 177-7 (165 mg, 95% purity) in the form of a white solid. LC-MS: [M+H].sup.+=540.0.
Step (6) Preparation of methyl (S)-2-((2-(2-chloro-4-(chlorosulfonyl)-6-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1468] ##STR00914##
[1469] Intermediate 177-7 (160 mg) was added to a reaction flask containing dichloromethane (5 mL), glacial acetic acid (90 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (160 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at 0° C. for 1 h. The starting material was consumed, and intermediate 177-8 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (7) Preparation of methyl (S)-2-((2-(2-chloro-6-fluoro-4-sulfamoylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1470] ##STR00915##
[1471] Aqueous ammonia (10 mL) was added dropwise slowly to the above reaction system at 0° C. The reaction system was reacted at 0° C. for 0.2 h. The starting material was consumed completely, and a target product was generated as detected by LCMS. The reaction system was concentrated to dryness, and purified by preparative chromatography. to give compound 177 (80 mg, 98.982% purity) in the form of a white solid. LC-MS: [M+H].sup.+=497.2.
[1472] 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J=7.1 Hz, 1H), 7.85 (s, 1H), 7.72 (s, 2H), 7.70 (s, 1H), 7.37 (s, 1H), 6.86 (d, J=7.1 Hz, 1H), 3.77 (d, J=11.6 Hz, 1H), 3.63 (d, J=11.9 Hz, 2H), 3.55 (s, 3H), 3.43 (s, 1H), 3.19 (dt, J=11.8, 5.8 Hz, 1H), 3.01 (qd, J=15.5, 6.0 Hz, 2H), 2.78 (s, 1H), 2.52 (s, 1H), 2.38 (s, 3H).
Example 178
[1473] ##STR00916## ##STR00917##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chlorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1474] ##STR00918##
[1475] To a 100 mL round-bottom flask were added compound 1-4 (680 mg, 1.0 eq), compound 176-1 (706 mg, 1.0 eq), 4-chloropyridin-2-amine (413 mg, 1.0 eq, compound 178-1), CuI (61 mg, 0.1 eq), Cu(OTf).sub.2 (116 mg, 0.1 eq) and DMSO (7 mL) sequentially. The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material compound 1-4 was consumed as detected by TLC. After the reaction system was cooled to room temperature, aqueous ammonium chloride solution (10 mL) and ethyl acetate (15 mL) were added. The reaction system was shaken for 5 min, followed by liquid separation to give an organic phase. The aqueous phase was extracted with ethyl acetate (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 178-2 (0.65 g) in the form of a yellow oil. LC-MS: [M+H].sup.+=540.2.
Step (2) Preparation of (S)-2-((2-(4-bromo-2-chlorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1476] ##STR00919##
[1477] Intermediate 178-2 (0.65 g) was dissolved in dichloromethane (2 mL), and a solution of HCl in dioxane (6 mL) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, The reaction system was concentrated by rotary evaporation, added with water (10 mL) and dichloromethane (20 mL), and extracted to give an aqueous phase. The aqueous phase was adjusted to pH 8-9 (weak alkalinity) with aqueous sodium carbonate solution, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated brine, dried, filtered and concentrated by rotary evaporation to give intermediate 178-3 (512 mg, 95% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=440.1.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2-chlorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1478] ##STR00920##
[1479] Intermediate 178-3 (500 mg, 1.0 eq) was dissolved in dichloromethane (5 mL), and triethylamine (206 mg, 2.0 eq) was added, followed by the dropwise addition of methyl chloroacetate (115 mg, 1.2 eq). The reaction system was reacted for 1.0 h and a product was generated as detected by LC-MS. After the reaction was completed, the reaction system was added with water (15 mL), and stirred for 30 min, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation to give intermediate 178-4 (0.52 g) in the form of a yellow oil. LC-MS: [M+H].sup.+=498.2.
Step (4) Preparation of methyl (S)-2-((2-(4-benzylthio-2-chlorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1480] ##STR00921##
[1481] Intermediate 178-4 (0.52 g, 1.0 eq) was dissolved in dioxane (6 mL), and BnSH (0.16 g, 1.2 eq), Pd.sub.2(dba).sub.3 (0.05 g, 0.05 eq), Xantphos (0.06 g, 0.1 eq) and DIEA (0.41 g, 3.0 eq) were added. The reaction system was purged with N.sub.2 three times and reacted at 80° C. overnight. The starting material was consumed completely as monitored by LCMS. After the reaction was completed, the reaction system was added with water (10 mL) and ethyl acetate (20 mL), followed by liquid separation to give an ethyl acetate phase. The aqueous phase was extracted with ethyl acetate (10 mL×2). The ethyl acetate phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 178-5 (0.48 g, 86% purity) in the form of a yellow oil. LC-MS: [M+H].sup.+=542.2.
Step (5) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-4-(chlorosulfonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1482] ##STR00922##
[1483] Intermediate 178-5 (220 mg) was added to a reaction flask of acetonitrile (3 mL), glacial acetic acid (121 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (218 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at 0° C. for 1 h. The starting material was consumed, and intermediate 178-6 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (6) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-4-sulfamoylphenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1484] ##STR00923##
[1485] Aqueous ammonia (1.5 mL) was diluted with acetonitrile (1 mL) and added dropwise to the above reaction system at 0° C. The reaction system was reacted at room temperature for 0.5 h. The starting material was consumed completely and a target product was generated as detected by LC-MS. The reaction system was extracted with water and ethyl acetate twice, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative chromatography to give compound 178 (30 mg, 99.6% purity) in the form of a white solid. LC-MS: [M+H].sup.+=499.1.
[1486] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.61 (d, J=7.4 Hz, 1H), 7.98 (s, 1H), 7.85 (d, J=9.6 Hz, 1H), 7.79 (d, J=2.1 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.61 (s, 2H), 7.09 (dd, J=7.4, 2.1 Hz, 1H), 3.79 (d, J=12.5 Hz, 1H), 3.63 (d, J=11.5 Hz, 3H), 3.56 (s, 4H), 3.51 (s, 1H), 3.26-3.21 (m, 2H), 3.20-3.14 (m, 1H), 3.12 (s, 1H), 3.03 (dd, J=15.6, 8.4 Hz, 1H), 2.81 (s, 1H).
Example 179
[1487] ##STR00924## ##STR00925##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1488] ##STR00926##
[1489] Intermediate 177-2 (2.16 g, 1.0 eq), 4-chloropyridin-2-amine (1.17 g, 1.0 eq, compound 179-1), compound 1-4 (1.92 g, 1.0 eq), CuI (0.19 g, 0.1 eq) and Cu(OTf).sub.2 (0.33 g, 0.1 eq) were added to isopropanol (25 mL). The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material compound 1-4 was consumed as detected by TLC. work-up: the reaction system was cooled to room temperature, added with aqueous ammonia (10 mL) and water (15 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with dichloromethane (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 179-2 (0.93 g, 92% purity) in the form of a light yellow foamy solid. LC-MS: [M+H].sup.+=558.0.
Step (2) Preparation of (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1490] ##STR00927##
[1491] Intermediate 179-2 (0.93 g) was dissolved in methanol (10 mL), and a solution of HCl in dioxane (10 mL) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated brine, dried, and concentrated by rotary evaporation to give intermediate 179-3 (0.78 g) in the form of a white solid, LC-MS: [M+H].sup.+=458.1. The crude product was used directly in the next step.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2-chloro-6-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1492] ##STR00928##
[1493] Intermediate 179-3 (690 mg, 1.0 eq) was dissolved in dichloromethane (10 mL), and triethylamine (380 mg, 2.0 eq) was added, followed by the dropwise addition of methyl chloroacetate (213 mg, 1.5 eq). The reaction system was reacted for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL), and stirred for 10 min, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 179-4 (472 mg, 96% purity) in the form of a white solid. LC-MS: [M+H].sup.+=515.9.
Step (4) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2-chloro-6-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1494] ##STR00929##
[1495] Intermediate 179-4 (420 mg, 1.0 eq) was dissolved in dioxane (10 mL), and BnSH (130 mg, 1.2 eq), Pd.sub.2(dba).sub.3 (84 mg, 0.1 eq), Xantphos (50 mg, 0.1 eq) and DIPEA (210 mg, 2.0 eq) were added. The reaction system was purged with N.sub.2 three times and reacted at 85° C. overnight. The starting material was consumed completely as monitored by TLC. After the reaction was completed, the reaction system was added with water (10 mL) and ethyl acetate (20 mL), and stirred for 10 min, followed by liquid separation to give an ethyl acetate phase. The aqueous phase was extracted with ethyl acetate (10 mL×2). The ethyl acetate phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 179-5 (465 mg, 94% purity) in the form of a white solid. LC-MS: [M+H].sup.+=560.1.
Step (5) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-4-(chlorosulfonyl)-6-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1496] ##STR00930##
[1497] Intermediate 179-5 (415 mg) was added to a reaction flask of dichloromethane (5 mL), glacial acetic acid (224 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (415 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at 0° C. for 1 h. The starting material was consumed, and intermediate 179-6 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (6) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-6-fluoro-4-sulfamoylphenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1498] ##STR00931##
[1499] Aqueous ammonia (10 mL) was added dropwise slowly to the above reaction system at 0° C. The reaction system was reacted at 0° C. for 0.2 h. The starting material was consumed completely, and a target product was generated as detected by LCMS. The reaction system was concentrated to dryness. The residue was purified by preparative chromatography to give compound 179 (170 mg, 99.778% purity) in the form of a white solid. LC-MS: [M+H].sup.+=517.2.
[1500] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.61 (d, J=7.4 Hz, 1H), 7.79 (dd, J=6.5, 4.4 Hz, 2H), 7.64 (dt, J=8.0, 4.0 Hz, 1H), 7.14-7.05 (m, 1H), 6.94 (s, 1H), 3.81 (d, J=11.7 Hz, 1H), 3.63 (d, J=11.6 Hz, 2H), 3.56 (s, 3H), 3.45 (d, J=3.5 Hz, 1H), 3.20 (td, J=11.4, 2.2 Hz, 1H), 3.04 (ddd, J=23.5, 15.5, 5.9 Hz, 2H), 2.79 (s, 1H), 2.51 (s, 1H).
Example 180
[1501] ##STR00932## ##STR00933##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1502] ##STR00934##
[1503] To a 100 mL round-bottom flask were added 4-bromo-2-chloro-5-fluorobenzaldehyde (1.5 g, 6.4 mmol, compound 180-1), compound 1-4 (2.67 g, 12.6 mmol) and compound 1-5 (0.68 g, 6.4 mmol) sequentially, and then toluene (15 mL) and N,N-dimethylacetamide (1 mL) were added, followed by the addition of catalysts copper(I) chloride (187.6 mg, 1.9 mmol) and copper(II) trifluoromethanesulfonate (685.4 mg, 1.9 mmol). The reaction system was purged with nitrogen three times, and reacted at 85° C. for 4 h. After the reaction was completed, a target product was generated as detected by LC-MS. The reaction system was concentrated by rotary evaporation to remove the solvent, dissolved with dichloromethane (50 mL), added with aqueous ammonia (50 mL), and stirred, followed by liquid separation to give an organic phase. The aqueous phase was extracted with DCM (150 mL×3). The organic phase was washed with saturated citric acid solution and saturated brine 3 times, respectively, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 180-2 (1.9 g, 59.9% yield) in the form of a light yellow foamy solid powder. LC-MS: [M+H].sup.+=538.1.
Step (2) Preparation of (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1504] ##STR00935##
[1505] Intermediate 180-2 (0.7 g, 1.4 mmol) was dissolved in dichloromethane (5 mL). The reaction system was added with a solution of HCl in 1,4-dioxane solution (4 mL, 4.0 mol/L) in an ice bath, and then reacted at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was concentrated by rotary evaporation to remove the solvent, added with water (5 mL) and ethyl acetate (5 mL), and left to stand for liquid separation to give an aqueous phase. The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with saturated aqueous sodium bicarbonate solution, and then extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with saturated saline 3 times, and concentrated to give intermediate 180-3 (560 mg, 91.5% yield) in the form of a light yellow oily liquid, which was used directly in the next step. LC-MS: [M+H].sup.+=438.1.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1506] ##STR00936##
[1507] Intermediate 180-3 (560 mg, 1.28 mmol) was dissolved in dichloromethane (5 mL), and triethylamine (260 mg, 2.56 mmol) was added. The reaction system was added with methyl chloroformate (145.5 mg, 1.54 mmol) in an ice bath, reacted at room temperature for 0.5 h, and a product was generated as detected by LC-MS. After the reaction was completed, the reaction system was added with water (5 mL) to quench the reaction and left to stand for liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (5 mL×2). The dichloromethane phases were combined, washed with saturated brine 3 times, dried over anhydrous sodium sulfate, and concentrated to give intermediate 180-4 (520 mg, 81.9% yield) in the form of a white solid. LC-MS: [M+H].sup.+=496.1.
Step (4) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2-chloro-5-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1508] ##STR00937##
[1509] Intermediate 180-4 (520 mg, 1.05 mmol) was dissolved in 1,4-dioxane (10 mL), and Pd.sub.2(dba).sub.3 (28.8 mg, 0.0315 mmol), Xantphos (30.3 mg, 0.0525 mmol), DIEA (401.7 mg, 3.15 mmol) and BnSH (169.6 mg, 1.36 mmol) were added. The reaction system was purged with nitrogen 3 times and reacted at 80° C. overnight. The starting material was consumed completely as detected by LC-MS. After the reaction was completed, water (10 mL) and ethyl acetate (20 mL) were added. The reaction system was stirred and left to stand for liquid separation to give an ethyl acetate phase. The aqueous phase was extracted with ethyl acetate (10 mL×2). The ethyl acetate phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to give intermediate 180-5 (500 mg, 88.5% yield) in the form of a light yellow solid. LC-MS: [M+H].sup.+=440.2.
Step (5) Preparation of methyl (S)-2-((2-(2-chloro-4-(chlorosulfonyl)-5-fluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1510] ##STR00938##
[1511] Substrate intermediate 180-5 (500 mg, 0.92 mmol) was added to a reaction flask of acetonitrile (15 mL), glacial acetic acid (276 mg, 4.6 mmol) was added, and sulfonyl chloride (500 mg, 3.7 mmol) was added dropwise slowly in an ice bath. The reaction system was reacted at 0° C. for 1 h. The starting material was consumed and intermediate 180-6 was generated as detected by LC-MS, LC-MS: [M+H].sup.+=515.9. The reaction system was used directly in the next step without treatment.
Step (6) Preparation of methyl (S)-2-((2-(2-chloro-5-fluoro-4-sulfamoylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1512] ##STR00939##
[1513] Aqueous ammonia (15 mL) was diluted with acetonitrile (10 mL) and added dropwise to the reaction system of the previous step at 0° C. The reaction system was reacted at room temperature for 0.5 h. The starting material was consumed completely and a target product was generated as detected by LC-MS. The reaction system was left to stand for liquid separation to give an organic phase. The aqueous phase was extracted with ethyl acetate 2 times. The organic phase was washed with saline solution, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative chromatography, and separated by preparative TLC to give compound 180 (140 mg, 99.5% purity) in the form of a white solid, LC-MS: [M+H].sup.+=497.1.
[1514] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ: 8.42 (d, J=7.1 Hz, 1H), 7.89 (s, 2H), 7.87 (d, J=6.6 Hz, 1H), 7.62 (d, J=10.2 Hz, 1H), 7.35 (s, 1H), 6.83 (dd, J=7.1, 1.6 Hz, 1H), 3.84-3.73 (m, 1H), 3.64 (t, J=11.0 Hz, 2H), 3.58-3.52 (m, 3H), 3.53-3.45 (m, 1H), 3.22 (td, J=11.7, 2.7 Hz, 1H), 3.12 (dd, J=15.6, 4.1 Hz, 1H), 3.00 (dd, J=15.6, 8.2 Hz, 1H), 2.81 (s, 1H), 2.53 (d, J=7.6 Hz, 1H), 2.42-2.29 (m, 3H).
Example 181
[1515] ##STR00940## ##STR00941##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1516] ##STR00942##
[1517] To a 100 mL round-bottom flask were added intermediate 180-1 (1.5 g, 1.0 eq), compound 179-1 (0.81 g, 1.0 eq), compound 1-4 (1.3 g, 1.0 eq), CuCl (0.19 g, 0.3 eq), Cu(OTf).sub.2 (0.69 g, 0.3 eq), toluene (20 mL) and DMA (2 mL) sequentially. The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material compound 1-4 was consumed as detected by TLC. Then the reaction system was cooled to room temperature, added with aqueous ammonia (10 mL) and water (15 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with dichloromethane (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 181-1 (0.35 g, 99% purity) in the form of a light yellow foamy solid. LC-MS: [M+H].sup.+=558.1.
Step (2) Preparation of (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
[1518] ##STR00943##
[1519] Intermediate 181-1 (0.1 g) was dissolved in methanol (5 mL), and HCl/EtOAc (10 mL, 3 M) was added. The reaction system was stirred at room temperature for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated brine, dried, and concentrated by rotary evaporation to give intermediate 181-2 (80 mg) in the form of a white solid. The crude product was used directly in the next step. LC-MS: [M+H].sup.+=458.1.
Step (3) Preparation of methyl (S)-2-((2-(4-bromo-2-chloro-5-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1520] ##STR00944##
[1521] Intermediate 181-2 (80 mg, 1.0 eq) was dissolved in dichloromethane (2 mL), and triethylamine (36 mg, 2.0 eq) was added, followed by the dropwise addition of methyl chloroacetate (25 mg, 1.5 eq). The reaction system was reacted for 1.0 h. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL), and stirred for 10 min, followed by liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (10 mL×2). The dichloromethane phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 181-3 (0.1 g, 96% purity) in the form of a white solid. LC-MS: [M+H].sup.+=515.9.
Step (4) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2-chloro-5-fluorophenyl)-7-chloroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1522] ##STR00945##
[1523] Intermediate 181-3 (0.45 g, 1.0 eq) was dissolved in dioxane (10 mL), and BnSH (0.13 g, 1.1 eq), Pd.sub.2(dba).sub.3 (0.08 g, 0.1 eq), Xantphos (0.05 g, 0.1 eq) and DIPEA (0.23 g, 2.0 eq) were added. The reaction system was purged with N.sub.2 three times and reacted at 85° C. overnight. The starting material was consumed completely as monitored by TLC. After the reaction was completed, the reaction system was added with water (10 mL) and ethyl acetate (20 mL), and stirred for 10 min, followed by liquid separation to give an ethyl acetate phase. The aqueous phase was extracted with ethyl acetate (10 mL×2). The ethyl acetate phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 181-4 (0.3 g, 95% purity) in the form of a white solid. LC-MS: [M+H].sup.+=560.2.
Step (5) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-4-(chlorosulfonyl)-5-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1524] ##STR00946##
[1525] Intermediate 181-4 (280 mg) was added to a reaction flask of dichloromethane (5 mL), glacial acetic acid (150 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (270 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at room temperature for 1 h. The starting material was consumed, and intermediate 181-5 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment.
Step (6) Preparation of methyl (S)-2-((7-chloro-2-(2-chloro-5-fluoro-4-sulfamoylphenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1526] ##STR00947##
[1527] A solution of NH.sub.3 in tetrahydrofuran (0.4 M, 5 mL) was added dropwise slowly to the above reaction system at 0° C. The reaction system was reacted at room temperature for 2 h. The starting material was consumed completely, and a target product was generated as detected by LCMS. The reaction system was concentrated to dryness. The residue was purified by preparative chromatography to give compound 181 (30 mg, 99% purity) in the form of a white solid. LC-MS: [M+H].sup.+=517.1.
[1528] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.62 (d, J=7.4 Hz, 1H), 7.94 (s, 2H), 7.90 (d, J=6.6 Hz, 1H), 7.81-7.79 (m, 1H), 7.67 (d, J=10.1 Hz, 1H), 7.10 (dd, J=7.4, 2.2 Hz, 1H), 3.84 (s, 1H), 3.65 (s, 2H), 3.57 (s, 3H), 3.52 (t, J=9.4 Hz, 1H), 3.27-3.16 (m, 2H), 3.04 (dd, J=15.6, 8.5 Hz, 1H), 2.82 (s, 1H), 2.52 (d, J=1.9 Hz, 1H).
Example 182
[1529] ##STR00948##
Step (1) Preparation of tert-butyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,6-difluorophenyl)-6-fluoro-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1530] ##STR00949##
[1531] To a 100 mL round-bottom flask were added intermediate 171-4 (1.5 g, 3.25 mmol), 5-fluoro-4-methylpyridin-2-amine (410 mg, 3.25 mmol) and intermediate 1-4 (686.7 mg, 3.25 mmol), and then toluene (15 mL) and dimethyl acetamide (5 mL) were added, followed by the addition of catalysts copper(I) chloride (96.5 mg, 0.98 mmol) and copper(II) trifluoromethanesulfonate (353 mg, 0.98 mmol). The reaction system was purged with nitrogen three times and reacted at 80° C. overnight. After the reaction was completed, a target product was generated as detected by LC-MS. The reaction system was concentrated by rotary evaporation to remove the solvent, dissolved with dichloromethane (50 mL), added with aqueous ammonia (50 mL), and stirred, followed by liquid separation to give an organic phase. The aqueous phase was extracted with dichloromethane (150 mL×3). The organic phase was washed with saturated citric acid solution and saturated brine 3 times, respectively, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 182-2 (920 mg, 36.3% yield) in the form of a light yellow oily liquid.
Step (2) Preparation of (S)-3,5-difluoro-4-(6-fluoro-7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)-N,N-bis(4-methoxybenzyl)benzenesulfonamide
[1532] ##STR00950##
[1533] Intermediate 182-2 (410 mg, 0.53 mmol) was dissolved in ethyl acetate (2 mL). The reaction system was added with a solution of HCl in 1,4-dioxane solution (2 mL, 4.0 mol/L) in an ice bath, and then reacted at room temperature for 1.0 h. The reaction was completed as detected by TLC. work-up: the reaction system was concentrated by rotary evaporation to remove the solvent, added with water (2 mL) and ethyl acetate (2 mL), and left to stand for liquid separation to give an aqueous phase. The aqueous phase was adjusted to pH 8-9 (weak alkalinity) with saturated aqueous sodium bicarbonate solution, and then extracted with ethyl acetate (3 mL×3). The organic phases were combined, washed with saturated saline 3 times, and concentrated to give intermediate 182-3 (330 mg, 92.5% yield) in the form of a light yellow oily liquid, which was used directly in the next step. LC-MS: [M+H].sup.+=681.2.
Step (3) Preparation of methyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,6-difluorophenyl)-6-fluoro-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1534] ##STR00951##
[1535] Intermediate 182-3 (330 mg, 0.49 mmol) was dissolved in dichloromethane (2 mL), and triethylamine (100 mg, 0.98 mmol) was added, followed by the dropwise addition of methyl chloroformate (70 mg, 0.73 mmol) in an ice bath. After the addition was completed, the reaction system was reacted at room temperature for 1 h. After the reaction was completed as detected by TLC, the reaction system was added with water (5 mL) to quench the reaction and left to stand for liquid separation to give a dichloromethane phase. The aqueous phase was extracted with dichloromethane (5 mL×2). The dichloromethane phases were combined, washed with saturated brine 3 times, dried over anhydrous sodium sulfate, and concentrated to give intermediate 182-4 (200 mg, 55.1% yield) in the form of a yellow oily liquid. LC-MS: [M+H].sup.+=739.1.
Step (4) Preparation of methyl (S)-2-((2-(2,6-difluoro-4-sulfamoylphenyl)-6-fluoro-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1536] ##STR00952##
[1537] Intermediate 182-4 (200 mg, 0.27 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (2 mL) was added. The reaction system was reacted at room temperature overnight. The starting material was consumed completely as detected by TLC, and then the work-up was performed. The reaction system was added with water (5 mL) to quench the reaction, then added with dichloromethane (3 mL), and left to stand for liquid separation to give an aqueous phase. The aqueous phase was adjusted to pH 8-9 (weak alkalinity) with saturated aqueous sodium bicarbonate solution, and then extracted with dichloromethane (5 mL×3). The dichloromethane phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation to remove the solvent, and purified by preparative chromatography to give compound 182 (82 mg, 97.8% purity, 60.98% yield) in the form of a white powdery solid. LC-MS: [M+H].sup.+=499.1.
[1538] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 8.71 (d, J=5.5 Hz, 1H), 7.68 (s, 2H), 7.59 (d, J=6.6 Hz, 2H), 7.50 (d, J=7.2 Hz, 1H), 3.80 (d, J=12.3 Hz, 1H), 3.59 (d, J=11.4 Hz, 2H), 3.53 (s, 3H), 3.44 (s, 1H), 3.26 (s, 1H), 3.18 (dd, J=11.8, 9.1 Hz, 1H), 3.06 (dd, J=15.4, 3.8 Hz, 1H), 2.98 (d, J=8.4 Hz, 1H), 2.76 (s, 1H), 2.32 (s, 3H).
Example 183
[1539] ##STR00953## ##STR00954##
Step (1) Preparation of methyl (S)-2-((2-(4-((tert-butoxycarbonyl)amino)-2,6-difluorophenyl)-7-chloro-6-fluoroimidazo[1,2-a]pyridin-3-yl) methyl)morpholine-4-carboxylate
[1540] ##STR00955##
[1541] To a 10 mL round-bottom flask were added tert-butyl (3,5-difluoro-4-formylphenyl)carboxylate (0.75 g, 1.0 eq, compound 183-1), 4-chloro-5-fluoropyridin-2-amine (0.43 g, 1.0 eq, compound 183-2), compound 1-4 (0.5 g, 1.0 eq), CuI (0.17 g, 0.3 eq), Cu(OTf).sub.2 (0.32 g, 0.3 eq), toluene (10 mL) and DMA (1 mL) sequentially. The reaction system was purged with nitrogen 3 times, heated in an oil bath at 85° C. and reacted overnight (12 h). The starting material compound 1-4 was consumed as detected by TLC. The reaction system was cooled to room temperature, added with aqueous ammonia (5 mL) and water (15 mL), and stirred for 5 min, followed by liquid separation to give a toluene phase. The aqueous phase was extracted with DCM (15 mL×2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated by rotary evaporation. The residue was purified by column chromatography to give intermediate 183-3 (0.18 g) in the form of a white solid. LC-MS: [M+H].sup.+=555.0.
Step (2) Preparation of methyl (S)-2-((2-(4-amino-2,6-difluorophenyl)-7-chloro-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1542] ##STR00956##
[1543] Intermediate 183-3 (0.18 g) was dissolved in methanol (2 mL), and HCl/EtOAc (3 M, 5 mL) was added. The reaction system was stirred at room temperature overnight. After the reaction was completed as detected by TLC, the reaction system was added with water (10 mL) and dichloromethane (20 mL). The aqueous phase was adjusted to pH 9-10 (weak alkalinity) with sodium carbonate, followed by liquid separation to give a DCM phase. The aqueous phase was extracted with DCM (10 mL×2). The DCM phases were combined, washed with saturated brine, dried, and concentrated by rotary evaporation to give intermediate 183-4 (0.12 g) in the form of a white solid. LC-MS: [M+H].sup.+=455.0.
Step (3) Preparation of methyl (S)-2-((2-(4-(benzylthio)-2,6-difluorophenyl)-7-chloro-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1544] ##STR00957##
[1545] Intermediate 183-4 (0.2 g, 1.0 eq) and BnSSBn (0.11 g, 1.0 eq) were dissolved in MeCN (3 mL). The reaction system was purged with nitrogen three times. Ascorbic acid (40 mg, 0.5 eq) was dissolved with DMSO (0.5 mL) and added to the reaction system, which was then stirred and reacted for 10 min, and then added with t-BuONO (70 mg, 1.5 eq). The starting material was consumed completely as detected by TLC. The reaction system was added with water (2 mL), and then extracted with EtOAc (10 mL×3). The EtOAc phase was washed with saturated brine, dried over Na.sub.2SO.sub.4, and concentrated. The residue was purified by column chromatography to give intermediate 183-5 (0.11 g) in the form of a yellow solid. LC-MS: [M+H].sup.+=562.1.
Step (4) Preparation of methyl (2S)-2-((7-chloro-2-(4-(chlorosulfonyl)-2,6-difluorocyclohexa-2,4-dien-1-yl)-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1546] ##STR00958##
[1547] Intermediate 183-5 (100 mg) was added to a reaction flask of DCM (1 mL), glacial acetic acid (53.4 mg, 5.0 eq) was added, and SO.sub.2Cl.sub.2 (96.1 mg, 4.0 eq) was added dropwise in an ice bath. The reaction system was reacted at room temperature for 2 h. The starting material was consumed, and intermediate 183-6 was generated as detected by LCMS. The reaction system was used directly in the next step without treatment. LC-MS: [M+H].sup.+=540.2.
Step (5) Preparation of methyl (S)-2-((7-chloro-2-(2,6-difluoro-4-sulfamoylphenyl)-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1548] ##STR00959##
[1549] NH.sub.3/MeOH (2 mL, 7 M) was added dropwise slowly to the above reaction system at 0° C. and reacted at room temperature for 2 h. The starting material was consumed completely and a target product was generated as detected by LC-MS. The reaction system was concentrated to dryness. The residue was purified by preparative chromatography to give compound 183 (3.0 mg) in the form of a white solid. LC-MS: [M+H].sup.+=519.1.
[1550] .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ 9.05 (d, J=5.3 Hz, 1H), 8.04 (d, J=7.1 Hz, 1H), 7.73 (s, 2H), 7.64 (d, J=6.7 Hz, 2H), 3.87 (d, J=12.7 Hz, 1H), 3.61 (d, J=8.1 Hz, 3H), 3.57 (s, 4H), 3.50 (d, J=9.9 Hz, 2H), 3.23-3.13 (m, 3H), 3.05-2.80 (m, 1H).
Example 184
[1551] ##STR00960## ##STR00961##
Step (1) Preparation of 4-(benzylthio)-2-methylbenzonitrile
[1552] ##STR00962##
[1553] 4-fluoro-2-methylbenzonitrile (5.00 g, 37.00 mmol) was dissolved in N,N-dimethylformamide (30 mL), and potassium carbonate (7.50 g, 54.35 mmol) and benzylthiol (3.5 mL) were added. The reaction system was stirred at 50° C. overnight. Then the reaction system was cooled to room temperature, added with water (80 mL) to quench the reaction and extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 184-2 (4.88 g, 52.4% yield) in the form of a yellow solid, LC-MS: [M+H].sup.+=239.8.
Step (2) Preparation of 4-cyano-3-methylbenzenesulfonyl chloride
[1554] ##STR00963##
[1555] Under nitrogen atmosphere, intermediate 184-2 (4.88 g, 20.39 mmol) was dissolved in a prepared solvent (75 mL of acetonitrile, 3.5 mL of acetic acid, 1.5 mL of water). The reaction system was cooled to 0° C., added with 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (8.04 g, 40.78 mmol) in portions, and reacted for 2 h. Then the reaction system was added with water (100 mL) to quench the reaction and extracted with ethyl acetate (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 184-4 (2.8 g, 60.3% yield) in the form of a white solid. .sup.1H NMR (301 MHz, CDCl3) δ 8.02 (s, 1H), 7.96 (d, J=8.2, 1H), 7.87 (d, J=8.2 Hz, 1H), 2.71 (s, 3H).
Step (3) Preparation of 4-cyano-N,N-bis(4-methoxybenzyl)-3-methylbenzenesulfonamide
[1556] ##STR00964##
[1557] Bis(4-methoxybenzyl)amine (2.80 g, 11.13 mmol) and triethylamine (3.40 g, 33.39 mmol) were dissolved in dichloromethane (50 mL). The reaction system was added with intermediate 184-4 (2.40 g, 11.13 mmol) in an ice water bath, and stirred at room temperature overnight. Then the reaction system was added with water (50 mL) to quench the reaction and extracted with dichloromethane (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 184-5 (3.30 g, 64.9% yield) in the form of a light yellow solid. LC-MS [M+H].sup.+=458.6.
Step (4) Preparation of 4-formyl-N,N-bis(4-methoxybenzyl)-3-methylbenzenesulfonamide
[1558] ##STR00965##
[1559] Intermediate 184-5 (3.00 g, 6.87 mmol) was dissolved in anhydrous tetrahydrofuran (60 mL). The reaction system was cooled to 0° C., then added dropwise with a solution of diisobutylaluminum hydride in n-hexane (1 N, 17.2 mL), and stirred at 0° C. overnight. Then the reaction system was added with diluted hydrochloric acid (60 mL, 1 N) to quench the reaction and filtered. The filtrate was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 184-6 (1.68 g, 55.7% yield) in the form of a white solid. LC-MS [M+H].sup.+=461.6.
Step (5) Preparation of tert-butyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2-methylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1560] ##STR00966##
[1561] Under nitrogen atmosphere, intermediate 184-6 (500 mg, 1.14 mmol), 4-methylpyridin-2-amine (123 mg, 1.14 mmol), tert-butyl (S)-2-ethynylmorpholin-4-carboxylate (242 mg, 1.14 mmol), copper(I) chloride (35 mg, 0.34 mmol) and copper(II) trifluoromethanesulfonate (124 mg, 0.34 mmol) were dissolved in anhydrous toluene (5 mL). The reaction system was heated to 85° C., then added with N,N′-dimethylacetamide (0.1 mL), and stirred at 85° C. overnight. After the reaction was completed, the reaction system was filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 184-7 (380 mg, 42.7% yield) in the form of a white solid. LC-MS [M+H].sup.+=740.5.
Step (6) Preparation of (S)—N,N-(4-methoxybenzyl)-3-methyl-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)benzenesulfonamide
[1562] ##STR00967##
[1563] Intermediate 184-7 (380 mg, 0.51 mmol) was dissolved in anhydrous dichloromethane (5 mL), and a solution of HCl in ethanol (1.5 mL, 4 N) was added. The reaction system was stirred at room temperature for 3 h. After the reaction was completed, the reaction system was concentrated by rotary evaporation to give intermediate 184-8 (450 mg, crude product) in the form of a white solid, LC-MS [M+H].sup.+=640.5.
Step (7) Preparation of methyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2-methylphenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1564] ##STR00968##
[1565] Intermediate 184-8 (450 mg, crude) and N,N′-diisopropylethylamine (325 mg, 2.53 mmol) were dissolved in anhydrous dichloromethane (5 mL) under nitrogen atmosphere. The reaction system was cooled in an ice water bath and added dropwise with a solution of methyl chloroformate in dichloromethane (10 mg/mL, 4.5 mL). After the completion of the dropwise addition, the reaction system was reacted at 0° C. for 2 h. After the reaction was completed, the reaction system was added with water (20 mL) and extracted with dichloromethane (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 184-9 (150 mg, 35.4% yield) in the form of a white solid, LC-MS [M+H].sup.+=698.5.
Step (9) Preparation of methyl (S)-2-((7-methyl-2-(2-methyl-4-sulfamoylphenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1566] ##STR00969##
[1567] Intermediate 184-9 (150 mg, 0.21 mmol) was dissolved in anhydrous dichloromethane (1 mL), and trifluoroacetic acid (2 mL) was added. The reaction system was stirred overnight at room temperature. After the reaction was completed, the reaction system was directly concentrated by rotary evaporation and purified by preparative reverse phase chromatography to give compound 184 (17 mg, 17.3% yield) in the form of a white solid. LC-MS [M+H].sup.+=458.5.
[1568] 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.87 (s, 1H), 7.77 (d, J=7.7 Hz, 1H), 7.56 (s, 1H), 7.42 (d, J=7.8 Hz, 1H), 6.80 (d, J=7.0 Hz, 1H), 5.53 (brs, 2H), 3.98-3.76 (m, 3H), 3.69 (s, 3H), 3.58-3.47 (m, 1H), 3.43-3.31 (m, 1H), 3.05-2.85 (m, 3H), 2.60-2.50 (m, 1H), 2.49 (s, 3H), 2.35 (s, 3H).
Example 185
[1569] ##STR00970##
[1570] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=472.1.
Example 186
[1571] ##STR00971##
[1572] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=440.2.
Example 187
[1573] ##STR00972##
[1574] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=479.1.
Example 188
[1575] ##STR00973##
[1576] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=499.1.
Example 189
[1577] ##STR00974## ##STR00975##
(1) Preparation of 4-(benzylthio)-2-(trifluoromethyl)benzonitrile
[1578] ##STR00976##
[1579] 4-fluoro-2-(trifluoromethyl)benzonitrile (5.00 g, 26.44 mmol) was dissolved in N,N-dimethylformamide (30 mL) and potassium carbonate (7.50 g, 54.35 mmol) was added. The reaction system was added with benzylmercaptan (2.80 mL), heated to 50° C. and stirred overnight. Then the reaction system was cooled to room temperature, added with water (80 mL) to quench the reaction, and extracted with ethyl acetate (40 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to give intermediate 189-2 (6.80 g, 83.3% yield) in the form of a yellow solid. LC-MS: [M+H].sup.+=293.7.
Step (2) Preparation of 4-cyano-3-(trifluoromethyl)benzenesulfonyl chloride
[1580] ##STR00977##
[1581] Intermediate 189-2 (6.80 g, 23.18 mmol) was dissolved in a prepared solvent (95 mL of acetonitrile, 4 mL of acetic acid, 2.5 mL of water) under nitrogen atmosphere. The reaction system was cooled to 0° C., added with 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (9.14 g, 46.37 mmol) in portions, and reacted for 2 h. Then the reaction system was added with water (100) to quench the reaction and extracted with ethyl acetate (60 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 189-3 (3.50 g, 51.5% yield) in the form of a white solid. LC-MS: [M+H].sup.+=270.2.
Step (3) Preparation of 4-cyano-N,N-bis(4-methoxybenzyl)-3-(trifluoromethyl)benzenesulfonamide
[1582] ##STR00978##
[1583] Triethylamine (3.93 g, 38.94 mmol) and bis(4-methoxybenzyl)amine (3.34 g, 12.98 mmol) were dissolved in dichloromethane (85 mL) under nitrogen atmosphere. The reaction system was cooled to 0° C., added with intermediate 189-3 (3.50 g, 12.98 mmol) in portions, warmed to room temperature and stirred overnight. Then the reaction system was added with water (50 mL) to quench the reaction. The aqueous phase was extracted with dichloromethane (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography to give intermediate 189-4 (5.00 g, 75.1% yield) in the form of a light yellow solid, LC-MS: [M+H].sup.+=512.7.
Step (4) Preparation of 4-(hydroxymethyl)-N,N-bis(4-methoxybenzyl)-3-(trifluoromethyl)benzenesulfonamide
[1584] ##STR00979##
[1585] Intermediate 189-4 (4.40 g, 8.97 mmol) was dissolved in anhydrous tetrahydrofuran (80 mL). The reaction system was cooled to 0° C., added dropwise with a solution of diisobutylaluminum hydride in n-hexane (1 N, 27 mL), slowly warmed to room temperature and stirred overnight. Then the reaction system was added with diluted hydrochloric acid (80 mL, 1 N) to quench the reaction, and then filtered, and the filtrate was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give intermediate 189-5 (5.00 g, crude product) in the form of a white solid, which was used directly in the next step. LC-MS: [M+H].sup.+=494.6.
Step (5) Preparation of 4-formyl-N,N-bis(4-methoxybenzyl)-3-(trifluoromethyl)benzenesulfonamide
[1586] ##STR00980##
[1587] Intermediate 189-5 (5.00 g, crude product) was dissolved in anhydrous dichloromethane (70 mL), and Dess-Martin periodinane (4.85 g, 11.56 mmol) was added in portions. The reaction system was stirred at room temperature for 1.5 h. Then the reaction system was added with saturated aqueous sodium thiosulfate solution (20 mL) to quench the reaction, and then added with water (30 mL). The aqueous phase was extracted with dichloromethane (40 mL×2). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and dried by rotary evaporation. The crude product was purified by silica gel column chromatography to give intermediate 189-6 (2.00 g, 45.2% yield over two steps) in the form of a white solid. LC-MS: [M+H].sup.+=515.5.
Step (6) Preparation of tert-butyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2-(trifluoromethyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1588] ##STR00981##
[1589] Intermediate 189-6 (500 mg, 1.01 mmol), 4-methylpyridin-2-amine (110 mg, 1.01 mmol), tert-butyl (S)-2-ethynylmorpholine-4-carboxylate (214 mg, 1.01 mmol), copper(I) chloride (30 mg, 0.30 mmol) and copper(II) trifluoromethanesulfonate (110 mg, 0.30 mmol) were dissolved in anhydrous toluene (5 mL) under nitrogen atmosphere. The reaction system was warmed to 85° C., added with 5 drops of N,N′-dimethylacetamide, and stirred at 85° C. overnight. The reaction system was cooled to room temperature and filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography to give intermediate 189-7 (280 mg, 34.8% yield) in the form of a colorless transparent oil, LC-MS: [M+H].sup.+=794.4.
Step (7) Preparation of (S)—N,N-bis(4-methoxybenzyl)-4-(7-methyl-3-(morpholin-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl)-3-(trifluoro methyl)benzenesulfonamide
[1590] ##STR00982##
[1591] Intermediate 189-7 (280 mg, 0.35 mmol) was dissolved in anhydrous dichloromethane (5 mL), and a solution of HCl in ethanol (0.6 mL, 4 N) was added dropwise. The reaction system was stirred at room temperature for 3 h. Then the reaction system was concentrated under reduced pressure to give intermediate 189-8 (300 mg, crude product) in the form of a white solid, LC-MS: [M+H].sup.+=694.5.
Step (8) Preparation of methyl (S)-2-((2-(4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2-(trifluoromethyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1592] ##STR00983##
[1593] Intermediate 189-8 (300 mg, crude product) was dissolved in anhydrous dichloromethane (4 mL) under nitrogen atmosphere, and N,N′-diisopropylethylamine (225 mg, 1.75 mmol) was added under nitrogen atmosphere. The reaction system was cooled in an ice water bath, added dropwise with a solution of methyl chloroformate in dichloromethane (10 mg/mL, 3.3 mL) and then reacted at 0° C. for 4 h. Then the reaction system was added with water (20 mL) to quench the reaction and extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation to give a crude product. The crude product was purified by silica gel column chromatography to give intermediate 189-9 (200 mg, 74.2% yield) in the form of a white solid, LC-MS [M+H].sup.+=752.4.
Step (9) Preparation of methyl (S)-2-((7-methyl-2-(4-sulfamoyl-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1594] ##STR00984##
[1595] Intermediate 189-9 (200 mg, 0.26 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (2 mL) was added. The reaction system was stirred overnight at room temperature. Then the reaction system was directly concentrated by rotary evaporation and purified by preparative reverse phase chromatography to give compound 189 (51 mg, 37.5% yield) in the form of a white solid, LC-MS: [M+H].sup.+=512.6.
[1596] 1H NMR (400 MHz, CDCl3) δ 8.25 (brs, 1H), 8.13 (brs, 1H), 8.04 (brs, 1H), 7.60 (brs, 1H), 7.47 (brs, 1H), 7.00-6.65 (m, 3H), 4.00-3.70 (m, 3H), 3.38 (s, 3H), 3.52-3.28 (m, 2H), 3.00-2.77 (m, 3H), 2.62-2.50 (m, 1H), 2.49 (s, 3H).
Example 190
[1597] ##STR00985##
[1598] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=480.2.
Example 191
[1599] ##STR00986##
[1600] The compound was prepared according to the preparation method as described in Example 181. LC-MS: [M+H].sup.+=481.4.
Example 192
Preparation of methyl (S)-2-((2-(4-(4-cyano-1H-imidazol-1-yl)-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
[1601] ##STR00987##
[1602] Compound 110 (100 mg, 0.2 mmol) and triethylamine (89 mg, 0.88 mmol) were dissolved in dichloromethane (5 mL), and a solution of trifluoroacetic anhydride (82 mg, 0.39 mmol) in dichloromethane (1 mL) was added dropwise under nitrogen atmosphere in an ice water bath. The reaction system was stirred overnight at room temperature. Then the reaction system was diluted with dichloromethane (30 mL), washed successively with saturated sodium bicarbonate solution (15 mL×2) and saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. The crude product was purified by preparative chromatography to give compound 192 (30 mg, 30% yield) in the form of a white solid. LC-MS: [M+H].sup.+=492.8.
[1603] .sup.1H NMR (400 MHz, MeOD) δ 8.83 (d, J=7.1 Hz, 1H), 8.61 (d, J=1.2 Hz, 1H), 8.54 (d, J=1.1 Hz, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.72 (s, 1H), 7.39 (d, J=7.1 Hz, 1H), 4.01 (d, J=12.9 Hz, 1H), 3.83 (d, J=13.4 Hz, 1H), 3.76 (d, J=10.8 Hz, 1H), 3.71-3.67 (m, 1H), 3.69 (s, 3H), 3.37-3.35 (m, 1H), 3.28-3.25 (m, 2H), 2.97-2.85 (m, 1H), 2.82-2.67 (m, 1H), 2.64 (s, 3H).
Biological Experiments
Example A: Evaluation of In Vitro Biological Activity
[1604] The antagonist property of the compounds disclosed herein was determined using the FLIPR (fluorescence imaging plate reader) method, showing that the compounds are inhibitors for the intracellular calcium increase induced by the activation of hP2X3 (human purinergic P2X receptor subtype 3, Accession No. NM_002559.4) expressed in HEK293 cells (human renal epithelial cell line, ATCC).
[1605] HEK293 cells that stably express hP2X3 were cultured in DMEM high glucose medium containing 10% FBS (fetal bovine serum, Gibco, 10099-141), 1% penicillin-streptomycin (Gibco, 15140-122) and 1 mg/mL G418 (Invitrogen, 10131027) in a cell incubator at 37° C., 5% humidity. Cells at 400,000 cells/mL were seeded into a 384-well plate (10,000 cells/well) 18-24 h prior to the FLIPR experiment and then incubated overnight in a cell incubator. On the day of the experiment, the medium was discarded and the cells were washed in an FLIPR buffer (each 30 mL buffer contains 0.3 mL of probenecid (Thermo, P36400), 0.6 mL of 1 M HEPES (Invitrogen, 15630080) and 29.1 mL of HBSS (Invitrogen, 14065056)). Each well was added with 20 μL of 0.5× Calcium 6 fluorescent dye (Molecular Devices, R8190) and then was subjected to dye-loading incubation at 37° C. for 1.5 h. Each well was added with 10 μL of test compound (which was dissolved in DMSO at a concentration of 10 mM and serially diluted with buffer) or vehicle, and then was left to equilibrate for 30 min at room temperature. The cell plate was then placed in the FLIPR for baseline fluorescence measurements (excitation at 485 nm and emission at 525-535 nm). An agonist (BZ-ATP (Sigma, B6396) at a final concentration of 2.5 μM) or a vehicle (ultrapure water) was then added at 10 μL/well, fluorescence values were measured for 2 min at 1-second intervals, and finally the output fluorescence counts were analyzed.
[1606] The IC.sub.50 values obtained by the above method are shown in Table 2.
TABLE-US-00003 TABLE 2 IC.sub.50 values of compounds of Examples 1-192 for P2X3 receptor Compound P2X3 IC.sub.50 (μM) Compound 1 D Compound 2 A Compound 3 B Compound 4 A Compound 5 A Compound 6 C Compound 7 A Compound 8 D Compound 9 D Compound 10 A Compound 11 B Compound 12 A Compound 13 B Compound 14 D Compound 15 A Compound 16 B Compound 17 B Compound 18 C Compound 19 D Compound 20 D Compound 21 D Compound 22 D Compound 23 D Compound 24 D Compound 25 A Compound 26 C Compound 27 A Compound 28 B Compound 29 A Compound 30 B Compound 31 D Compound 32 D Compound 33 D Compound 34 A Compound 35 D Compound 36 B Compound 37 A Compound 38 A Compound 39 D Compound 40 D Compound 41 D Compound 42 A Compound 43 A Compound 44 A Compound 45 D Compound 46 D Compound 47 D Compound 48 C Compound 49 A Compound 50 A Compound 51 C Compound 52 A Compound 53 A Compound 54 A Compound 55 A Compound 56 A Compound 57 A Compound 58 A Compound 59 A Compound 60 A Compound 61 A Compound 62 D Compound 63 C Compound 64 C Compound 65 C Compound 66 C Compound 67 B Compound 68 B Compound 69 B Compound 70 B Compound 71 A Compound 72 C Compound 73 C Compound 74 C Compound 75 B Compound 76 C Compound 77 A Compound 78 B Compound 79 B Compound 80 B Compound 81 A Compound 82 B Compound 83 C Compound 84 C Compound 85 C Compound 86 B Compound 87 C Compound 88 B Compound 89 B Compound 90 B Compound 91 A Compound 92 B Compound 93 B Compound 94 C Compound 95 B Compound 96 B Compound 97 C Compound 98 B Compound 97 C Compound 98 B Compound 99 B Compound 100 B Compound 101 B Compound 102 A Compound 103 C Compound 104 C Compound 105 A Compound 106 B Compound 107 B Compound 108 D Compound 109 C Compound 110 B Compound 111 B Compound 112 D Compound 113 D Compound 114 B Compound 115 D Compound 116 B Compound 117 B Compound 118 D Compound 119 B Compound 120 A Compound 121 D Compound 122 D Compound 123 C Compound 124 A Compound 124-2 A Compound 125 A Compound 126 B Compound 127 A Compound 128 D Compound 129 B Compound 130 D Compound 131 B Compound 132 A Compound 133 B Compound 134 B Compound 135 A Compound 136 C Compound 137 B Compound 138 A Compound 139 A Compound 140 C Compound 141 B Compound 142 A Compound 143 A Compound 144 B Compound 145 C Compound 146 C Compound 147 B Compound 148 A Compound 149 A Compound 150 A Compound 151 A Compound 152 A Compound 153 C Compound 154 A Compound 155 A Compound 156 A Compound 157 A Compound 158 A Compound 159 A Compound 160 A Compound 161 B Compound 162 A Compound 163 A Compound 164 B Compound 165 A Compound 166 A Compound 167 A Compound 168 B Compound 169 A Compound 170 C Compound 171 0.0021 Compound 172 0.0007 Compound 173 0.0018 Compound 174 0.0016 Compound 175 >10 Compound 176 0.0075 Compound 177 0.0011 Compound 178 0.0001 Compound 179 0.0004 Compound 180 0.0002 Compound 181 0.0018 Compound 182 0.0035 Compound 183 0.0055 Compound 184 0.0056 Compound 185 0.013 Compound 186 0.065 Compound 187 0.050 Compound 188 0.009 Compound 189 0.0100 Compound 190 A Compound 191 A Compound 192 B Positive compound 1 0.0115 Positive compound 2 0.0522 A: IC.sub.50 ≤ 10 nM, B: 10 < IC.sub.50 ≤ 50 nM, C: 50 < IC.sub.50 ≤ 200 nM, D: 200 < IC.sub.50 ≤ 5000 nM. Positive Compound 1:
[1607] As can be seen from the data in Table 2, the compounds disclosed herein exhibit good inhibitory activity against P2X3, wherein most of the compounds show stronger inhibitory activity than that of positive compound 2, and some of the compounds show stronger inhibitory activity than that of positive compound 1. Compounds with stronger inhibitory activity than that of positive compound 2 are preferred, and compounds with stronger inhibitory activity than that of positive compound 1 are more preferred.
Example B: Evaluation of In Vitro P2X2/3 Receptor Selectivity
[1608] The selectivity of the compounds disclosed herein for the P2X2/3 receptor was determined using the FLIPR (fluorescence imaging plate reader) method, showing that the compounds were inhibitors for the intracellular calcium increase induced by the activation of hP2X2/3 (heterodimeric receptors formed by human purinergic P.sub.2X receptors subtype 2 and subtype 3, Accession No. NM_002559.4 for P2X2 and Accession No. NM_002559.4 for P2X3) expressed in HEK293 cells (human renal epithelial cell line, ATCC).
[1609] HEK293 cells that stably express hP2X2/3 were cultured in DMEM high glucose medium containing 10% FBS (fetal bovine serum, Gibco, 10099-141), 1% penicillin-streptomycin (Gibco, 15140-122) and 1 mg/mL G418 (Invitrogen, 10131027) in a cell incubator at 37° C., 5% humidity. Cells at 250000 cells/mL were seeded into a 96-well plate (25000 cells/well) 18-24 h prior to the FLIPR experiment and then incubated overnight in a cell incubator. On the day of the experiment, the medium was discarded and the cells were washed in an FLIPR buffer (0.3 mL of probenecid (Thermo, P36400), 0.6 mL of 1 M HEPES (Invitrogen, 15630080) and 29.1 mL of HBSS (Invitrogen, 14065056) per 30 mL of buffer). Each well was added with 75 μL of 1 mM Fluo-4 AM fluorescent dye (Thermo, F14202) and then was subjected to dye-loading incubation at 37° C. for 1.0 h. The 96-well plate was then washed once with buffer, added with a buffer containing a test compound or a vehicle at 50 μL per well and then incubated for 30 min at room temperature. The cell plate was then placed in the FLIPR for baseline fluorescence measurements (excitation at 485 nm and emission at 525-535 nm). An agonist (BZ-ATP (Sigma, B6396) at a final concentration of 5. M) or a vehicle (ultrapure water) was then added at 50 μL/well, fluorescence values were measured for 2 min at 1-second intervals, and finally the output fluorescence counts were analyzed.
[1610] The IC.sub.50 values obtained by the above method are shown in Table 2.
TABLE-US-00004 TABLE 3 IC.sub.50 values and folds of selectivity of some of the compounds for P2X2/3 receptors Folds of Folds of Compound IC.sub.50 selectivity Compound IC.sub.50 selectivity Compound 2 >60 A Compound 3 >60 A Compound 4 14.31 A Compound 5 >60 A Compound 7 >60 A Compound 10 37.39 A Compound 11 17.56 B Compound 12 12.13 A Compound 13 14.44 B Compound 15 21.56 B Compound 17 29.81 B Compound 25 >60 A Compound 54 >60 A Compound 58 >60 A Compound 61 >60 A Compound 138 >60 A Compound 149 >60 A Compound 151 >60 A Compound 158 >60 A Compound 159 >60 A Compound 160 >60 A Compound 161 >60 A Compound 162 >60 A Compound 163 >60 A Compound 164 >60 A Compound 165 >60 A Compound 166 >60 A Compound 167 >60 A Compound 168 >60 A Compound 169 >60 A Compound 171 36.78 45975 Compound 172 >60 >85714 Compound 173 33.86 18811 Compound 191 >60 A Positive >60 >5217 Positive 0.36 6.9 compound 1 compound 2 A: folds of selectivity >1000, B: 200< folds of selectivity ≤1000, C: folds of selectivity ≤200.
[1611] As can be seen from the data in Table 3, the compounds disclosed herein exhibit poor inhibitory activity against P2X2/3 heterodimeric receptor and good selectivity for P2X3 and P2X2/3. Folds of selectivity=(IC.sub.50 for P2X2/3)/(IC.sub.50 for P2X3). Compounds with the folds of selectivity of more than 200 are preferred, and compounds with the folds of selectivity of more than 1000 are more preferred.
Example C: Activity Test in Citric Acid Only Cough Models
[1612] Male Dunkin Hartley guinea pigs (300-350 g) were placed in an animal atomization box, and then the door of the atomization box was closed while the ultrasonic atomizer (Guangdong Yuehua) was turned on. 17.5% citric acid gas was introduced into the atomization box at a maximum atomization rate (about 2 mL/min) for 20 s, and coughs of the animals within 10 min were continuously observed from the time of the start of atomization. During the 10-min observation, coughs of the animals were counted manually, and the number of coughs were judged according to cough postures of the guinea pigs, such as abdominal twitching, mouth opening, and head inclining downward abruptly. The number of coughs during the first 5 min and that during 10 min were recorded, and the cough latency of the guinea pigs, namely the time from the initiation of citric acid induction to the appearance of the first cough, was also recorded.
TABLE-US-00005 TABLE 4 The number of coughs, cough inhibition rate and cough latency obtained in vivo for some of the compounds Cough inhibition Cough inhibition Mean number of rate Vs rate Vs Mean cough Group coughs Vehicle (%) Baseline (%) latency Vehicle group Before 17.22 / / 108.44 administration After 18.33 105.78 administration Positive Before 18.63 42.6 47.0 80.13 compound 1 administration 30 mg/kg After 9.88 226.75 administration Compound 2 Before 18.50 34.2 38.7 94.50 30 mg/kg administration After 11.33 194.83 administration Compound 7 Before 18.50 38.3 42.6 87.13 30 mg/kg administration After 10.63 177.00 administration Compound 53 Before 18.63 47.7 51.7 138.00 30 mg/kg administration After 9.00 250.13 administration Compound 149 Before 19.33 62.7 66.8 75.92 30 mg/kg administration After 6.42 229.00 administration Compound 161 Before 18.57 63.5 66.2 130.71 30 mg/kg administration After 6.29 302.43 administration Compound 162 Before 18.29 42.8 46.1 144.43 30 mg/kg administration After 9.86 278.43 administration Compound 164 Before 18.29 65.2 67.2 144.86 30 mg/kg administration After 6.00 275.14 administration Compound 165 Before 17.57 53.6 54.5 135.71 30 mg/kg administration After 8.00 190.71 administration Compound 172 Before 19.56 43.9 50.6 87.56 30 mg/kg administration After 9.67 118.89 administration
[1613] The above experiment was conducted on the following representative compounds: compound 2, compound 7, compound 53, compound 149, compound 161, compound 162, compound 164, compound 165 and compound 172. The results as shown in Table 4 and
Example D: Activity Test in ATP-Citric Acid Cough Models
[1614] Male Dunkin Hartley guinea pigs (300-400 g) were placed into a whole-body plethysmography box to adapt for 3-5 min, then ATP atomization is carried out for 2 min, and 3 min later, 5 min of citric acid atomization was followed, with all atomization rates being about 300 uL/min. The number of coughs and the cough latency of the animals within 10 min from the start of the citric acid atomization were recorded. During the 10-min observation, coughs of the animals were counted manually, and the coughs were judged according to cough postures of the guinea pigs, such as abdominal twitching, mouth opening, head inclining downward abruptly and the like. The number of coughs during 10 min were recorded, and the cough latency of the guinea pigs was also recorded.
[1615] The animals were divided into a vehicle group, a dextromethorphan (63 mg/kg) positive group, an AF-219 (30 mg/kg) positive group and Example 173 compound (3, 10, 30 mg/kg) administration groups, and all the compounds were orally administered. Except that dextromethorphan was administered 40 min before ATP-citric acid exposure, the remaining compounds were administered 2 h before ATP-citric acid exposure.
TABLE-US-00006 TABLE 5 Ratios of quinine/water intake obtained for the compounds Cough inhibition Number of coughs ratio vs. Compound during 10 min vehicle (%) Vehicle 20.83 Dextromethorphan group (63 mg/kg) 8.00 61.60 AF-219 30 mg/kg 11.42 45.20 Compound 172 3 mg/kg 14.42 30.80 10 mg/kg 10.17 51.20 30 mg/kg 9.83 52.80
[1616] As shown in Table 5 and
Example E: In Vitro Cytotoxicity Assay
[1617] In vitro cytotoxicity assay for the compounds disclosed herein was performed in HepG2 cells using the CCK-8 method. HepG2 cells (Beina Bio) in the logarithmic growth phase were collected, the concentration of cell suspension was adjusted, and then the cells were plated on a 96-well cell culture plate at 50,000 cells/well. The cells were then incubated overnight in a cell incubator of 5% humidity at 37° C., and after 80-90% cell confluence was achieved, test compounds or vehicle (DMSO) at various concentration gradients were added after medium change. The plate was incubated in a cell incubator of 5% humidity at 37° C. for 48 h. After the treatment, the medium in the plate was discarded. The plate was washed twice with PBS, added with CCK-8 working solution (Beyotime) at 100 μL per well, and then incubated at 37° C. for 1.5 h away from light. Absorbance at OD.sub.450nm was measured for each well on a microplate reader, and CC.sub.50 value of each compound was analyzed and calculated.
[1618] The CC.sub.50 values obtained by the above method are shown in Table 6.
TABLE-US-00007 TABLE 6 CC.sub.50 values obtained for some of the compounds HepG2 HepG2 Compound CC.sub.50 (μM) Compound CC.sub.50 (μM) Compound 2 123.5 Compound 3 59.30 Compound 4 13.21 Compound 5 72.02 Compound 7 194.6 Compound 10 15.77 Compound 11 79.44 Compound 12 52.73 Compound 13 66.48 Compound 15 52.63 Compound 17 50.95 Compound 25 >100 Compound 26 >100 Compound 149 >100 Compound 158 >100 Compound 159 >100 Compound 160 >100 Compound 161 >100 Compound 162 >100 Compound 163 >100 Compound 164 >100 Compound 165 >100 Compound 166 >100 Compound 167 >100 Compound 168 >100 Compound 169 >100 Compound 171 200 Compound 172 57.05 Compound 173 >200 Compound 174 >200 Compound 176 >200 Compound 181 138.14 Compound 182 >200 Compound 184 >200 Positive 128.4 Positive >200 compound 1 compound 2
[1619] As can be seen from the data in Table 4, most of the compounds disclosed herein exhibit relatively good safety, and the CC.sub.50 ranges are all more than 10 μM, which satisfies the requirement for in vitro cytotoxicity of general compounds. Compounds with a CC.sub.50 value of more than 30 μM are preferred, and compounds with a CC.sub.50 value of more than 50 μM are more preferred.
Example F: Test of In Vitro Metabolic Stability
[1620] The in vitro metabolic stability of the compounds disclosed herein was determined through incubation of liver microsomes of various species. A proper amount of test compound was added into a liver microsome reaction system (1 mg/mL liver microsome protein, 25 U/mL glucose-6 phosphate dehydrogenase, 1 mM NADP, 6 mM D-glucose 6-phosphate and 5 mM MgCO.sub.2), and then the mixture was incubated in a water bath kettle at 37° C. to start the reaction. At each time point, 100 μL of the reaction mixture was added into a centrifuge tube containing 400 μL of internal standard working solution (containing a 200 ng/mL solution of dexamethasone, diclofenac, tolbutamide and labetalol in acetonitrile) precooled at 0° C. so as to terminate the reaction, and the mixture was then centrifuged at 10,000 g for 10 min at 4° C. The supernatant was collected for LC-MS assay so as to obtain the values of in vitro metabolic half-life of the test compounds in liver microsomes of various species.
[1621] The T.sub.1/2 values obtained by the above method are shown in Table 7.
TABLE-US-00008 TABLE 7 T.sub.1/2 values obtained for some of the compounds T.sub.1/2 in human T.sub.1/2 in rat T.sub.1/2 in guinea pig liver microsome liver microsome liver microsome Compound min min min Compound 2 895.35 52.34 95.33 Compound 3 260.22 28.72 50.49 Compound 4 61.05 4.91 4.38 Compound 5 648.70 37.31 47.62 Compound 7 127.80 19.58 20.89 Compound 10 222.61 30.80 13.51 Compound 11 151.19 5.65 4.27 Compound 12 91.92 7.78 7.56 Compound 13 61.51 2.24 2.25 Compound 15 190.59 25.39 16.51 Compound 17 997.99 19.35 8.61 Compound 25 297.97 227.75 NA Compound 26 253.12 80.94 127.80 Compound 149 206.63 52.50 178.02 Compound 168 522.56 57.59 29.24 Compound 169 827.52 35.47 164.42 Compound 171 523.3 8.48 140.1 Example 172 824.3 223.4 410.3 Example 173 NA 101.2 646.6 Example 174 NA 398.3 1110.5 Example 175 >30 >30 >30 Example 176 235.9 3.61 60.96 Compound 177 324.61 / / Compound 178 1233.69 / / Compound 181 1400.2 187.65 234.42 Compound 182 217.27 10.95 60.96 Compound 184 24383.0 5.66 173.41 Compound 189 144.57 / / Positive 1454.06 53.42 112.04 compound 1 Positive NA 1090.01 892.21 compound 2 Note: NA indicates essentially not metabolized; “/” indicates not detected.
[1622] As can be seen from the data in Table 5, the compounds disclosed herein exhibit relatively good metabolic stability in human, rat and guinea pig. As compared with positive compound 1, the compounds disclosed herein have similar metabolic half-life in human liver microsome but longer half-life in rat and guinea pig. In addition, as compared with positive compound 1, the metabolism of the compounds disclosed herein in rat and guinea pig are more close to that in human, which is beneficial to the related experimental evaluation of the compounds in rat and guinea pig. Compounds with a T.sub.1/2>30 min in human liver microsome are preferred, and compounds with a T.sub.1/2>90 min in human liver microsome are more preferred.
Example G: Two-Bottle Dysgeusia Test
[1623] Male SD rats (SPF grade, aged 6-8 weeks) were subjected to adaptive drinking training for 3 days after warehousing, and the specific training content was as follows: animals were fed in separate cages, and two bottles of water (both were common drinking water) were placed in each cage; during the adaptive training, drinking water was completely prohibited at night every day (drinking water bottles were removed out) and then resupplied during 8:30 am to 5:30 pm; and the operation was repeated for 3 days, the positions of the two bottles of water were changed every day, and the animals could eat freely during the whole adaptive training period. All drinking water bottles were removed out 20 h before the start of the formal experiment, and all the animals were deprived of water until the start of the experiment. In the experiment, all the animals were randomly grouped and then subjected to a single intraperitoneal injection of a test compound or a vehicle before water was resupplied. The administration time was determined according to the T.sub.max of the test compound. Then the animals were placed in separate cages, and two bottles of drinking water (one bottle of normal drinking water and one bottle of 0.3 mM quinine water) were provided. The water intake of the animals was observed within 15 min, statistical analysis was performed based on quinine water intake/normal water intake, and positive compound 2 was used as the dysgeusia positive control.
TABLE-US-00009 TABLE 8 Ratios of quinine/water intake obtained for some of the compounds Compound Quinine/tap water* 100% Vehicle 4.54% Positive compound 2 59.41% Compound 2 5.49% Compound 7 6.91% Compound 53 7.65% Compound 149 4.54% Compound 161 5.03% Compound 162 6.34% Compound 164 6.69% Compound 165 3.90%
[1624] The above experiment was conducted on the following representative compounds: compound 2, compound 7, compound 53, compound 149, compound 161, compound 162, compound 164 and compound 165. The results as shown in Table 8 and
TABLE-US-00010 TABLE 9 Ratios of quinine/water intake obtained for the compounds Compound Quinine/tap water* 100% Vehicle 7.19% Positive compound 2 10 18.62% 20 34.99% Compound 172 5 7.05% 10 7.41% 20 8.66%
[1625] The above experiment was conducted on the representative compound 172. The results as shown in Table 9 and
[1626] Although examples of the present invention are illustrated and described above, it will be appreciated that the above examples are exemplary and not to be construed as limiting the present invention, and that changes, modifications, substitutions and alterations can be made to the above examples by those skilled in the art within the scope of the present invention.